0001144204-13-027117.txt : 20130508 0001144204-13-027117.hdr.sgml : 20130508 20130508170130 ACCESSION NUMBER: 0001144204-13-027117 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20130331 FILED AS OF DATE: 20130508 DATE AS OF CHANGE: 20130508 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PHARMATHENE, INC CENTRAL INDEX KEY: 0001326190 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 202726770 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-32587 FILM NUMBER: 13825317 BUSINESS ADDRESS: STREET 1: ONE PARK PLACE, SUITE 450 CITY: ANNAPOLIS STATE: MD ZIP: 21401 BUSINESS PHONE: 410 269 2600 MAIL ADDRESS: STREET 1: ONE PARK PLACE, SUITE 450 CITY: ANNAPOLIS STATE: MD ZIP: 21401 FORMER COMPANY: FORMER CONFORMED NAME: HEALTHCARE ACQUISITION CORP DATE OF NAME CHANGE: 20050505 10-Q 1 v341092_10q.htm FORM 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2013

TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number: 001-32587

PHARMATHENE, INC.

(Exact name of registrant as specified in its charter)

Delaware		20-2726770
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

One Park Place, Suite 450, Annapolis, MD		21401
(Address of principal executive offices)		(Zip Code)

(410) 269-2600

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data file required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer ¨		Accelerated Filer x

Non-Accelerated Filer ¨		Smaller Reporting Company ¨
(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ¨ No x

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: The number of shares of the registrant’s Common Stock, par value $0.0001 per share, outstanding as of May 2, 2013 was 49,460,686.

PHARMATHENE, INC.

TABLE OF CONTENTS

		Page

PART I — FINANCIAL INFORMATION		1

Item 1. Financial Statements		1

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations		15

Item 3. Quantitative and Qualitative Disclosures about Market Risk		21

Item 4. Controls and Procedures		22

PART II — OTHER INFORMATION		22

Item 1. Legal Proceedings		22

Item 1A. Risk Factors		23

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds		23

Item 3. Defaults Upon Senior Securities		23

Item 4. Mine Safety Disclosures		23

Item 5. Other Information		23

Item 6. Exhibits		23

Certifications

Item 1. Financial Statements

PHARMATHENE, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

	March 31, 2013 (Unaudited)			December 31, 2012

ASSETS
Current assets:
Cash and cash equivalents	$	12,873,411		$	12,701,517
Accounts receivable (billed)		1,865,916			2,432,641
Unbilled accounts receivable		3,713,797			4,114,442
Prepaid expenses and other current assets		614,388			547,245
Total current assets		19,067,512			19,795,845

Property and equipment, net		456,842			483,976
Other long-term assets and deferred costs		99,578			113,130
Goodwill		2,348,453			2,348,453
Total assets	$	21,972,385		$	22,741,404

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:
Accounts payable	$	1,289,627		$	1,697,280
Accrued expenses and other liabilities		3,294,315			2,328,877
Deferred revenue		874,404			1,381,755
Current portion of long-term debt		999,996			749,997
Short-term debt		1,329,233			1,330,507
Total current liabilities		7,787,575			7,488,416

Other long-term liabilities		580,238			579,427
Long-term debt, less current portion		1,460,417			1,704,108
Derivative instruments		2,201,390			1,295,613
Total liabilities		12,029,620			11,067,564

Stockholders' equity:
Common stock, $0.0001 par value; 100,000,000 shares authorized; 48,416,483 and 48,352,651 shares issued and outstanding at March 31, 2013 and December 31, 2012, respectively		4,842			4,835
Additional paid-in-capital		210,877,892			210,495,905
Accumulated other comprehensive loss		(219,012	)		(217,328	)
Accumulated deficit		(200,720,957	)		(198,609,572	)
Total stockholders' equity		9,942,765			11,673,840
Total liabilities and stockholders' equity	$	21,972,385		$	22,741,404

The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.

PHARMATHENE, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

	Three months ended March 31,
	2013			2012

Contract revenue	$	6,475,138		$	6,149,052

Operating expenses:
Research and development		5,233,475			4,705,357
General and administrative		2,279,795			2,948,481
Depreciation and amortization		52,602			85,910
Total operating expenses		7,565,872			7,739,748

Loss from operations		(1,090,734	)		(1,590,696	)
Other income (expense):
Interest income		783			2,988
Interest expense		(99,791	)		(3,028	)
Other income (expense)		(6,123	)		52,915
Change in fair value of derivative instruments		(905,777	)		(991,662	)
Total other income (expense)		(1,010,908	)		(938,787	)

Net loss before income taxes		(2,101,642	)		(2,529,483	)

Income tax expense		(9,743	)		(150,405	)

Net loss	$	(2,111,385	)	$	(2,679,888	)

Basic and diluted net loss per share	$	(0.04	)	$	(0.06	)
Weighted average shares used in calculation of basic and diluted net loss per share		48,359,181			48,269,894

The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.

PHARMATHENE, INC

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OTHER COMPREHENSIVE LOSS

	Three months ended March 31,
	2013			2012

Net Loss	$	(2,111,385	)	$	(2,679,888	)

Other comprehensive income (loss):
Foreign currency translation adjustment		(1,684	)		13,369

Comprehensive loss	$	(2,113,069	)	$	(2,666,519	)

The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.

PHARMATHENE, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

	Three months ended March 31,
	2013			2012

Operating activities
Net loss	$	(2,111,385	)	$	(2,679,888	)
Adjustments to reconcile net loss to net cash used in operating activities:
Change in fair value of derivative instruments		905,777			991,662
Depreciation and amortization expense		52,602			85,910
Gain on the disposal of property and equipment		-			(66,626	)
Deferred income tax expenses		9,743			150,405
Non-cash interest expense		32,431			-
Share-based compensation expense		328,581			548,664
Changes in operating assets and liabilities:
Accounts receivable		566,725			3,278,062
Unbilled accounts receivable		400,645			(1,254,867	)
Prepaid expenses and other current assets		39,486			137,362
Accounts payable		(407,653	)		(35,280	)
Accrued expenses and other liabilities		950,800			131,338
Deferred revenue		(507,351	)		(495,372	)
Net cash provided by operating activities		260,401			791,370

Investing activities
Purchase of property and equipment		(25,468	)		-
Proceeds from the sale of property and equipment		-			67,400
Net cash provided (used) by investing activities		(25,468	)		67,400

Financing activities
Proceeds from issuance of long-term debt		-			2,500,000
Net (repayment of) proceeds from revolving credit agreement		(1,274	)		857,808
Deferred financing costs		-			(220,234	)
Controlled equity offering issuance costs		(112,500	)		-
Change in restricted cash requirements		-			100,000

Proceeds from issuance of common stock		53,413			-
Other		-			(32,960	)
Net cash (used) provided by financing activities		(60,361	)		3,204,614
Effects of exchange rates on cash		(2,678	)		4,034
Increases in cash and cash equivalents		171,894			4,067,418
Cash and cash equivalents, at beginning of period		12,701,517			11,236,771
Cash and cash equivalents, at end of period	$	12,873,411		$	15,304,189

Supplemental disclosure of cash flow information
Cash paid for interest	$	67,360		$	3,028
Noncash financing activities
Value of warrants issued to lender in connection with loan	$	-		$	69,876

The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.

PHARMATHENE, INC.

Notes to Unaudited Condensed Consolidated Financial Statements

March 31, 2013

Note 1 - Organization and Business

We are a biopharmaceutical company focused on developing biodefense countermeasure applications. We are subject to those risks associated with any biopharmaceutical company that has substantial expenditures for research and development. There can be no assurance that our research and development projects will be successful, that products developed will obtain necessary regulatory approval, or that any approved product will be commercially viable. In addition, we operate in an environment of rapid technological change and are largely dependent on the services and expertise of our employees, consultants and other third parties.

Historically, we have performed under government contracts and grants and raised funds from investors to sustain our operations.

Note 2 - Summary of Significant Accounting Policies

Basis of Presentation

Our unaudited condensed consolidated financial statements include the accounts of PharmAthene, Inc. and its wholly-owned subsidiaries. All significant intercompany transactions and balances have been eliminated in consolidation. Our unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”). In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to present fairly our financial position, results of operations and cash flows. The unaudited condensed consolidated balance sheet at December 31, 2012 has been derived from audited consolidated financial statements at that date. The interim results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and footnote disclosure normally included in the financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to instructions, rules and regulations prescribed by the U.S. Securities and Exchange Commission. We believe that the disclosures provided herein are adequate to make the information presented not misleading when these unaudited condensed consolidated financial statements are read in conjunction with the Consolidated Financial Statements and Notes included in our Annual Report on Form 10-K for the year ended December 31, 2012, filed with the Securities and Exchange Commission. We currently operate in one business segment.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Our unaudited condensed consolidated financial statements include significant estimates for the expected economic life and value of our intangible assets, the amount of our net operating losses, our share-based compensation, the value of our financial instruments, among other things. Because of the use of estimates inherent in the financial reporting process, actual results could differ significantly from those estimates.

Foreign Currency Translation

The functional currency of our wholly owned foreign subsidiaries is their local currency. Assets and liabilities of our foreign subsidiaries are translated into United States dollars based on exchange rates at the end of the reporting period. Income and expense items are translated at the weighted average exchange rates prevailing during the reporting period. Translation adjustments for subsidiaries that have not been sold, substantially liquidated or otherwise disposed of, are accumulated in other comprehensive income (loss), a component of stockholders’ equity. Foreign currency translation adjustments are the sole component of accumulated other comprehensive loss at March 31, 2013 and December 31, 2012. Transaction gains or losses are included in the determination of net loss.

Comprehensive Loss and Accumulated Other Comprehensive Income

Comprehensive loss includes the total of our net loss and all other changes in equity other than transactions with owners, including (i) changes in equity for cumulative translation adjustments resulting from the consolidation of foreign subsidiaries as the financial statements of the subsidiaries located outside of the United States are accounted for using the local currency as the functional currency, and (ii) unrealized gains and losses on short term available-for-sale investments.

Cash and Cash Equivalents

Cash and cash equivalents are stated at market value. We consider all highly liquid investments with original maturities of three months or less to be cash equivalents.

Revolving Line of Credit and Term Loan

As discussed further in Note 6, we entered into a loan agreement with General Electric Capital Corporation (“GE Capital”) in March 2012. As part of that agreement, we issued stock purchase warrants to GE Capital that expire in March 2022. The fair value of the warrants was charged to additional paid-in-capital, resulting in a debt discount to the Term Loan at the date of issuance. The debt discount and the financing costs, incurred in connections with the agreement, are being amortized over the term of the loan using the effective interest method. The amortization of both the debt discount and deferred financing costs are included in interest expense in the unaudited condensed consolidated statements of operations.

Significant Customers and Accounts Receivable

Our primary customers are the U.S. Department of Defense (the “DoD”) - Chemical Biological Medical Systems (“CBMS”), and the Biomedical Advanced Research and Development Authority (“BARDA”). As of March 31, 2013 and December 31, 2012, the Company’s trade receivable and unbilled receivable balances were comprised solely of receivables from CBMS and BARDA.

Goodwill

Goodwill represents the excess of purchase price over the fair value of net identifiable assets associated with acquisitions. We review the recoverability of goodwill annually as of December 31^st by comparing our market value (as measured by our stock price multiplied by the number of outstanding shares as of the end of the year) to the net book value of our equity. If our market value exceeds our net book value, no further analysis is required. Changes in our business strategy or adverse changes in market conditions could impact the impairment analyses and require the recognition of an impairment charge equal to the excess of the carrying value over its estimated fair value. We completed our last annual impairment assessment of goodwill as of December 31, 2012 and determined that there was no impairment as of that date.

Revenue Recognition

We generate our revenue from different types of contractual arrangements: cost-plus-fee contracts, cost reimbursable grants and fixed price contracts.

Revenues on cost-plus-fee contracts are recognized in an amount equal to the costs incurred during the period plus an estimate of the applicable fee earned. The estimate of the applicable fee earned is determined by reference to the contract: if the contract defines the fee in terms of risk-based milestones and specifies the fees to be earned upon the completion of each milestone, then the fee is recognized when the related milestones are earned, as further described below; otherwise, we estimate the fee earned in a given period by using a proportional performance method based on costs incurred during the period as compared to total estimated project costs and application of the resulting fraction to the total project fee specified in the contract.

Under the milestone method of revenue recognition, milestone payments (including milestone payments for fees) contained in research and development arrangements are recognized as revenue when: (i) the milestones are achieved; (ii) no further performance obligations with respect to the milestone exist; (iii) collection is reasonably assured; and (iv) substantive effort was necessary to achieve the milestone.

Milestones are considered substantive if all of the following conditions are met:

it is commensurate with either our performance to meet the milestone or the enhancement of the value of the delivered item or items as a result of a specific outcome resulting from our performance to achieve the milestone,

it relates solely to past performance,

the value of the milestone is reasonable relative to all the deliverables and payment terms (including other potential milestone consideration) within the arrangement.

If a milestone is deemed not to be substantive, the Company recognizes the portion of the milestone payment as revenue that correlates to work already performed; the remaining portion of the milestone payment is deferred and recognized as revenue as the Company completes its performance obligations.

Revenue on fixed price contracts (without substantive milestones as described above) is recognized on the percentage-of-completion method. The percentage-of-completion method recognizes income as the contract progresses (generally related to the costs incurred in providing the services required under the contract). The use of the percentage-of-completion method depends on the ability to make reasonable dependable estimates and the fact that circumstances may necessitate frequent revision of estimates does not indicate that the estimates are unreliable for the purpose for which they are used.

As a result of our revenue recognition policies and the billing provisions contained in our contracts, the timing of customer billings may differ from the timing of recognizing revenue. Amounts invoiced to customers in excess of revenue recognized are reflected on the balance sheet as deferred revenue. Amounts recognized as revenue in excess of amounts billed to customers are reflected on the balance sheet as unbilled accounts receivable.

We analyze each cost reimbursable grant to determine whether we should report such reimbursements as revenue or as an offset to our expenses incurred. For the three months ended March 31, 2013 and 2012, we recorded approximately $0.02 million and $0.5 million, respectively, of costs reimbursed by the government as an offset to research and development expenses.

Share-Based Compensation

We expense the estimated fair value of share-based awards granted to employees under our stock compensation plans. The fair value of stock options is determined at the grant date using an option pricing model. We have estimated the fair value of each stock option award using the Black-Scholes option pricing model. The Black-Scholes model considers, among other factors, the expected life of the award and the expected volatility of our stock price. The value of the award that is ultimately expected to vest is recognized as expense on a straight line basis over the employee’s requisite service period.

The fair value of restricted stock grants is determined based on the closing price of our common stock on the award date and is recognized as expense ratably over the requisite service period.

Employee share-based compensation expense recognized in the three months ended March 31, 2013 and 2012 was calculated based on awards ultimately expected to vest and has been reduced for estimated forfeitures at a rate of approximately 12%, based on historical forfeitures.

Share-based compensation expense for the three months ended March 31, 2013 and 2012 was:

	Three months ended March 31,
	2013		2012

Research and development	$	88,634	$	117,067
General and administrative		239,947		431,597
Total share-based compensation expense	$	328,581	$	548,664

During the three months ended March 31, 2013, we granted 60,000 options to employees and consultants and made no restricted stock grants. During the three months ended March 31, 2012, we granted 15,948 options to employees and made no restricted stock grants. At March 31, 2013, we had total unrecognized share-based compensation expense related to unvested awards of approximately $2.0 million net of estimated forfeitures, which we expect to recognize as expense over a weighted-average period of 2.25 years.

Income Taxes

We account for income taxes using the asset and liability approach, which requires the recognition of future tax benefits or liabilities on the temporary differences between the financial reporting and tax bases of our assets and liabilities. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized. We also recognize a tax benefit from uncertain tax positions only if it is “more likely than not” that the position is sustainable based on its technical merits. Our policy is to recognize interest and penalties on uncertain tax positions as a component of income tax expense.

Income tax expense was $9,743 and $150,405 during the three months ended March 31, 2013 and 2012, respectively. Income tax expense is a result of the difference between the treatment of goodwill for income tax purposes and for U.S. GAAP, resulting in a deferred tax liability, which cannot offset deferred tax assets. This deferred tax liability is included in our condensed consolidated balance sheet in other long-term liabilities.

Basic and Diluted Net Loss Per Share

Income (loss) per share: Basic income (loss) per share is computed by dividing consolidated net income (loss) by the weighted average number of common shares outstanding during the period, excluding unvested restricted stock.

For periods of net income when the effects are not anti-dilutive, diluted earnings per share is computed by dividing our net income by the weighted average number of shares outstanding and the impact of all potential dilutive common shares, consisting primarily of stock options, unvested restricted stock and stock purchase warrants. The dilutive impact of our dilutive potential common shares resulting from stock options and stock purchase warrants is determined by applying the treasury stock method.

For the periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all dilutive potential common shares is anti-dilutive due to the net losses. A total of approximately 11.6 million and 11.5 million potential dilutive securities have been excluded in the calculation of diluted net loss per share in the three months ended March 31, 2013 and 2012, respectively, because their inclusion would be anti-dilutive.

Recent Accounting Pronouncements

We have evaluated all Accounting Standards Updates through the date the unaudited condensed consolidated financial statements were issued and believe the adoption of these will not have a material impact on our results of operations, financial position, or cash flows.

Note 3 - Fair Value Measurements

We define fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. We report assets and liabilities that are measured at fair value using a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. This hierarchy maximizes the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:

Level 1 — Quoted prices in active markets for identical assets or liabilities.

Level 2 — Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.

Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs.

An asset’s or liability’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. At each reporting period, we perform a detailed analysis of our assets and liabilities that are measured at fair value. All assets and liabilities for which the fair value measurement is based on significant unobservable inputs or instruments which trade infrequently and therefore have little or no price transparency are classified as Level 3.

We have segregated our financial assets and liabilities that are measured at fair value into the most appropriate level within the fair value hierarchy based on the inputs used to determine the fair value at the measurement date in the table below. We have no non-financial assets and liabilities that are measured at fair value on a recurring basis. As of March 31, 2013 and 2012 we had Level 3 derivative liabilities of approximately $2.2 million and $2.9 million, respectively.

The following table represents the Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis:

	As of March 31, 2013
	Level 1		Level 2		Level 3		Balance
Liabilities
Derivatives instruments	$	-	$	-	$	2,201,390	$	2,201,390

	As of December 31, 2012
	Level 1		Level 2		Level 3		Balance
Liabilities
Derivatives instruments	$	-	$	-	$	1,295,613	$	1,295,613

The following table sets forth a summary of changes in the fair value of the Company’s Level 3 liabilities for the three months ended March 31, 2013:

Description	Balance as of December 31, 2012		Unrealized Losses		Balance as of March 31, 2013

Derivative liabilities related to stock purchase warrants	$	1,295,613	$	905,777	$	2,201,390

The following table sets forth a summary of changes in the fair value of the Company’s Level 3 liabilities for the three months ended March 31, 2012:

Description	Balance as of December 31, 2011		Unrealized Losses		Balance as of March 31, 2012

Derivative liabilities related to stock purchase warrants	$	1,886,652	$	991,662	$	2,878,314

At March 31, 2013 and 2012, derivative liabilities are comprised of warrants to purchase 2,899,991 shares of common stock. The warrants are considered to be derivative liabilities due to the presence of net settlement features and, as a result, are recorded at fair value at each balance sheet date, with changes in fair value recorded in the unaudited condensed consolidated statements of operations. The fair value of our warrants is determined based on the Black-Scholes option pricing model. Use of the Black-Scholes option pricing model requires the use of unobservable inputs such as the expected term, anticipated volatility and expected dividends.

Changes in any of the assumptions related to the unobservable inputs identified above may change the stock purchase warrants’ fair value; increases in expected term, anticipated volatility and expected dividends generally result in increases in fair value, while decreases in the unobservable inputs generally result in decreases in fair value. Gains and losses on the fair value adjustments for these derivative instruments are classified in other expenses as the change in fair value of derivative instruments in our unaudited condensed consolidated statements of operations. The $0.9 million change in the market value of derivative instruments during the three-month period ended March 31, 2013 is due primarily to the change in the closing price of PharmAthene stock, which was $1.12 per share as of December 31, 2012 and $1.70 per share as of March 28, 2013. The $1.0 million change in the market value of derivative instruments during the three-month period ended March 31, 2012 is due primarily to the change in the closing price of PharmAthene stock, which was $1.27 per share as of December 30, 2011 and $1.77 per share as of March 30, 2012.

Assets Measured at Fair Value on a Nonrecurring Basis

The Company measures its long-lived assets, including, property and equipment and goodwill, at fair value on a nonrecurring basis. These assets are recognized at fair value when they are deemed to be other-than-temporarily impaired. (see Note 2). As of March 31, 2013, the Company had no other assets or liabilities that were measured at fair value on a nonrecurring basis.

Note 4 - Commitments and Contingencies

SIGA Litigation

In December 2006, we filed a complaint against SIGA Technologies, Inc. (“SIGA”) in the Delaware Court of Chancery. The complaint alleged, among other things, that we have the right to license exclusively development and marketing rights for SIGA’s drug candidate, Arestvyr™ (Tecovirimat), pursuant to a merger agreement between the parties that was terminated in 2006. The complaint also alleged that SIGA failed to negotiate in good faith the terms of such a license pursuant to the terminated merger agreement.

In September 2011, the Court issued an opinion in the case finding that SIGA had breached certain contractual obligations to us and upholding our claims of promissory estoppel. The Court awarded us the right to receive 50% of all net profits (as defined in the court’s final judgment) related to the sale of Arestvyr™ and related products for 10 years following initial commercial sale of the drug once SIGA earns $40 million in net profits from the sale of Arestvyr™ and related products. The Court also awarded us one-third of our reasonable attorney's fees and expert witness fees, which amounts to approximately $2.4 million plus interest. In May 2012, the Court issued its final judgment. SIGA has appealed aspects of the decision to the Delaware Supreme Court. In response, we cross-appealed other aspects of the decision. In January 2013, the Delaware Supreme Court heard oral argument in the case.

We can provide no assurances that SIGA will not prevail on its appeal, that we will be successful in our appeal, and that the Delaware Supreme Court will not overturn the trial court’s decision awarding us a 10 year 50% net profit of the sales of Arestvyr™ and related products (once SIGA retains the first $40 million in net profit). We have not yet recorded any amount due from SIGA in relation to this case.

Vendor Litigation

One of our vendors mishandled the storage of certain biological materials. While we have been engaged in discussions with the vendor to address our concerns, so far we have not come to agreement. The vendor filed suit against us in Delaware state court seeking a declaration that they are not liable for damages and seeking damages from us for allegedly not maintaining the required amount and type of insurance. We filed suit against the vendor in Maryland state court seeking damages related to the loss of the property. We believe we did maintain the appropriate amount and type of insurance, that in no event did we harm the vendor, and thus their damages claim is without merit. We plan to vigorously defend against their claims while pursuing our own.

Government Contracting

Payments to the Company on cost-plus-fee contracts are provisional and are subject to adjustment upon audit by the Defense Contract Audit Agency and BARDA. In our opinion, adjustments that may result from audits are not expected to have a material effect on our financial position, results of operations, or cash flows.

Registration Rights Agreements

We entered into a Registration Rights Agreement with the investors who participated in the July 2009 private placement of convertible notes and related warrants. We subsequently filed two registration statements on Form S-3 with the Securities and Exchange Commission to register the shares underlying the convertible notes and related warrants, which registration statements have been declared effective. We are obligated to maintain the registration statements effective until the date when all shares underlying the convertible notes and related warrants (and any other securities issued or issuable with respect to in exchange for such shares) have been sold. The convertible notes were converted or extinguished in 2010, although the related warrants remain outstanding. The warrants will expire on January 28, 2015.

We have separate registration rights agreements with investors, under which we have obligations to keep the corresponding registration statements effective until the registrable securities (as defined in each agreement) have been sold, and under which we may have separate obligations to file registration statements in the future on either a demand or “piggy-back” basis or both.

Under the terms of the convertible notes, which were converted or extinguished in 2010, if after the 2nd consecutive business day (other than during an allowable blackout period) on which sales of all of the securities required to be included on the registration statement cannot be made pursuant to the registration statement (a “Maintenance Failure”), we will be required to pay to each selling stockholder a one-time payment of 1.0% of the aggregate principal amount of the convertible notes relating to the affected shares on the initial day of a Maintenance Failure. Our total maximum obligation under this provision at March 31, 2013, would be approximately $0.2 million.

Following a Maintenance Failure, we will also be required to make to each selling stockholder monthly payments of 1.0% of the aggregate principal amount of the convertible notes relating to the affected shares on every 30th day after the initial day of a Maintenance Failure, in each case prorated for shorter periods and until the failure is cured. Our total maximum obligation under this provision would be approximate $0.2 million for each month until the failure, if it occurs, is cured.

Note 5 - Stockholders’ Equity

Long-Term Incentive Plan

In 2007, the Company’s stockholders approved the 2007 Long-Term Incentive Compensation Plan (the “2007 Plan”) which provides for the granting of incentive and non-qualified stock options, stock appreciation rights, performance units, restricted common awards and performance bonuses (collectively “awards”) to Company officers and employees. Additionally, the 2007 Plan authorizes the granting of non-qualified stock options and restricted stock awards to Company directors and to independent consultants.

In 2008, the Company’s shareholders approved amendments to the 2007 Plan, increasing from 3.5 million shares to 4.6 million shares the maximum number of shares authorized for issuance under the plan and adding an evergreen provision pursuant to which the number of shares authorized for issuance under the plan will increase automatically in each year, beginning in 2009 and continuing through 2015, according to certain limits set forth in the 2007 Plan. At March 31, 2013, there are approximately 9.3 million shares approved for issuance under the 2007 plan, of which approximately 2.6 million shares are available to be issued. The Board of Directors in conjunction with management determines who receives awards, the vesting conditions and the exercise price. Options may have a maximum term of ten years.

Warrants Classified as Equity

In connection with the July 2009 private placement, we issued warrants to purchase an aggregate of 2,572,775 shares of the Company’s common stock at an exercise price of $2.50 per share. The warrants will expire on January 28, 2015. Also outstanding are warrants to purchase an aggregate of 100,778 shares of common stock at $3.97 per share, which will expire on March 30, 2017.

In connection with the March 30, 2012, debt financing (see Note 6), we issued warrants to purchase an aggregate of 46,584 shares of the Company’s common stock at an exercise price of $1.61 per share to GE Capital Equity Investments, Inc. The relative fair value attributable to the warrants of $69,876 was recorded in equity during the quarter ended March 31, 2012. The warrants will expire on March 30, 2022.

Warrants

At March 31, 2013 and 2012 there were warrants outstanding to purchase 5,620,128 shares of our common stock, respectively. The warrants outstanding as of March 31, 2013 and 2012 were as follows:

Number of Common Shares Underlying Warrants			Issue Date/Exercisable Date	Exercise Price		Expiration Date
	100,778	(1)	Mar-07 / Mar-07	$	3.97	Mar-17
	705,354	(2)	Mar-09 / Sep-09	$	3.00	Sep-14
	2,572,775	(1)	Jul-09 / Jan-10	$	2.50	Jan-15
	500,000	(2)	Apr-10 / Oct-10	$	1.89	Oct-15
	1,323,214	(2)	Jul-10 / Jan-11	$	1.63	Jan-17
	371,423	(2)	Jun-11 / Jun-11	$	3.50	Jun-16
	46,584	(1)	Mar-12 / Mar-12	$	1.61	Mar-22
	5,620,128

(1)

These warrants to purchase common stock are classified as equity.

(2)

These warrants to purchase common stock are classified as derivative liabilities. The fair value of these liabilities (see note 3) is remeasured at the end of every reporting period and the change in fair value is reported in the unaudited condensed consolidated statements of operations as other income (expense).

Note 6 – Financing Transactions

Controlled Equity Offering

On March 25, 2013, we entered into a controlled equity offering with a sales agent pursuant to which we may offer and sell, from time to time, through the agent shares of our common stock having an aggregate offering price of up to $15.0 million. Under the arrangement, the agent may sell shares by any method permitted by law and deemed to be an “at-the-market” offering as defined in Rule 415 promulgated under the Securities Act of 1933, as amended, including sales made directly on NYSE MKT, or any other existing trading market for our Common Stock or to or through a market maker. We are not obligated to sell any shares under the arrangement. Subject to the terms and conditions of that agreement, the agent will use commercially reasonable efforts, consistent with its normal trading and sales practices and applicable state and federal law, rules and regulations and the rules of NYSE MKT, to sell shares from time to time based upon our instructions. We are obligated to pay the agent a commission of 3.0% of the aggregate gross proceeds from each sale of shares. Total expenses incurred for the offering, excluding commission payable to the agent, were approximately $277,000. Through March 31, 2013, we sold 19,900 shares of our common stock under this arrangement, which did not settle until April 2013, that resulted in net proceeds to the company of approximately $33,000. As of March 31, 2013, aggregate gross sales for additional common stock of approximately $14.97 million remained available under the arrangement.

Loan Agreement with GE Capital

On March 30, 2012, we entered into a Loan Agreement with GE Capital. The Loan Agreement provides for a senior secured debt facility including a $2.5 million term loan and a revolving line of credit of up to $5 million based on our outstanding qualified accounts receivable. On March 30, 2012, the term loan was funded for an aggregate amount of $2.5 million.

Under the terms of the revolving line of credit, the Company may draw down from the revolving line of credit up to 85% of qualified billed accounts receivable and 80% of qualified unbilled accounts receivable. As of March 31, 2013, the total amount available to draw was approximately $2.3 million, of which $1.3 million was drawn and outstanding.

The fixed interest rate on the term loan is 10.14% per annum. The revolving line of credit has an adjustable interest rate based upon the 3-month London Interbank Offered Rate (LIBOR), with a floor of 1.5%, plus 5%. As of March 31, 2013, the interest rate was 6.5%. Both the term loan and the revolving line of credit mature in September 2015. Payments on the term loan were originally interest-only for the first 10 months, which has since been extended to 12 months pursuant to terms of the agreement. Subsequently, the term loan will fully amortize over its remaining term as of March 31, 2013. Principal payments on the term loan are scheduled as follows:

Year		Principal Payments
	2013	$749,997
	2014	999,996
	2015	750,007
		$2,500,000

The term loan, net of discount of $39,587, is recorded on the 2013 condensed consolidated balance sheet, net of debt discount, as follows:

Current portion of long-term debt		$	999,996
Long-term debt, less current portion		$	1,460,417

If we prepay the term loan and terminate the revolving line of credit prior to the scheduled maturity date, we are obligated to pay a prepayment premium equal to 3% of the then outstanding principal amount of the term loan if prepaid during the first two years of the loan and 2% if prepaid during the third year or thereafter. In addition, we are obligated to pay a final payment fee of 3% of the term loan balance. The final payment fee is being accrued and expensed over the term of the agreement, using the effective interest method and is included in other long-term liabilities on the condensed consolidated balance sheet.

Our obligations under the Loan Agreement are collateralized by a security interest in substantially all of our assets. While the security interest does not, except in limited circumstances, cover our intellectual property, it does cover any proceeds received by us from the use or sale of our intellectual property.

In connection with the Loan Agreement, we issued GE Capital warrants to purchase 46,584 shares of the Company’s common stock at an exercise price of $1.61 per share. The warrants are exercisable immediately and subject to customary and standard anti-dilution adjustments. The warrants are classified in equity and, as a result, the fair value of the warrants was charged to additional paid-in capital resulting in a debt discount at the date of issuance. The debt discount is being amortized over the term of the loan agreement using the effective interest method. Financing costs incurred in connection with this agreement are also being amortized over the term of the agreement using the effective interest method.

The fair value of the Company’s outstanding borrowings under its revolving credit facility at March 31, 2013 was consistent with its carrying value as of that date primarily due to the short term nature of the Revolver’s repayment terms. The Company determined the fair value of the Term Loan approximated its carrying value as of March 31, 2013.

Note 7 – Subsequent Events

Subsequent to March 31, 2013, we sold 1,030,870 shares of our common stock under the controlled equity offering, which resulted in net proceeds of approximately $1.63 million. (See Note 6). Aggregate gross proceeds of up to approximately $13.29 million remain available under the arrangement.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. This information may involve known and unknown risks, uncertainties and other factors that are difficult to predict and may cause our actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by any forward-looking statements. These risks, uncertainties and other factors include, but are not limited to, risk associated with the following:

the reliability of the results of the studies relating to efficacy and safety, and possible adverse effects resulting from the administration, of the Company’s product candidates;

funding delays, reductions in or elimination of U.S. government funding and/or non-renewal of expiring funding for one or more of our development programs;

the award of government contracts to our competitors or delays caused by third parties challenging government contract awards to us;

unforeseen safety and efficacy issues;

challenges related to the development, technology transfer, scale-up, and/or process validation of manufacturing processes for our product candidates; and

unexpected determinations that these product candidates prove not to be effective and/or capable of being marketed as products;

as well as risks detailed under the caption “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2012, and in our other reports filed with the U.S. Securities and Exchange Commission (the “SEC”) from time to time thereafter. In particular, there can be no assurance that the Company will prevail in the appeal to the Delaware Supreme Court of the ruling of the Delaware Court of Chancery awarding PharmAthene 50% of all net profits (as defined in the court’s final judgment) related to the sale of Arestvyr™ (formerly called ST-246®) and related products for 10 years following initial commercial sale of the drug once SIGA earns $40 million in net profits from the sale of Arestvyr™ and related products. Further, the timing and amount of any future sales and revenues of Arestvyr™ is uncertain. Significant additional non-clinical animal studies, human clinical trials, and manufacturing development work remain to be completed for all our products candidates, including Valortim® and rBChE, and with FDA’s August 2012 clinical hold of SparVax®, it is unclear when, if ever, we can re-initiate human clinical trials for that product candidate. At this point future government funding to support the development of Valortim® is unlikely and remains uncertain. It is also uncertain whether any of our product candidates will be shown to be safe and effective and approved by regulatory authorities for use in humans. Forward-looking statements describe management’s current expectations regarding our future plans, strategies and objectives and are generally identifiable by use of the words “may,” “will,” “should,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “project,” “potential” or “plan” or the negative of these words or other variations on these words or comparable terminology. Such statements include, but are not limited to:

statements about potential future government contract or grant awards;

potential payments under government contracts or grants;

potential regulatory approvals;

future product advancements; and

anticipated financial or operational results.

Forward-looking statements are based on assumptions that may be incorrect, and we cannot assure you that the projections included in the forward-looking statements will come to pass.

We have based the forward-looking statements included in this Quarterly Report on Form 10-Q on information available to us on the date of this Quarterly Report, and we assume no obligation to update any such forward-looking statements, other than as required by law. Although we undertake no obligation to revise or update any forward-looking statements, whether as a result of new information, future events or otherwise, you are advised to consult any additional disclosures that we may make directly to you or through reports that we, in the future, may file with the SEC, including Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.

The following discussion should be read in conjunction with our unaudited condensed consolidated financial statements which present our results of operations for the three months ended March 31, 2013 and 2012, as well as our financial positions at March 31, 2013 and December 31, 2012, contained elsewhere in this Quarterly Report on Form 10-Q. The following discussion should also be read in conjunction with the Annual Report on Form 10-K for the year ended December 31, 2012, filed on March 13, 2013, including the consolidated financial statements contained therein.

Overview

We are a biodefense company engaged in the development and commercialization of next generation medical countermeasures against biological and chemical threats. Our current biodefense portfolio includes the following product candidates:

SparVax^®, a next generation recombinant protective antigen (“rPA”) anthrax vaccine,

rBChE (recombinant butyrylcholinesterase) bioscavanger, a medical countermeasure for nerve agent poisoning by organophosphorous compounds, including nerve gases and pesticides, and

Valortim^®, a fully human monoclonal antibody for the prevention and treatment of anthrax infection.

In addition, we were awarded by the Delaware Court of Chancery in September 2011 the right to receive 50% of all net profits (as defined in the court’s final judgment) related to the sale of SIGA Technologies, Inc.’s (SIGA) Arestvyr™ (formerly known as ST-246^®) and related products for 10 years following initial commercial sale of the drug once SIGA earns $40 million in net profits from the sales of Arestvyr™ and related products. In May 2012, the Court issued its final judgment. SIGA has appealed aspects of the decision to the Delaware Supreme Court. In response, we have cross-appealed other aspects of the decision. In January 2013, the Delaware Supreme Court heard oral argument in the case.

Critical Accounting Policies

A “critical accounting policy” is one that is both important to the portrayal of our financial condition and results of operations and that requires management’s most difficult, subjective or complex judgments. Such judgments are often the result of a need to make estimates about the effect of matters that are inherently uncertain. The preparation of our financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates. We believe that the disclosures provided herein are adequate to make the information presented not misleading when these unaudited condensed consolidated financial statements are read in conjunction with the Consolidated Financial Statements and Notes included in our Annual Report on Form 10-K for the year ended December 31, 2012, filed with the Securities and Exchange Commission.

There were no significant changes in critical accounting policies from those at December 31, 2012.

Results of Operations

Revenue

We recognized revenue of $6.5 million and $6.1 million during the three months ended March 31, 2013 and 2012, respectively.

	Three months ended March 31,
Revenue ($ in millions)	2013		2012		% Change
SparVax^®	$	5.1	$	5.2		-1.9	%
rBChE bioscavanger		1.4		0.8		75.0	%
Valortim^®		0.0		0.1		-100.0	%
Total Revenue	$	6.5	$	6.1		6.6	%

Our revenue was derived primarily from contracts with the U.S. government for the development of SparVax^®, and our rBChE bioscavanger. Our revenue in the three months ended March 31, 2013 changed from the comparable period of 2012 primarily due to the following:

Under our contract for the development of SparVax^®, we recognized approximately $5.1 million and $5.2 million of revenue for the three months ended March 31, 2013 and 2012, respectively. During the quarter ended March 31, 2013 revenue was primarily attributable to work related to manufacturing process characterization, ongoing stability testing of bulk drug substance (BDS) and final drug product (FDP), immunopotency assay development, and the completion of a rabbit dose ranging efficacy study. During the quarter ended March 31, 2012 revenue for the Company's SparVax^® program was primarily attributable to work related to the manufacture of final drug product of SparVax^® as well as activities related to the Phase 2 clinical trial planned to commence later in 2012 and the completion of certain activities related to the development of analytical assays. Milestone revenue for the three months ended March 31, 2013 was $0.07 million and for the three months ended March 31, 2012 was $0.9 million. During the quarter, we submitted our complete response to the FDA in response to a clinical hold notification for our proposed Phase II clinical trial of SparVax^®.

We recognized approximately $1.4 million and $0.8 million related to work on our second generation rBChE bioscavanger in the first three months of 2013 and 2012, respectively, under the $5.7 million August 2011 Firm Fixed Price contract with the DoD for the development of the advanced expression system for rBChE. In the first three months of 2012 our activities related to clone generation and initiation of process development, while in the comparable 2013 period we continued with the process development work and focused on material generation for non-clinical studies.

Research and Development Expenses

Our research and development expenses were $5.2 million and $4.7 million for the three months ended March 31, 2013 and 2012, respectively. These expenses resulted from research and development activities in both periods related primarily to our SparVax^® and rBChE bioscavanger programs. Direct expenses included salaries and other costs of personnel, raw materials and supplies, and an allocation of indirect expenses. We also incurred third-party costs, such as contract research, consulting and clinical development costs for individual projects. Research and development expenses for the three months ended March 31, 2013 and 2012 were net of cost reimbursements under certain of our government grants of $0.02 million and $0.5 million, respectively.

Research and development expenses for the three months ended March 31, 2013 and 2012 were attributable to research programs as follows:

	Three Months ended March 31,
Research and Development Expenses ($ in millions)	2013		2012		% Change
SparVax^®andValortim^®	$	4.4	$	4.2		4.8	%
rBChE bioscavenger		0.8		0.4		100.0	%
Internal research and development		0.0		0.1		-100.0	%
Total research and development expenses	$	5.2	$	4.7		10.6	%

For the three months ended March 31, 2013, research and development expenses increased $0.5 million from the same period in the prior year, due to increased costs related to our SparVax^® program, as a result of the completion of a significant number of BDS process characterization activities and the conduct of activities required to address the FDA clinical hold issues, and our rBChE bioscavanger program. These increases were offset by the reduction in direct costs related to our Valortim^® program as a result of the completion of work under the contract in the first quarter of 2012.

General and Administrative Expenses

General and administrative functions include executive management, finance and administration, government affairs and regulations, corporate development, human resources, legal, and compliance. For each function, we may incur expenses such as salaries, supplies and third-party consulting and other external costs and non-cash expenditures such as expense related to stock option and restricted share awards. An allocation of indirect costs such as facilities, utilities and other administrative overhead is also included in general and administrative expenses.

Expenses associated with general and administrative functions were $2.3 million for the three months ended March 31, 2013 and $2.9 million for the three months ended March 31, 2012. The $0.6 million dollar decrease from the same period in the prior year, was principally due to reduced labor and associated share-based compensation costs and lower professional and consulting fees.

Depreciation and Amortization

Depreciation and amortization expenses were approximately $0.1 million for the three months ended March 31, 2013 and 2012, respectively.

Other Income (Expense)

Other income (expense) primarily consists of income on our investments, interest expense on our debt and other financial obligations, changes in fair value of our derivative financial instruments, foreign currency transaction gains or losses, and the gain on the disposal of property and equipment.

Other expense in 2013 was $1.01 million, compared to $0.94 million in 2012, an increase of $0.07 million. The increase was primarily the result of (i) $0.1 million of additional interest expense in 2013 generated from our loans with GE Capital, (ii) a $0.07 million gain in 2012 on the disposal of property and equipment, and (iii) a $0.1 million difference in losses related to the changes in fair value of our derivative instruments.

Income Taxes

Income tax expense was $0.01 million and $0.15 million during the three months ended March 31, 2013 and 2012, respectively. Income tax expense in 2012 resulted from the difference between the treatment of goodwill for income tax purposes and for U.S. Generally Accepted Accounting Principles.

Liquidity and Capital Resources

Overview

Our primary source of cash during the first quarter 2013 was provided by our operating activities. Our future capital requirements will depend on many factors, including, the progress of our research and development programs; the progress of pre-clinical and clinical testing; the time and cost involved in obtaining regulatory approval; the cost of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; changes in our existing research relationships; competing technological and marketing developments; our ability to establish collaborative arrangements and to enter into licensing agreements and contractual arrangements with others; and any future change in our business strategy. These cash requirements could change materially as a result of shifts in our business and strategy. The need to raise additional capital will depend on many factors, including but not limited to, our future cash requirements, future contract funding, whether SIGA prevails in its appeal challenging the trial court ruling awarding us an interest in a portion of the net profits of Arestvyr™, the timing, amount, and profitability of sales of Arestvyr™, if any (including the timing of SIGA’s recognition of revenue related thereto), and if the trial court ruling is upheld, our ability to collect our portion of net profits related to Arestvyr™.

For the three months ended March 31, 2013 and 2012, we generated positive cash flows from operations, however, historically, we have not generated positive cash flows from operations. To bridge the gap between payments made to us under our government contracts and grants and our operating and capital needs, we have had to rely on a variety of financing sources, including the issuance of equity securities and equity-linked securities and proceeds from loans and other borrowings. On March 25, 2013, we entered into a controlled equity offering pursuant to which we may offer and sell, from time to time, through a sales agent, shares of our common stock having an aggregate offering price of up to $15.0 million. (See Financing Activities below). For the foreseeable future, we will continue to need these types of financing vehicles and potentially others to help fund our future operating and capital requirements.

Global economic uncertainty continues to make capital markets more volatile and is threatening to once again tighten the credit markets. As a result, there can be no assurances that we would be successful in obtaining sufficient financing on commercially reasonable terms or at all. In addition, due to the U.S. government’s continuing substantial efforts to stabilize the economy, the U.S. government may be forced or choose to reduce or delay spending in the biodefense field, which could decrease the likelihood of future government contract awards, the likelihood that the government will exercise its right to extend any of its existing contracts with us and/or the likelihood that the government would procure products from us.

Our unaudited condensed consolidated financial statements have been prepared on a basis which assumes that we will continue as a going concern and which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business and do not include any adjustments that might result if the carrying amount of recorded assets and liabilities are not realized.

Sources and Uses of Cash

Cash and cash equivalents were $12.9 million and $12.7 million at March 31, 2013 and December 31, 2012, respectively.

Cash Flows

The following table provides information regarding our cash flows for the three months ended March 31, 2013 and 2012:

	Three months ended March 31,
	2013			2012
Net cash provided by (used in):
Operating activities	$	260,401		$	791,370
Investing activities		(25,468	)		67,400
Financing activities		(60,361	)		3,204,614
Effects of exchange rates on cash		(2,678	)		4,034
Total increase in net cash	$	171,894		$	4,067,418

Operating Activities

Net cash provided by operating activities was $0.3 million and $0.8 million and for the three months ended March 31, 2013 and 2012, respectively.

Net cash provided by operating activities during the three months ended March 31, 2013 reflects our net loss of $2.1 million, adjusted for the increase in the fair value of derivative instruments of $0.9 million and other noncash expenses of $0.4 million. A decrease in receivables (billed and unbilled) of approximately $1.0 million and an increase in accrued expenses and other liabilities of $1.0 million was partially offset by a decrease in accounts payable of $0.4 million and deferred revenue of $0.5 million.

Net cash provided by operations during the three months ended March 31, 2012 reflects our net loss of $2.7 million, adjusted for the increase in the fair value of derivative instruments of $1.0 million and other noncash expenses of $0.8 million. A decrease in accounts receivable of $3.3 million was partially offset by an increase in unbilled accounts receivable of $1.3 million.

Investing Activities

There were no significant investing activities during the three months ended March 31, 2013 and March 31, 2012.

Financing Activities

Net cash used by financing activities was $0.06 million for the three months ended March 31, 2013, as compared to, $3.2 million provided by financing activities for the three months ended March 31, 2012.

Net cash used by financing activities for the three months ended March 31, 2013 was principally the result of issuance costs incurred in connection with the controlled equity offering which were partially offset from proceeds received from the issuance of common stock in connection with stock option exercises. The majority of our cash provided by financing for the three months ended March 30, 2012, was a result of us entering into a senior fully-secured debt facility with GE Capital as described in Note 6 to the unaudited condensed consolidated financial statements, which is included in Part 1 of this Form 10-Q.

On March 25, 2013, we entered into a controlled equity offering pursuant to which we may offer and sell, from time to time, through a sales agent, shares of our common stock having an aggregate offering price of up to $15.0 million. Under the arrangement, the agent may sell shares by any method permitted by law and deemed to be an “at-the-market” offering as defined in Rule 415 promulgated under the Securities Act of 1933, as amended, including sales made directly on NYSE MKT, on any other existing trading market for the Common Stock or to or through a market maker. We are not obligated to sell any shares under the Sales Agreement. We are obligated to pay the agent a commission of 3.0% of the aggregate gross proceeds from each sale of shares. See additional discussion in Note 6 to the unaudited condensed consolidated financial statements which are included in Part 1 of this Form 10-Q.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements.

Contractual Obligations

The following are contractual commitments at March 31, 2013:

Contractual Obligations(1)	Total		Less than 1 Year		1-3 Years		3-5 Years		More than 5 years

Operating facility leases	$	3,429,900	$	803,500	$	1,631,200	$	995,200	$	-
Research and development agreements		4,760,000		4,760,000		-		-		-
Term loan, principal payments only		2,500,000		999,996		1,500,004		-		-
Total contractual obligations	$	10,689,900	$	6,563,496	$	3,131,204	$	995,200	$	-

(1) This table does not include any royalty payments relating to future sales of products subject to license agreements the Company has entered into in relation to its in-licensed technology, as the timing and likelihood of such payments are not known. In addition, the table does not include the final payment fee of $75,000 on the term loan, which is being accrued and expensed over the term of the agreement, using the effective interest method, or the debt discount, which is being amortized over the term of the agreement. The debt discount and final payment accrual at March 31, 2013 were $39,587 and $32,009 respectively. See additional discussion in Note 6 to the unaudited condensed consolidated financial statements which are included in Part 1 of this Form 10-Q.

Item 3. Quantitative and Qualitative Disclosures about Market Risk.

Our exposure to market risk is currently confined to our cash and cash equivalents and our revolving line of credit. We currently do not hedge interest rate exposure or foreign currency exchange exposure. We have not used derivative financial instruments for speculation or trading purposes.

The Company’s current operations in foreign countries are minimal. We have closed our active operations in Canada and maintain only nominal operations in the United Kingdom. A 10% change in exchange rates (against the U.S. dollar) would not have a material impact on earnings, fair values or cash flow.

Because of the short-term maturities of our cash and cash equivalents, we do not believe that an increase in market interest rates would have a significant impact on their realized value. Our term loan with GE Capital is at a fixed 10.14% rate. Because of the fixed rate, a change in market interest rates would not have a material impact on interest expense associated with the loan. The interest rate on the revolving line of credit is variable; therefore, a 1% increase in market interest rates above the interest rate floor of 1.5%, would increase interest expense associated with the line by $50,000 if the maximum amount of the line ($5.0 million) was drawn for a full year.

The change in fair value of our derivative instruments is calculated utilizing the Black-Scholes model; therefore, a 10% increase/decrease in the closing price of PharmAthene’s common stock at March 31, 2013, would result in a change in fair value of derivative instruments and our earnings of approximately $0.3 million.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

Our management, including our principal executive and principal financial officers, has evaluated the effectiveness of our disclosure controls and procedures as of March 31, 2013. Our disclosure controls and procedures are designed to provide reasonable assurance that the information required to be disclosed in reports we file or submit under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive and principal financial officers, to allow timely decisions regarding required disclosure. Based on that evaluation, our principal executive and principal financial officers have concluded that our disclosure controls and procedures are effective at the reasonable assurance level.

Changes in Internal Control Over Financial Reporting

Our management, including our principal executive and principal financial officers, has evaluated any changes in our internal control over financial reporting that occurred during the quarterly period ended March 31, 2013, and has concluded that there was no change that occurred during the quarterly period ended March 31, 2013 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II — OTHER INFORMATION

Item 1. Legal Proceedings

Except as noted below, we are not a defendant in any legal proceedings.

Item 1A. Risk Factors

Investing in our securities involves risks. In addition to the other information in this quarterly report on Form 10-Q, stockholders and potential investors should carefully consider the risks and uncertainties discussed in the section "Item 1A. Risk Factors" in our annual report on Form 10-K for the year ended December 31, 2012. If any of the risks and uncertainties set forth in our 2012 annual report on Form 10-K actually materialize, our business, financial condition and/or results of operations could be materially adversely affected, the trading price of our common stock could decline and a stockholder could lose all or part of his or her investment. The risks and uncertainties set forth in our 2012 annual report on Form 10-K are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently consider immaterial may also impair our business operations.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Default upon Senior Securities

Not applicable

Item 4. Mine Safety Disclosures

Not applicable

Item 5. Other Information

None.

Item 6. Exhibits.

No.		Description
10.30.4		Amendment to Employment Agreement, dated as of December 23, 2010, between the Company and Eric I. Richman (2)
10.61		Controlled Equity Offering^SM Sales Agreement between PharmAthene, Inc. and Cantor Fitzgerald & Co. dated March 25, 2013. (1)
10.62		Employment Agreement, dated as of April 18, 2008, between the Company and Francesca Cook.
31.1		Certification of Principal Executive Officer Pursuant to SEC Rule 13a-14(a)/15d-14(a)
31.2		Certification of Principal Financial Officer Pursuant to SEC Rule 13a-14(a)/15d-14(a)
32.1		Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350
32.2		Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350

(101)		The following condensed consolidated financial statements from the PharmAthene, Inc. Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2013, formatted in Extensive Business Reporting Language ("XBRL"): (i) Condensed Consolidated Balance Sheets as of March 31, 2013 and December 31, 2012, (ii) Unaudited Condensed Consolidated Statements of Operations for the three months ended March 31, 2013 and 2012, (iii) Unaudited Condensed Consolidated Statements of Comprehensive Loss for the three months ended March 31, 2013 and 2012, (iv) Unaudited Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2013 and 2012, and (v) Notes to consolidated financial statements.*

101.INS		Instance Document*

101.SCH		XBRL Taxonomy Extension Schema Document*

101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document*

101.DEF		XBRL Taxonomy Extension Definition Linkbase Document*

101.LAB		XBRL Taxonomy Extension Label Linkbase Document*

101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document*

(1)		Incorporated by reference to the Current Report on Form 8-K filed by the Registrant on March 25, 2013

(2)		Incorporated by reference to the Current Report on Form 8-K filed by the Registrant on December 30, 2010

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused the report to be signed on its behalf by the undersigned, thereunto duly authorized.

	PHARMATHENE, INC.

Dated: May 8, 2013	By:	/s/ Eric I. Richman
		Eric I. Richman
		President and Chief Executive Officer

Dated: May 8, 2013	By:	/s/ Linda L. Chang
		Linda L. Chang
		Chief Financial Officer

EX-10.62 2 v341092_ex10-62.htm EXHIBIT 10.62

Exhibit 10.62

EMPLOYMENT AGREEMENT

This EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into this April 18, 2008 by and between Francesca Cook (the “Executive”) and PharmAthene, Inc., a Delaware corporation (the “Company”).

W I T N E SS E T H:

WHEREAS, the Company desires to employ the Executive and the Executive desires to accept employment with the Company subject to the terms and conditions herein agreed upon:

NOW, THEREFORE, in consideration of the foregoing and of the mutual covenants and obligations hereinafter set forth, the parties hereto hereby agree as follows:

Employment; Term. The Company hereby agrees to employ the Executive and the Executive hereby accepts employment with the Company upon the terms and conditions hereinafter set forth for the period commencing on April 18, 2008 (the “Effective Date”) and ending on the first anniversary of such date. The term of this Agreement shall be automatically extended for an additional year on each anniversary of the date hereof unless written notice of non-extension is provided by either party to the other party at least 90 days prior to such anniversary. The period of the Executive’s employment under this Agreement, as it may be terminated or extended from time to time as provided herein is referred to as the “Employment Period.”

Position and Duties.

Position and Duties Generally. The Executive shall be employed by the Company in the position of Vice President, Policy & Government Affairs and shall faithfully render such executive, managerial, administrative and other services as are customarily associated with and incident to such position and as the Company may from time to time reasonably require consistent with such position. The Executive shall report to the President and CEO, David P. Wright.

Other Positions. The Executive shall hold such other positions and executive offices with the Company and/or of any of the Company’s subsidiaries or affiliates as may from time to time be authorized by the Board. The Executive shall not be entitled to any compensation other than the compensation provided for herein for serving during the Employment Period in any other office or position of the Company or any of its subsidiaries or affiliates, unless the Compensation Committee specifically approves such additional compensation.

Devotion to Employment. Except for vacation time taken in accordance with the Company’s vacation policy in effect from time to time and in accordance with the terms of this Agreement and for absences due to temporary illness, the Executive shall be a full-time employee of the Company and shall devote full time, attention and efforts during the Employment Period to the business of the Company and the duties required of him in his position. During the Employment Period, the Executive shall not be engaged in any other business activity which, in the reasonable judgment of the Board or its designee, conflicts with the duties of the Executive hereunder, whether or not such activity is pursued for gain, profit or other pecuniary advantage.

Page 1 of 10

Compensation; Reimbursement.

Base Salary. For the Executive’s services, the Company shall pay to the Executive an annual base salary of not less than $231,612.00 per annum, payable in equal periodic installments according to the Company’s customary payroll practices, but no less frequently than monthly. The Executive’s base salary shall be subject to review annually by the Compensation Committee and shall be subject to increase at the option and sole discretion of the Compensation Committee.

Bonus. The Executive shall be eligible to receive at the sole discretion of the Compensation Committee, an annual cash bonus of up to an additional 30% of the Executive’s base salary. In addition, the Executive may be eligible for additional bonuses at the option and sole discretion of the Compensation Committee based upon the achievement of certain pre-determined performance milestones.

Benefits Generally.

In addition to the salary and cash bonus described above, the Executive shall be entitled during the Employment Period to participate in such employee benefit plans and programs of the Company, and shall be entitled to such other fringe benefits, as are from time to time made available by the Company generally to employees of the level, position, tenure, salary, age, health and other qualifications of the Executive including, without limitation, medical, dental and vision insurance coverage for the Executive and the Executive’s dependents, disability, death benefit and life insurance and pension plans.

ii.

Without limiting the generality of the foregoing, the Executive shall be eligible for such awards, if any, including stock and stock options under the Company’s 2007 Long-Term Incentive Plan or such other plan as the Company may from time to time put into effect as shall be granted to the Executive by the Compensation Committee or other appropriate designee of the Board acting in its sole discretion.

iii.

The Executive acknowledges and agrees that the Company does not guarantee the adoption or continuance of any particular employee benefit plan and participation by the Executive in any such plan or program shall be subject to the rules and regulations applicable thereto.

Vacation. The Executive shall be entitled to 20 days of vacation in each calendar year.

Expenses. The Company shall reimburse the Executive in accordance with the practices in effect from time to time for other officers or staff personnel of the Company for all reasonable and necessary business and travel expenses and other disbursements incurred by the Executive for or on behalf of the Company in the performance of the Executive’s duties hereunder, upon presentation by the Executive to the Company of appropriate supporting documentation.

Page 2 of 10

Perquisites. The Executive shall be entitled to those perquisites as the Company shall make available from time to time to other executive officers of the Company, which shall include, without limitation, the costs associated with the use of an automobile in an amount not to exceed $1,000 per month and the costs for Executive’s use of a cellular telephone and personal digital assistant to the extent such equipment is used for business purposes.

Death; Disability. In the event that the Executive dies or is incapacitated or disabled by accident, sickness or otherwise, so as to render the Executive mentally or physically incapable of performing the services required to be performed by the Executive under this Agreement for a period that would entitle the Executive to qualify for long-term disability benefits under the Company’s then-current long-term disability insurance program or, in the absence of such a program, for a period of 120 consecutive days or longer (such condition being herein referred to as a “Disability”) then (i) in the case of the Executive’s death, the Executive’s employment shall be deemed to terminate on the date of the Executive’s death and (ii) in the case of a Disability, the Company, at its option, may terminate the employment of the Executive under this Agreement immediately upon giving the Executive notice to that effect. The determination to terminate the Executive in the event of a Disability shall be made by the Board or the Board’s designee. In the case of a Disability, until the Company shall have terminated the Executive’s employment hereunder in accordance with the foregoing, the Executive shall be entitled to receive compensation provided for herein notwithstanding any such physical or mental disability.

Termination For Cause. The Company may terminate the employment of the Executive hereunder at any time during the Employment Period for “cause” (such termination being herein referred to as a “Termination for Cause”) by giving the Executive notice of such termination, which termination shall be effective on the date of such notice or such later date as may be specified by the Company. For purposes of this Agreement, “Cause” means (i) the Executive’s willful and substantial misconduct that is materially injurious to the Company and is either repeated after written notice from the Company specifying the misconduct or is continuing and not corrected within 20 days after written notice form the Company specifying the misconduct, (ii) the Executive’s repeated neglect of duties or failure to act which can reasonably be expected to affect materially and adversely the business or affairs of the Company after written notice from the Company specifying the neglect or failure to act, (iii) the Executive’s material breach of any of the agreements contained in Sections 11, 12, 13 or 14 hereof or of any of the Company’s policies, (iv) the commission by the Executive of any material fraudulent act with respect to the business and affairs of the Company, (v) the Executive’s conviction of (or plea of nolo contendere to) a crime constituting a felony, (vi) demonstrable gross negligence, or (vii) habitual insobriety or use of illegal drugs by the Executive while performing the Executive’s duties under this Agreement which adversely affects the Executives performance of the Executive’s duties under this Agreement.

Page 3 of 10

Termination Without Cause. The Company may terminate the employment of the Executive hereunder at any time without “cause” or fail to extend this Agreement pursuant to the terms hereof (such termination being herein referred to as “Termination Without Cause”) by giving the Executive notice of such termination, upon the giving of which such termination shall take effect not later than 30 days from the date such notice is given.

Voluntary Termination by Executive. Any termination of the employment of the Executive by the Executive otherwise than as a result of death or Disability or for Good Reason (as defined below) (such termination being herein referred to as “Voluntary Termination”). A Voluntary Termination will be deemed to be effective immediately upon such termination.

Termination by Executive for Good Reason. Any termination of the employment of the Executive by the Executive for Good Reason which shall be deemed to be equivalent to a Termination without Cause. For purposes of this Agreement “Good Reason” means (i) any material breach by the Company of any of its obligations under this Agreement, (ii) any material reduction in the Executive’s duties, authority or responsibilities without the Executive’s consent, (iii) any assignment to the Executive of duties or responsibilities materially inconsistent with the Executive’s position and duties contained in this Agreement without the Executive’s consent, (iv) a relocation of the Company’s principal executive offices or the Company determination to require the Executive to be based anywhere other than within 25 miles of the location at which the Executive on the date hereof performs the Executive’s duties; (v) the taking of any action by the Company which would deprive the Executive of any material benefit plan (including, without limitation, any medical, dental, disability or life insurance); or (vi) the failure by the Company to obtain the specific assumption of this Agreement by any successor or assignee of the Company or any person acquiring substantially all of the Company’s assets; provided, however, that the Executive may not terminate the Employment Period for Good Reason unless the Executive first provides the Company with written notice specifying the Good Reason and providing the Company with 20 days in which to remedy the stated reason.

Effect of Termination of Employment.

Voluntary Termination; Termination For Cause. Upon the termination of the Executive’s employment as a result of the Executive’s Voluntary Termination or a Termination For Cause, the Executive shall not have any further rights or claims against the Company under this Agreement except the right to receive (i) the unpaid portion of the base salary provided for in Section 3(a) hereof, computed on a pro rata basis to the date of termination, (ii) payment of the Executive’s accrued but unpaid amounts and extension of applicable benefits in accordance with the terms of any incentive compensation, retirement, employee welfare or other employee benefit plans or programs of the Company in which the Executive is then participating in accordance with the terms of such plans or programs, and (iii) reimbursement for any expenses for which the Executive shall not have theretofore been reimbursed as provided in Section 3 hereof.

Page 4 of 10

Termination Without Cause; Termination for Good Reason. Upon the termination of the Executive’s employment as a result of a Termination Without Cause or for Good Reason, the Executive shall not have any further rights or claims against the Company under this Agreement except the right to receive (i) the payments and other rights provided for in Section 9(a) hereof and (ii) severance payments in the form of a continuation of the Executive’s base salary as in effect immediately prior to such termination for a period of 6 (six) months following the effective date of such termination. To the extent that severance payments shall be payable under this Agreement such payments shall be in consideration for and only after the Executive executes a General Release containing terms reasonably satisfactory to the Company.

Death and Disability. Upon the termination of the Executive’s employment as a result of death or Disability, neither the Executive nor the Executive’s beneficiaries or estate shall have any further rights or claims against the Company under this Agreement except the right to receive the payments and other rights provided for in Section 9(a) hereof.

Forfeiture of Rights. In the event that, subsequent to termination of employment hereunder, the Executive (i) breaches any of the provisions of Sections 11, 12, 13 or 14 hereof or (ii) makes or facilitates the making of any adverse public statements or disclosures with respect to the business or securities of the Company, all payments and benefits to which the Executive may otherwise have been entitled shall immediately terminate and be forfeited, and any portion of such amounts as may have been paid to the Executive shall forthwith be returned to the Company.

10.

Disclosure of Confidential Information. The Executive shall not, directly or indirectly, at any time during or after the Employment Period, disclose to any person, firm, corporation or other business entity, except as required by law, or use for any purpose except in the good faith performance of the Executive’s duties to the Company, any Confidential Information (as herein defined). For purposes of this Agreement, “Confidential Information” means all trade secrets and other non-public information of a business, financial , marketing, technical or other nature pertaining to the Company or any subsidiary, including information of others that the Company or any subsidiary has agreed to keep confidential; provided, however, that Confidential Information shall not include any information that has entered or enters the public domain (other than through breach of the Executive’s obligations under this Agreement) or which the Executive is required to disclose by law or legal process. Upon the Company’s request at any time, the Executive shall immediately deliver to the Company all materials in the Executive’s possession which contain Confidential Information.

Page 5 of 10

11.

Restrictive Covenant.

Term of Restrictive Covenant. The Executive hereby acknowledges and recognizes that, during the Employment Period, the Executive shall be privy to trade secrets and Confidential Information critical to the Company’s business and the Executive further acknowledges and recognizes that the Company would find it extremely difficult or impossible to replace the Executive and, accordingly, the Executive agrees that, in consideration of the benefits to be received by the Executive hereunder, the Executive shall not, from and after the date hereof, throughout the Employment Period, and for a period of 12 months following the termination of the Employment Period (i) directly or indirectly engage in the development, production, marketing or sale of products that compete (or, upon commercialization, would compete) with products of the Company being developed (so long as such development has not been abandoned), marketed or sold at the time of the termination of the Employment Period (such business or activity being herein referred to as a “Competing Business”) whether such engagement shall be as an officer, director, owner, employee, partner, affiliate or other participant in any Competing Business, (ii) assist others in engaging in any Competing Business in the manner described in the foregoing clause (i), or (iii) induce other employees of the Company or any subsidiary thereof to terminate their employment with the Company or any subsidiary thereof or engage in any Competing Business or hire any employees of the Company or any subsidiary unless such persons have not been employees of the Company for at least 12 months.

Sufficient Consideration. The Executive understands that the foregoing restrictions may limit the ability of the Executive to earn a livelihood in a business similar to the business of the Company, but nevertheless believes that the Executive has received and shall receive sufficient consideration and other benefits, as an employee of the Company and as otherwise provided hereunder, to justify such restrictions which, in any event (given the education, skills and ability of the Executive), the Executive believes would not prevent the Executive from earning a living.

12.

Non-Disparagement. The Executive shall not engage in conduct, through word, act, gesture or other means, or disclose any information to the public or any third party which (i) directly or indirectly discredits or disparages in whole or in part the company, its subsidiaries, divisions, affiliates and/or successors as well as the products and the respective officers, directors, stockholders and employees of each of them; (ii) is detrimental to the reputation, character or standing of these entities, their products or any of their respective officers, directors, stockholders and/or employees; or (iii) which generally reflects negatively on the management decisions, strategy or decision-making of these entities.

13.

Company Right to Inventions. The Executive shall promptly disclose, grant and assign to the Company, for its sole use and benefit, any and all inventions, improvements, technical information and suggestions relating in any way to the business of the Company which the Executive may develop or acquire during the Employment Period (whether or not during usual working hours), together with all patent applications, letters patent, copyrights and reissues thereof that may at any time be granted for or upon any such invention, improvement or technical information. In connection therewith: (i) the Executive shall, without charge, but at the expense of the Company, promptly at all times hereafter execute and deliver such applications, assignments, descriptions and other instruments as may be necessary or proper in the opinion of the Company to vest title to any such inventions, improvements, technical information, patent applications, patents, copyrights or reissues thereof in the Company and to enable it to obtain and maintain the entire right and title thereto throughout the world, and (ii) the Executive shall render to the Company, at its expense (including a reasonable payment for the time involved in case the Executive is not then in its employ), all such assistance as it may require in the prosecution of applications for said patents, copyrights or reissues thereof, in the prosecution or defense of interferences which may be declared involving any said applications, patents or copyrights and in any litigation in which the Company may be involved relating to any such patents, inventions, improvements or technical information.

Page 6 of 10

14.

Enforcement. It is the desire and intent of the parties hereto that the provisions of this Agreement be enforceable to the fullest extent permissible under the laws and public policies applied in each jurisdiction in which enforcement is sought. Accordingly, to the extent that a restriction contained in this Agreement is more restrictive than permitted by the laws of any jurisdiction where this Agreement may be subject to review and interpretation, the terms of such restriction, for the purpose only of the operation of such restriction in such jurisdiction, shall be the maximum restriction allowed by the laws of such jurisdiction and such restriction shall be deemed to have been revised accordingly herein.

15.

Remedies; Survival.

Injunctive Relief. The Executive acknowledges and understands that the provisions of the covenants contained in Sections 11, 12, 13 and 14 hereof, the violation of which cannot be accurately compensated for in damages by an action at law, are of crucial importance to the Company, and that the breach or threatened breach of the provisions of this Agreement would cause the Company irreparable harm. In the event of a breach or threatened breach by the Executive of the provisions of Sections 11, 12, 13 or 14 hereof, the Company shall be entitled to an injunction restraining the Executive from such breach. Nothing herein contained shall be construed as prohibiting the Company from pursuing any other remedies available for any breach or threatened breach of this Agreement.

Survival. Notwithstanding anything contained in this Agreement to the contrary, the provisions of the Sections 3, 9, and 11 through 17 hereof shall survive the expiration or earlier termination of this Agreement until, by their terms, such provisions are no longer operative.

16.

Notices. Notices and other communications hereunder shall be in writing and shall be delivered personally or sent by air courier or first class certified or registered mail, return receipt requested and postage prepaid, addressed as follows:

if to the Company:

PharmAthene, Inc.
One Park Place, Suite 450
Annapolis, Maryland 21401

Page 7 of 10

with a copy to:
McCarter & English, LLP
Four Gateway Center
100 Mulberry Street
Newark, New Jersey 07102
Attention: Jeffrey Baumel, Esq.

if to the Executive to:

with a copy to :

All notices and other communications given to any party hereto in accordance with the provisions of this Agreement shall be deemed to have been given on the date of delivery, if personally delivered; on the business day after the date when sent, if sent by air courier; and on the third business day after the date when sent, if sent by mail, in each case addressed to such party as provided in this Section 16 or in accordance with the latest unrevoked direction from such party.

17.

Binding Agreement; Benefit. The provisions of this Agreement shall be binding upon, and shall inure to the benefit of, the respective heirs, legal representatives and successors of the parties hereto.

18.

Governing Law; Jurisdiction. This Agreement shall be governed by, and construed and enforced in accordance with, the laws of the State of Maryland applicable to contract made and to be performed therein. Any action to enforce any of the provisions of this Agreement shall be brought in a court of the State of Maryland or in Federal court located within that State. The parties consent to the jurisdiction of such courts and to the service of process in any manner provided by Maryland law. Each party irrevocably waives any objection which it may now or hereafter have to the laying of the venue of any such suit, action or proceeding brought in such court and any claim that such suit, action or proceeding brought in such court has been brought in an inconvenient forum and agrees that service of process in accordance with the foregoing shall be deemed in every respect effective and valid personal service of process upon such party.

19.

Waiver of Breach. The waiver by either party of a breach of any provision of this Agreement by the other party must be in writing and shall not operate or be construed as a waiver of any subsequent breach by such other party.

20.

Entire Agreement; Amendments. This Agreement contains the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior agreements or understandings among the parties with respect thereof. This Agreement may be amended only by an agreement in writing signed by the parties hereto.

21.

Headings. The section headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement.

22.

Severability. Any provision of this Agreement that is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof, and any such prohibition or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction.

Page 8 of 10

23.

409A Compliance. The intent of the Executive and the Company is that the severance and other benefits payable to the Executive under this Agreement not be deemed “deferred compensation” under, and shall otherwise comply with, Section 409A of the Internal Revenue Code of 1986, as amended. The Executive and the Company agree to use reasonable best efforts to amend the terms of this Agreement from time to time as may be necessary to avoid the imposition of liability under Section 409A of the Code in any manner that does not materially alter the substantive rights and obligations of the parties hereunder.

24.

Executive’s Acknowledgement. The Executive acknowledges (a) that the Executive has had the opportunity to consult with independent counsel of his own choice concerning this Agreement and (b) that the Executive has read and understands the Agreement, is fully aware of its legal effect and has entered into it freely based on the Executive’s own judgment.

25.

Assignment. This Agreement is personal in its nature and the parties hereto shall not, without the consent of the other, assign or transfer this Agreement or any rights or obligations hereunder; provided, that the provisions hereof shall inure to the benefit of, and be binding upon, each successor of the Company, whether by merger, consolidation, transfer of all or substantially all of its assets or otherwise.

26.

Counterparts. This Agreement may be executed in two or more counterparts, each of which shall for all purposes constitute one agreement which is binding on all of the parties hereto.

Page 9 of 10

IN WITNESS WHEREOF, the parties have duly executed this Agreement as of the date first above written.

	EXECUTIVE

	/s/ Francesca Cook
	Francesca Cook

	PHARMATHENE, INC.


	By	/s/ David P. Wright
	Name:	David P. Wright
	Title:	President and Chief Executive Officer

Page 10 of 10

EX-31.1 3 v341092_ex31-1.htm EXHIBIT 31.1

Exhibit 31.1

Certification of Principal Executive Officer

Pursuant to SEC Rule 13a-14(a)/15d-14(a)

I, Eric I. Richman, certify that:

I have reviewed this Form 10-Q of PharmAthene, Inc. for the period ended March 31, 2013;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statement for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: May 8, 2013	/s/ Eric I. Richman
	Name: Eric I. Richman
	Title: Chief Executive Officer

EX-31.2 4 v341092_ex31-2.htm EXHIBIT 31.2

Exhibit 31.2

Certification of Principal Financial Officer

Pursuant to SEC Rule 13a-14(a)/15d-14(a)

I, Linda L. Chang, certify that:

I have reviewed this Form 10-Q of PharmAthene, Inc. for the period ended March 31, 2013;

(a)

(b)

(c)

(d)

(a)

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: May 8, 2013	/s/ Linda L. Chang
	Name: Linda L. Chang
	Title: Chief Financial Officer

EX-32.1 5 v341092_ex32-1.htm EXHIBIT 32.1

Exhibit 32.1

Certification Pursuant to Section 1350 of Chapter 63

of Title 18 of the United States Code

In connection with the Quarterly Report on Form 10-Q of PharmAthene, Inc. (the “Company”) for the period ended March 31, 2013, as filed with the Securities and Exchange Commission (the “Report”), I, Eric I. Richman, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

1.		The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934.

2.		The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Eric I. Richman
Eric I. Richman
Chief Executive Officer
May 8, 2013

A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

This certification is being furnished pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that section. This certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934.

EX-32.2 6 v341092_ex32-2.htm EXHIBIT 32.2

Exhibit 32.2

Certification Pursuant to Section 1350 of Chapter 63

of Title 18 of the United States Code

In connection with the Quarterly Report on Form 10-Q of PharmAthene, Inc. (the “Company”) for the period ended March 31, 2013, as filed with the Securities and Exchange Commission (the “Report”), I, Linda L. Chang, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

1.		The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934.

2.		The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Linda L. Chang
Linda L. Chang
Chief Financial Officer
May 8, 2013

EX-101.INS 7 pip-20130331.xml XBRL INSTANCE DOCUMENT false --12-31 Q1 2013 2013-03-31 10-Q 0001326190 49460686 Accelerated Filer PHARMATHENE, INC PIP 3294315 2328877 P10Y P3M 2007-03-01 2009-03-01 2009-07-01 2010-04-01 2010-07-01 2011-06-01 2012-03-01 0.03 2400000 0.015 2015-09 0.03 0.85 0.8 0.03 0.02 15000000 40000000 200000 200000 0.01 0.01 0.5 2500000 14970000 13290000 0.12 0.12 P10Y 69876 2015-01-28 2022-03-30 2015-01-28 2017-03-30 2017-03-30 2014-09-30 2015-01-28 2015-10-31 2017-01-31 2016-06-30 2022-03-30 46584

1289627

1697280

-219012

-217328

210877892

210495905

277000

88634

117067

239947

431597

328581

548664

11600000

11500000

21972385

22741404

19067512

19795845

<div> <div> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <em>Basis of Presentation</em></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Our unaudited condensed consolidated financial statements include the accounts of PharmAthene, Inc. and its wholly-owned subsidiaries. All significant intercompany transactions and balances have been eliminated in consolidation. Our unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States ("U.S. GAAP"). In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to present fairly our financial position, results of operations and cash flows. The unaudited condensed consolidated balance sheet at December 31, 2012 has been derived from audited consolidated financial statements at that date. The interim results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and footnote disclosure normally included in the financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to instructions, rules and regulations prescribed by the U.S. Securities and Exchange Commission. We believe that the disclosures provided herein are adequate to make the information presented not misleading when these unaudited condensed consolidated financial statements are read in conjunction with the Consolidated Financial Statements and Notes included in our Annual Report on Form 10-K for the year ended December 31, 2012, filed with the Securities and Exchange Commission. We currently operate in one business segment.</p> </div> </div>

1865916

2432641

12873411

12701517

15304189

11236771

171894

4067418

<div> <div> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <em>Cash and Cash Equivalents</em></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Cash and cash equivalents are stated at market value. We consider all highly liquid investments with original maturities of three months or less to be cash equivalents.</p> </div> </div>

2007-03-01

2009-09-01

2010-01-01

2010-10-01

2011-01-01

2011-06-01

2012-03-01

1.61

2.50

3.97

3.00

2.50

1.89

1.63

3.50

1.61

5620128

46584

2572775

100778

705354

2572775

500000

1323214

371423

46584

2899991

4600000

3500000

0.0001

100000000

48416483

48352651

48416483

48352651

33000

4842

4835

6475138

6149052

20000

500000

9743

150405

0.05

2500000

0.065

0.1014

Payments on the term loan were originally interest-only for the first 10 months, which has since been extended to 12 months pursuant to terms of the agreement. Subsequently, the term loan will fully amortize over its remaining term as of March 31, 2013.

39587

9743

150405

874404

1381755

52602

85910

2201390

1295613

2201390

1295613

2201390

1295613

2878314

1886652

2201390

1295613

-0.04

-0.06

-2678

4034

2000000

P2Y3M

<div> <div> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong>Note 3 - Fair Value Measurements</strong></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> We define fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. We report assets and liabilities that are measured at fair value using a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. This hierarchy maximizes the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:</p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <table style="WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 18px"> </td> <td style="FONT: 10pt Symbol; WIDTH: 18px">·</td> <td style="FONT: 10pt Times New Roman, Times, Serif">Level 1 - Quoted prices in active markets for identical assets or liabilities.</td> </tr> </table> <p style="TEXT-INDENT: 1.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <table style="WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 18px"> </td> <td style="FONT: 10pt Symbol; WIDTH: 18px">·</td> <td style="FONT: 10pt Times New Roman, Times, Serif">Level 2 - Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.</td> </tr> </table> <p style="TEXT-INDENT: 1.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <table style="WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 18px"> </td> <td style="FONT: 10pt Symbol; WIDTH: 18px">·</td> <td style="FONT: 10pt Times New Roman, Times, Serif">Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs.</td> </tr> </table> <p style="TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> An asset's or liability's level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. At each reporting period, we perform a detailed analysis of our assets and liabilities that are measured at fair value. All assets and liabilities for which the fair value measurement is based on significant unobservable inputs or instruments which trade infrequently and therefore have little or no price transparency are classified as Level 3.</p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> We have segregated our financial assets and liabilities that are measured at fair value into the most appropriate level within the fair value hierarchy based on the inputs used to determine the fair value at the measurement date in the table below. We have no non-financial assets and liabilities that are measured at fair value on a recurring basis. As of March 31, 2013 and 2012 we had Level 3 derivative liabilities of approximately $2.2 million and $2.9 million, respectively.</p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The following table represents the Company's fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis:</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt"> </td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; COLOR: black" colspan="14">As of March 31, 2013</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt"> </td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; COLOR: black" colspan="2">Level 1</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; COLOR: black" colspan="2">Level 2</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; COLOR: black" colspan="2">Level 3</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; COLOR: black" colspan="2">Balance</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> Liabilities</td> <td style="FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt" colspan="2">  </td> <td style="FONT-SIZE: 10pt"> </td> <td style="FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt" colspan="2">  </td> <td style="FONT-SIZE: 10pt"> </td> <td style="FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt" colspan="2">  </td> <td style="FONT-SIZE: 10pt"> </td> <td style="FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt" colspan="2">  </td> <td style="FONT-SIZE: 10pt"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; WIDTH: 44%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> Derivatives instruments</td> <td style="WIDTH: 2%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> $</td> <td style="TEXT-ALIGN: right; WIDTH: 10%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> -</td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="WIDTH: 2%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> $</td> <td style="TEXT-ALIGN: right; WIDTH: 10%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> -</td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="WIDTH: 2%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> $</td> <td style="TEXT-ALIGN: right; WIDTH: 10%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> 2,201,390</td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="WIDTH: 2%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> $</td> <td style="TEXT-ALIGN: right; WIDTH: 10%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> 2,201,390</td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> </tr> </table> <p style="TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt"> </td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; COLOR: black" colspan="14">As of December 31, 2012</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt"> </td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; COLOR: black" colspan="2">Level 1</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; COLOR: black" colspan="2">Level 2</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; COLOR: black" colspan="2">Level 3</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; COLOR: black" colspan="2">Balance</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> Liabilities</td> <td style="FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt" colspan="2">  </td> <td style="FONT-SIZE: 10pt"> </td> <td style="FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt" colspan="2">  </td> <td style="FONT-SIZE: 10pt"> </td> <td style="FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt" colspan="2">  </td> <td style="FONT-SIZE: 10pt"> </td> <td style="FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt" colspan="2">  </td> <td style="FONT-SIZE: 10pt"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; WIDTH: 44%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> Derivatives instruments</td> <td style="WIDTH: 2%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> $</td> <td style="TEXT-ALIGN: right; WIDTH: 10%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> -</td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="WIDTH: 2%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> $</td> <td style="TEXT-ALIGN: right; WIDTH: 10%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> -</td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="WIDTH: 2%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> $</td> <td style="TEXT-ALIGN: right; WIDTH: 10%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> 1,295,613</td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="WIDTH: 2%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> $</td> <td style="TEXT-ALIGN: right; WIDTH: 10%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> 1,295,613</td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> </tr> </table> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The following table sets forth a summary of changes in the fair value of the Company's Level 3 liabilities for the three months ended March 31, 2013:</p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> Description</td> <td style="FONT: 10pt Times New Roman, Times, Serif"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif" colspan="2">Balance as of<br /> December 31,<br /> 2012</td> <td style="FONT: 10pt Times New Roman, Times, Serif"> </td> <td style="FONT: 10pt Times New Roman, Times, Serif"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif" colspan="2">Unrealized Losses</td> <td style="FONT: 10pt Times New Roman, Times, Serif"> </td> <td style="FONT: 10pt Times New Roman, Times, Serif"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif" colspan="2">Balance as of<br /> March 31,<br /> 2013</td> <td style="FONT: 10pt Times New Roman, Times, Serif"> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="WIDTH: 58%; FONT-SIZE: 10pt"> </td> <td style="WIDTH: 2%; FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">  </td> <td style="TEXT-ALIGN: right; WIDTH: 10%; FONT-SIZE: 10pt">  </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">  </td> <td style="WIDTH: 2%; FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">  </td> <td style="TEXT-ALIGN: right; WIDTH: 10%; FONT-SIZE: 10pt">  </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">  </td> <td style="WIDTH: 2%; FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">  </td> <td style="TEXT-ALIGN: right; WIDTH: 10%; FONT-SIZE: 10pt">  </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">  </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> Derivative liabilities related to stock purchase warrants</td> <td style="FONT: 10pt Times New Roman, Times, Serif"> </td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> $</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 1,295,613</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif">  </td> <td style="FONT: 10pt Times New Roman, Times, Serif"> </td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> $</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 905,777</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif">  </td> <td style="FONT: 10pt Times New Roman, Times, Serif"> </td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> $</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 2,201,390</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif">  </td> </tr> </table> <p style="TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The following table sets forth a summary of changes in the fair value of the Company's Level 3 liabilities for the three months ended March 31, 2012:</p> <p style="TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT: 10pt Times New Roman, Times, Serif"> Description</td> <td style="FONT: 10pt Times New Roman, Times, Serif"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif" colspan="2">Balance as of<br /> December 31,<br /> 2011</td> <td style="FONT: 10pt Times New Roman, Times, Serif"> </td> <td style="FONT: 10pt Times New Roman, Times, Serif"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif" colspan="2">Unrealized Losses</td> <td style="FONT: 10pt Times New Roman, Times, Serif"> </td> <td style="FONT: 10pt Times New Roman, Times, Serif"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif" colspan="2">Balance as of<br /> March 31,<br /> 2012</td> <td style="FONT: 10pt Times New Roman, Times, Serif"> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="WIDTH: 58%; FONT-SIZE: 10pt"> </td> <td style="WIDTH: 2%; FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">  </td> <td style="TEXT-ALIGN: right; WIDTH: 10%; FONT-SIZE: 10pt">  </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">  </td> <td style="WIDTH: 2%; FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">  </td> <td style="TEXT-ALIGN: right; WIDTH: 10%; FONT-SIZE: 10pt">  </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">  </td> <td style="WIDTH: 2%; FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">  </td> <td style="TEXT-ALIGN: right; WIDTH: 10%; FONT-SIZE: 10pt">  </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">  </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> Derivative liabilities related to stock purchase warrants</td> <td style="FONT: 10pt Times New Roman, Times, Serif"> </td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> $</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 1,886,652</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif">  </td> <td style="FONT: 10pt Times New Roman, Times, Serif"> </td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> $</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 991,662</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif">  </td> <td style="FONT: 10pt Times New Roman, Times, Serif"> </td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> $</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 2,878,314</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif">  </td> </tr> </table> <p style="TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> At March 31, 2013 and 2012, derivative liabilities are comprised of warrants to purchase 2,899,991 shares of common stock. The warrants are considered to be derivative liabilities due to the presence of net settlement features and, as a result, are recorded at fair value at each balance sheet date, with changes in fair value recorded in the unaudited condensed consolidated statements of operations. The fair value of our warrants is determined based on the Black-Scholes option pricing model. Use of the Black-Scholes option pricing model requires the use of unobservable inputs such as the expected term, anticipated volatility and expected dividends.</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; COLOR: black" colspan="7">Quantitative Information about Level 3 Fair Value Measurements</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif; COLOR: black" colspan="2">Fair Value at 3/31/2013</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="BORDER-BOTTOM: black 1pt solid; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> Valuation Technique</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="BORDER-BOTTOM: black 1pt solid; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> Unobservable Inputs</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> $</td> <td style="TEXT-ALIGN: right; WIDTH: 20%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> 2,201,390</td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="WIDTH: 2%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="TEXT-ALIGN: left; WIDTH: 42%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> Black-Scholes option pricing model</td> <td style="WIDTH: 2%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="TEXT-ALIGN: left; WIDTH: 32%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> Expected term</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> </td> <td style="FONT-SIZE: 10pt"> </td> <td style="FONT-SIZE: 10pt"> </td> <td style="FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> Expected dividends</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> </td> <td style="FONT-SIZE: 10pt"> </td> <td style="FONT-SIZE: 10pt"> </td> <td style="FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> Anticipated volatility</td> </tr> </table> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Changes in any of the assumptions related to the unobservable inputs identified above may change the stock purchase warrants' fair value; increases in expected term, anticipated volatility and expected dividends generally result in increases in fair value, while decreases in the unobservable inputs generally result in decreases in fair value. Gains and losses on the fair value adjustments for these derivative instruments are classified in other expenses as the change in fair value of derivative instruments in our unaudited condensed consolidated statements of operations. The $0.9 million change in the market value of derivative instruments during the three-month period ended March 31, 2013 is due primarily to the change in the closing price of PharmAthene stock, which was $1.12 per share as of December 31, 2012 and $1.70 per share as of March 28, 2013. The $1.0 million change in the market value of derivative instruments during the three-month period ended March 31, 2012 is due primarily to the change in the closing price of PharmAthene stock, which was $1.27 per share as of December 30, 2011 and $1.77 per share as of March 30, 2012.</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <em>Assets Measured at Fair Value on a Nonrecurring Basis</em></p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The Company measures its long-lived assets, including, property and equipment and goodwill, at fair value on a nonrecurring basis. These assets are recognized at fair value when they are deemed to be other-than-temporarily impaired. (see Note 2). As of March 31, 2013, the Company had no other assets or liabilities that were measured at fair value on a nonrecurring basis.</p> </div> </div>

<div> <div> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; COLOR: black" colspan="7">Quantitative Information about Level 3 Fair Value Measurements</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif; COLOR: black" colspan="2">Fair Value at 3/31/2013</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="BORDER-BOTTOM: black 1pt solid; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> Valuation Technique</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="BORDER-BOTTOM: black 1pt solid; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> Unobservable Inputs</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> $</td> <td style="TEXT-ALIGN: right; WIDTH: 20%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> 2,201,390</td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="WIDTH: 2%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="TEXT-ALIGN: left; WIDTH: 42%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> Black-Scholes option pricing model</td> <td style="WIDTH: 2%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="TEXT-ALIGN: left; WIDTH: 32%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> Expected term</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> </td> <td style="FONT-SIZE: 10pt"> </td> <td style="FONT-SIZE: 10pt"> </td> <td style="FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> Expected dividends</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: left; FONT-SIZE: 10pt"> </td> <td style="FONT-SIZE: 10pt"> </td> <td style="FONT-SIZE: 10pt"> </td> <td style="FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> Anticipated volatility</td> </tr> </table> </div> </div>

<div> <div> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The following table sets forth a summary of changes in the fair value of our Level 3 liabilities for the three months ended March 31, 2013:</p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif"> Description</td> <td style="FONT: 10pt Times New Roman, Times, Serif"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif" colspan="2">Balance as of<br /> December 31,<br /> 2012</td> <td style="FONT: 10pt Times New Roman, Times, Serif"> </td> <td style="FONT: 10pt Times New Roman, Times, Serif"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif" colspan="2">Unrealized Losses</td> <td style="FONT: 10pt Times New Roman, Times, Serif"> </td> <td style="FONT: 10pt Times New Roman, Times, Serif"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif" colspan="2">Balance as of<br /> March 31,<br /> 2013</td> <td style="FONT: 10pt Times New Roman, Times, Serif"> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="WIDTH: 58%; FONT-SIZE: 10pt"> </td> <td style="WIDTH: 2%; FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">  </td> <td style="TEXT-ALIGN: right; WIDTH: 10%; FONT-SIZE: 10pt">  </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">  </td> <td style="WIDTH: 2%; FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">  </td> <td style="TEXT-ALIGN: right; WIDTH: 10%; FONT-SIZE: 10pt">  </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">  </td> <td style="WIDTH: 2%; FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">  </td> <td style="TEXT-ALIGN: right; WIDTH: 10%; FONT-SIZE: 10pt">  </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">  </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> Derivative liabilities related to stock purchase warrants</td> <td style="FONT: 10pt Times New Roman, Times, Serif"> </td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> $</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 1,295,613</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif">  </td> <td style="FONT: 10pt Times New Roman, Times, Serif"> </td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> $</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 905,777</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif">  </td> <td style="FONT: 10pt Times New Roman, Times, Serif"> </td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> $</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 2,201,390</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif">  </td> </tr> </table> <p style="TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The following table sets forth a summary of changes in the fair value of the Company's Level 3 liabilities for the three months ended March 31, 2012:</p> <p style="TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT: 10pt Times New Roman, Times, Serif"> Description</td> <td style="FONT: 10pt Times New Roman, Times, Serif"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif" colspan="2">Balance as of<br /> December 31,<br /> 2011</td> <td style="FONT: 10pt Times New Roman, Times, Serif"> </td> <td style="FONT: 10pt Times New Roman, Times, Serif"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif" colspan="2">Unrealized Losses</td> <td style="FONT: 10pt Times New Roman, Times, Serif"> </td> <td style="FONT: 10pt Times New Roman, Times, Serif"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif" colspan="2">Balance as of<br /> March 31,<br /> 2012</td> <td style="FONT: 10pt Times New Roman, Times, Serif"> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="WIDTH: 58%; FONT-SIZE: 10pt"> </td> <td style="WIDTH: 2%; FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">  </td> <td style="TEXT-ALIGN: right; WIDTH: 10%; FONT-SIZE: 10pt">  </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">  </td> <td style="WIDTH: 2%; FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">  </td> <td style="TEXT-ALIGN: right; WIDTH: 10%; FONT-SIZE: 10pt">  </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">  </td> <td style="WIDTH: 2%; FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">  </td> <td style="TEXT-ALIGN: right; WIDTH: 10%; FONT-SIZE: 10pt">  </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT-SIZE: 10pt">  </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> Derivative liabilities related to stock purchase warrants</td> <td style="FONT: 10pt Times New Roman, Times, Serif"> </td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> $</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 1,886,652</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif">  </td> <td style="FONT: 10pt Times New Roman, Times, Serif"> </td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> $</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 991,662</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif">  </td> <td style="FONT: 10pt Times New Roman, Times, Serif"> </td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> $</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 2,878,314</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif">  </td> </tr> </table> </div> </div>

66626

2279795

2948481

2348453

<div> <div> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <em>Goodwill</em></p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Goodwill represents the excess of purchase price over the fair value of net identifiable assets associated with acquisitions. We review the recoverability of goodwill annually as of December 31<sup>st</sup> by comparing our market value (as measured by our stock price multiplied by the number of outstanding shares as of the end of the year) to the net book value of our equity. If our market value exceeds our net book value, no further analysis is required. Changes in our business strategy or adverse changes in market conditions could impact the impairment analyses and require the recognition of an impairment charge equal to the excess of the carrying value over its estimated fair value. We completed our last annual impairment assessment of goodwill as of December 31, 2012 and determined that there was no impairment as of that date.</p> </div> </div>

-2101642

-2529483

9743

150405

<div> <div> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <em>Income Taxes</em></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> We account for income taxes using the asset and liability approach, which requires the recognition of future tax benefits or liabilities on the temporary differences between the financial reporting and tax bases of our assets and liabilities. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized. We also recognize a tax benefit from uncertain tax positions only if it is "more likely than not" that the position is sustainable based on its technical merits. Our policy is to recognize interest and penalties on uncertain tax positions as a component of income tax expense.</p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Income tax expense was $9,743 and $150,405 during the three months ended March 31, 2013 and 2012, respectively. Income tax expense is a result of the difference between the treatment of goodwill for income tax purposes and for U.S. GAAP, resulting in a deferred tax liability, which cannot offset deferred tax assets. This deferred tax liability is included in our condensed consolidated balance sheet in other long-term liabilities.</p> </div> </div>

-407653

-35280

-566725

-3278062

950800

131338

-507351

-495372

-39486

-137362

-400645

1254867

99791

3028

67360

3028

783

2988

12029620

11067564

21972385

22741404

7787575

7488416

2300000

1300000

5000000

999996

749997

750007

999996

1460417

1704108

-60361

3204614

-25468

67400

260401

791370

-2111385

-2679888

-1010908

-938787

7565872

7739748

-1090734

-1590696

99578

113130

-1684

13369

-2113069

-2666519

580238

579427

-6123

52915

32431

220234

112500

25468

614388

547245

53413

1630000

-32960

-1274

857808

100000

67400

456842

483976

5233475

4705357

-200720957

-198609572

<div> <div> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <em>Revenue Recognition</em></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> We generate our revenue from different types of contractual arrangements: cost-plus-fee contracts, cost reimbursable grants and fixed price contracts.</p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Revenues on cost-plus-fee contracts are recognized in an amount equal to the costs incurred during the period plus an estimate of the applicable fee earned. The estimate of the applicable fee earned is determined by reference to the contract: if the contract defines the fee in terms of risk-based milestones and specifies the fees to be earned upon the completion of each milestone, then the fee is recognized when the related milestones are earned, as further described below; otherwise, we estimate the fee earned in a given period by using a proportional performance method based on costs incurred during the period as compared to total estimated project costs and application of the resulting fraction to the total project fee specified in the contract.</p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Under the milestone method of revenue recognition, milestone payments (including milestone payments for fees) contained in research and development arrangements are recognized as revenue when: (i) the milestones are achieved; (ii) no further performance obligations with respect to the milestone exist; (iii) collection is reasonably assured; and (iv) substantive effort was necessary to achieve the milestone.</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Milestones are considered substantive if all of the following conditions are met:</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0"> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"> </td> <td style="FONT-FAMILY: Symbol; TEXT-ALIGN: left; WIDTH: 0.25in"> ·</td> <td style="FONT-FAMILY: Times New Roman, Times, Serif; TEXT-ALIGN: justify"> it is commensurate with either our performance to meet the milestone or the enhancement of the value of the delivered item or items as a result of a specific outcome resulting from our performance to achieve the milestone,</td> </tr> </table> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0"> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"> </td> <td style="FONT-FAMILY: Symbol; TEXT-ALIGN: left; WIDTH: 0.25in"> ·</td> <td style="FONT-FAMILY: Times New Roman, Times, Serif; TEXT-ALIGN: justify"> it relates solely to past performance,</td> </tr> </table> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0"> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"> </td> <td style="FONT-FAMILY: Symbol; TEXT-ALIGN: left; WIDTH: 0.25in"> ·</td> <td style="FONT-FAMILY: Times New Roman, Times, Serif; TEXT-ALIGN: justify"> the value of the milestone is reasonable relative to all the deliverables and payment terms (including other potential milestone consideration) within the arrangement.</td> </tr> </table> <p style="TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> If a milestone is deemed not to be substantive, the Company recognizes the portion of the milestone payment as revenue that correlates to work already performed; the remaining portion of the milestone payment is deferred and recognized as revenue as the Company completes its performance obligations.</p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Revenue on fixed price contracts (without substantive milestones as described above) is recognized on the percentage-of-completion method. The percentage-of-completion method recognizes income as the contract progresses (generally related to the costs incurred in providing the services required under the contract). The use of the percentage-of-completion method depends on the ability to make reasonable dependable estimates and the fact that circumstances may necessitate frequent revision of estimates does not indicate that the estimates are unreliable for the purpose for which they are used.</p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> As a result of our revenue recognition policies and the billing provisions contained in our contracts, the timing of customer billings may differ from the timing of recognizing revenue. Amounts invoiced to customers in excess of revenue recognized are reflected on the balance sheet as deferred revenue. Amounts recognized as revenue in excess of amounts billed to customers are reflected on the balance sheet as unbilled accounts receivable.</p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> We analyze each cost reimbursable grant to determine whether we should report such reimbursements as revenue or as an offset to our expenses incurred. For the three months ended March 31, 2013 and 2012, we recorded approximately $0.02 million and $0.5 million, respectively, of costs reimbursed by the government as an offset to research and development expenses.</p> </div> </div>

<div> <div> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The term loan, net of discount of $39,587, is recorded on the 2013 condensed consolidated balance sheet, net of debt discount, as follows:</p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <table style="WIDTH: 54%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; WIDTH: 40%; FONT: 10pt Times New Roman, Times, Serif"> Current portion of long-term debt</td> <td style="WIDTH: 2%; FONT: 10pt Times New Roman, Times, Serif">  </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT: 10pt Times New Roman, Times, Serif"> $</td> <td style="TEXT-ALIGN: right; WIDTH: 10%; FONT: 10pt Times New Roman, Times, Serif"> 999,996</td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT: 10pt Times New Roman, Times, Serif">  </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> Long-term debt, less current portion</td> <td style="FONT: 10pt Times New Roman, Times, Serif"> </td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> $</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 1,460,417</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif">  </td> </tr> </table> </div> </div>

<div> <div> <p style="TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Share-based compensation expense for the three months ended March 31, 2013 and 2012 was:</p> <p style="TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt"> </td> <td style="FONT: 10pt Times New Roman, Times, Serif"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif" colspan="6">Three months ended March 31,</td> <td style="FONT: 10pt Times New Roman, Times, Serif"> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt"> </td> <td style="FONT: 10pt Times New Roman, Times, Serif"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif" colspan="2">2013</td> <td style="FONT: 10pt Times New Roman, Times, Serif"> </td> <td style="FONT: 10pt Times New Roman, Times, Serif"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif" colspan="2">2012</td> <td style="FONT: 10pt Times New Roman, Times, Serif"> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt"> </td> <td style="FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt" colspan="2">  </td> <td style="FONT-SIZE: 10pt"> </td> <td style="FONT-SIZE: 10pt"> </td> <td style="FONT-SIZE: 10pt" colspan="2"> </td> <td style="FONT-SIZE: 10pt"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; WIDTH: 72%; FONT: 10pt Times New Roman, Times, Serif"> Research and development</td> <td style="WIDTH: 2%; FONT: 10pt Times New Roman, Times, Serif">  </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT: 10pt Times New Roman, Times, Serif"> $</td> <td style="TEXT-ALIGN: right; WIDTH: 10%; FONT: 10pt Times New Roman, Times, Serif"> 88,634</td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT: 10pt Times New Roman, Times, Serif">  </td> <td style="WIDTH: 2%; FONT: 10pt Times New Roman, Times, Serif">  </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT: 10pt Times New Roman, Times, Serif"> $</td> <td style="TEXT-ALIGN: right; WIDTH: 10%; FONT: 10pt Times New Roman, Times, Serif"> 117,067</td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT: 10pt Times New Roman, Times, Serif">  </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> General and administrative</td> <td style="FONT: 10pt Times New Roman, Times, Serif"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 239,947</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif">  </td> <td style="FONT: 10pt Times New Roman, Times, Serif"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 431,597</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif">  </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> Total share-based compensation expense</td> <td style="FONT: 10pt Times New Roman, Times, Serif"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 328,581</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif">  </td> <td style="FONT: 10pt Times New Roman, Times, Serif"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 548,664</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif">  </td> </tr> </table> </div> </div>

<div> <div> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The following table represents the Company's fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis:</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt"> </td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; COLOR: black" colspan="14">As of March 31, 2013</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt"> </td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; COLOR: black" colspan="2">Level 1</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; COLOR: black" colspan="2">Level 2</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; COLOR: black" colspan="2">Level 3</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; COLOR: black" colspan="2">Balance</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> Liabilities</td> <td style="FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt" colspan="2">  </td> <td style="FONT-SIZE: 10pt"> </td> <td style="FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt" colspan="2">  </td> <td style="FONT-SIZE: 10pt"> </td> <td style="FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt" colspan="2">  </td> <td style="FONT-SIZE: 10pt"> </td> <td style="FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt" colspan="2">  </td> <td style="FONT-SIZE: 10pt"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; WIDTH: 44%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> Derivatives instruments</td> <td style="WIDTH: 2%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> $</td> <td style="TEXT-ALIGN: right; WIDTH: 10%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> -</td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="WIDTH: 2%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> $</td> <td style="TEXT-ALIGN: right; WIDTH: 10%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> -</td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="WIDTH: 2%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> $</td> <td style="TEXT-ALIGN: right; WIDTH: 10%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> 2,201,390</td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="WIDTH: 2%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> $</td> <td style="TEXT-ALIGN: right; WIDTH: 10%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> 2,201,390</td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> </tr> </table> <p style="TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt"> </td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; COLOR: black" colspan="14">As of December 31, 2012</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt"> </td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; COLOR: black" colspan="2">Level 1</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; COLOR: black" colspan="2">Level 2</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; COLOR: black" colspan="2">Level 3</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; COLOR: black" colspan="2">Balance</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> Liabilities</td> <td style="FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt" colspan="2">  </td> <td style="FONT-SIZE: 10pt"> </td> <td style="FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt" colspan="2">  </td> <td style="FONT-SIZE: 10pt"> </td> <td style="FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt" colspan="2">  </td> <td style="FONT-SIZE: 10pt"> </td> <td style="FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt" colspan="2">  </td> <td style="FONT-SIZE: 10pt"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; WIDTH: 44%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> Derivatives instruments</td> <td style="WIDTH: 2%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> $</td> <td style="TEXT-ALIGN: right; WIDTH: 10%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> -</td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="WIDTH: 2%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> $</td> <td style="TEXT-ALIGN: right; WIDTH: 10%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> -</td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="WIDTH: 2%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> $</td> <td style="TEXT-ALIGN: right; WIDTH: 10%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> 1,295,613</td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="WIDTH: 2%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> $</td> <td style="TEXT-ALIGN: right; WIDTH: 10%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> 1,295,613</td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> </tr> </table> </div> </div>

<div> <div> <table style="WIDTH: 35%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; COLOR: black" colspan="2">Year</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> Principal<br /> Payments</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="WIDTH: 1%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="TEXT-ALIGN: center; WIDTH: 15%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> 2013</td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="WIDTH: 2%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="TEXT-ALIGN: right; WIDTH: 15%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> $749,997</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> 2014</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> 999,996</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="TEXT-ALIGN: center; PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> 2015</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> 750,007</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt">  </td> <td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt">  </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt">  </td> <td style="PADDING-BOTTOM: 2.5pt; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> $2,500,000</td> </tr> </table> </div> </div>

<div> <div> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> At March 31, 2013 and 2012 there were warrants outstanding to purchase 5,620,128 shares of our common stock, respectively. The warrants outstanding as of March 31, 2013 and 2012 were as follows:</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; COLOR: black" colspan="2">Number of Common Shares Underlying Warrants</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> Issue Date/Exercisable Date</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; COLOR: black" colspan="2">Exercise Price</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> Expiration Date</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="TEXT-ALIGN: right; WIDTH: 22%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> 100,778</td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> (1)</td> <td style="WIDTH: 2%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="TEXT-ALIGN: center; WIDTH: 24%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> Mar-07 / Mar-07</td> <td style="WIDTH: 2%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> $</td> <td style="TEXT-ALIGN: right; WIDTH: 21%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> 3.97</td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="WIDTH: 2%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="TEXT-ALIGN: right; WIDTH: 23%; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> Mar-17</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> 705,354</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> (2)</td> <td style="FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> Mar-09 / Sep-09</td> <td style="FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> $</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> 3.00</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> Sep-14</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> 2,572,775</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> (1)</td> <td style="FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> Jul-09 / Jan-10</td> <td style="FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> $</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> 2.50</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> Jan-15</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> 500,000</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> (2)</td> <td style="FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> Apr-10 / Oct-10</td> <td style="FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> $</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> 1.89</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> Oct-15</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> 1,323,214</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> (2)</td> <td style="FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> Jul-10 / Jan-11</td> <td style="FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> $</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> 1.63</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> Jan-17</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> 371,423</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> (2)</td> <td style="FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> Jun-11 / Jun-11</td> <td style="FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> $</td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> 3.50</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> Jun-16</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> 46,584</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> (1)</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="TEXT-ALIGN: center; PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> Mar-12 / Mar-12</td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> $</td> <td style="TEXT-ALIGN: right; PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> 1.61</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="TEXT-ALIGN: right; PADDING-BOTTOM: 1pt; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> Mar-22</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif; COLOR: black"> 5,620,128</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; FONT: 10pt Times New Roman, Times, Serif; COLOR: black">  </td> <td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"> </td> <td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"> </td> <td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt">  </td> <td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt">  </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt">  </td> <td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"> </td> <td style="PADDING-BOTTOM: 2.5pt; FONT-SIZE: 10pt"> </td> </tr> </table> <p style="TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 3%"> </td> <td style="COLOR: black; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 5%"> (1)</td> <td style="COLOR: black; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 92%"> These warrants to purchase common stock are classified as equity.</td> </tr> </table> <p style="TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 3%"> </td> <td style="COLOR: black; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 5%"> (2)</td> <td style="COLOR: black; FONT: 10pt Times New Roman, Times, Serif; WIDTH: 92%"> These warrants to purchase common stock are classified as derivative liabilities. The fair value of these liabilities (see note 3) is remeasured at the end of every reporting period and the change in fair value is reported in the unaudited condensed consolidated statements of operations as other income (expense).</td> </tr> </table> </div> </div>

328581

548664

9300000

2600000

60000

15948

<div> <div> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <em>Share-Based Compensation</em></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> We expense the estimated fair value of share-based awards granted to employees under our stock compensation plans. The fair value of stock options is determined at the grant date using an option pricing model. We have estimated the fair value of each stock option award using the Black-Scholes option pricing model. The Black-Scholes model considers, among other factors, the expected life of the award and the expected volatility of our stock price. The value of the award that is ultimately expected to vest is recognized as expense on a straight line basis over the employee's requisite service period.</p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The fair value of restricted stock grants is determined based on the closing price of our common stock on the award date and is recognized as expense ratably over the requisite service period.</p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Employee share-based compensation expense recognized in the three months ended March 31, 2013 and 2012 was calculated based on awards ultimately expected to vest and has been reduced for estimated forfeitures at a rate of approximately 12%, based on historical forfeitures.</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Share-based compensation expense for the three months ended March 31, 2013 and 2012 was:</p> <p style="TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt"> </td> <td style="FONT: 10pt Times New Roman, Times, Serif"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif" colspan="6">Three months ended March 31,</td> <td style="FONT: 10pt Times New Roman, Times, Serif"> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt"> </td> <td style="FONT: 10pt Times New Roman, Times, Serif"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif" colspan="2">2013</td> <td style="FONT: 10pt Times New Roman, Times, Serif"> </td> <td style="FONT: 10pt Times New Roman, Times, Serif"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif" colspan="2">2012</td> <td style="FONT: 10pt Times New Roman, Times, Serif"> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt"> </td> <td style="FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt" colspan="2">  </td> <td style="FONT-SIZE: 10pt"> </td> <td style="FONT-SIZE: 10pt"> </td> <td style="FONT-SIZE: 10pt" colspan="2"> </td> <td style="FONT-SIZE: 10pt"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; WIDTH: 72%; FONT: 10pt Times New Roman, Times, Serif"> Research and development</td> <td style="WIDTH: 2%; FONT: 10pt Times New Roman, Times, Serif">  </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT: 10pt Times New Roman, Times, Serif"> $</td> <td style="TEXT-ALIGN: right; WIDTH: 10%; FONT: 10pt Times New Roman, Times, Serif"> 88,634</td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT: 10pt Times New Roman, Times, Serif">  </td> <td style="WIDTH: 2%; FONT: 10pt Times New Roman, Times, Serif">  </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT: 10pt Times New Roman, Times, Serif"> $</td> <td style="TEXT-ALIGN: right; WIDTH: 10%; FONT: 10pt Times New Roman, Times, Serif"> 117,067</td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT: 10pt Times New Roman, Times, Serif">  </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> General and administrative</td> <td style="FONT: 10pt Times New Roman, Times, Serif"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 239,947</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif">  </td> <td style="FONT: 10pt Times New Roman, Times, Serif"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 431,597</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif">  </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> Total share-based compensation expense</td> <td style="FONT: 10pt Times New Roman, Times, Serif"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 328,581</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif">  </td> <td style="FONT: 10pt Times New Roman, Times, Serif"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 548,664</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif">  </td> </tr> </table> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> During the three months ended March 31, 2013, we granted 60,000 options to employees and consultants and made no restricted stock grants. During the three months ended March 31, 2012, we granted 15,948 options to employees and made no restricted stock grants. At March 31, 2013, we had total unrecognized share-based compensation expense related to unvested awards of approximately $2.0 million net of estimated forfeitures, which we expect to recognize as expense over a weighted-average period of 2.25 years.</p> </div> </div>

1.12

1.77

1.70

1.27

1329233

1330507

<div> <div> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong>Note 2 - Summary of Significant Accounting Policies</strong></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <em>Basis of Presentation</em></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Our unaudited condensed consolidated financial statements include the accounts of PharmAthene, Inc. and its wholly-owned subsidiaries. All significant intercompany transactions and balances have been eliminated in consolidation. Our unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States ("U.S. GAAP"). In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to present fairly our financial position, results of operations and cash flows. The unaudited condensed consolidated balance sheet at December 31, 2012 has been derived from audited consolidated financial statements at that date. The interim results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and footnote disclosure normally included in the financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to instructions, rules and regulations prescribed by the U.S. Securities and Exchange Commission. We believe that the disclosures provided herein are adequate to make the information presented not misleading when these unaudited condensed consolidated financial statements are read in conjunction with the Consolidated Financial Statements and Notes included in our Annual Report on Form 10-K for the year ended December 31, 2012, filed with the Securities and Exchange Commission. We currently operate in one business segment.</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <em>Use of Estimates</em></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Our unaudited condensed consolidated financial statements include significant estimates for the expected economic life and value of our intangible assets, the amount of our net operating losses, our share-based compensation, the value of our financial instruments, among other things. Because of the use of estimates inherent in the financial reporting process, actual results could differ significantly from those estimates<font style="FONT: 10pt Times New Roman, Times, Serif">.</font></p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <em>Foreign Currency Translation</em></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The functional currency of our wholly owned foreign subsidiaries is their local currency. Assets and liabilities of our foreign subsidiaries are translated into United States dollars based on exchange rates at the end of the reporting period. Income and expense items are translated at the weighted average exchange rates prevailing during the reporting period. <font style="COLOR: black">Translation adjustments for subsidiaries that have not been sold, substantially liquidated or otherwise disposed of, are accumulated in other comprehensive income (loss), a component of stockholders' equity.</font> Foreign currency translation adjustments are the sole component of accumulated other comprehensive loss at March 31, 2013 and December 31, 2012. <font style="COLOR: black">Transaction gains or losses are included in the determination of net loss.</font></p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <em>Comprehensive Loss and Accumulated Other Comprehensive Income</em></p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Comprehensive loss includes the total of our net loss and all other changes in equity other than transactions with owners, including (i) changes in equity for cumulative translation adjustments resulting from the consolidation of foreign subsidiaries as the financial statements of the subsidiaries located outside of the United States are accounted for using the local currency as the functional currency, and (ii) unrealized gains and losses on short term available-for-sale investments.</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <em>Cash and Cash Equivalents</em></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Cash and cash equivalents are stated at market value. We consider all highly liquid investments with original maturities of three months or less to be cash equivalents.</p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <em>Revolving Line of Credit and Term Loan</em></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> As discussed further in Note 6, we entered into a loan agreement with General Electric Capital Corporation ("GE Capital") in March 2012. As part of that agreement, we issued stock purchase warrants to GE Capital that expire in March 2022. The fair value of the warrants was charged to additional paid-in-capital, resulting in a debt discount to the Term Loan at the date of issuance. The debt discount and the financing costs, incurred in connections with the agreement, are being amortized over the term of the loan using the effective interest method. The amortization of both the debt discount and deferred financing costs are included in interest expense in the unaudited condensed consolidated statements of operations.</p> <p style="TEXT-INDENT: 9pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <em>Significant Customers and Accounts Receivable</em></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Our primary customers are the U.S. Department of Defense (the "DoD") - Chemical Biological Medical Systems ("CBMS"), and the Biomedical Advanced Research and Development Authority ("BARDA"). As of March 31, 2013 and December 31, 2012, the Company's trade receivable and unbilled receivable balances were comprised solely of receivables from CBMS and BARDA.</p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <em>Goodwill</em></p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Goodwill represents the excess of purchase price over the fair value of net identifiable assets associated with acquisitions. We review the recoverability of goodwill annually as of December 31<sup>st</sup> by comparing our market value (as measured by our stock price multiplied by the number of outstanding shares as of the end of the year) to the net book value of our equity. If our market value exceeds our net book value, no further analysis is required. Changes in our business strategy or adverse changes in market conditions could impact the impairment analyses and require the recognition of an impairment charge equal to the excess of the carrying value over its estimated fair value. We completed our last annual impairment assessment of goodwill as of December 31, 2012 and determined that there was no impairment as of that date.</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <em>Revenue Recognition</em></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> We generate our revenue from different types of contractual arrangements: cost-plus-fee contracts, cost reimbursable grants and fixed price contracts.</p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Revenues on cost-plus-fee contracts are recognized in an amount equal to the costs incurred during the period plus an estimate of the applicable fee earned. The estimate of the applicable fee earned is determined by reference to the contract: if the contract defines the fee in terms of risk-based milestones and specifies the fees to be earned upon the completion of each milestone, then the fee is recognized when the related milestones are earned, as further described below; otherwise, we estimate the fee earned in a given period by using a proportional performance method based on costs incurred during the period as compared to total estimated project costs and application of the resulting fraction to the total project fee specified in the contract.</p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Under the milestone method of revenue recognition, milestone payments (including milestone payments for fees) contained in research and development arrangements are recognized as revenue when: (i) the milestones are achieved; (ii) no further performance obligations with respect to the milestone exist; (iii) collection is reasonably assured; and (iv) substantive effort was necessary to achieve the milestone.</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Milestones are considered substantive if all of the following conditions are met:</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0"> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"> </td> <td style="FONT-FAMILY: Symbol; TEXT-ALIGN: left; WIDTH: 0.25in"> ·</td> <td style="FONT-FAMILY: Times New Roman, Times, Serif; TEXT-ALIGN: justify"> it is commensurate with either our performance to meet the milestone or the enhancement of the value of the delivered item or items as a result of a specific outcome resulting from our performance to achieve the milestone,</td> </tr> </table> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0"> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"> </td> <td style="FONT-FAMILY: Symbol; TEXT-ALIGN: left; WIDTH: 0.25in"> ·</td> <td style="FONT-FAMILY: Times New Roman, Times, Serif; TEXT-ALIGN: justify"> it relates solely to past performance,</td> </tr> </table> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0"> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"> </td> <td style="FONT-FAMILY: Symbol; TEXT-ALIGN: left; WIDTH: 0.25in"> ·</td> <td style="FONT-FAMILY: Times New Roman, Times, Serif; TEXT-ALIGN: justify"> the value of the milestone is reasonable relative to all the deliverables and payment terms (including other potential milestone consideration) within the arrangement.</td> </tr> </table> <p style="TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> If a milestone is deemed not to be substantive, the Company recognizes the portion of the milestone payment as revenue that correlates to work already performed; the remaining portion of the milestone payment is deferred and recognized as revenue as the Company completes its performance obligations.</p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Revenue on fixed price contracts (without substantive milestones as described above) is recognized on the percentage-of-completion method. The percentage-of-completion method recognizes income as the contract progresses (generally related to the costs incurred in providing the services required under the contract). The use of the percentage-of-completion method depends on the ability to make reasonable dependable estimates and the fact that circumstances may necessitate frequent revision of estimates does not indicate that the estimates are unreliable for the purpose for which they are used.</p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> As a result of our revenue recognition policies and the billing provisions contained in our contracts, the timing of customer billings may differ from the timing of recognizing revenue. Amounts invoiced to customers in excess of revenue recognized are reflected on the balance sheet as deferred revenue. Amounts recognized as revenue in excess of amounts billed to customers are reflected on the balance sheet as unbilled accounts receivable.</p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> We analyze each cost reimbursable grant to determine whether we should report such reimbursements as revenue or as an offset to our expenses incurred. For the three months ended March 31, 2013 and 2012, we recorded approximately $0.02 million and $0.5 million, respectively, of costs reimbursed by the government as an offset to research and development expenses.</p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <em>Share-Based Compensation</em></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> We expense the estimated fair value of share-based awards granted to employees under our stock compensation plans. The fair value of stock options is determined at the grant date using an option pricing model. We have estimated the fair value of each stock option award using the Black-Scholes option pricing model. The Black-Scholes model considers, among other factors, the expected life of the award and the expected volatility of our stock price. The value of the award that is ultimately expected to vest is recognized as expense on a straight line basis over the employee's requisite service period.</p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The fair value of restricted stock grants is determined based on the closing price of our common stock on the award date and is recognized as expense ratably over the requisite service period.</p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Employee share-based compensation expense recognized in the three months ended March 31, 2013 and 2012 was calculated based on awards ultimately expected to vest and has been reduced for estimated forfeitures at a rate of approximately 12%, based on historical forfeitures.</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Share-based compensation expense for the three months ended March 31, 2013 and 2012 was:</p> <p style="TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt"> </td> <td style="FONT: 10pt Times New Roman, Times, Serif"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif" colspan="6">Three months ended March 31,</td> <td style="FONT: 10pt Times New Roman, Times, Serif"> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt"> </td> <td style="FONT: 10pt Times New Roman, Times, Serif"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif" colspan="2">2013</td> <td style="FONT: 10pt Times New Roman, Times, Serif"> </td> <td style="FONT: 10pt Times New Roman, Times, Serif"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT: 10pt Times New Roman, Times, Serif" colspan="2">2012</td> <td style="FONT: 10pt Times New Roman, Times, Serif"> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="FONT-SIZE: 10pt"> </td> <td style="FONT-SIZE: 10pt"> </td> <td style="TEXT-ALIGN: right; FONT-SIZE: 10pt" colspan="2">  </td> <td style="FONT-SIZE: 10pt"> </td> <td style="FONT-SIZE: 10pt"> </td> <td style="FONT-SIZE: 10pt" colspan="2"> </td> <td style="FONT-SIZE: 10pt"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; WIDTH: 72%; FONT: 10pt Times New Roman, Times, Serif"> Research and development</td> <td style="WIDTH: 2%; FONT: 10pt Times New Roman, Times, Serif">  </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT: 10pt Times New Roman, Times, Serif"> $</td> <td style="TEXT-ALIGN: right; WIDTH: 10%; FONT: 10pt Times New Roman, Times, Serif"> 88,634</td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT: 10pt Times New Roman, Times, Serif">  </td> <td style="WIDTH: 2%; FONT: 10pt Times New Roman, Times, Serif">  </td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT: 10pt Times New Roman, Times, Serif"> $</td> <td style="TEXT-ALIGN: right; WIDTH: 10%; FONT: 10pt Times New Roman, Times, Serif"> 117,067</td> <td style="TEXT-ALIGN: left; WIDTH: 1%; FONT: 10pt Times New Roman, Times, Serif">  </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> General and administrative</td> <td style="FONT: 10pt Times New Roman, Times, Serif"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 239,947</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif">  </td> <td style="FONT: 10pt Times New Roman, Times, Serif"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 431,597</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif">  </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> Total share-based compensation expense</td> <td style="FONT: 10pt Times New Roman, Times, Serif"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 328,581</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif">  </td> <td style="FONT: 10pt Times New Roman, Times, Serif"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; FONT: 10pt Times New Roman, Times, Serif"> 548,664</td> <td style="TEXT-ALIGN: left; FONT: 10pt Times New Roman, Times, Serif">  </td> </tr> </table> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> During the three months ended March 31, 2013, we granted 60,000 options to employees and consultants and made no restricted stock grants. During the three months ended March 31, 2012, we granted 15,948 options to employees and made no restricted stock grants. At March 31, 2013, we had total unrecognized share-based compensation expense related to unvested awards of approximately $2.0 million net of estimated forfeitures, which we expect to recognize as expense over a weighted-average period of 2.25 years.</p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <em>Income Taxes</em></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> We account for income taxes using the asset and liability approach, which requires the recognition of future tax benefits or liabilities on the temporary differences between the financial reporting and tax bases of our assets and liabilities. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized. We also recognize a tax benefit from uncertain tax positions only if it is "more likely than not" that the position is sustainable based on its technical merits. Our policy is to recognize interest and penalties on uncertain tax positions as a component of income tax expense.</p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Income tax expense was $9,743 and $150,405 during the three months ended March 31, 2013 and 2012, respectively. Income tax expense is a result of the difference between the treatment of goodwill for income tax purposes and for U.S. GAAP, resulting in a deferred tax liability, which cannot offset deferred tax assets. This deferred tax liability is included in our condensed consolidated balance sheet in other long-term liabilities.</p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <em>Basic and Diluted Net Loss Per Share</em></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <em>Income (loss) per share:</em> Basic income (loss) per share is computed by dividing consolidated net income (loss) by the weighted average number of common shares outstanding during the period, excluding unvested restricted stock.</p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> For periods of net income when the effects are not anti-dilutive, diluted earnings per share is computed by dividing our net income by the weighted average number of shares outstanding and the impact of all potential dilutive common shares, consisting primarily of stock options, unvested restricted stock and stock purchase warrants. The dilutive impact of our dilutive potential common shares resulting from stock options and stock purchase warrants is determined by applying the treasury stock method.</p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> For the periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all dilutive potential common shares is anti-dilutive due to the net losses. A total of approximately 11.6 million and 11.5 million potential dilutive securities have been excluded in the calculation of diluted net loss per share in the three months ended March 31, 2013 and 2012, respectively, because their inclusion would be anti-dilutive.</p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <em>Recent Accounting Pronouncements</em></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="COLOR: black; FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"> We have evaluated all Accounting Standards Updates through the date the unaudited condensed consolidated financial statements were issued and believe the adoption of these will not have a material impact on our results of operations, financial position, or cash flows.</p> </div> </div>

9942765

11673840

19900

1030870

3713797

4114442

-905777

-991662

-905777

-991662

<div> <div> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <em>Use of Estimates</em></p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Our unaudited condensed consolidated financial statements include significant estimates for the expected economic life and value of our intangible assets, the amount of our net operating losses, our share-based compensation, the value of our financial instruments, among other things. Because of the use of estimates inherent in the financial reporting process, actual results could differ significantly from those estimates<font style="FONT: 10pt Times New Roman, Times, Serif">.</font></p> </div> </div>

48359181

48269894

xbrli:shares iso4217:USD xbrli:pure iso4217:USD pip:warrants iso4217:USD xbrli:shares 0001326190 us-gaap:SubsequentEventMember 2013-04-01 2013-05-08 0001326190 pip:WarrantTrancheSevenMember 2013-01-01 2013-03-31 0001326190 pip:WarrantTrancheSixMember 2013-01-01 2013-03-31 0001326190 pip:WarrantTrancheFiveMember 2013-01-01 2013-03-31 0001326190 pip:WarrantTrancheFourMember 2013-01-01 2013-03-31 0001326190 pip:WarrantTrancheThreeMember 2013-01-01 2013-03-31 0001326190 pip:WarrantTrancheTwoMember 2013-01-01 2013-03-31 0001326190 pip:WarrantTrancheOneMember 2013-01-01 2013-03-31 0001326190 pip:EquityOfferingMember 2013-01-01 2013-03-31 0001326190 pip:StockIncentivePlanTwentyZeroSevenMember 2013-01-01 2013-03-31 0001326190 pip:LiquidityArrangementsMember us-gaap:MaximumMember 2013-01-01 2013-03-31 0001326190 pip:GroupTwoMember 2013-01-01 2013-03-31 0001326190 pip:GroupThreeMember 2013-01-01 2013-03-31 0001326190 pip:GroupOneMember 2013-01-01 2013-03-31 0001326190 pip:GroupFourMember 2013-01-01 2013-03-31 0001326190 us-gaap:ResearchAndDevelopmentExpenseMember 2013-01-01 2013-03-31 0001326190 us-gaap:LoansPayableMember 2013-01-01 2013-03-31 0001326190 us-gaap:LineOfCreditMember 2013-01-01 2013-03-31 0001326190 us-gaap:GeneralAndAdministrativeExpenseMember 2013-01-01 2013-03-31 0001326190 us-gaap:FairValueInputsLevel3Member us-gaap:WarrantMember 2013-01-01 2013-03-31 0001326190 2013-01-01 2013-03-31 0001326190 2012-03-01 2012-03-30 0001326190 us-gaap:ResearchAndDevelopmentExpenseMember 2012-01-01 2012-03-31 0001326190 us-gaap:GeneralAndAdministrativeExpenseMember 2012-01-01 2012-03-31 0001326190 us-gaap:FairValueInputsLevel3Member us-gaap:WarrantMember 2012-01-01 2012-03-31 0001326190 2012-01-01 2012-03-31 0001326190 pip:PharmAtheneMember 2011-09-01 2011-09-30 0001326190 us-gaap:MaximumMember pip:PharmAtheneMember 2011-09-01 2011-09-30 0001326190 2009-07-01 2009-07-31 0001326190 us-gaap:SubsequentEventMember 2013-05-08 0001326190 2013-05-02 0001326190 pip:WarrantTrancheSevenMember 2013-03-31 0001326190 pip:WarrantTrancheSixMember 2013-03-31 0001326190 pip:WarrantTrancheFiveMember 2013-03-31 0001326190 pip:WarrantTrancheFourMember 2013-03-31 0001326190 pip:WarrantTrancheThreeMember 2013-03-31 0001326190 pip:WarrantTrancheTwoMember 2013-03-31 0001326190 pip:WarrantTrancheOneMember 2013-03-31 0001326190 pip:EquityOfferingMember 2013-03-31 0001326190 pip:StockIncentivePlanTwentyZeroSevenMember 2013-03-31 0001326190 pip:GroupTwoMember 2013-03-31 0001326190 pip:GroupOneMember 2013-03-31 0001326190 us-gaap:LoansPayableMember 2013-03-31 0001326190 us-gaap:LineOfCreditMember 2013-03-31 0001326190 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2013-03-31 0001326190 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2013-03-31 0001326190 us-gaap:FairValueInputsLevel3Member pip:DerivativeLiabilitiesMember us-gaap:WarrantMember 2013-03-31 0001326190 us-gaap:FairValueInputsLevel3Member us-gaap:WarrantMember 2013-03-31 0001326190 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2013-03-31 0001326190 us-gaap:FairValueMeasurementsRecurringMember 2013-03-31 0001326190 2013-03-31 0001326190 us-gaap:FairValueInputsLevel3Member pip:DerivativeLiabilitiesMember us-gaap:WarrantMember 2013-03-28 0001326190 pip:EquityOfferingMember 2013-03-25 0001326190 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2012-12-31 0001326190 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2012-12-31 0001326190 us-gaap:FairValueInputsLevel3Member pip:DerivativeLiabilitiesMember us-gaap:WarrantMember 2012-12-31 0001326190 us-gaap:FairValueInputsLevel3Member us-gaap:WarrantMember 2012-12-31 0001326190 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2012-12-31 0001326190 us-gaap:FairValueMeasurementsRecurringMember 2012-12-31 0001326190 2012-12-31 0001326190 us-gaap:FairValueInputsLevel3Member pip:DerivativeLiabilitiesMember us-gaap:WarrantMember 2012-03-31 0001326190 us-gaap:FairValueInputsLevel3Member us-gaap:WarrantMember 2012-03-31 0001326190 2012-03-31 0001326190 us-gaap:LoansPayableMember 2012-03-30 0001326190 us-gaap:LineOfCreditMember 2012-03-30 0001326190 us-gaap:FairValueInputsLevel3Member pip:DerivativeLiabilitiesMember us-gaap:WarrantMember 2012-03-30 0001326190 2012-03-30 0001326190 us-gaap:FairValueInputsLevel3Member us-gaap:WarrantMember 2011-12-31 0001326190 2011-12-31 0001326190 us-gaap:FairValueInputsLevel3Member pip:DerivativeLiabilitiesMember us-gaap:WarrantMember 2011-12-30 0001326190 pip:StockIncentivePlanTwentyZeroSevenMember 2008-12-31 0001326190 pip:StockIncentivePlanTwentyZeroSevenMember 2007-12-31 These warrants to purchase common stock are classified as equity. These warrants to purchase common stock are classified as derivative liabilities. The fair value of these liabilities (see note 3) is remeasured at the end of every reporting period and the change in fair value is reported in the unaudited condensed consolidated statements of operations as other income (expense).

EX-101.SCH 8 pip-20130331.xsd XBRL TAXONOMY EXTENSION SCHEMA 104 - Disclosure - Commitments and Contingencies link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 40401 - Disclosure - Commitments and Contingencies (Details) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 001 - Document - Document and Entity Information link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 106 - Disclosure - Financing Transactions link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 40601 - Disclosure - Financing Transactions (Details) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 306 - Disclosure - Financing Transactions (Tables) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 103 - Disclosure - Fair Value Measurements link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 40303 - Disclosure - Fair Value Measurements (Narrative) (Details) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 40302 - Disclosure - Fair Value Measurements (Summary of Changes in Fair Value of Our Level 3 Liabilities) (Details) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 40301 - Disclosure - Fair Value Measurements (Schedule of Liabilities Measured at Fair Value) (Details) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 303 - Disclosure - Fair Value Measurements (Tables) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 101 - Disclosure - Organization and Business link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 105 - Disclosure - Stockholders' Equity link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 107 - Disclosure - Subsequent Events link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 40701 - Disclosure - Subsequent Events (Details) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 40501 - Disclosure - Stockholders' Equity (Narrative) (Details) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 40502 - Disclosure - Stockholders' Equity (Schedule of Warrants) (Details) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 305 - Disclosure - Stockholders' Equity (Tables) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 102 - Disclosure - Summary of Significant Accounting Policies link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 40201 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 202 - Disclosure - Summary of Significant Accounting Policies (Policy) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 40202 - Disclosure - Summary of Significant Accounting Policies (Schedule of Share-based Compensation Expense) (Details) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 302 - Disclosure - Summary of Significant Accounting Policies (Tables) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 007 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 004 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 006 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OTHER COMPREHENSIVE LOSS link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink 005 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) link:calculationLink link:definitionLink link:presentationLink link:labelLink link:referenceLink EX-101.CAL 9 pip-20130331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 10 pip-20130331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 11 pip-20130331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Amendment Flag Amendment Flag Current Fiscal Year End Date Current Fiscal Year End Date Document Fiscal Period Focus Document Fiscal Period Focus Document Fiscal Year Focus Document Fiscal Year Focus Document Period End Date Document Period End Date Document Type Document Type Entity Central Index Key Entity Central Index Key Entity Common Stock Shares Outstanding Entity Common Stock, Shares Outstanding Entity Filer Category Entity Filer Category Entity Registrant Name Entity Registrant Name Trading Symbol Trading Symbol Document and Entity Information [Abstract] Document and Entity Information [Abstract] Accrued Expenses And Other Current Liabilities Accrued expenses and other liabilities Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Also includes the aggregate carrying amount, as of the balance sheet date, of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered and of liabilities not separately disclosed in the balance sheet. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Accounts Payable Current Accounts payable Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax Accumulated other comprehensive loss Additional Paid In Capital Common Stock Additional paid-in-capital Assets Total assets Assets [Abstract] ASSETS Assets Current Total current assets Assets Current [Abstract] Current assets: Billed Contract Receivables Accounts receivable (billed) Cash And Cash Equivalents At Carrying Value Cash and cash equivalents Common Stock Value Common stock, $0.0001 par value; 100,000,000 shares authorized; 48,416,483 and 48,352,651 shares issued and outstanding at March 31, 2013 and December 31, 2012, respectively Deferred Revenue Deferred revenue Derivative Liabilities Noncurrent Derivative instruments Goodwill Goodwill Liabilities Total liabilities Liabilities And Stockholders Equity Total liabilities and stockholders' equity Liabilities And Stockholders Equity [Abstract] LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities Current Total current liabilities Liabilities Current [Abstract] Current liabilities: Long Term Debt Current Current portion of long-term debt Long Term Debt Noncurrent Long-term debt, less current portion Other Assets Noncurrent Other long-term assets and deferred costs Other Liabilities Noncurrent Other long-term liabilities Prepaid Expense And Other Assets Current Prepaid expenses and other current assets Property Plant And Equipment Net Property and equipment, net Restricted Cash And Cash Equivalents At Carrying Value Restricted cash Retained Earnings Accumulated Deficit Accumulated deficit Short Term Borrowings Short-term debt CONDENSED CONSOLIDATED BALANCE SHEETS [Abstract] Stockholders Equity Total stockholders' equity Stockholders Equity [Abstract] Stockholders' equity: Unbilled Contracts Receivable Unbilled accounts receivable Common Stock Par Or Stated Value Per Share Common stock, par value Common Stock Shares Authorized Common stock, shares authorized Common Stock Shares Issued Common stock, shares issued Common Stock Shares Outstanding Common stock, shares outstanding Current Income Tax Expense (Benefit) Income tax expense Gain (Loss) on Disposition of Assets Gain on the sale of assets held for sale Interest expense Other Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment Realized Upon Sale Or Liquidation Realization of cumulative translation adjustment Income statement impact of the reclassification adjustment for translation gain (loss) realized upon the sale or complete or substantially complete liquidation of an investment in a foreign entity. Contracts Revenue Contract revenue Depreciation and amortization Earnings Per Share Basic And Diluted Basic and diluted net loss per share General And Administrative Expense General and administrative Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments Net loss before income taxes UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract] Interest Expense Investment Income Interest Interest income Net loss Nonoperating Income Expense Total other income (expense) Nonoperating Income Expense [Abstract] Other income (expense): Operating Expenses Total operating expenses Operating Expenses [Abstract] Operating expenses: Operating Income Loss Loss from operations Other Nonoperating Income Expense Other income (expense) Research And Development Expense Research and development Change in fair value of derivative instruments Weighted Average Number Of Share Outstanding Basic And Diluted Weighted average shares used in calculation of basic and diluted net loss per share Other Comprehensive Income (Loss), Net of Tax Comprehensive loss Other Comprehensive Income (Loss), Net of Tax [Abstract] Other comprehensive income (loss): Net Loss Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax Foreign currency translation adjustment UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OTHER COMPREHENSIVE LOSS [Abstract] Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction Deferred financing costs not paid as of March 31st Gain on the disposal of property and equipment Accounts receivable Increase (Decrease) in Deferred Revenue Deferred revenue Prepaid expenses and other current assets Unbilled accounts receivable Net loss Payments of Stock Issuance Costs Controlled equity offering issuance costs Purchase of property and equipment Deferred financing costs Non Cash Financing Activity [Abstract] Noncash financing activities Non Cash Financing Activity [Abstract] Proceeds From Issuance Of Common Stock And Warrants Proceeds from issuance of common stock and warrants Proceeds from the issuance of common stock or common stock and warrants. Proceeds From Issuance Of Long Term Debt And Warrants Proceeds from issuance of long-term debt Proceeds from Issuance of Long Term Debt and Warrants Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Cash and cash equivalents, at beginning of period Cash and cash equivalents, at end of period Cash And Cash Equivalents Period Increase Decrease Increases in cash and cash equivalents Deferred Income Tax Expense Benefit Deferred income tax expenses Depreciation And Amortization Depreciation and amortization expense Effect Of Exchange Rate On Cash And Cash Equivalents Effects of exchange rates on cash Gain Loss On Sale Of Property Plant Equipment Increase Decrease In Accounts Payable Accounts payable Increase Decrease In Accounts Receivable Increase Decrease In Accrued Liabilities And Other Operating Liabilities Accrued expenses and other liabilities Increase Decrease In Operating Capital [Abstract] Changes in operating assets and liabilities: Increase Decrease In Prepaid Deferred Expense And Other Assets Increase Decrease In Unbilled Receivables Interest Paid EX-101.PRE 12 pip-20130331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 R25.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Narrative) (Details) (USD $)	1 Months Ended		3 Months Ended					3 Months Ended
Stockholders' Equity (Narrative) (Details) (USD $)	Mar. 30, 2012	Jul. 31, 2009	Mar. 31, 2013	Mar. 31, 2012	Mar. 31, 2013 2007 Long Term Incentive Plan [Member]	Dec. 31, 2008 2007 Long Term Incentive Plan [Member]	Dec. 31, 2007 2007 Long Term Incentive Plan [Member]	Mar. 31, 2013 Expiration 2015 [Member]	Mar. 31, 2013 Expiration 2017 [Member]
Stockholders Equity [Line Items]
Common stock reserved						4,600,000	3,500,000
Shares approved for issuance					9,300,000
Shares available to be issued					2,600,000
Options award term					10 years
Warrants issued to purchase shares of common stock	46,584		5,620,128	5,620,128				2,572,775	100,778
Warrant exercise price	1.61							2.50	3.97
Warrant expiration date	Mar. 30, 2022	Jan. 28, 2015						Jan. 28, 2015	Mar. 30, 2017
Value of warrants issued to lender in connection with loan				$ 69,876

- Definition

The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).

+ References+ Details

XML 15 R9.htm IDEA: XBRL DOCUMENT

Fair Value Measurements

3 Months Ended

Mar. 31, 2013

Fair Value Measurements [Abstract]

Fair Value Measurements

Note 3 - Fair Value Measurements

Level 1 - Quoted prices in active markets for identical assets or liabilities.

Level 2 - Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.

Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs.

An asset's or liability's level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. At each reporting period, we perform a detailed analysis of our assets and liabilities that are measured at fair value. All assets and liabilities for which the fair value measurement is based on significant unobservable inputs or instruments which trade infrequently and therefore have little or no price transparency are classified as Level 3.

The following table represents the Company's fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis:

	As of March 31, 2013
	Level 1		Level 2		Level 3		Balance
Liabilities
Derivatives instruments	$	-	$	-	$	2,201,390	$	2,201,390

	As of December 31, 2012
	Level 1		Level 2		Level 3		Balance
Liabilities
Derivatives instruments	$	-	$	-	$	1,295,613	$	1,295,613

The following table sets forth a summary of changes in the fair value of the Company's Level 3 liabilities for the three months ended March 31, 2013:

Description	Balance as of December 31, 2012		Unrealized Losses		Balance as of March 31, 2013

Derivative liabilities related to stock purchase warrants	$	1,295,613	$	905,777	$	2,201,390

The following table sets forth a summary of changes in the fair value of the Company's Level 3 liabilities for the three months ended March 31, 2012:

Description	Balance as of December 31, 2011		Unrealized Losses		Balance as of March 31, 2012

Derivative liabilities related to stock purchase warrants	$	1,886,652	$	991,662	$	2,878,314

Changes in any of the assumptions related to the unobservable inputs identified above may change the stock purchase warrants' fair value; increases in expected term, anticipated volatility and expected dividends generally result in increases in fair value, while decreases in the unobservable inputs generally result in decreases in fair value. Gains and losses on the fair value adjustments for these derivative instruments are classified in other expenses as the change in fair value of derivative instruments in our unaudited condensed consolidated statements of operations. The $0.9 million change in the market value of derivative instruments during the three-month period ended March 31, 2013 is due primarily to the change in the closing price of PharmAthene stock, which was $1.12 per share as of December 31, 2012 and $1.70 per share as of March 28, 2013. The $1.0 million change in the market value of derivative instruments during the three-month period ended March 31, 2012 is due primarily to the change in the closing price of PharmAthene stock, which was $1.27 per share as of December 30, 2011 and $1.77 per share as of March 30, 2012.

Assets Measured at Fair Value on a Nonrecurring Basis

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13504-108611

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 15C, 15D

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 133

-Paragraph 44A, 44B

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 15A

-Subparagraph a-d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 3, 10, 14, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13433-108611

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 159

-Paragraph 17-22, 27, 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13537-108611

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 15B

-Subparagraph a, b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 157

-Paragraph 32, 33, 34

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7578670&loc=d3e19207-110258

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 30

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

+ Details

EXCEL 16 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%]A-C$W83DU8E\U9#,W7S0V-CA?830Y8E\R,F1E M,&0Q8F0W8S4B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E5.055$251%1%]#3TY$14Y3141?0T].4T],241! M5#$\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I%>&-E;%=OF%T:6]N7V%N9%]"=7-I;F5S M#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D9A:7)?5F%L=65?365A#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-U M8G-E<75E;G1?179E;G1S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U M#I%>&-E;%=O5]O9E]3:6=N:69I8V%N=%]!8V-O=6YT,3PO>#I. M86UE/@T*("`@(#QX.E=O#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D9I;F%N8VEN9U]4#I%>&-E;%=O5]O M9E]3:6=N:69I8V%N=%]!8V-O=6YT,SPO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-U;6UA#I7;W)K#I7 M;W)K#I7;W)K#I7;W)K#I7;W)K#I7;W)K#I7;W)K#I7;W)K#I%>&-E M;%=O#I!8W1I=F53:&5E=#XP/"]X.D%C=&EV95-H965T/@T*("`\>#I0#I% M>&-E;%=O7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA2!);F9O'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$6UB M;VP\+W1D/@T*("`@("`@("`\=&0@8VQA'0^4$A!4DU!5$A%3D4L($E.0SQS<&%N/CPO'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'1087)T7V$V,3=A.35B M7S5D,S=?-#8V.%]A-#EB7S(R9&4P9#%B9#=C-0T*0V]N=&5N="U,;V-A=&EO M;CH@9FEL93HO+R]#.B]A-C$W83DU8E\U9#,W7S0V-CA?830Y8E\R,F1E,&0Q M8F0W8S4O5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$3PO=&0^#0H@("`@("`@(#QT9"!C;&%S M7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%]A-C$W83DU8E\U9#,W7S0V-CA?830Y8E\R,F1E,&0Q M8F0W8S4-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO838Q-V$Y-6)? M-60S-U\T-C8X7V$T.6)?,C)D93!D,6)D-V,U+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'!E;G-E3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]A M-C$W83DU8E\U9#,W7S0V-CA?830Y8E\R,F1E,&0Q8F0W8S4-"D-O;G1E;G0M M3&]C871I;VXZ(&9I;&4Z+R\O0SHO838Q-V$Y-6)?-60S-U\T-C8X7V$T.6)? M,C)D93!D,6)D-V,U+U=O'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$2!T7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$2!A;F0@97%U:7!M96YT M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\ M2!O M<&5R871I;F<@86-T:79I=&EE2!A;F0@97%U:7!M M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S M<#L\'0^)FYB'0^)FYB M'0^)FYB'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]A-C$W83DU8E\U9#,W M7S0V-CA?830Y8E\R,F1E,&0Q8F0W8S4-"D-O;G1E;G0M3&]C871I;VXZ(&9I M;&4Z+R\O0SHO838Q-V$Y-6)?-60S-U\T-C8X7V$T.6)?,C)D93!D,6)D-V,U M+U=O'0O M:'1M;#L@8VAAF%T:6]N M(&%N9"!"=7-I;F5S'0^ M/"$M+41/0U194$4@:'1M;"!054),24,@(BTO+U&AT M;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@+2T^/&1I=CX@/&1I M=CX\(2TM4W1A6QE/3-$)U1%6%0M24Y$14Y4.B`P+C5I M;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA M;BP@5&EM97,L(%-E2!B:6]P:&%R;6%C975T:6-A;"!C;VUP M86YY('1H870@:&%S('-U8G-T86YT:6%L(&5X<&5N9&ET=7)E2!A<'!R;W9E9"!P6QE/3-$)U1%6%0M24Y$14Y4.B`P M+C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2 M;VUA;BP@5&EM97,L(%-E7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&AT;6PQ+71R86YS:71I;VYA;"YD=&0B M("TM/CQD:78^(#QD:78^/"$M+5-T87)T1G)A9VUE;G0M+3X@/'`@6QE/3-$)U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P<'0@ M,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)U1% M6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`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`P+C5I;CL@ M34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@ M5&EM97,L(%-E6QE/3-$)U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P<'0@ M,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@ M1D].5#H@,3!P="!4:6UE'!I6QE/3-$)U1%6%0M24Y$14Y4.B`Y<'0[($U!4D=)3CH@ M,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE#L@1D].5#H@,3!P="!4:6UE#L@1D].5#H@,3!P="!4:6UE6QE/3-$)TU! M4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE&-E2!C;VUP87)I;F<@ M;W5R(&UA65A&-E6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE#L@1D].5#H@,3!P="!4:6UEF5D(&%S(')E=F5N=64@=VAE;CH@*&DI('1H92!M:6QE6QE/3-$ M)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)TU! M4D=)3BU43U`Z(#!P>#L@1D].5#H@,3!P="!4:6UE3L@5D525$E#04PM04Q)1TXZ('1O<"<^(#QT9"!S='EL93TS1"=7 M24142#H@,"XR-6EN)SXF;F)S<#L\+W1D/B`\=&0@"<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X@/'1R('-T>6QE M/3-$)U1%6%0M04Q)1TXZ(&IU6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`P+C(U:6X[)SX@ M)FUI9&1O=#L\+W1D/B`\=&0@"<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$ M,#X@/'1R('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&IU6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`P+C(U:6X[)SX@)FUI9&1O=#L\+W1D/B`\=&0@#L@1D].5#H@,3!P="!4:6UE#L@1D].5#H@,3!P="!4:6UE6QE/3-$ M)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE2!D:69F97(@9G)O;2!T:&4@=&EM:6YG(&]F M(')E8V]G;FEZ:6YG(')E=F5N=64N($%M;W5N=',@:6YV;VEC960@=&\@8W5S M=&]M97)S(&EN(&5X8V5S&-E6QE/3-$)U1%6%0M24Y$14Y4.B`P+C5I;CL@ M34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@ M5&EM97,L(%-E7IE(&5A8V@@8V]S="!R96EM8G5R'!E;G-E&EM871E;'D@)#`N,#(@;6EL;&EO;B!A;F0@)#`N-2!M:6QL:6]N+"!R M97-P96-T:79E;'DL(&]F(&-O6QE/3-$)U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P M<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E M'!E;G-E('1H92!E'!E8W1E9"!V;VQA=&EL:71Y(&]F(&]UF5D(&%S(&5X<&5N6QE/3-$)U1%6%0M M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P<'0@,'!X.R!& M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-EF5D(&EN M('1H92!T:')E92!M;VYT:',@96YD960@36%R8V@@,S$L(#(P,3,@86YD(#(P M,3(@=V%S(&-A;&-U;&%T960@8F%S960@;VX@87=A6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE3L@34%21TE..B`P<'0@,'!X.R!&3TY4 M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E3L@34%21TE..B`P<'0@,'!X M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)FYB6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE6QE/3-$)T9/3E0M4TE:13H@,3!P M="<^)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P="<^ M)FYB6QE/3-$)T9/3E0M4TE:13H@,3!P="<@8V]L M6QE/3-$)T9/3E0M4TE:13H@ M,3!P="<^)FYB6QE/3-$)T)!0TM'4D]5 M3D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"D[(%9%4E1)0T%,+4%,24=..B!B M;W1T;VTG/B`\=&0@6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)3L@1D].5#H@,3!P="!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`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`D,BXP(&UI;&QI;VX@;F5T(&]F(&5S=&EM M871E9"!F;W)F96ET=7)E'!E;G-E(&]V97(@82!W96EG:'1E9"UA=F5R86=E('!E6QE/3-$)TU! M4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P M="!4:6UE2!A<'!R;V%C:"P@=VAI8V@@2!D:69F97)E;F-E2!T;R!R961U8V4@9&5F97)R960@=&%X(&%S'!E8W1E9"!T;R!B92!R96%L:7IE9"X@5V4@86QS M;R!R96-O9VYI>F4@82!T87@@8F5N969I="!F2!IF4@:6YT97)E#L@1D].5#H@,3!P="!4:6UE"!E>'!E;G-E('=A6QE/3-$)U1%6%0M24Y$14Y4.B`P+C5I;CL@ M34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@ M5&EM97,L(%-E&-L=61I;F<@=6YV97-T960@ M6QE/3-$)U1%6%0M24Y$14Y4 M.B`P+C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E2!D:79I9&EN9R!O M=7(@;F5T(&EN8V]M92!B>2!T:&4@=V5I9VAT960@879E6QE/3-$)U1% M6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E&-L=61E9"!I;B!T:&4@8V%L8W5L871I;VX@;V8@9&EL=71E9"!N M970@;&]S6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D]. M5#H@,3!P="!4:6UE#L@ M1D].5#H@,3!P="!4:6UE3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]A-C$W83DU8E\U M9#,W7S0V-CA?830Y8E\R,F1E,&0Q8F0W8S4-"D-O;G1E;G0M3&]C871I;VXZ M(&9I;&4Z+R\O0SHO838Q-V$Y-6)?-60S-U\T-C8X7V$T.6)?,C)D93!D,6)D M-V,U+U=O'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/"$M M+41/0U194$4@:'1M;"!054),24,@(BTO+U&AT;6PQ M+T141"]X:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@+2T^/&1I=CX@/&1I=CX\ M(2TM4W1A#L@1D].5#H@,3!P="!4:6UE2!M87AI;6EZ97,@=&AE('5S92!O9B!O8G-EF5S('1H92!U#L@1D].5#H@ M,3!P="!4:6UE6QE/3-$)U=)1%1(.B`Q,#`E.R!&3TY4.B`Q,'!T(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)T9/3E0Z(#$P<'0@4WEM8F]L.R!724142#H@,3AP>"<^ M)FUI9&1O=#L\+W1D/B`\=&0@6QE/3-$)U9%4E1)0T%,+4%,24=..B!T M;W`G/B`\=&0@6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE6QE/3-$)U9%4E1)0T%,+4%,24=..B!T;W`G/B`\=&0@6QE M/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2!L:71T;&4@;W(@;F\@;6%R:V5T(&%C=&EV:71Y(&%N9"!T:&%T M(&%R92!S:6=N:69I8V%N="!T;R!T:&4@9F%I2!I;G!U="!T:&%T(&ES('-I9VYI9FEC86YT('1O('1H92!F M86ER('9A;'5E(&UE87-U7-I6QE/3-$)U1%6%0M24Y$14Y4.B`P+C5I;CL@ M34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@ M5&EM97,L(%-E&EM871E;'D@)#(N,B!M M:6QL:6]N(&%N9"`D,BXY(&UI;&QI;VXL(')E2X\+W`^(#QP M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P<'0@,'!X M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)FYB6QE/3-$)U!!1$1)3D6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VTG M/B`\=&0@6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K M(#%P="!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4.B`Q,'!T(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE M/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$ M)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@ M8V5N=&5R.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E M6QE/3-$)U9%4E1)0T%,+4%,24=. M.B!B;W1T;VTG/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)FYB M6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)FYB6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-) M6D4Z(#$P<'0G(&-O;'-P86X],T0R/B`F;F)S<#L\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`T-"4[($9/ M3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)U=)1%1(.B`R)3L@1D].5#H@,3!P="!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)3L@1D].5#H@ M,3!P="!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!724142#H@,3`E.R!&3TY4.B`Q M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M.R!724142#H@,3`E.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E#L@1D].5#H@,3!P M="!4:6UE6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VTG M/B`\=&0@6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K M(#%P="!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4.B`Q,'!T(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P M="!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4.B`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$ M)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)T9/3E0M4TE:13H@,3!P="<^)FYB6QE M/3-$)T9/3E0M4TE:13H@,3!P="<^)FYB6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-)6D4Z(#$P<'0G(&-O;'-P86X] M,T0R/B`F;F)S<#L\+W1D/B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P M="<^)FYB6QE/3-$)T)!0TM'4D]53D0M M0T],3U(Z(')G8B@R,#0L,C4U+#(P-"D[(%9%4E1)0T%,+4%,24=..B!B;W1T M;VTG/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT.R!724142#H@,3`E.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@ M5&EM97,L(%-E6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)3L@1D].5#H@,3!P="!4 M:6UE6QE/3-$)U=)1%1(.B`R)3L@1D].5#H@,3!P M="!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M(%=)1%1(.B`Q)3L@1D].5#H@,3!P="!4:6UE6QE M/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE2!O9B!C:&%N9V5S(&EN('1H92!F86ER('9A;'5E(&]F('1H92!# M;VUP86YY)B,S.3MS($QE=F5L(#,@;&EA8FEL:71I97,@9F]R('1H92!T:')E M92!M;VYT:',@96YD960@36%R8V@@,S$L(#(P,3,Z/"]P/B`\<"!S='EL93TS M1"=415A4+4E.1$5.5#H@,"XU:6X[($U!4D=)3CH@,'!T(#!P>#L@1D].5#H@ M,3!P="!4:6UE6QE/3-$)U=)1%1(.B`Q,#`E.R!"3U)$15(M0T],3$%0 M4T4Z(&-O;&QA<'-E.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E6QE/3-$)T)/4D1%4BU"3U143TTZ M(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4.B`Q M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE6QE/3-$)U9%4E1)0T%, M+4%,24=..B!B;W1T;VTG/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)3L@1D]. M5"U325I%.B`Q,'!T)SX@)FYB6QE/3-$)U=)1%1( M.B`R)3L@1D].5"U325I%.B`Q,'!T)SXF;F)S<#L\+W1D/B`\=&0@6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)3L@1D].5"U325I%.B`Q M,'!T)SX@)FYB6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT.R!724142#H@,3`E.R!&3TY4+5-)6D4Z(#$P<'0G/B`F;F)S<#L\+W1D M/B`\=&0@6QE/3-$)T9/3E0Z(#$P<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)T9/ M3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)U1%6%0M24Y$14Y4.B`P+C5I M;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA M;BP@5&EM97,L(%-E6QE/3-$ M)U1%6%0M04Q)1TXZ(&IU6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE6QE/3-$)T9/3E0Z M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$ M)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)3L@1D].5"U325I%.B`Q,'!T M)SX@)FYB6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M.R!724142#H@,3`E.R!&3TY4+5-)6D4Z(#$P<'0G/B`F;F)S<#L\+W1D/B`\ M=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)3L@1D]. M5"U325I%.B`Q,'!T)SX@)FYB6QE/3-$)U=)1%1( M.B`R)3L@1D].5"U325I%.B`Q,'!T)SXF;F)S<#L\+W1D/B`\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0Z(#$P<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA M;BP@5&EM97,L(%-E6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0Z(#$P M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4.B`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E6QE M/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)TU!4D=) M3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE M/3-$)U=)1%1(.B`Q,#`E.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!& M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$58 M5"U!3$E'3CH@6QE M/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P M="!S;VQI9#L@1D].5#H@,3!P="!4:6UE6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)3L@1D].5#H@,3!P="!4 M:6UE6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)3L@1D].5#H@,3!P="!4:6UE M6QE/3-$)U=)1%1(.B`R)3L@1D].5#H@,3!P="!4 M:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=) M1%1(.B`T,B4[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[($9/3E0M4TE:13H@,3!P="<^)FYB6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!&3TY4+5-)6D4Z(#$P<'0G M/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!& M3TY4+5-)6D4Z(#$P<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4 M+5-)6D4Z(#$P<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-) M6D4Z(#$P<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4.B`Q,'!T M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E3PO=&0^(#PO='(^ M(#PO=&%B;&4^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@ M,3!P="!4:6UE'!E8W1E9"!T97)M+"!A;G1I8VEP871E9"!V;VQA=&EL:71Y(&%N M9"!E>'!E8W1E9"!D:79I9&5N9',@9V5N97)A;&QY(')E2!R97-U;'0@:6X@9&5C2!T;R!T:&4@8VAA;F=E(&EN('1H92!C;&]S:6YG('!R:6-E(&]F(%!H87)M M071H96YE('-T;V-K+"!W:&EC:"!W87,@)#$N,C<@<&5R('-H87)E(&%S(&]F M($1E8V5M8F5R(#,P+"`R,#$Q(&%N9"`D,2XW-R!P97(@6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D]. M5#H@,3!P="!4:6UE6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@ M,3!P="!4:6UE2!A;F0@97%U:7!M96YT(&%N9"!G;V]D=VEL;"P@870@9F%I MF5D(&%T(&9A:7(@=F%L=64@=VAE;B!T:&5Y(&%R92!D M965M960@=&\@8F4@;W1H97(M=&AA;BUT96UP;W)A2!I;7!A:7)E9"X@ M*'-E92!.;W1E(#(I+B!!'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE M/3-$)U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4 M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)U1%6%0M24Y$14Y4.B`P+C5I M;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA M;BP@5&EM97,L(%-E2X@5&AE(&-O;7!L M86EN="!A;&QE9V5D+"!A;6]N9R!O=&AE&-L=7-I=F5L>2!D979E;&]P;65N M="!A;F0@;6%R:V5T:6YG(')I9VAT7(F=')A9&4[("A496-O=FER:6UA="DL('!U6QE/3-$)U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P<'0@,'!X M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2`D M,BXT(&UI;&QI;VX@<&QU6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@ M1D].5#H@,3!P="!4:6UE65A6QE/3-$)TU! M4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE M/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE7!E(&]F(&EN6QA;F0@7!E(&]F(&EN2!D969E;F0@86=A:6YS="!T:&5I6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@ M1D].5#H@,3!P="!4:6UE#L@1D].5#H@,3!P="!4:6UE M6QE/3-$)U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P M<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E M2`R,#`Y('!R:79A=&4@<&QA8V5M96YT(&]F(&-O;G9E2!O=&AE6QE/3-$)TU!4D=) M3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE2!H M879E('-E<&%R871E(&]B;&EG871I;VYS('1O(&9I;&4@#L@1D].5#H@ M,3!P="!4:6UE6QE M/3-$)U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4 M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E2!P M87EM96YT7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA M3QB&AT;6PQ+71R86YS:71I;VYA;"YD=&0B M("TM/CQD:78^(#QD:78^/"$M+5-T87)T1G)A9VUE;G0M+3X@/'`@6QE/3-$)TU!4D=) M3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)U1%6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P<'0@,'!X.R!& M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E28C,SD[65E2!D:7)E8W1O6QE/3-$)TU!4D=)3CH@,'!T M(#!P>#L@1D].5#H@,3!P="!4:6UE2!I;B!E86-H('EE87(L M(&)E9VEN;FEN9R!I;B`R,#`Y(&%N9"!C;VYT:6YU:6YG('1H&EM871E;'D@.2XS(&UI;&QI;VX@3PO96T^/"]P/B`\ M<"!S='EL93TS1"=415A4+4E.1$5.5#H@,"XU:6X[($U!4D=)3CH@,'!T(#!P M>#L@1D].5#H@,3!P="!4:6UE28C,SD['!I2`R."P@ M,C`Q-2X@06QS;R!O=71S=&%N9&EN9R!A6QE/3-$ M)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE'!I6QE/3-$)TU!4D=)3CH@,'!T M(#!P>#L@1D].5#H@,3!P="!4:6UE#L@1D].5#H@,3!P="!4:6UE M6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4 M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE M/3-$)U!!1$1)3D&5R8VES86)L92!$871E/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D&5R8VES92!0 M6QE M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E' M3CH@8V5N=&5R.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E'!I6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE6QE/3-$)U1%6%0M04Q) M1TXZ(')I9VAT.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T9/3E0Z(#$P M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)U1%6%0M04Q)1TXZ M(')I9VAT.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E M6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE6QE/3-$)U1%6%0M M04Q)1TXZ(')I9VAT.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM M97,L(%-E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T9/3E0Z M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)U1%6%0M04Q) M1TXZ(')I9VAT.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE6QE/3-$)U1% M6%0M04Q)1TXZ(')I9VAT.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@ M5&EM97,L(%-E6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!0041$24Y'+4)/5%1/33H@ M,7!T.R!&3TY4.B`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`Q M,#`E.R!"3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!&3TY4.B`Q,'!T(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)U1% M6%0M24Y$14Y4.B`P+C5I;CL@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)U=) M1%1(.B`S)2<^)FYB6QE/3-$)T-/3$]2.B!B;&%C M:SL@1D].5#H@,3!P="!4:6UE6QE/3-$)T-/3$]2.B!B;&%C M:SL@1D].5#H@,3!P="!4:6UE7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA M&AT;6PQ+71R86YS:71I;VYA M;"YD=&0B("TM/CQD:78^(#QD:78^/"$M+5-T87)T1G)A9VUE;G0M+3X@/'`@ M#L@1D].5#H@,3!P M="!4:6UE6QE/3-$)TU!4D=)3CH@,'!T M(#!P>#L@1D].5#H@,3!P="!4:6UE2!S96QL('-H87)E2!A;GD@;65T:&]D('!E2!L87<@86YD(&1E96UE9"!T;R!B92!A;B`B870M=&AE+6UA2!O=&AE&ES=&EN9R!T2!S:&%R97,@=6YD97(@ M=&AE(&%R2`D,C XML 17 R28.htm IDEA: XBRL DOCUMENT v2.4.0.6

Subsequent Events (Details) (USD $)
3 Months Ended 1 Months Ended

Mar. 31, 2013

Mar. 31, 2012

May 08, 2013

Subsequent Event [Member]

Subsequent Event [Line Items]

Number of shares sold 1,030,870

Amount remaining available under the arrangement $ 13,290,000

Proceeds from issuance of common stock $ 53,413    $ 1,630,000

X

- Definition

The remaining value of common stock issuable under the controlled equity offering.

+ References

No definition available.

+ Details

Name: pip_RemainingValueOfStockIssuableUnderStockOffering

Namespace Prefix: pip_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The cash inflow from the additional capital contribution to the entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 19

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 18

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Number of new stock issued during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_SubsequentEventLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 18 R8.htm IDEA: XBRL DOCUMENT v2.4.0.6

Summary of Significant Accounting Policies
3 Months Ended

Mar. 31, 2013

Summary of Significant Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Note 2 - Summary of Significant Accounting Policies

Basis of Presentation

Our unaudited condensed consolidated financial statements include the accounts of PharmAthene, Inc. and its wholly-owned subsidiaries. All significant intercompany transactions and balances have been eliminated in consolidation. Our unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States ("U.S. GAAP"). In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to present fairly our financial position, results of operations and cash flows. The unaudited condensed consolidated balance sheet at December 31, 2012 has been derived from audited consolidated financial statements at that date. The interim results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and footnote disclosure normally included in the financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to instructions, rules and regulations prescribed by the U.S. Securities and Exchange Commission. We believe that the disclosures provided herein are adequate to make the information presented not misleading when these unaudited condensed consolidated financial statements are read in conjunction with the Consolidated Financial Statements and Notes included in our Annual Report on Form 10-K for the year ended December 31, 2012, filed with the Securities and Exchange Commission. We currently operate in one business segment.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Our unaudited condensed consolidated financial statements include significant estimates for the expected economic life and value of our intangible assets, the amount of our net operating losses, our share-based compensation, the value of our financial instruments, among other things. Because of the use of estimates inherent in the financial reporting process, actual results could differ significantly from those estimates.

Foreign Currency Translation

The functional currency of our wholly owned foreign subsidiaries is their local currency. Assets and liabilities of our foreign subsidiaries are translated into United States dollars based on exchange rates at the end of the reporting period. Income and expense items are translated at the weighted average exchange rates prevailing during the reporting period. Translation adjustments for subsidiaries that have not been sold, substantially liquidated or otherwise disposed of, are accumulated in other comprehensive income (loss), a component of stockholders' equity. Foreign currency translation adjustments are the sole component of accumulated other comprehensive loss at March 31, 2013 and December 31, 2012. Transaction gains or losses are included in the determination of net loss.

Comprehensive Loss and Accumulated Other Comprehensive Income

Comprehensive loss includes the total of our net loss and all other changes in equity other than transactions with owners, including (i) changes in equity for cumulative translation adjustments resulting from the consolidation of foreign subsidiaries as the financial statements of the subsidiaries located outside of the United States are accounted for using the local currency as the functional currency, and (ii) unrealized gains and losses on short term available-for-sale investments.

Cash and Cash Equivalents

Cash and cash equivalents are stated at market value. We consider all highly liquid investments with original maturities of three months or less to be cash equivalents.

Revolving Line of Credit and Term Loan

As discussed further in Note 6, we entered into a loan agreement with General Electric Capital Corporation ("GE Capital") in March 2012. As part of that agreement, we issued stock purchase warrants to GE Capital that expire in March 2022. The fair value of the warrants was charged to additional paid-in-capital, resulting in a debt discount to the Term Loan at the date of issuance. The debt discount and the financing costs, incurred in connections with the agreement, are being amortized over the term of the loan using the effective interest method. The amortization of both the debt discount and deferred financing costs are included in interest expense in the unaudited condensed consolidated statements of operations.

Significant Customers and Accounts Receivable

Our primary customers are the U.S. Department of Defense (the "DoD") - Chemical Biological Medical Systems ("CBMS"), and the Biomedical Advanced Research and Development Authority ("BARDA"). As of March 31, 2013 and December 31, 2012, the Company's trade receivable and unbilled receivable balances were comprised solely of receivables from CBMS and BARDA.

Goodwill

Goodwill represents the excess of purchase price over the fair value of net identifiable assets associated with acquisitions. We review the recoverability of goodwill annually as of December 31^st by comparing our market value (as measured by our stock price multiplied by the number of outstanding shares as of the end of the year) to the net book value of our equity. If our market value exceeds our net book value, no further analysis is required. Changes in our business strategy or adverse changes in market conditions could impact the impairment analyses and require the recognition of an impairment charge equal to the excess of the carrying value over its estimated fair value. We completed our last annual impairment assessment of goodwill as of December 31, 2012 and determined that there was no impairment as of that date.

Revenue Recognition

We generate our revenue from different types of contractual arrangements: cost-plus-fee contracts, cost reimbursable grants and fixed price contracts.

Revenues on cost-plus-fee contracts are recognized in an amount equal to the costs incurred during the period plus an estimate of the applicable fee earned. The estimate of the applicable fee earned is determined by reference to the contract: if the contract defines the fee in terms of risk-based milestones and specifies the fees to be earned upon the completion of each milestone, then the fee is recognized when the related milestones are earned, as further described below; otherwise, we estimate the fee earned in a given period by using a proportional performance method based on costs incurred during the period as compared to total estimated project costs and application of the resulting fraction to the total project fee specified in the contract.

Under the milestone method of revenue recognition, milestone payments (including milestone payments for fees) contained in research and development arrangements are recognized as revenue when: (i) the milestones are achieved; (ii) no further performance obligations with respect to the milestone exist; (iii) collection is reasonably assured; and (iv) substantive effort was necessary to achieve the milestone.

Milestones are considered substantive if all of the following conditions are met:

· it is commensurate with either our performance to meet the milestone or the enhancement of the value of the delivered item or items as a result of a specific outcome resulting from our performance to achieve the milestone,

· it relates solely to past performance,

· the value of the milestone is reasonable relative to all the deliverables and payment terms (including other potential milestone consideration) within the arrangement.

If a milestone is deemed not to be substantive, the Company recognizes the portion of the milestone payment as revenue that correlates to work already performed; the remaining portion of the milestone payment is deferred and recognized as revenue as the Company completes its performance obligations.

Revenue on fixed price contracts (without substantive milestones as described above) is recognized on the percentage-of-completion method. The percentage-of-completion method recognizes income as the contract progresses (generally related to the costs incurred in providing the services required under the contract). The use of the percentage-of-completion method depends on the ability to make reasonable dependable estimates and the fact that circumstances may necessitate frequent revision of estimates does not indicate that the estimates are unreliable for the purpose for which they are used.

As a result of our revenue recognition policies and the billing provisions contained in our contracts, the timing of customer billings may differ from the timing of recognizing revenue. Amounts invoiced to customers in excess of revenue recognized are reflected on the balance sheet as deferred revenue. Amounts recognized as revenue in excess of amounts billed to customers are reflected on the balance sheet as unbilled accounts receivable.

We analyze each cost reimbursable grant to determine whether we should report such reimbursements as revenue or as an offset to our expenses incurred. For the three months ended March 31, 2013 and 2012, we recorded approximately $0.02 million and $0.5 million, respectively, of costs reimbursed by the government as an offset to research and development expenses.

Share-Based Compensation

We expense the estimated fair value of share-based awards granted to employees under our stock compensation plans. The fair value of stock options is determined at the grant date using an option pricing model. We have estimated the fair value of each stock option award using the Black-Scholes option pricing model. The Black-Scholes model considers, among other factors, the expected life of the award and the expected volatility of our stock price. The value of the award that is ultimately expected to vest is recognized as expense on a straight line basis over the employee's requisite service period.

The fair value of restricted stock grants is determined based on the closing price of our common stock on the award date and is recognized as expense ratably over the requisite service period.

Employee share-based compensation expense recognized in the three months ended March 31, 2013 and 2012 was calculated based on awards ultimately expected to vest and has been reduced for estimated forfeitures at a rate of approximately 12%, based on historical forfeitures.

Share-based compensation expense for the three months ended March 31, 2013 and 2012 was:

Three months ended March 31,

2013 2012

Research and development $ 88,634 $ 117,067

General and administrative 239,947 431,597

Total share-based compensation expense $ 328,581 $ 548,664

During the three months ended March 31, 2013, we granted 60,000 options to employees and consultants and made no restricted stock grants. During the three months ended March 31, 2012, we granted 15,948 options to employees and made no restricted stock grants. At March 31, 2013, we had total unrecognized share-based compensation expense related to unvested awards of approximately $2.0 million net of estimated forfeitures, which we expect to recognize as expense over a weighted-average period of 2.25 years.

Income Taxes

We account for income taxes using the asset and liability approach, which requires the recognition of future tax benefits or liabilities on the temporary differences between the financial reporting and tax bases of our assets and liabilities. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized. We also recognize a tax benefit from uncertain tax positions only if it is "more likely than not" that the position is sustainable based on its technical merits. Our policy is to recognize interest and penalties on uncertain tax positions as a component of income tax expense.

Income tax expense was $9,743 and $150,405 during the three months ended March 31, 2013 and 2012, respectively. Income tax expense is a result of the difference between the treatment of goodwill for income tax purposes and for U.S. GAAP, resulting in a deferred tax liability, which cannot offset deferred tax assets. This deferred tax liability is included in our condensed consolidated balance sheet in other long-term liabilities.

Basic and Diluted Net Loss Per Share

Income (loss) per share: Basic income (loss) per share is computed by dividing consolidated net income (loss) by the weighted average number of common shares outstanding during the period, excluding unvested restricted stock.

For periods of net income when the effects are not anti-dilutive, diluted earnings per share is computed by dividing our net income by the weighted average number of shares outstanding and the impact of all potential dilutive common shares, consisting primarily of stock options, unvested restricted stock and stock purchase warrants. The dilutive impact of our dilutive potential common shares resulting from stock options and stock purchase warrants is determined by applying the treasury stock method.

For the periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all dilutive potential common shares is anti-dilutive due to the net losses. A total of approximately 11.6 million and 11.5 million potential dilutive securities have been excluded in the calculation of diluted net loss per share in the three months ended March 31, 2013 and 2012, respectively, because their inclusion would be anti-dilutive.

Recent Accounting Pronouncements

We have evaluated all Accounting Standards Updates through the date the unaudited condensed consolidated financial statements were issued and believe the adoption of these will not have a material impact on our results of operations, financial position, or cash flows.

X

- Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for all significant accounting policies of the reporting entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18861-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18743-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18854-107790

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18726-107790

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 22

-Paragraph 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_SignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 19 R2.htm IDEA: XBRL DOCUMENT v2.4.0.6

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)

Mar. 31, 2013

Dec. 31, 2012

Current assets:

Cash and cash equivalents $ 12,873,411 $ 12,701,517

Accounts receivable (billed) 1,865,916 2,432,641

Unbilled accounts receivable 3,713,797 4,114,442

Prepaid expenses and other current assets 614,388 547,245

Total current assets 19,067,512 19,795,845

Property and equipment, net 456,842 483,976

Other long-term assets and deferred costs 99,578 113,130

Goodwill 2,348,453 2,348,453

Total assets 21,972,385 22,741,404

Current liabilities:

Accounts payable 1,289,627 1,697,280

Accrued expenses and other liabilities 3,294,315 2,328,877

Deferred revenue 874,404 1,381,755

Current portion of long-term debt 999,996 749,997

Short-term debt 1,329,233 1,330,507

Total current liabilities 7,787,575 7,488,416

Other long-term liabilities 580,238 579,427

Long-term debt, less current portion 1,460,417 1,704,108

Derivative instruments 2,201,390 1,295,613

Total liabilities 12,029,620 11,067,564

Stockholders' equity:

Common stock, $0.0001 par value; 100,000,000 shares authorized; 48,416,483 and 48,352,651 shares issued and outstanding at March 31, 2013 and December 31, 2012, respectively 4,842 4,835

Additional paid-in-capital 210,877,892 210,495,905

Accumulated other comprehensive loss (219,012) (217,328)

Accumulated deficit (200,720,957) (198,609,572)

Total stockholders' equity 9,942,765 11,673,840

Total liabilities and stockholders' equity $ 21,972,385 $ 22,741,404

X

- Definition

Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Also includes the aggregate carrying amount, as of the balance sheet date, of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered and of liabilities not separately disclosed in the balance sheet. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

No definition available.

+ Details

Name: pip_AccruedExpensesAndOtherCurrentLiabilities

Namespace Prefix: pip_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 52

-Paragraph 12, 13

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 130

-Paragraph 17, 18, 19, 22, 23, 24, 25, 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e637-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 10A

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=20435746&loc=SL7669646-108580

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 52

-Paragraph 31

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14

-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e681-108580

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 133

-Paragraph 45

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 30

-Section 45

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=6915805&loc=d3e32022-110900

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14A

-URI http://asc.fasb.org/extlink&oid=20435746&loc=SL7669686-108580

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 30

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901

+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.30(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AdditionalPaidInCapitalCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 12

-Article 7

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Concepts (CON)

-Number 6

-Paragraph 25

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 18

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 9

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.9)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6801-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amounts due for billed services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the Company and, at a minimum, one other party. An example would be amounts billed to customers under contracts or programs but not paid as of the balance sheet date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3(c))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_BilledContractReceivables

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 8, 9

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 7, 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3044-108585

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 7

-Footnote 1

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response)

-URI http://asc.fasb.org/extlink&oid=6600647&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name: us-gaap_DeferredRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Fair values as of the balance sheet date of all liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments, and which are expected to be extinguished or otherwise disposed of after one year or beyond the normal operating cycle, if longer, net of the effects of master netting arrangements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Staff Position (FSP)

-Number FIN39-1

-Paragraph 10A, 10B

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13433-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Section A

-Paragraph 7

-Chapter 3

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 133

-Paragraph 4, 17

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13495-108611

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41228-113958

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41271-113958

+ Details

Name: us-gaap_DerivativeLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying amount as of the balance sheet date, which is the cumulative amount paid and (if applicable) the fair value of any noncontrolling interest in the acquiree, adjusted for any amortization recognized prior to the adoption of any changes in generally accepted accounting principles (as applicable) and for any impairment charges, in excess of the fair value of net assets acquired in one or more business combination transactions.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 142

-Paragraph 45

-Subparagraph e

-Clause 1

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=14024403&loc=d3e13816-109267

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388280&loc=d3e13770-109266

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 141R

-Paragraph 68

-Subparagraph l

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 141R

-Paragraph 34

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 142

-Paragraph 43

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 142

-Paragraph 45

-Subparagraph e

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 141R

-Paragraph 72

-Subparagraph d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19-26)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total of all Liabilities and Stockholders' Equity items (or Partners' Capital, as applicable), including the portion of equity attributable to noncontrolling interests, if any.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.32)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 25

-Article 7

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 32

-Article 5

+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.21)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 21

-Article 5

+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Carrying amount of long-term debt, net of unamortized discount or premium, scheduled to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Article 5

+ Details

Name: us-gaap_LongTermDebtCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying amount of long-term debt, net of unamortized discount or premium, excluding amounts to be repaid within one year or the normal operating cycle, if longer (current maturities). Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

+ Details

Name: us-gaap_LongTermDebtNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.17)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 17

-Article 5

+ Details

Name: us-gaap_OtherAssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations not separately disclosed in the balance sheet. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.24)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 24

-Article 5

+ Details

Name: us-gaap_OtherLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The total of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer, and the aggregate carrying amount of current assets, as of the balance sheet date, not separately presented elsewhere in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 8

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Section A

-Paragraph 4

-Chapter 3

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount, net of accumulated depreciation, depletion and amortization, of long-lived physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 12

-Paragraph 5

-Subparagraph b, c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The cumulative amount of the reporting entity's undistributed earnings or deficit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.31(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.(a),16(a)(1))

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 16

-Subparagraph a(1)

-Article 7

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 13

-Subparagraph 2, 3

-Article 9

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.13)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

+ Details

Name: us-gaap_ShortTermBorrowings

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A3

-Appendix A

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Unbilled amounts due for services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the entity and, at a minimum, one other party. An example would be amounts associated with contracts or programs where the recognized revenue for performance thereunder exceeds the amounts billed under the terms thereof as of the date of the balance sheet.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Section A

-Paragraph 4, 21

-Chapter 11

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3(c)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3

-Subparagraph c(3)

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 912

-SubTopic 310

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6471842&loc=d3e55302-109406

+ Details

Name: us-gaap_UnbilledContractsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

ZIP 20 0001144204-13-027117-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001144204-13-027117-xbrl.zip M4$L#!!0````(`#V(J$+(%(K\27X``![-!``0`!P`<&EP+3(P,3,P,S,Q+GAM M;%54"0`#1KV*44:]BE%U>`L``00E#@``!#D!``#L7>MS&S>2_WY5]S\@/'LK MJ2*I&;XIV]FE7HXJ>D6BD\U]`V=`$NMY[6!&C_WKKQO`O,@A38H<24Y=',OB M#-#H_J'1:*`;X,>_/[H.N6>AX+[WJ68VC1IAGN7;W)M]JGVY:XSNCL_/:T1$ MU+.IXWOL4\WS:W__^;__Z^,/C<9QR&C$;#)Y(K]S+Z(S1LZX`W4%^;'V^UGM MIT9#EPQ"WXXM*.I[I&68[8;1;1A]\@_2/S1:9'2I"CY.0H<`1YXX!"I?/]7F M410<'AP\/#PT\5W3#V<'+<-H'^#K"16LIHL'/"B4#N8T=&DT9QYK6KY[@&T: M[;:9E$=J?`U][J'(5DK_<1ZY3J'\0UN6-H?#X8%\FQ9=8KU0%-\F16V6\2#; M%\QJSOS[`WB!++<:AMG(F(Y%8T9I)NB4BHFDK%^45.'"[[3,_CI)50E=81-( MH*<(^8AR'`IKSEQZRZ9$RG48/06@(8*[@8/0R6?SD$T_U:"#&DDG-!^%72,' MB@Z(>CARF6?#W^C,H3/"[4^UPI.FV6YUC6;N3XU8OA>QQ^@6:4]#WVTHK3+Q M_\C7G]J`Q')EJ/[SE#J"?3Q8:CSCZ3@.0WS(A46=/QD-3SW[!+1=LK?J906< M-AK0IVU3\;JJW8SM$]^*W;3(#0NY;Y_!,R'Y7OFV`L9_TSRO;',5TRC7*I;3 M=Q4PC._+6$[;7&9829/7C-(W%3&KWA=9+K2[S/`8!FB!3WQ0`7NFT?BMR!@V ME/%SZD4\>CJ&YR%USCV;/?[*GB1CI6\JX-`PH$"K9PX-Q6=INTL,^Z[K>W>1 M;WV]@QF&B>LXDG,CS'EY[M<40VZ&W=6B4-'PIXUTCFPME\<:L<=5<2'IUXC- M+.Z"4?M4`]DZPT[/Z`UZ!\Z(JZ+,=R\44%/-_\,KJ]'(U_.;TZK9/SJ^,\R\7& M,Y['(478[Y[](9@M/JN#R_$8Q5FA(<013\R$@'\;,/GT,F">8&'GV-3A/ MH9YO+CB=@%\7<:9L\L:ED9G.8#-E3Y@OEB\H^Y>[DP5-A['1:9O=CP=;"?$R M<@\WD+NE9O?E\M^0N]5N#0;]_K/E/@+/W9I?3X]]M'=6%%,'#02/T%2/'FAH MJXE$BKUI89"B8PR:((K9[)B#?K,[,-O]9F?8[:U68M#@8:;$\E/;T)2,U;1^ MOC&-/Y7XF[*727],Q?STWS&_IPX4$9#;J<[E#][F[B6H/VJGE%>,W6U M@CAD>5^K!2O%IM'6"%S\MNS\9'FQ,8>K($B]-AR,E\#L'%QUW%TJ`6!E M66T1OB'^9D9EF0@:E2ZH1YG$*UG*Y#WC'G5NZ)/-\RBX'#/W'4"-DSS6H5Z1O`#O28 MVK-,.W?`%V]23GJ7'EA)]+6ZP)1=L%,/K)0IUP6^-\-Q@E;D)F2!&C[PF\MC M-Z5X$W+/X@'5"&]7YTT8ARUY?C9`:JT_?O"?@U1:^74A:ST+LI3Y#+M+^LC= MV/V=.C'Z4+BM+5U=,`)?/)N%\LGU=`HU]=;\5C4J]C)+G"JS:^2\JJV8S5"Y M8@"B/\56(H`0'%7T-:6;>L2F?LA.<#^:3V+YR@\7M\XD4+L2>3W?M%?[6;FF M"8R[BI)#UH^8``\`>R#UZE,%O4U4>.2B-50P;E,CMZ78:K;-]G"785E&9:T_ MGT=L&ZY?`QYC+_`L4JD8GM(U85I-E;YE-G,#5$2)SW957DY_RNVZWH+8CNG7 MP:=B!:HH=+ M[8QL5:,LLOHH^*''G4\U6.:R70.M"X9$9X0)7I8/!G;%//CGY<6=3*)J9"EG M!R^+AUF4H`R`5@&`5@X`.#U;>'Y;UM%!Z"U] MOUSP>CO?KP.^7V?8SY#9DMT7QJ8SZ,"8-HPA_OC6YIO.\]2U2NNMQ:7=&NX! M%[G#>D0%LX]]%V/D%*WK"%5KQG"Z/GK*BNA='FF9SB@/96,C:$799#'R/%@# M@Z\X93P">W>;A`,J;V7_:2'?F+5,O5JK7+*_9E=59%??3%?)P:9*YE(OT'HK MD%>_S[RQ;KO9'O3-712ZA$HN.60-%SE1XB!P)#S4T5,.VA5FGWM0QV,65O^# M1_/\]*2$?$[-[\X+>0U\7LPKZ0T'_9Y6EN=PF\&DJYP^!CR4XRX-%9>^D3[U MFB0Q+6:2:*'$5)^DF`N5L^B-V6CIS=W2=G=@&*;QS?JEO=@OQG)EQ7!+OZ^& MX735MW,:TS*1RM%.F=\Y@V>9"#+?KQSYZA+(7HCY:I+#S(Y:55?,?#6)7R^@ M\Q4F=74;IB$/353*?$4)6WUUN*MBYBM*QNIA,E;E.E]-HM5S)BFA7(>Q?Q.' MUAS\[=P)C+P_,?8QD6`T"YGT//)2/I/$2X7XRL^>]+J#3@&G9TJA`-5'&P^3 M.+/>>]>Y[4E6?LFKRH\>F*W!L-?J?SQ8S^(^Q*CR)('9&_9;`V-K,6(W=O"@ MCCIJ`(O-D,UAO-EHDVHP#@OH7XOM&O4GT!_7X;G9&70]^V.9:C#F:%>1;' MXX)3'X^;XU3`A>7X(@[9&&0\DUC@X^*-]?'!P,CXA__QE?'E!8*U&)"R:[X.#TZL:*=E!&-^J M`_`F5M:_-J)73VHDSL6 M\FDMI26B$%;O^!&#N:1'&D1WB3=3`E,Y'0DL?)"5EA^#99;&I_\<-\ZO3DZ1 M$5AJ<>\#V95-Z@8?O(D(5C:Z!QR8B[_*/3$?,[D('B^*GDBR?RZ;5H6JXJ)J M,:\].U$G#XPPF;EK$^Y%/J%R4&D$F$+`3P(D#SR:0PF!^2*$ M8IXW">(08U41@;H/#GV00MGHE-G8 MV(0A4S4:-8!@PZ7A5Q;5,M:H@+)3[DF`R6WL,-(QN\"Q#U9Y)H_VQBE_=\S" MC&(\7SFR(A3('+:AEX`(Q6L9F%T'*I83RP/6JA]<:C-B\Q"<1N<)[Q.Y^O/N ME%S^.JX3/Y1R^&CW"7OD(L)JD3KR2A2K!(RN1%MYH42ZH5@31,.?NH]H4MRE M7UG8)'\@F(QX/G`Y<;@2!*I(&+%1#65!\ESU`YY)8,*DD+,3Y`Z0/&15@83%#F$U!L`CT'R@*D%Q5 M`OWED0"V8:)Q4B2DEDHP`]P/!UU2S-`@<+@ER8D(%0X?3AE(!)5!$^HDC!U= M%E0R5A.F^HRLJK<@1]8E"40:GJ510?`6%U")`+H">X7+='-E@%/4"X@'H+P9 M+E0"H@YE8,OMIO%>(&QR]0!V7(67&!F5X2!2RNV&N2L1^!J$R?I$7= M0P?!EDJ#)!,UKT.91"US#`3*9TZZ6;*(-@=D`&Q#_Q$N!UJ=0:4F@P4`.K>FB(#!4.Q+M\C'WO4Y:V=R,RV&2;0S(T?SYE!S3@(.6 M_I7FY[8A%:95-C^O1P$'$%LL`^ISS^U$T4#U/0Z_")QL&$YE$Y@%=*I[;GJA M,"J;W531T$83!PE+TPB*=^\[9P/A]$A&&2+)?*%X>8"I<8H*KVQ2P3V@*KL2^,D+\MT.A,R-4=.EMNJK M^D$A=:P-%;HX=@C.B^T_>'K:65-9]^"@*R>/K)/4(8>ROI):,3`6RL?>ZAJK M;*244,X[N@,SRP8L22&PUQ$Z4E76_IV9/9:UL+K2X)P6KE2)[W$M M@^-_RA^5P9!'\D@HG65O8>C`_&AB&/(]>K@`B1>[RGJL5(HYP@[HR1T!=0ZK MT$3.=\&FV@T73\6!-?)L>"1/"$ZH]U4MJ:"D3$#Y\>+\Z/KVIWJRNICBX4'I M^C:[[^LD<&)!NN_7*4N1">SE7A-K'('CNR!SZIFM$M'%,WU($B`-(N9.`!H, MDS2)S@X1RT!*?\8/^0Q/Q3E/*3\-WX-/B:LTY2&P:,*Z!$$1B3^"F`HPNH`> M8QZX49'T\U'5S98N6UAE%09_ZAM+EUK`@@U^=YZ6K"1ZR],8F8,Q%4;\/\#P M/8C&Y8C4>62J`BW!&:1/CR4%*W%`UQ1OP+-C.>)QNG$<_T$GMXWCZXN+T"`- M+Z,B3%CX_?1V?'X\NFB,+LX_@[P3/XI\-U?23DK>C$Y.SJ\^ M-XZNQ^/K2^`GB#9G[0,!P:YO@;Y#K:^E&$5V2:,:E:1-61M;1L^?VV#:L.LT MZY9TBY[-$P(.V'F8+X:JCT?&OGV^OOUR=-'0#X6SR8\OHU%O=;AW^_>D#V5SS]3`UWU4ORO8)V[]+D<(@*W7L-B_\J$^VR0KPZ&\DHV#LCN(!Z\TB\ M>7=K#X.LWS7JAO%RL\8BIJUF-T&U<7?^OZ=*#EES/V-F30//-6I5-E&-$&OH MO;@NR[:)[<>P$-Z[.K]KU;L&:K2Q3J,/Y"K\C>P^[&%S+]UPJWKX+N\Q0N3Z3#ER"?M-"$'OX^I$`T/ MTBA+%KM>"-I-%6UN$SN6"699;"EZ\,D3HV$:'4JE;KU?43&:\]"6E52R%PL9 MG4:8X'7NI2DIZP2=8LPKB0F1*9,@YB1,&=?^15/')Q=K@;+]G6 M>4>VBE6E]!9C7W42BT0@-IWBZ8G[7%10I_$A02YT?H/*[%&)<=E$Z.2^WT"[ M3)MX2]]M1L$U)F.H/I5Y:UGBT$(""7:^=*$B3'WC_U&YD%2ED*BL$0TVH"KB M"2ITI%+RX$>2I46%8!%FL%\F$,A9(@@YW.8)N\="*774> M6R;VH5:H)+D(?#,F3[)CLDO`PN@)/&!-3A7$+(@TC4ME(2@Q8I'E0V!&(:;& MZ#2XE<3_4AD#,-2M]-21"L,OZX`T`ER>7,JE&Y&'Y*X=M`CZ/!/I]&`)TLGE MZ.4R4:0T_],>?A#%/#=,],3P-^9R"I9E]+XSFSU39BA(3 M)OB!WA23.Y1"EF1)6Z"Q3TA",4.SE&RI=#!$83AQ&&EVG*;XBCETHNHW3Z72 M:!EN)4,LS`F1^4@RIT5I;I*P9C/EJC%[Q7B2%ZM(&Y7+!+-7,[Z0T;+0@3\T M&J>>73QJ(XOD#^#;J*B6L=,> MF,U.S]SI9'@)D34@#0:]=B>'T4;LO@0:YJ9HK+]M:#LT3+-O]/IO$0ZCV6IW M.SLK1PF1M=]F-QQVWB0.[>#`;S0>?WW.@ZZ`_,M0O!B M]Y)U.X->;U>3"8L]M=:[9]E9R]-'M26$5Z\BB3B2%*ZGIS3$O&C\"B/92.ZZ M[KU0JE*'EB\CD;?JFSU]Y^Q>(7G[*%>DIJM0[KX`RG(W3<&D-M:J7P,,^ZWV M(.\5RX8WX:M2=[W5[Y@=H[,)7X4;9O)/JK\?9P@N3K=P,4J^_>V9K?06G&%_ MV!UTEKJZE%FPO5S@UY,P@5=%RDM#//N.SSP^Y1;U(GV%#FCTC>]P"S2_>!G( M+@3^_UZ0BNX%44=I9=?@]DF^<^1>R/JCMM_C/CB&0V*/QK:*-I1'?J;)/H^Z M$D`=A=)!);5/F9QT1-#`>+LC#/.Q.CGWK*:*0N$F\-QWG*>&_X`;7!@Q@>F! MAOA5V62$UP-DNJ^V-I,#YU'N0A9)3$>B!%Z0D9PAPX")1Z-T$U9S+R_#>+Z0 M60,RD*CW>%'HF.69A1$&+>+;AJB[H\/W(PZN,['3[]?_:>_?FMI%<;_BK M\/4S4V5728I$W3-GIDJQDQSO)G&>.-EY]ORS18DMF3L4J>7%CLZG?P%T-]FD M2-VIFSFUM9$ELB]H-!I``S^(Q;/GB>O?0-Q$+TQP&7]'_*GLAW@I,'-5@,6H M.9LJBD<>:`BRRLBSAOQ2DK8&=J5`PN`;H#(^(:2#%M=>)5B0(6QZ]LPX]>A> M*)J\+_/_30WO]RV>J&F8&)`0D.,>,5U$)FU,2L&ZC,-E0%\VXV@I+QBU`$_[ M:W!C-O]XN-J&E$[_#IW4S>.MVD3D6.L1*%._`LVX7-48$A8Z1'-)8UZ2\BG'"/$^-3"K'KP,+@;17& M0/ELDH7#L>7%PRXJ4TI[HP1]B04?UX[D*GSNK\7KR[U.N]_H*%/.&\K^YE.H ME=)JZIU68^/YW,()`$N+_R`BV;-AXPX8!+?BDHNJ%/"BR.L\>0@9=+M9;S5Z_9.;='.-23?BE4X^ MO_*J0F]VNMTBV)N7]00S`6',&!Q-].^2N6>_<%C/=*,+'-!:18WLD1Z:*`?S M5;?JG2[LC`*I@F?Z/.E%6>O)TEU2J+L$B4]Z(GU0EN%"72;1?,E.9?%\.1A, M0!H\V7,$'DGQ.%Q?1ML:@Y70ZGZR)D^@.=L6O(^*_#,3=C57PR6TC@R_MF10 MH<>81,@!U9XR#3@@9WHT>U*ZU]IAJ>V+(8,/8P']_N!]@ZGZ`0+DH]/_3_0: M2%AX_F/@OU?C&7%?[]1$X95'ZEU>WD8ATTX#/EWZ%5/\!"L8]5\%_0JJOU+G M[UP^_0HJ`5.O$@DOGWX%5:%IO!;^*Z@03@,+X;P&^A53BT>6ESL<_0+Q-%;J MQB+%Z<9RJ;;J1>%K6E&H)]=#M:PV#]AH_YHQ[U\R"R-5,1233)83<-78CTNV MEK[$MDTY>NJ+S[\F4B&OK*B`F,MA&>^M2S:]UJY?`MF6*'%+R=;PWZ0I+:RG9MMRDER#;5AA82\G6VHYL MC5KB[N1LR;;$KEI*MO:V9.LT+X%L2\RII63K;"O;+F.3+K&BEI*MNS6W%:_N M?@DQ".5A'`>;W!H8'/!NOCX%UV]CSR$`F65/VQVT-WHK*+?^F$^2B'N\77^U M1-RGY;JL`.\%D[`HBS:3G'J[JW>[[5=!T'W;NID$;=3KW>YE[_&BC.#73L]] M6\>9].S6V\WVY0O0(LSF5RU`BS"HL[6D5*[E!=-SWY9VM@!MZDV]\3IV_+YM M\$R"-KN-EK[*97$9]-RW<7X:&OV#@K:52R_E(3$UO0XG+4;'HE)8;^/';JT- M%DQ-;S2;:U)G52,K#IM>'_Y;Y/YN-3`E!\>F(A1@"YE MUS`'&PC_CERXI M8C>.57Z\_SC0/L%Z32XYJ?O>B9/\]'J]0SBF/,>/:J7/;,-"+,J)@4F:&A'E M.QL].:[M3BQLC/*VKZ_PEZL;F3=ZQVSC!6.<;]W0(YSFVR=,$O7F/"-6:1F. MG0E#C-"IBYG$A#D1A^C*]-"9E( M\$5Z^*XD"G^/:#XV:$V@2X=-W,`2*903US7Q-Z62*P5_^R&F6T=42A1(%<^) M8:3'?VG0O8DZM0U9]1F94J#U&DZ40"^8=X09-&.+'^'Q$CP9IC;TF(%PY]I( M9%>/1'XB)M6J6-%`Z)!+SG#VY-K4%.;?CF"5^1+-X+2"(;C>7`.6 M34KDQQ`A]T47U#6,808\RQ'[1Y[K^]6H52Z/<]JFM_]F."'".<0%I[.[TIX8 M`DJ['L+W>Y.0A*6RX\X6)A[3=0Q'H@AHCHM([J''84=B\4%%IA$K`&B"%=LQ M^1Y7EI,Z/NOHN2%#$8YX$./0EKG[\DE>I5L`&>00.^H-P:*#T!/%J#V^(Y," M(6(5VAF$%()XW6)/DZ2)=Z+D`=R&_D9RXCK>[1Y#X>DKQ1ER=_X-Y4.1`H#3 MF<,/4=TF1'P1E2`08YE$!+5O.;S[B/\M?SF/G>/A%JNJ_V"."4)X(V7UU&?W MX$0E!IYI>CZ";(`2:=H"\QH.33"+>%D2<1H/+5)+1SP9CB&W1P45I!K),8"< MB3'A1R0B@82$5.''L!:\2X$_[Z&,I\,;.=A#C!(X1L:P-5X4SH1SCM!"E)KS MW^.6N$KMAU:L2],)$.]?R@;D>U/S&?N+,'1P;]J&)SA9[/EY!!F#%3E@:G@" MF\849L2/)_FZ_(XV1LA/:J%:PH%$N"6H<\KR]H0R\Y_00F@7L:U(U,QG'$+? M$5*-=F3&A!3"67B@>7-;U!)8F)@<64KW`(,_.F2B6A(J?LL+(K>8T;`YQA$> MLS./5.)EPQ8B%J6+JT%C*#6@+5I#;ZJ,7DI8KGI9,6U)><-R`<@G;HAH^IX5 MT`!!>R=1\VQ-7,\-?3)'QM"<2ATKTO]>B"5)+9>:H?OBG"LL?RR)/N)QX]#1 M+I$[8'X7:CO+,NR2>R4VO^M0L8]DN*@L]+6B"CT>:/"W'$ MN%E@.N"AC!!"$O/H#GG*9Q%QM0'].D#'#*_<\6[P[6Y`BADQ%;=L*BH:5PPA MQ3&E%'RK&(P*-=R1V)DDXHQ(HHJR$CC-C0"[*IB%K`!VG>O)%'/[-S:Q_$!( M9W%A$%6$N=2<=A!V5`B93D]R@2PE0WRF\L1U/,A?GESN&L%B7D%LJ?XMM-&. MJ/<1".^9BFC8QH@W@Z>\ZZ`R:^&1YQ"ZE:IGR@!%$L<(&0A'&8>:$$6>*4S&LVKA&#<%AV7#2'<,S0O;#+I+1KDG`H%,F0]&.:"N,6E04L M:8#M$.G1&A6B$*L(2:JC[D)>+3Z<&X4>OFN;THV6'M0+\Z*O>6_L)QY)(>B2 MT@G7J(-\M/%$GSP)6J5F`8:5825JT:7*'Y&Y!3+3PC50;.(>P::U+\KND.:8 MCRB`R"D)UA*NUD@+%DIUM/DKH@H/9W:I0*=<9W\Q-A-(,F+..UO&T`W5U4?31(YKDOQ#=42QOU_!DA$=W@>O&Q1-X/ M4;]/J=9GD5DCS"B.MQ*!,+K+9#%ZD5#U&B*/F8M.^YRWK@WMZC-*>N80#.<' MP[*!MZYN*JHW21T1E?YT.>_[S+9QWE1E#AW5Q(OD%X4%BVI0PA0;M7I4M]*8 MP):9B"I7F24Y%R4Q=\C@Z<&G8]"F11M2U,%SA);`W<:X/DA?+6-N'*8W<`.R M\W]:TW"J;,*H3J/EQ[KV8ETO((\;VB82)^6HK==TZ8NZJ`WW(?+-9U(UYA=1 M=2[!-!P$=0G7$-(0D&\FK:+#\`P8\G#0-NMPQB#+Q#M_'4:J1&<`W?D`%W@< MEQ65#2S5!FWQO2_NS)T"GC<(S%J-!1.DO6<2*UNP;\YGWS$S0MS_0(2@+6D4!(1N]A2D/ M#0I';S=KS5ZWL3RZJMZK2EQ#?*V>^>**\A6M=(V0C0=]/$KUUZ=45Z%4?SM* M-1=B3_=&J:^&]^`1XK%)`)*R%$B:-GG/[1_GE;+DB`XJ&5I7?\"3]03^R.K1 M%3OMO2*]'F3:G$L&(=AH'I5`34TW_?LA4O@:=?%?YA33(]KOU/:W@L5/[5Y< M8F=-B_]VB-5J]5J-3JO77#(C/IC]S*;@!8*)M/5..WMW;3";A5C5)0^N;D-VE`K.3*>JFY'+!I MB=1F^T1%XG?CJR[P8AG'GMB#D9E MWCMX+PJ.Y.P"S/J&OK)J,1]`"(1<"Q44,BL$F]TN47KMA,%">9*&R%@X>FF#5Q M$N6TL/A[;IT?Z==4GQ=%1>DJ!*/=Q#/),E540(<76!'.%/2Z3D2(!T;G\'HP M>&4M^A=%;I2?N//]V@*RA(['#)NT8PJFH%]P#;@+B#PUY$36#(RL0[E?A5ZK M%"JJX&7OSRVREM!*RT41!/`-8T\B29[\\K#%"3JM;KO15)/!4\/9=@8'JR30 M:;3Z];:^_@S\X&'\C5G38>@1G*=:UC?WUP.N2K5%H-=)]2=G6/N;VV'6"UU" MBQZA]2;'ZT?QS?;=^"D>>L<7O%&A/V\'F]4VRQD3^B4%9Q"T_*M.V"Z4)1%[+$#%4(Y7.MNHX]C\N/4A)'HR[J MSC&'E5 M^P2[XD*#CP>^S-=!QT+HD8O%A%M[;\/AY5DC M35Q&:[>N-W-%A-7UU>V,[%!AXF-1P(1C!S464$<0\T!A';2N$Q*-]& M3QA>$D6+PL#BMOG[(G94Z477>8PIUL;FE<&D7(RC3D&<0=/>A(M4PS0%W\+8 M++-J.=41[Z.B.(BPP#%(AF%`E"1A):)K(N;19)%DBFX<\P!=2OSY3MF?ZKL\ M52;R($$'F/O`/5MH#,@RQ@Y3W5\)\5XAA]&04622%$-27DR=5C-V)L6! MG_)8TJ8L>')%.+!H+/*`80BE2&!-3P&3=6BTJ7G0T-0BRE%'3%K7_,1<6>LY MZ5B+TR+VY)3*$,1I"XUN.X/D.2,&4WYDR4+B`U6P\-'G_G[83=/6.W5= MG53NN/8[P8/ME%Z[WZAO-4%**8*SXH.\ZXC57_^390PMFX*W/\!Y2]>:<8BC MH,#V#<2(9RT.S]7HUSOPB:ON5]I/WWKK6/;O5]`<6Q_Y++NQ)/%^3FW'?PL= M_)ZA`.OU>N/-__O\Z7'T!'92%?-4\9R_TMZ<&O'ZNQ$O+25>%_&(\SK[Y+SL MQBZ2>/W=B)?!>:^(>"K*8VJ^&$[+J56THF+[?039\3VLS@U@O8W)&@&^VU, MT(;>;W<:SK7P1M,8,WQL>7I?Z,B<+ M`UE&`\>\L^PP$)DO*YXIV..5G7&F7_U1A4<50;%BE,5,NS@_V-)I=_8T[:PK MWA7/E->]A5[WTO+1%95DQ2\LX"'ZL"`:K&J#8(B_C,"'/2 MH?H9')0*DV$B0`(EYTP@BA"6(6$(5#A:.4=8I:ATAHA)/EY!!_*Z^,(0)V+\ M!*"50E]"EXJO<&/@.<,)K*J)K`[G544S!=,S(8366%*9I"%Z6KV$&6LG;[6M MZ0Q1]@30R\P-8+L3J(088'+Y*\1.ED_W[#/$B_"2`.Q-`>+FKS^$[ ML\,&Q.V[[#D>&DXX^CH>8Y(S4QDBB0$MZQ7);#(.&,$;C]5(P:NH]-E3N,4*I2BE99&,>QA+"$&,$WUP;@W_"6%5X)_W_PE!0[4:M';C+00]/D8%?2K7JSM1>23&>V.V<,A,^S-6)2>V:+&_R3P6A'[L2),"4*:[U8DQV3AO0T M&D5A?2:%4()0OL]#8GTS@D*H!OB(;.@*]!1MBQ$1E M$*G-B`)`/*\:8W5!OPL0#1-C?DGSPX4?$XZC+?Q]<\3AA6:M@#<9U>F*H?A< M1/#SP?XRGPU*7'%#7U30BK(\HJ[B=C&:�\C["!U3SWJ`Z6:"/">Z:*!HO-<4:$XRQQV:8SDU]B4SOV&LI@JV]Z%T3VU(HR&.##:Y.5FVL"*;^_&2! M\0=:Y9PW!--W497]7Y'H;SE@3OK0B,`\Y'TH#:`-!AIWW`QA_47OHQJ*!MD0 MX1F#%4/C6?>R`I/_]A0V2\#A=WG' M?][???]O;+3^ZP8=:"-FVSZ81+"NJ&W1WS,,=>=_QWUYLJ-_O/_V_?YV\*DZ M^'3_$685N#/E,3,]GM[L9Q;,1&!FO*,,^W$^';HV;.2L9J:6:;K!>@VM)O`G M8N,&R,G_&[J\IHXUXC`1!@]_YYN,5_BP3+38$&5!["%EP\(6JJ4']2;PE,^X M8BN8!NS#65`RS5DPC0Y,\[`@CA1HDO^D."HVXP77540Q03_U*&&D MX,_?,MJ(V76M!B6G1PD!-$\HX<4(4M%*/!X(G!Q=R@@7X=S M]2%Q:,&A9)3[Y37M%U1&?RR>R3$G^>$,]1/.,<"6`6 ML\!&&0.;Q^E6BXE=V?*:JQP1()&L=85;"'6=J6N"BE")TIDP[T@661'^6%&K ME;MYQ0X+L(BK]9]0ZE2HCZB#S%),=MX)9Z*;#X16K=3(4Y5>Y6NN8&)*FP3V MS](U8?F&://*[&I8&HR%33#C+^`E9`VP!^=44X#?'&RG:$._MIWW+HIUG@">/_`$458P'A4) MB4-29-M8:Q"^'WM1I1=Q;>,QQ+KBWNG$%A7V%%HI8(]P`"HL*H!USJ%_JJ(I MSKWF15UBQ#4[!`B[F:K=M*6Y14FV9,J1[:A48EMO9R2V1,="9K@H4>7NU2=@[*!%V`%HOL*7N3$E'P%\Y+A M.(F>%RYF?M$5)'AL#+[HRR^2ER`7Q:N4]!R5*N"KZ6&:E\]X];*HTII:FC>+ MNTB]%,5SEZ[Z!HN=:U'U?R& M;A"XTRSE#T=1?;S_G_=\*&LK@%\'=W?W7SY6WSU\__[P&5Y&]7G=*?VF`4$> MOKWEU5LRB9O9J:"F[)/>QIXUB@\!ML2M)*8\(I"!K<>$"P4T=WZ_:K1H@%GR MXR3(HVIX)0<4P0&ZZN$Y,8*\SE703XP@KW,53D/^O=Y5>&?8F%-Z$@39QRFT M[:B4D/GECJ9MCCEU_:AP(J>@VE1Z7=;BFVW'4\ZCG,?^QI.];=\-;O_^\=O# MCR]W5;';O,GP6J^W*GJ[78%_;W[3UM_:ZDQM-@XB5W&KM8$#/&OCQUDSONI\ MRB>.Z%C?L=]-US+9Y&_%3I^SU[.SOA^[UC(T;Y:,+]>QI.J-+]6[I_7]LJ MG,;.>^VK4+I_2_=OZ?XMW8WE/,YV'J7[MW1`E,["?/+N[9W,7ZEA^B//(@2NY2KWVDT>VZ>0YT7@91=Q'$-/>R,F'_N[$S\L M]WWOG1SG3=\?CL<,FR!^/A'.5TFYG3DSDI-IMEQR0.Z)%KLZNH0(;?=^733X MUUV%E"*UJ_LA4UU(-[JQVI6C`NW<[OY&6Y*Q)..QR7@-F=MUF;6]EO>VDOI"\N@]%GLZQZ\=$\L=4\L"=,JC>S2/7$L]T3Q7K/2 M/7'F!F%)QI*,IT/&TCUQ^89;H]+K=2J=]I+#J326]^V>Z#JP$:>D>A5WJCC6]`I%_E#EC<`I?82QZL;,5DORF>(0TE@A6-F!%AI`B=4 M017?$-6Y*M29QT:(IY\&HS,$SN=0F`;^$^,(Q:Q",(NJCT9Y+6I-N&Y"QPA- MBU!B7<=DCL\_Q47P_`#^X3B;B!`Z8YY!1<(X69*>'\20S"L49BC(CN_06*H^ MCIY<&^E-3H4D@&U-^^%'SJ35CVN(^6DA#9=CZ4?8U;RL`@(FXAK"("M4%@H+ M$N`WSR[6JK(E;&_T)!658X[IYR(LEGZF@UK*N6DK71K)_PUQ50.^,^\=Q+XE M[M6,H1L&D4]R6;F1/1J\FQ!BPX-G1?J.,D&0&\TWS<:;D\$4//&DJEWZ1XIS M?OLNX;5?T>P3N.GW)']/P^8[9GRN?IGP#*<5>=W:M??5&L=I$Z"Y:^_O5=UH MVUW[\@2*Y>[NF8)2WG:S-`^9O[?+>X=EO[VP7*1DG\9I4;+@JV'!0:8)N(V' MY=2]*;>Q=/-:C?Q MHEH.Y:-AB4+JO.*V='VH'AP3(U:X:T5$PO@)5Y):XR15EP1ZXY6MY?`ZT,^K!X-?4D!>@O(#\5P:%2+S"`KT^&-QW`3XY@T(JH'_,"%/RE M46OH2C%R(QN,B9??:-2Z]85G^2#U'A^D(`]6;CTL>?2BR*-WEY"G3GTW(O(L M/BL&R1_4#^Y%VV?96C;%CP->0>2S4C%$<;90Q9`OKA,7#7F'14-H5/S]5)V_R>T9N0"Q[\FKFN^ MP":I9%5=<50:BBH[WTE>RA(NPE,N*IPGFW@!=D9VY^6=3`:23'KN28I6L?1A M%03^8R>K,](A:SUG^$=?@7EKE.J=D-G??*.@WJF=5<:Q^QP,S MIZCV=FV49;>5LMOE+4!Y"U#>`IR9'[R\!2AO`E;9N\>,'NW!!?;6BE^+?F2)1E+ M,IX.&^(L M*%>"BY4&86E7EV2\9#*6[HG+-]Q*<+$27.SR*7ZJX&*[!KWL,9PD%0GC>LR: M.+?0$'-&-Z<6!=- M+HRF+`5QVO+TNK/UH87.B"^*-I(SE\!K3R[F)KLO"+_'`HA?@1AW(^`H;(XI_7H>F[E>0.FHE-A:T^Z=D3ME4:*W`TH/=#%= MZ%ZT]<)0HN+?SPR8D*6[G'GLV8#900]*1NUBM[AJ8]BKU.%FC17'B(N7@>RXD'2][K)P MZ:Q-*`$?,R]Y_CT.DB>BQN"'$I^03TD@,^+S24JD]O.V)]VV)TGR.$-@`71P M/3B/ALT>QE]%1NU7&[CI?911BV?7>H]F'50_?>NM8]F_7P5>R'8]M[00Y`*] M^^/Q#MJ>VH[_%GKX/>,LTNOUQIO_]_G3X^B)38TJYL"C;^I*>W,(*C16']=Z M8MJZ,NW&\FF;;&1-#=M'S_H?'="9.S%KK#?$%`4X&@6PSL`$%K;\P"/;\;V4 MDSCUY<_L7T59-F==[_:[_;8RZ^6C*V:Z!UMBO=_JM7J-;:4GL-53WW?HL7$N/-@>HE83Y'$BTX1'S2:>. M_'<"=`5TU8R+;E1%),`270-+H`O?=T<6:50$\VR,X'S@2^O7M#]1G7VV8(!< MLQUAZURC)T-!@FR`BN6$I'HN0-P@,?R0".,'1"3QES:8: M6HKP+.!1?$`X+&F>H`<&ULRV^*\X/">D+LG,"/"@QYMGB<+-QY6R$.;,\&XD MD@U2:.BZ?R4S%80JJ]V/%X>(:\!,GWY(OEU!S(YQZ''4#M@D<]\B@TD`2X-1 MH$!FX?O#T+<<7%&2XVPR1UW3,(')+Q)\#&V3$$9&W&SA8"," M"`6[9MP6$WU'2SEQ+*FH&H[Z%G3GH;7S'UA229V8WPCGQ_"\.5)7T`IY#M%: MF!^`A$5F4L&K_N1JO,U(;X?)VH8?")9)C!8U:W\JE/V8MY:@)BF0X&0;(<$9 M@0O!`B2:YD,W.*;YGJ!/UA;WR3.%FZ&HH7T`,7\+8M]R0J#F0X2#]8ZAEF32F\%0Z8'^'U0&K>J/> MZ+3T>$4..-77M:8'4W2K>AMUW>;)K"DT*'3J=Z!RCZU`H?_";X?E_WZWM4"G MA2'M9TX'6_]&N]ZJM[>=59;//>_'4@:XQ>I)PB(F"(RGE;!QB/1=L5AMRYE^`@!-H MH!)R;JZ9UGC,T#$(/PY9\,*8B'ZU',,!?=]6W-0X,FJ<@$>%WFMD^O!KVH"4 M.N&TQ0!/,Q M!8Z`8U)[`+K-A#/`Y[.60[7$040$!3EFV'+=\D9,A7L2WN^8O>3M12[@Y3EN MION%Z7&0T'X%3CF!`=JN5^!P6,`O798MKM1U@@5`WK*>8=EK6?U9<;$D:>G$ M&RFQCP+@RV#!4DD*`;3,\;J%[R+\[4?ML:9]'`R^5D0O.`O$3$YNC$A,2.DP M`EO)Q:[&*$DR-A&B5U*!I*Q6<%KJ505N[QQ&7#!ZW\UYAQ5F9_TRY\ZL'G2JG<[[:2&MGQ\Q4WZ7F?J\1"+GOT!UUWO]NH=?>_3]T)F M*M$\8,H]H%`2UI\S47[+)\T&C1S8A&O7>_55VV6#T9\J00]G/S8;S6;O<`2] M$V?N-_;,G#!O=Z:>.K1@JG>;[<8RFJ3&5]RD#R>/6OUVL[M4'&TXZ:]@,AF6 M*=\2_@C).R+H*9L2Z[QZ8)YH]EN]SC+JK#/F4R#9X3BJT>PVEQ]P^Z#9#P=$ MCXU<*0_)/!)E/'EP!;?>:2W5>#+&6#P!#G?8Z&W81=T="J[`ZLD M_6X_<5@DQK+=X`^V(LVZWMMP[%]AQR8&CE\;W"37WYI!A^]H^')7\W>=V4/:1]S>J`(6.]WJ;32NO^*36^T'"QAE[7^QU= MV0>Y:OBJ8189.-9HU#O==J>UV3!!!WA48J7Y_6-Z[)D/%1^FU^AW]6:OG3FA MS"$5-XNO"UZO;[77;W>SE$F/89>A%+D*W MU>NU&IU-ANZPA_$MZ-)6\,$8D3_[G>MY!/QR:R#:2#!7X#[$Q#9[29P7S7JC M5=-[O>XN1\YB(W_\<$P1DH\`;!AO(140R-.UG_"&HBF9[QH MIOOB\#NN92]KX0POGGKM7_$[#.#B!?ZX#BIO*S$.+7(GXN5$KYYZ/G3RWZBI MR[<9I5"^/KZMMC":NXW_+*9,WU-54B=(: M'\8#NB=]4"(<\RBS[*7#4J>Q#G66#7@#FV],;:E.'* M65V\M1%E0#2TZVL0)F^D*:*XSN0[R)<[-@P24G[Q^\)/J#[^ITKYQ3'L-OAB MSR@8?'?+P7\V@M"CX^P;FQES"BK#!!S+P1(`]KWS!<;Y_879S^PSO[-.3W/C M%L0$F_5V>[NMO/#>EL39>.0[D/&?S/"^T]7_QO2+7CTLX7"K;TNX:,B[4NS% MW9)>+^Y!J;5,@*P[X'Q:?7&=48Z0B7\JWMQM=>JM1@Y+Q./8QS0*-8>[,(MZ M;[-I?#;^[7JWH1^X4S"W>.1'5NCF&L^549R%1G$^6A,'3(*1`5P6+039#/(R M7XL]VQ<:YDEQ?53X>JZ-8AJ(5!H*ZKH#4>1%`6%X_X/>\&O\_>K.O;NZT:K: M[1.;4KS@.\NUW0E]_`R*'O[[./<)B.#ZZO;=Y\BH<&YC-& M9YE`<9]1D!O/;']FMLL3E`=A\$2![]#0N\&WN\%53I'A[)SXA.FIX*$"DYHL M;3-&)J+RO8@?\WDY8DK.MS#(#%/Y;YF_7$> MDAR'NZ+0ZZU.HU48/;A/?6UZ9#Q^Z'RI=JO36TF.C'$>DAR'@TWHME3;>\_4 MB(*)UJ-&QN,'!E0`=;2^6G9DC/.0Y#@8L0XXX]4S../[FX`F3 MC4;BJB\OT0^P4-?8Z8>8)3WSA>691`F]% M&8!,@:I@DML(1*XVMMV7?:6;;+K+4X(%GI<"GPL?-?`I]]<#"_E&O5'OJRZ9 MW('M;W:'.PCZS5ZWU]U\[2=Q.`VPV^QW6[W-)Y'2FC*^/[A`Z->[ MS5;&3/(TJ$WG_#%PS*\<4XG^?!A_ MD(?08W0(WEG^R'81A2BI+>Z[T5*;+$B;]`,XY"?XYQ<7M*&&5M74M>.N1P&^ MQ.&IHA=.2J_<`U0!`KYJ0\N=/1G>U!BQ,""W\DB$&HW=42CRVTWN4T8-$YXW MA3N;U";F"50NQ#``5^ M"FO+D[1!B0T]48W+4[W@9NP%QV1H&OPQ-FB$^(UVA.\*P[I#3^&/?`8Q,$JW4]@?<`2CPI MM=0*SI-_"^^+)J,^@1!3YHTXFN\S`;9APKJ&U;2X;OS"A/K,*('H\GMR,HNC42>>M(=B]`]&") MB#:=V>Z<(7^A"0'*O.$(I`B>+1X\61Y,";9V1I;X66^B_[9\6$VDI3VG)2!3 M!^@#[#BEJ#F,])L@'!I?")3@GC$2Y)EX$:4\@^Y%QO"&N`>QR,WH>@0<(4`G MB-ZQE;0G$VC?1U?JM(TSG5(7U)F_'"`6J=U5=;BL0>P^@V(#SIN-9GWS*=RJ MV-@*_%4N<'02-WH007)_8<'#^+OQ,Z;!WIL^M$+94%^78(>:_B'O`CJ==F/WZ2O9!UF2/O/GP@^L=J^N-],G M5N90]CFC(@^P=K??TKM;SFBY4W+Y(X<.OFCHS=0LUW1.[F>F!]N`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`B;A2/G&* MZ9/%@P(MF,]X;2T9$8BE3PW/PX!,4D/?PB]^4)W9P.=CQN+(P0K]`.U:TV'H M^02SH`02CJV?%#^*)7&C=RXJZ%*P$A7+RJ$1A;-&Q;9,$1'+*XHER]B.^-T0 MCS1@T7)OF-IW'4>U:@\4U2L M=HC1P;*P5#0V/IVW6*A,_0+K.J'=RRNX,8KXC:`D,;ZZR@N332T;0T@=$;F+ MQ:X0S3%ZSQ44V'S-&3W%3!`GBQ#W[*IU?Y$\>(X&=&($G M.ZI@+3-9#-DD,,@AHVQ"]^4W'C/\8OF,`FHC6LH.)?6P2-;$`DZ0"P44Y"7V M#(R>IEIV*`QE-"Y%>T^IOF=CTN3"\R;DXW@[.02T035);^H'1P#H$;$9>&$&&XQ%2J'E:4 M!Z6=KEWS&F9(V(Q?,2$`6?R&2$@:!=(T-\Q?E;UI\6'XT:"0P]]"US?)X?-7 M8*-@/JSY&SP`3R@EOU4F=(>V->$!W#SW092ADUP13X;]M/R`&K-P&K;-1K(* M(183<+$(X9PG,V"G.*5KZ_DFSI+`3.$Q=!SP"MAJ`48QUF2/N5QVZASU.;D0 MF(=@`8\ATI!""Q"CF"XM]N78Q7*5R#Y*\71\&UCQ[:$)$=#QD.BD^OWAZ]O- M.I%;O_KNX?OWA\_T-JBQS+9]A`AU)JAUT]\SS!SA?\=C\!)"9?#I_B/,%(-F MK?'\-^T?[[]]O[\=?)(_!.Y,>=>4[_YY?_?]OU$4Z2"+LG2NP,QX"V=8_3#X M?/_IGV^UQ_ETZ-J_:>HP;#9&[6JA<4[2J66:;K!N^RMHF#%[WA4O%DJY.`XF M$`6,;V!FT29'=4_=Z+#+IE@V,;FI72[YF/-DB$1SR9"8TQ\I#2:S@661@ZV` M3?$MBP#!C&1)2D,>&2/H/J!*D^IY`SIGQJ@R]WXE3;PW@:=$CBWYTL\-^"MF0'&B<)O)5N5;+496RV(PEAVJHJ/,#+P7$>1!N>Z(C8YGB#5 M5N8*H;"/%)V1YR;.W(#Q=-*X%ZD]D(YV0R)>:..*DEC;AJ_/45F_QT,FL00F M8YC9W:3T/@GT_(X`WZ1>(4J$]1B&C M,L=7[>F&CSCT(PFV:O`\X]J7!)%UNE&!-/YBJLSC3])'Z8;P(VC8,4Z3;QS+ M&X53?D'K4\T0;OQ9F+<+>B$,'K<",+OE2S=/U)SIPO_A[K8H@B!=2SN&-+J+6BQ#G]S6N5P[=S_K3/S(O:(8.D*JYZ>Q7?!0@DVQI9RC(A M3"Y)*N0LG\S.A(]"U&.7[E[R%%E3.K/&$=ZP;(6O+GAJ M&J^G@7S^[%HCSOTQD#$,@?U$;LGPQI"4)._(&+T1\29.5HHW%!F[T&NVP$WT M:HA'!:)P8GCK=;^T8,TE<2'B;#B&/?]?QCVU.;<#2,/(WXQN+%)_7I!B;FCC M*N'!B>`63]';TAL6+Q+L:H/YX[#-JE"`@(I0F(3AKV@M2'V'.%I(*N+Y'-3% MA!2+6X9EC9KGER?DNO1SO92'E&,)FUI8CNW6K[]I[QZ^W;W_5KU]^/1I\/7Q M_5OR8!LSGVW0]196];O![=\_?GOX\>6N*J`WOM^J^;DE#FH2@6BNTZDRKQ$BYROF$M.M4W[G,=KT#N'!L;=_?+ M>KUXUN1)Z69S4O;[_4J_WSG(G/))J)K\RQ@0%.&`[<9UFPWY4X*M*M`&J%6C M)/LM]^)L&U"QYF(4R56;M=VHM#KU2JO1+6[XZS%0RF>TI7*Q3!G(TRO>"P"O M1V[;/CZ!AOT.K\C1^0&G%$=/@1-G)&"@OD4*_%>Z)J?\V3RE9,^MEQI-ED:3 MZ4K>\<2GE1*1)"-EK:0^'-G\ZZOX>`V]7&G9\QPVTEH:]?KQU);U#P=RLC_> M_\][/I2-G/][%>N"4O(6A!#.M08T3PIMTL./[B_F;41"%RGH_'[5H0%]7\)D MA<\Y^Z`OERQOR70:$&[]`\[M[(FE7S0?;_->CG:G-I6FXUH6SZ'GL6K0^^][ M7=.D$-NXN[F=^BW'^5::Q.OVT^M5.LW6D2WB^/MU!&PWAJT<'GJS7^FWCN+N*)=NMZ5K@:W3[A_= M4W4X?6+#>QE*I_!7N"V.S91ZK0T=F&XXM-GN?+GD^-JP]ZTXLJGW*NU>XS4( MDXM:MW8+M,7.1MKB.?B\]^QKSG.8?S`L[Q\8HL:&K34I/':\6)KHIH.J,&!VA*&O6`L`5]_3&&T\EWII==\;ZZ; MKX.[N_LO'R-Q#/K<)ID":O7/8C3)33V/J3'%KJA&BP8XH`"\Y`7.29#G6,[+ MU\,!W!GY";UOVA*=[B@$>9VKL.1*H%R%@ZW":+V[=MSX6] MW%ME=5[\S5Q6K]4CS+2@^]1R1R%V=L+W>\=&;#IDGG3_GH83JG3_EN[?U[8*I['S7OLJE.[?TOU;NG]+ M=V,YC[.=1^G^+1T0I;.P7-%R12]@11L5O=^N=):%I94K6Z[L(=R_.T>L[R'P M.R]*_;,1A!ZU\S!&0*#OS)NNA)!;[Z4RUER)-<]RC#?;Y^`7?VV.A'\RPSL) M+\+K60+J_2M(KI$U,VP8]AJ!]0&CJJ*9*VD[+Z]ZUWMTL2` MUZB!I;2A70G\2[>%*(<+^;Z%)?$??BL<@_]WY/E"DB:WG=\1N'N7+G-@.P\A M\8]RT"XRQ-&'(7?!W@<"6Z-]\I0X>75K#YNLVZY7ZO7#G1IIFE*J^J*7?YL+ M@VQ.6=+!MD*MR"Z*F<22]@[.RWL#)\C4@O1*NXX__X_H17,O[@!^Y/*1P7^@_<-R9*+F+OAVZ4SIH#$_T&0BV&+A3.8 M]D+_)]8$:R]BL1U>)LC%*CBC)\-G6KO2T>N5AM[CL#2^K!.#-21=!\8*ZY>L M7L%K!V4V;&1D9BO0NCB@-6H#E/&AI^22^A)2I"6LZRUGB4?.)U0BV9[CLLN- M?V):S;>^#AQ?(Q)XBT>R).X&Z] M76FV#^9&O]:7B-%SNW\@,=D'>?G(9O#A-":V^QH54^`I6QHN^I'*"YRUNT2V M6[P!.VUPX!,AG5YI=W50)3>Z)"E,?SPWP?>WT.:"[V^&4VTLV<*EX,MAOUJ[ M%'P[\!^RW<+6+96\O"YSKFQ*)6^-/@1D$IZ[;QV=1Z2U3C4M:M MZ)+8;FM9]ZJ5O$:EJ3H MY)6>O/6=*=U&I:4?C.,N3-:AB$-9%Y:R;CM/7FG0[LI_1XG$+JY4VYD$Z+8Z ME79O(PUQ[T$,2WV#EQNC3E=UNKAN/A%>_=@WZZ4:VXUQ,Q=`CJ M(]/K"TQ?F'I;:!6]\XE?CT*`=V'\`T7W[SF5X[2;*Q--SI8G3@V0^>1CWP-W MEB6B)5K%KVLOGRI7-I%'HJ?VKVOHGSOVT==%)]^?F*^D4JAY&6K^A69X\(5M M^+XUMK#NHJ\QRKJIE6QW:6RWS(-T?+8SF<3Y4RN"\HP@M13H&'.0_,1#VK7/ MF.:X`=.:-YKE:QY3"XEBH5+FF/@J>V;>'(N8NEZ`Z24SAH5O*8\(GX*!.A.F M68[:([6'+T!K\`L^%SI&:%H!%=EV3"RL39_(8C;P:S^`?PC@@Y*>H!L#`]1] M2F/"'"IH">C!M&M1F/MFD_VVAE]UQRFN@-?JF2]&E.1IARHQJ^VK/_K-.OZWBIP[3*J8E7@V+!O% MP`?7^XC[=*\+DF[\".NB=PI:E_3<]K0\#S,2Z=2D?^_P&NH?/=?W=UN9_':+ M%*2+:P*"I[.G!^52?P%)/%C6VR*'VE%JK0DFKHFI"7R1U*VU7$+.^W8P9^@[7.E MFFO^?@";")7RI!5!FZPZ)*H8N#%\;8)[`OX$JX5-9[8[9]!7B,GHA%O`+9>1 MJB'.D(FS;!3^K,OW&IH0)@N8-[6N63$DWC\^_0MJN"$>#:B,60V=/WA>?H!S)N++06 M*IH!1MQ$&#%C8Q2X^"41^B?B.,#@;&LL[30Q"&E?18\\NS80$*RWN02%X$/' MX3`^#-7<$\T$3T`ZH&5H0(M"+9Z!M M`V-TF#9$/%G-!9N0CTZL.7'H_VGV?\.FP#J"OV2YQ&*YB%]"$?Y$M);(]LD;M>8#&#TC:/ ME^=5K,5[P8,)\900.1%]8JH)KT3PY,&+0/#@R4>'!_R2BY<"A!X9]BBT29Q$ M*RD$X;(-AFT\P>M#QAP8A!F.4+2ZGBIH76_,K"!$+`_8L0:N)?&$,9MY[D_9 M=$/_M1)W_60!FP#S&+;Z?N[B'J:\H'#E_3N$N8WG.[//XZI%13INOI2Y<#=% MS.%\';+[+X^W$>6.C9VA0)=T:$#?ES!9X7,^5D7#V(M MB7*Z`#X^WY)4^W\O/>@+*Z/5W00GA+?\C?F,Q#FJ"B86#^]7J73W"A6=>LI%808<]'+TVAT*_5.T?@^JTAX@ADR MO+6/S&$>6%.X_0T33'8+O1_H>CW1`W^;21XYPEW`"S3[E7YK(T;<_RS+I=MF MZ5I@Z[0WPP@[M.`X3DZQ<`VZ`4B05;ZH8S/EON*J5QY?Q090B]0NO5=I]S;* M%#A787)1Z]9N@;;8*23W?1-)DA>:>>J.[[O0DQ=5*YV?%>V%19=U'<):B:[: M$G=WJ/K@U55H!W1_@7]/#1-C!?/N.&J;C$1/C*31!BV@ES^2E3TOX*Y3\T\& M.M]1#H>.XO1?XX*`._=A'*&#KOOXHG/!%?^+7JMK4\NVL0&'!72CF.7/KZ`> M"R-\D9=YV'PTJL1]&][;&/`@;B9F5@WXVYC(2QOL0*_I;6T.-NJ"EW_;`,?- M0P\R8AX(R#D.9:`_*:ZI7]/KNEYK]/HMC&^JM_%CM]9NMF`FC68S)S1*K\+_ M1&A4OU9?V8@:"/@OH-:_:*75:!#]Z@]H3D]-G`:Z_GQ:>F/;^6#<15TTL;?Y M=+N[S:?;[FPW'XHCT7NBB?W-)QTXM?%\NMO-IT'\5A=-[&T^^EKKXWH!5@MY MYWJ>^P)B5,9?+7P?10KFQ/SD1A:N&S0+S_?U9E,=],(@=AM]?XW1IS?_^J-O MUMOU[B:CMT`$CZT1'"6#T<@-'0QP)R%GL72UE;4>+:.R"HK*@M/?=2;X)T;= M:[I6U1[#Z=3P*!A&61PM7AU-+@^=?'$+2V]^SRSV`=OBX6CO>&#.6/L**@"7)M>UYU7W!\!T_'/J6:1D>I=D,;&A;83T++]]0KS2/69+[##)N(.9QV:&QYO'Z7HF#D%[L8(G M;<)]G:#)PB]L1JINO'=FO`0OAK.)4)D?#@WD$?OQM>NK'[7'FO9Q,/AZ=5,# MDM$S[LQR4!T&BL+2&3RJMA)1FRB#K>^V>#!HS3`Q.(.^K_!0.Y_T[K@=G M`FK8O`1Z\EFNBV,NE<-@-7P4(9ARQ7<-!75A!!40/Q[#S.52D2HO@6&TD*&$ M-I/A/VECK*3$8_%63E'P`Q@E#(P'(]#N8#Q4W$=:2G',$"5Z(5G@_-"4=E<0 MC*(F#1XPR4=%+&I-\^;A44I81!D+*&$Y)G`WY9B)P$+Y+C4]-8!8HQ&22\3A MC$-8GK'E8U026BHU[99Y@0%<9#EC7!H>:>F@C>0&E(%FPM.VB\EG8O&H7UKL M*%(K'^+^!3:P'#@G0KYK8;5#6]BA'IM@ MW!=1"5EEY%E#7,,YWQK8U2/R&\^MPS?>_Q29<5BGR?)]VM-_XCALBSTS3CU\ M.9X\-NT^6SAI+!F&<\(272;[3XC!8#"\J?$7EUTJ*07KPENX=M"7S0RJ__4" MXDQD_FVWX;![#QH3TNG?H4.4X?3%8=RJ37R(FGA4F@!2X)'M)Q84M]?`<4)X M]AOE"6(TVP>8$1P!U;]'K(3L(WP("YNC`D.VX8=H+&O2'X4"C`SW.#$^I2ZZ M&-F*8;_`]IK/2),Y7AC=WG2"'SYMVO?"*^%?J#J`@HU+`KXA8,HYYP=R,6X< M#*)."0D*E<4]&!].$8B;"[^1K9NR_ M2R?Z[J*(R`-;59)B6LI='H7+,F@1A/*(1\/C`*/H:A08<';!AK8P8I)32"@6 M-#GY$#GB^(D&4P#R^DAJBI;/')] MA3EQ2XV!B[:ZD.#2#E]?)AU.71+$H@\.$P84TVY)W(_FW"JV+]DJHIP$<40# M%XWDS`53U"12";-%TSQ$!%%D&-AN;+G0OVI*.=4TZUE-= MPB&"B:_8PU*)F-YI"^!)"K.IU@>)O`29Z/P@_11U-])10:::%7H*+V`L4H9M M"PXG+FA1<44)]((%%.$(`=L$OQU7N+((JO@TE#07L@JEG<=`&?11BY";2!FAR2T6,5J0,VM:#"`DS(PE>U.'FS56'",N M7D8@_X)"N.ZR<)M+3"=8P>=WFG25J&@8MJ00NB($XY(@(263 M[Y9(43"']!1N3U'ANYXOT6]JB M3W#N1\>HRA%B,WK6Q$+>`SU:^A"(L950!CPIT#L`>LR0+8SFHA(J8V[[QIY= M^QFW[B=,_L6JXQX#.Y!6!&_6X*PP+E6?'OADHH<^*ECCT!,85.3.TCH49T+I M-E*]-4`D@:PW)L`UY#X@WI(AQ>]M,'(],&YOC9F%Q\FMZX%>R:7S]=7']_*' MJQOLA&L\7*^!@&999M9SJB/=140XC=&&"%C4,B))DI\.[V&[$ M/&FW!DX'G;A\0,EWI6-#G%;0P!"6[RD8K&HM-VZ(JN%Z=@,C#H MO=AI(N>QH(-&'47&S8Y8:NN)J3X";)[Z[HR%E'K[>PL:$:BD7J2_Z3:7U]=?ON\^/53>QGA(>GXJ&!^8R;UTQF M4MW%F52:@/P"U?;ZZMW@V]T`KP\'Q*?K6'D5<>]`5XD*Z@0HQB8E^(MUIK=# M9VC9>$F@?!]=P[XPCUNCGH7[!XU3>\Y=I/)AGVO3.%]JC\9[H4?]1]5ESAZ)04R!M2^B>//S3T0(-T`A`N1NQUQG]<,)4" M>?EDC#C(!@E85#T]]FS!`+GO:(2M>JA^`OO&^D6G7Q3:(RJ:J]V#2U%()[#>1HC1IOBJ3RSK?CBTB'4-V[9!NAO M(DN48VF)<:5\<'@E=R,/<:30T'7_2GK/A;-(NQ\O#A'7@&$TK3"DX[%3R11*. M=0L(*:YM\*/ED7SB74?7OM1WM)1PT,CS'70#Y2VN&>'44XS4.UB`1-.1PDGQ`^=O.W_C=U^H#_R6M4U\FCD8B>4!&'T-KAMY4)0<&5_\B&4:X> M1.`_-HXO2UD107S-0)J/B/K8-8AFAPES9*U'T^!4"/-,O#%B\=CX=-YJUCCQ M!5HQ*'[YPT%-??HMO6+B5 M+VDI.Y340^MV`A:A(Q<**"APZ?!2EZZ-N(G,/(K70<)RHS&^]EJY^FAXTZ'/ M+6_NC(Z/#>CHWQA^($Q(=$KSM9:TBV.VN']87("(!>;-R49P=G*)HFL0N>07 MM8-_$$8A3B_B#[DT<9B$>NA7E`=G'!P4C*'8?Y_Q*WJ^D<5OB(2&)9C&RT&9 M2,C>M/@P_&A0R.%OZ;X@,7SI=W_"^#+S-^XZ5Y0JE0G=H6U-#,5)`F.2J4E) MFK"?EA]08W@_X=HV]ZWP36?XP-Y#TF%)Z_Q-^.R?;^(+S&=RG:"'GG0,->A2 MC#79X]DJ&I^3"R$=T")L6-("Q"A=&HD`'B`H92:HZBF^#:R8"U%V$#0RWDGU M^\/7MYMU(K=^E#H*;V\#198)Q+99P8AZ30=9M!FVS8?!Y_M/_WRK/\"%I/B3BH+CKT@:6);]JP*;XEHBN\!&@D(X4,H7DD3%",Y*B M"U+WD1FCRMS["QAJQTS3+;?#>6P'KN?YTH.'P?QH+"O\5K)5R5:;L=6"*(QE MIZKX"".#(C-<.M<5L*SLA#1&9NP"C22^E%:@^DH]V0B!?: MN*(DGGS!J7UMIGL\9!)+8.)U'L]XX/:CHF,E[@AB'9J;G,(H6UQ7N4B*HDW. MKY'K20D#/;VXWE^PT)@5,9;F1-0<>G0,%5G=`,Q"T@=S1F*?HB.$;. M1'H$?7(!<#<` M-1'IP)@PS$)6G`_J'>^*AU16$U&68@4CIPG8V1/0C="_?!TGX"FP$QG^(,L1 M>4'2+R"PO&/7N`#<5WNZ$5EH<6CZJL&;;,8?Y(^)C,C M^!W*2&2=C2QO%$YQ54:45C$7QI^%E].@%\+@<2O@;8DOW3Q13N)4\1)JM2AJ6\89:M\-45B0I1`&+\O-P7^*<8 M74T;B*04RWEVK1'G_OCJVG*4^Y/4C$A*DG=D;//,$<&SJ91*1<8N])HM<&-YZW4?WSU&J<7RW?%%<^"?C]V;_R[BG-N=V`&D8^9O1C47JSPM2 MC&[D>*0]R/+14_2V](;%BX2W?.0.=\=CGU&C=.THDYFDX*QAA#KGQ+6AX3EEOIZRW4];;*>OMG/Q:E/5VRGH[&R]E66^GK+=3 MUMNY["4KZ^UL0ZRRWD[ZO;+>3EEO)X\>94&79#]EO9V37IZRWDY9;^CMEO9W3JMM2UMLYSW4KZ^V4]7;*>CO[J;=SUEJ55;ZN9 MK)L$8*EA5+6L_JQDR"-%W$<;*;&/`N#+8`$<(2D$9+2HR%R'WR),\`PD*V5C M1&)"2H>1X6#`J@CFRMA$B!GXG6L%II2'RUZH<$<&\VJXSJ1*`E2H+CG8Y MO=?*-B..!F39(1+@"TR;0$J_PK3IPOI"CZZ%P1$>4)UB+,FT0#(F9Q`3HYAHZ1$30<-48%DEG(9:]@>*W(?8D4 MOK2N>5'R$D-0^=S]"%.(TS?"*>#`O:02 M74?TM'H),]9.QL,)E!R7IRW'J4IR@,GE3]3BX8!D%D?52D0;5O)7GZ-$9(,9 M"DQ`V7,\-)QP]'4\QB1GIG)2D^&/2WI=1,E`@(5Y=+9Y!+DT%Z^+?)%+X^%X M#T=\C/(A9D^"1$ZR9AR\Y5M@N!D>S\X*(QSG5)!7H]9)Q'7#%U%<=Q;+^W&I&:68U\\D>+B_QL-++)U>1@VM_\81RA7:/*(\IT<+#]F)D]J?/+<<"*P2B7*S7;U7@A2 M4>#14LF[J-85EK$2X=Q<94?YBLHX'G@T8@/!EV%F`M]L1"6A>#I31JFR2F9U M-L1*C\NPI0B^;8'DM0I_INJ**D44WG,<=ZHANO!UX15=^_V6WNVTE>DLC&&7 MH1=:SK71Z39[K?HN8T>HYKNHS%*JHNNZ3Y=%70]3U+6-15TSRX_PY:']N;J, MZXEC\\4'UB>TUPD'.ZJRKF&9]5,]J';V'('N4N_F`?BJA6>X?O8LDHCP+2V+ M6&JB&%%.H!G3"_CWU8UPS8BZBG'-,;K.$-FI5M0@GEF.ZU01G(\CH*6L%F&A MP.@8(L!BOW01!S^IZ?@HU?R*:MH(C57<;7#W8OS\T'5"2@F7^%JHUFE7_.DK M@EN5&`#N&,XBB6\=W=V`*$BQK?;%V4VLF9N9?+S*C7+S"S`;+4Y)J2,$^B-2(( M>S0D(_.TJ9@@PM"!EUJ*I2*_18`)`XR9<+IHT4=+SUV;$EQ?`0R8$8=0_)6P M^T%Y9![BY3MQ=GBB2&J44[]U?Z3ZB1DS?,G%6J8C@Q=^Y8F">.N&ILW$6%*7!PR$UPKK["D=NNB"*P]+VK29<]5ED.L*XG70`%3]+@BJB?>:W) M<7$)4B]A+?9KS?021"N<,V?J:$;+#*02%8@3C>J+ZTH]RW(VXIZ%Z]8B!]+% M)#6$^8TV8%:9UFE(BS]>X M]$5<^>)O(;(7;AQ8MF>T[X`11POE0]1Z(9$'C*J9@"28B-PXO=+NZI5NMQTY M#,ZT]L5:CUFDH+K9D%1QAV-['=:`JJ%9R M!HP0O91\8R,`+6@8!E(4!RJC8G>=?J77[=!5:(0>$1=Q4^Y!0-GR0#IF1NHL MWP`JZ77]`N[UI)`^BCPN'I@GLVHEI<-RS>*%J>)*E6/J)FE7.GJ]TM!5895. M6T_?F2>X*"$@\\JL\"Q=TG=\@4F;G[%;)N?N%`.^:<[@;UJBCFDZB>Q+I(+? MO.>G%'$Y?O%Z*9/FX??R_/Z*Y_>)T>72%X-Z?X]J!G=H9;'F4?-* M-\F$VY;>^4E_^B:YC%G="V-CDZ#[/4W\NG&3W^L6F9K[(*YD5ME]:\?^09FI MUKO:&_'AY.:[UP7=*FM5W[57-(6/,-F"THT+D!#-/?!P8X'$)YBTNT?:[=)E MM]ZN--N%I#%EBE%]B1@]ANS<65[V05X^LAE\.(V)[;Y&FTG&W:1AO7ZH6>TS M#?)$]BZR76-AZYYVGO&)D"[ROA],\"W3'\]-\/TMM+G@^YOA5!M+MG`I^'+8 MK]8N!=\._(=LM[!U2R4OK\MVG9*F2R5OBSX',S`HZB#K'D9!*>NV\=G4>DM4 MXU+6K>B2V&YK6?>JE;Q&I:DW*_JBBEP*OC65/!)\=-HN`:@I!5^>X.LL`6\M M!=\Z2E[IR5O?F=)M5%KZP3CNPF0=BCB4=6$IZ[;SY)4&[:[\USF&DE<*;D)[^X]B&&I;_`H(1-9\G7O`Z&K.EU<-R^#;C\Z"0I:]\W$\]Z[ MQ[#>H\[_9".&#D%]9'I]@>D+4V\+!>3[F!?FWJ?710SB5-^!.\L2T6*HS5_77KYMX4Y$ M3^U?U]`_=^RCKXM.OG.[&+Y3`[!HZ+34NZ>@[E[S1M>\G)*P&9Q-5CF4+XQIH?/%61:@98L MTX1AH,Z$0*V4'JD]?"'&QUH),:0`"R6P?RB-B1`O)5*A0`:]V62_;0L'M"YJ M3`8T#>6"F!R[^RL1C>?J`&/03WZ,2[/R48$KTVNWVGWZ_\XNX#29S438/#SS M+`W/T^_7T]@\*T==.%%:O6:_UJ[7Z?^Z*TG22I"D7857>!/UK$96$*3>K/>Z MNY(D'/IP=@!'OG]&SD]!%N7]6D(4'0:BJ(L01=$B:'P52%"`39?DHZJ`%\@#WJ(:6/*5&@7@9IA+\20ZH@/PT\%A$:<>>Z( ML4S\?[R;E"`9->WZ,4XUKVD#),48>LLZBVF"4:;YQ"/T1:6?<(933O?6K.G] M"),##D-$$HGQ.&B.M!38*U&04.[PS.9P&_O"G\O;\TG!\<.!@QSH?(L4-T:! M_XW0/6BL*#J6_%XX"%VSVVAV^]UX3DL&L]]9%8E/UVHT6JV6OM6L)%[^1V`J M!+)^<.XBS;6,"EHRMFNHW5T]43T]65Z38VFFZ_ MT>GH1YYNO48X#XU>OU5K-UMZ36\TF]NN=&Y39[#J&Y%A.0=L1X:=N,%G#^/W MHDR-F'7BJU)U*TAUXX@B/WPR=R-RTR%[>>!/:.#/P,(V1!(W%J3)0NCE"&$( M/(C*&,'Z1.4NXO(V"F88*$93XR\655KB<&`&F"Y364,*Z[$8A&$OZN((.U_6 MBD%-+K-.#8*'2[N9@S`1+B%VF_V"=$28`C$H62LGGF8E"K&#UIUP:O&;,=)+(HZ:'Y,8RP0DL)1QF5TV'0HCM%>'1KS/$H(X\-JMF6 M$X!Z::'ZPRE44:KRR(>H-A;WEL`4./IYA7[)J\R?0Q\6"B(_Q)"T'\6Z<0#I^LJH;D3J.7%]ASK05L-$FJB74^?UH[TE9GSP:_A3U&`:\'`,'`\>4Q4_P"-GNU2*5QDR72*O7;/<;O49,C^T&?@IT*TC[S*&; MWNF#EK(?NOT<>K;U%GLD&H@>Z;?H5^'J_8/_Q1_YKS?)WZBQ-W%KF:VC_I3= MM.6[+;W1?0M/;-7R#)Y<.FI\8-LQ_PODY;^DQSW5"Y558>*[Q-NP#"AF72_Z M<=-9TQMOEK6H='?'\&QPEG$L$A.GH"U>1W5;_WV:@V<9_?W-[__>J/ M>ATZU3N-?ET..GXYW:S/Z#1,$].$8?R<886$X#,C=#(3SEH'<81_O\KQ:WV? MS]C@IP62\.?4=ORWO)UHF/@G&2%ZO=YYPW^\^B.G+=[I?[W)',O"(B8G(;]- MT%%,EVN#"T1`6P9!D_Z(%R]J._HM]1(#&1V_`BO-_PO-R8H5!XBB;0)(:Y/:*Q<%R&:FS. M4+C&QV.H3LE02QC*^EFRTT;LU"[9*9^=/EC/K.2GC?BI5?+3$GYR0Z_DIXWX MJ5GR4SX_?<>BAB5#;<10>LE02QCJQ2W9:2-V:I3LE,].#TXIG=9GIZPXT3-C M*&0!'KC[($+1MN*B9!,E"ZW-0NU>H]VL-7O=QKERD!1)6#GLBS'=W&V)_,.# M@V7E06SJ^PM\GO\/\]S2Y[0Q2^D@E;IZK:FW&K56H]<]9[ZZ-?RG@6/B/RAE MG@T;[]ZWXK)/%C1@PK0'<5RJOQYG;3+B;]CVUM[[S[QH7,GP&S%\:74F./VC MYX:STC;8E(M`9#::_7-G(XS!O)7!8UB7_=W\BQ&$'GL8QU_/=^"KTHFQ,6>5 M5NQM_8R)TXF,3`LU)O73\`MOQ&$;F?+&=[=?X; M\QEF#V(8(ABRMCO#^;WG<=8EEZ[-I[VSY])/KC/!@N!W;+A;F-CYFRNY*1UDDB;+9;Y;E9U+GYD3G, M,VPX-@?FU'(L/_`HH;`\.3?FTYPLSS/EU@^&Y?T#<[/>S:./_PU]H)(U_X0J MUM8\%[5W[\S"P*?&FOOW#W^0&5_W42[9UD,6MGBY'=;>#HG9T=L<74-B&VF'^!Q%Z24E<:\J_1D-A$J3:_ M2K7Y[/BT5)M+M;G<#EGY^N>HR9T8L6$X_9C8]!>JSJGP'YY%_IPKOG^(V]LNP"NKW"R3@?!$SOJS;%8NTVX22SP<;@I#@-,\M6Y M\M0!X^M*5C\Q5L?A="-6YW_1*=6JI]$JS^V4DE/;@-AR_OLFMHIQ*O$V6O42 M;^,$\380CPPTV0SH#/G+GIE!1Y6PWS[#S;9`*KU(4B6P@4M@D=,#%DFR@ZKL M'X0=2EB09>QP:%B0(S-#">JQA!D.#^IQ9&XH(3F6<3LR,Y1I14N8X>#Y14=DAA**XA2@*([(`"60Q"D"21R7 M(4K5\12RXH_,`Z6*L,@#KTDS*!/GY/(?/W'NJ&Q0IKV=2MK;$=E`K^L='M4( M"X6?SAL72AO@8*PT*[2*I;@#+U7918!O[=* M?M^6WQLEOY\?O\NH]5ZCWL:/W3B`O63[M=B^B.#U>`:?1`7'.1DU6QDQ<7W5 M3W$YR#+B_D0W8ID^/8:3'&D:L3>EG:SM%Q.4%A=T+YO%.P/2S/S M&>_[PY"J3M'#W5)7.=WM7^HJIR"S"CN`Z[U(9K4:)+T&:*[#X:P+>>OMV/7#1PW`.'L_*7]I*^"^0Q6#AYCCLG,*_&MY]K) M]53IUGR#/[_!!R-.232?:-ICOAMZ(R:;MHTALW^_^B">_9?>:OS+'MJ;]"S[ MH36&!IT)S,"I_GB\^N/[$_.9]L)ENJ\%KC:#SI\,^'+D3J>NH_FXSIKAP1=X MS"$3FIKA:XQR"6K_]28QE7W,3S^)^9G1T:S9\=ETJY]QC2:>?-&LWP-8P4H9`!:#O!Y#;@'7X5]XLWA9ZR":3D3C7.E9L"O M^!0,U)DPS7+4'JD]?`%:@U_PN=`Q0M/"+X"'32Q[29]\U[9,`[_V9:4F'WMU MH1NJR^GC1%UHP8.6@!Y,NV:\;.;-TH6UW5%B3:G.I^O)-7ORV/CWJ_^3"6'W M)<3M_S!^Q+@)HM:M8=O,?#<7S_GB05_D'"Z"_B89IZ!>_@5SNM+>9/+SP$M. M'[17.2CXN()CQ1-OQL8HJ"J;QUDQ5N7M^(94SJ//=X^R(JW M+V_%,Z9T'BO>.?WY9.:8,ILXG[M:Q7M7()NR:Q;/?E:_EI6NE.>\-A MN<0\Y%K((2[^6G9)^>=__/4O/_VM4NE1C#QLE9[?2]]MUT,ON'1G._!95OI[ M^?M=^<=*)1BYHL1:FS"4N*6:IAL5K5'16J5_EEI?M%JI>[\="!_][0O_\8P8 M+@%K+ONRLE=?RPO/6WVYN7E]?:VN%H@ND;?`+JZ:9'G#OTTS#+T^9B;/C'72^QZ7=<:N)[MO0_= M.>'#0$#@P__2!<7SKV6`K1)"P[G\@;]A(6R'P[SW%1@3LYL2U ML,NP!7\PXM@6-\I;Y'`HI@N,/2;`FVD^LZOP]H@H:'2!/=M$CB"C*PFS^D^RU,/?G+HV7@^7F'J0RZBU[5I,D*NRR]\DO;(X<\BK,L#F7P.^8OB#7_L.''6;_[9K9+A92(D'/$OB9KI=+1-_' M\ZG]XMISF#O@E4R3K,$MN2^/H$C3QB+L,<*0C.ETAVSZ'3EK?(\16],MF@+\ MS#=+*6YHN;0]GP=`#TR-:PDBO9B.3&3*@-`CYF\+XEB0?@Q^7T,T$8$+R\#* M=L$?@T9F%+D,F:*^;>Y=S;+]WT(*X_8MP\#%^)RA9T=\'LK09^I$%&8+IJ,4 MIM(L3IPI[WJ&]X`H#_X;W,<>LAUA:%U+OQK//#VWU@Z&8?`EF*?!%L\'(.[Z M`6WPQO_,*Q'\@!7-I2PVDK2W0."ZV="-AD&&LZ8CO,'.#'C&(QL]PRK,`\'% M)0([A\S!GF$<9R+"76",0&CK@S^#D1(<>8@4,K@;3]2GC(+L9PI>,JZ(>^: M9YN(RXEBSPS_O@9N!AO!#(UAO69<*B;DF!C>Y7Q1Y$\3OB888'6]Z#,YW8^S M1/.-I#"QBW*>62.'H;T9'>OT5SZW.%*(^[X4H1P.,8-1#GK&SMKS9WE9>L4\X1>_8K=FM6>4%HQ8N;M1OL>"Q\A^NY5M'TH/;W0_#V+JE= MAAU>@"0TU/M!CGFM@4<_^,7AWB#'CX=>#TSR'3R3/ZNKS4:C*4T2(1:$)$S8 M5I>&PLXI60JAXY$354(HS!:_EJYKFE8NO6+[9>'Y;\"K%;4)A7D$UETNK1EP M3U:YN*3<8<<-X2L@_7('P^Z%J`&.$$+^U'<>W?8]"Q)E@$X.( M?(I7FUI'GKUFDKT@LD*BQVC6%$#SR7W>$8K%4E7UEEZK20/T`.4+0BHJ?XRJ MH0"JCQ2OD&T%JU1P1GY!>UKUFR)NN`AQ<$.6\^HC1KBN`]@0SC]HF7U`) MA1Z]8=0U:&\I7$^^/:Y#7'+A#<&I:D` M*(^4K##UWA\=M-T/!\M;\67*`^;>I]EI2?3&V:0O@:"PZ#&B+0403421!^*: M82`Q:C5Y4*;2O`2&QX6-P6LK`-XOA%BOD/M5=F2' MO,A1>#L$>>@:ARL&%BX9`KD2JH'9J'725LEI-4[QK[T&@"<('(.J0NEJ1-R7 M&:;+/G[V(HW4:FV)WF6?XL61/29UC*$*!:OI@E"/BW-+*"6OO'6XJC?KAKR, M*X7BQ3$$G6,H0KEJ3Z>8Y#8FN`-=F&AW6JTY25@'XA='+H#PL:IF0HA,1D# M=+VER2L-RXN#*8Q';O(PJ/$,4Z$DZ,?NA$0[*[9Z75[`RR9\.20%A8\15:&D MEXSB28$@D'JG.,_)D1%A4Q)<+N&$>,L0IUPS21F\VFQ/5'T7`\ MHH$(SIH*:Q'>Q4M<7Z2@,4=FU]5':N=`4L@@H^:D`^+&\U"%2G'7LNPM_4=D M6T.WAU:VAYR$@-5&4YV:$%*S3_=?%3) M"%Z+MYO7/[2;/SUTG_K#V;;=/*WQ?#J#7_>#A]FT-+XKC1\'D^YL"`/RM:!_ MYN1][J;TQ#P'(]F>(#M.)CBF-W;KH_DT/4PQ8RW?.Q^R]:P M[K&W(/"?#=[Z"%@6:,V&/)=\04E.WT2&=3#9\N.^;$D%>W)5O=;NR*O<9=(] MAU.YK@V%WDI,M6I5Y<>[`G'E\$T@B8U_*13_/"9R3)V!<=34,`Y(NI)RU%HM M><6G'5JGN[]@[R5".9BAMQ#_YI!-M&H2MPH/TSZ'D1\#)%JF"VLARUM5KFZ1 M9U+%M?R"6C/=7YX=B&]&O2[O!-YAXF>9-SF2HIUM0#&5J!7RGUR*D6/_@:U? M8/'%;7KLQELJC)];:LH\MW60^K70SJ,4!:?VX6++]N@_N+E$Z66"30EH1=XH MS5:$^=7H\3SH6]DE>:^$#M6F`> M$CJ`KU&\-#P#OS#IW0H?B@8RU0UYB6(6V>LA*J"&`-JF&C,S*F"$G?R\?-&\ M0#4HI'?ZTG^"&08Q^]ZP:.&SR6=9[O:3WL_OYS4_NY\^^#28PX/YQ,O@&HX??!Z71>"IO M=__@/?6Y=_H/]?A$_3NZHMWIM]+=:/RKM+"R]P"1 MW)$D_8*M1PQ@\:U8BA&_/'W[N]IL2#S"EH>3TP/+8#[')MCXX,WT+UN?@#+' M;CKM:KNERUL#Y>'D'-/^H](24>)11GI/`6\8JFP%PDE MOB/47^6GYEQUHREO>S8G-Q)M12Q93_,F>;6HF$=)2#ID;,V?AC*>)XX>P\0( MGU/C=[BE92:I/89YOKF0P.=2A[JYQ@2O`@L?SW>O6L^P=(GW+I[,5R$-Z'3- M9K6E%=2:(BDCN7J$\49)HRVQ;2"+;'%L040O66UJ"N072?L>\:=$@Z>DV.*' MQ^MUB8^@$>*A.%:06V.!2;04F?VI(3-Y!=R'F)E:(,V10F1\=2$!SZ>0`/BV MRL`G;ZT!HZY+7(,>HU]PB\C2E%J%S3C(^9*$XH6!KM62MQURB'1QL!?5CV*% MAH_5VZ$;7$6_>T.=OV2."K4[5PEJK9:\[IO/LB?1?L1J_HESU.?3LUJUB531 MDX^K`-G:$CNXCM(OMI%D:DJMO=5]V8+'`H8WM*<^'A`$[ACREB"G,55@>\FM MTZPL19EP%3Y"-/D\6%W7='GYBA`/!;:18QK+JH$J8Q*ATTP^3%9K-^3MCXBP M4&"#.*(OQ0[7;B]?_9?-;YT)SY,:C8Z\9IU]@H7!^H@NU#I;&P:US&N9FC7Y MS[&1>SO5YQ'/H22UZI/3!:+X%OE]TTLNTO8TG]ZL2=R;2"=:&+`%=*)6+3*^ ML".E^2?1V*'I'7G7)(@Q41@C.$%G@5%T%(GH?]83S6=R^'F..D.2KX0C^/-? MLG8.[$^X=4TOX%6569W6ZI[&.PNZ1\_DZJI3Z-C,=PM84PXMHFZZ4.(7,2G_O\VQ M4YC1MR6_+/BJ7:ER'+?DO0!#EWETS3.M'J+TG0.^Y$65:LN0&*@.418RZE1Y MDCT.]\A;4]]LDTTOC]0&+:Z0,W3_@Q&=@4S\HJ^:1!]]&E/GF-GYX$U[>.*) M2E1KFR^_P*_$%U=>7?84EE2RF`\*5&M#,)>X#^".9Z_8V>![XGH+YC^$5.(C MD#_#FR(6=%"EA6M>RLPL@G_P'\^0,<$[_P=02P,$%`````@`/8BH0@&!MR!$ M'@``'<$!`!0`'`!P:7`M,C`Q,S`S,S%?9&5F+GAM;%54"0`#1KV*44:]BE%U M>`L``00E#@``!#D!``#M75ESXSB2?M^(_0\:S\-T/U@6=:MC:F=EEUWC")?E MM5T]._NR`9.0Q&V*5//P,;]^`?"4!%(@B22AZNJ'ZBI;`O++_'!E)A)__=O[ MQNJ\8MGG4\']D&LAP;?SJSG;._ M_<>__]M?_W1^?N5BY&.C\_+1^=6T?;3"G1O3(M_U.C^=_7IS]O/Y>?3)K>L8 M@4X^ZMB=?D\;G/=&Y[U)YS\[DU]Z_<[\:_A!\M7??J%_O"`/=XAHMO?+UMQ^ M.EO[_O:7BXNWM[?N=HW<#?+7V,9=W=E(HN:XFF-L>\)R*;K+UXKLCT@EVATC7U31Y:@H%L`2;_9 M*#!,GTEZ*/*33_ZDIO<6R\46N\SD(GH-=-USG';E)=]TKYS-UL6D"<]\Q7>. M)RZ[;K4J_17RUC>6\R8LL+X$D'?AKI!M_HN9G8S^R\`S;2RD1`>]`,CS%&PV MR/U8+)_,E6TNR=@ALY*N.P&9ENS5`U&D;F(1\3S'0Q##Z0:9[J_("O!7C+S` M#:TI(,_R=0,R#6TVIL]D(-8C5*-:(BN]F(YTI$.8T'?TW]:.99#MQ_7O`5E- M1,R%(6QEVF0^)AIY=I'M(5UT;EOZK3&;_5](893?$`07D_,9O5CBXQ!"G]R! M*"P6&8X@0O$8)RZ4WQ[Q[I%+%_]7_!G[R+2$36L;6FLRT^VY$5B8?(PT@NDV MV*#[`;+NL@7M^IW^M2PB\@R"G,)\#%$1&>DYV#N7QU',MJ#%0%,A%!;0CY"E9(<>'(0@DAV^%*6644 M8I@A6.7<4/;,$V[$85:Q%P__'A!IKE\%=V@>UOJ#IM:$$@/#;VXN2N;3S%P3 M?<"8^\EW2DX_U@8M7X&6B5TKEQDU,`(=C.A4I_^@8[NDD)[SULS$([Z?P[Z` MXI"KQT)%?\W*E7BP3-N_,,S-1?29"V3MS1HY;J_8XT==9B,F6N:;TJ6R'7]> M6;#=+TN7;4T:=/7@!9^3GU(GR+[#3EC0@I:D2YWT<&XX&V16%3FO&?GRLN;/ M-WCS@MVJPO+:@-0L7J+`\NNK=K>=?(G)!TW;I*O;'?EG_''3M\CGASTRD73. M.Y]-3[<X]N.,G_Z`S[BBRV!7TWO>YT MTN].NV.N99A5ELA[8:8)O/,50EL:#.E?8,OWXI_0>;E_WM.B6,&?HQ\7]+H+ MQ*+1"\>-#5B(Y!%[OFOJ="?(;9W_TZ^,Y]WA4!M`@:TCF)`Z4D;/W5@Q2]?9 ME+6P[TC5I..2=9M%]>A_9YVM:SHN6<,_G9%_!![!XVRIT.D6/)H=:DP?H9[( MQX0HE<>$PC)TQ\Z^.-1_$,9]V9 MD"G%FJQ.N>,14RKNJ"=#7-:O$Z'#H>?J%>`6Q\.O/= M`*<_=&R?'+FO+<;@3V<>7M&_2&7J@>,0A)]B4PTT/^\#.AR3@(V]>@H5ZG7) MG#">0,W_N=TV35_.5"FDDG3OV%=PHMQ?&Y`?4.$>,)'2(,A[LZ$@_PI;4L!8 MPDA3@ZFXLETYGK]8/F)S\Q*X'ITBHT2%[D0;<^8*2=Z1O%Y5,*R`1E*;CA6T M*4M`N=Q/0,GLORX_TH\\H`^6;?V&7",)JLX]+]@P!-[@)B0PJ14@9Q,628]O\CU: M"G,R7.W)4(U^1#^G$;7`^2^:A?(]L_>8[5)*:PI2^M;6G0U^1N_1YN02V\0, M/AE_8SAW;4ZG"K!$0!VI/54\.,T)8L.T`AKN?\(Z/4L0Y-?ONA48V+@ABJ)\ M#GQ&Y\7R&KDVO0-)2,Q&Q'Q#=4;U,X8ROA0)%:"*;$VGO!HHR*O*.]-%N!G] MPM($;^UPMOSB.I[7U<;]R0B*9@`"*T`Z8#-$')QT1RINOX3=LJ,F7=%5DD4. M!%0B6:0&=7.TGW5R'5,'8!+$T330BGD00&8LEPVLA*@Y:M]->+/>QD M[ORM1-YFOT[>9IS^SCY,9]MS=DNKDYV2.]$&$CBUL]IML=*)GT*'I[EE1?4C MJ-MS]WA$#TZ9]4V;:)R`88,G6W%9:T1.$]O($2D\=5R?*N\S$XEJ#^RD#2-RK?1V3-1-#QR?Z45S9TNGS8@(<9;98`J6 MW2G0OS+CZRA1,IGN)92J=G+)%[+1=I%%H,R-#5&QYX?7HW;1]`/F1*C(\58^U"=0],FCAJT_/D)P$4F:+*]P1[T[3%"T5 M3:UC1/7O`S:C>Z#[2W_,Z0%(F7_PZ8%S70W\F.8:Z^OJ#]-9IZKBE+]77P$8D"=+/B.* M`=_:V\#WF.D'L3^IU^^#PSOL5R:]*YGQ@.6%NE';)9M@X!1I7-B/-+W2->T5 MV2B8WC?;>?'([H%N.!ADND.P=?(M%"VG46>@E*M2+K%O; M(^9G*TQ&Q+3\;7+4Z$ZU'MAZ6D_SI+AP5&V*.(^K&Q_*\5?#^%P0 M[-V()7;I`R9A*(!8>+'D[92>2>,>_U>19V2D#<&HJ#(=B>?:_(%C\HT>/6=]DZS-I$\&6[XJ8DQS^2 MRJV\8I#BXDF_/R&HQL(0Q0&V[ZALHI"BQ/P.4'QCOH'%,AK/"_?17*W]!3DO M^<@VR,31'4]&8*?D8YTWQ57>>U[B>DGG/!6?_/BCI.R7M&_Y['M%[U*RD@H/ MKJEC6MJ?]U"BQ!<66#\M6HT/-KT>H:*!CJYZ8N\7U%S1?UQ!*&&&NK<)3C>A M_'1O$Y0QJ^C%@+;?/:@;H(2[;)N@F\=,>UT^#EQSU]#!DOENF//YCQ M!MH`+)M)7(SJJ^QN'U'[D7]EH`VGS6#;Z5?"(*UAP'C,BBE&_?A#654`.>:5 MX'(CV-KF,B>L(*88Y:,$1V$`G2[KVI<+YHOK!%M6@2Y-9.'E1'#/6_M?EDZS M8N4F1=8+,*C]-BF3_,8)W(S@G$=?\I6??K=-W?,1J/U\Y]Y3;D#[BW(/U^4+ M&K\GH4W!MD*9?B1P*5^].V_I'>!2?R>SAPQH,8<@#J2H4,3A;"/XN)3?-AR( M#?783DES<(7]BM[-3;")Q!WTAV!O`^WT)(L_.6J.&92'+EVQ5*PA]!2&;:,% M>3B9@CT/M]-3=1(]4'_)G/E+TMT!+Y^8N[\Y^+8$]?=% M`GBAGFYIC'I0`)JG'F=?E8=7^9U5ZH+?]\#'`9'>;"P80C[25@TV';<)U-,; MM8=',=M*JS\AG*!*3B%B7-8]"F1KR?YM(,-74M8IQ)OW#J]`1B[G&P"R(0]J M9**1RB8JB-?>99*K>C/1+&>1!FODG@K9IZRDU=X'R,J,,8HF?$",Z6$@:#?11ENW817TK9(R"[F\]7*Q2LB_H-K$OA;9,TW3F"3.<+`&R8C&_:<*R)'-S'' MFV[=D-4UD5IXHJ"%[QT?>P_H@QX3#G$]XBWZ8(L^`\A@B:8XE6JY=?M6UD-J MWNDIEFT>'29[/_F._MO:L0@N[R^=Z]\#@D9&S>9LNV&KT@HV<^]31N[XV1CL MUEI!MS7S"A?9`&J?DT*0G]BVD!CU+:'7G;0VKOAJYPB$J9!O3D9NT7/=[E=; M5#M7_%3M*EX@YD)ESM'9&"Q%++?3&M[&(R9K$HFT:*BP<0KOM>]K0?GW/HIA M`R51M,#))I$TQ$E.7HB0%IJ)U-=)$GFPD'V/-DE6^70"EL2VVU6=P#W9\-W: M]-Q$]GBTU>/_\&N\X1?L9TN5B/1M5:P30E$.Z+P-!1?&B3D!"CAS!_A M#H/(TXD&M79E.ZH15>&8"5A@:7-9H:H3ST,>0.77T4-X0"L.').`!09D$F8C\UC0H M>!_03A?+4!'SP%\35/_"1E<;#^"*U4L7MRU&@>I=[3"Y+.BOR+3H.D(&WQ=Z M&F<:X!S]U&+>OM2G3L`B*ZB=)L#UY23HZ`,F[&61*[(3P,;E1_0Y+_J@UQU/ MQIPD.T"WE[ALK:V3TE2J=BH#%^?U.W9UTPN+/B:_W`'7;/#PB$!*D41<>6JG M0*B;>U3)5B52CEK*6#A^%ELP`;Q,_NDS=C<,A&A^44$[K:W?8M"2(H(C%=W# M3\%V&Q[BD151C9Z@L'%K$TPVUJEH_S#]]9UCKRBTS_B%)>BU!C)> MZ0"!9'OE`$U'*811#61[U6'OQ2`V"U8N%)NTEFVL;LH@G8?3 M"LWI3*_U)[-#G[T<&N;T67TFW&TP)*'6G_::`2`K0B%JBO0UT2+4^V'1DXU* M%*H%Z%`JG:&TB<7RRL6&Z=\@G57.CHI(73JNZ[R187V%MN0W_D=7TV:\7:*D M"_XE)($F-6P?>:BN`M>ESDH>JAG88S%E)%'$_"**`BP<`&3^ MI);^8AG>ILB^>T20P7G5 M1A$JB"HLHL+DA*D07;A;+/\K0):Y-+%Q:=(0Q%S7Z1CP'K&.3?8\?7T-K;OLE09#WY5?89EHXEVV[9O"71QW95U>E7#EE8EY1.;!2BZ+V]JIVH;VFN/N+4,$6]-G$B>9A' M^>P\!*Z^1A[.W.C+)E<^.W<.LN%C$2!GQRY68*=]) M"]:6H8_8Y(HZ`S,0/Y-MJ[T*E[0,7)K:RFI/Q]#36VM=;3S6X![[JR-:NVRI MI\J8,HIZ$')PAK=?A8#RGF(`Y8R@;.J0IH(R8]8HZE_854P&30J2K9_4^0J7 MIB@L1>L.:3$-Q497U&UP:QN!3N_3A0R`^$"=+0#>G7`?@9!50:>P[S;.#,+:B,VJ:)Y/'`"-",FN6FH:H/^7 MTV$K([00=APA5-3=D_5H11GO+%H%]LP[I\.6'7D1V`95?:R2&FG39LNVXT&/3*>H!HW=AK:BVTPW& MBR4%0YV\E\BBZ2%1"(`Y>$1+90BVV8*U*J"-MRB*#KW\C*T;RW'<3+86Q21: M,D.XU=9/C8*(XZCD25CQ"KGNAVFOHL>!)H-Q4^Z!G8Y;MVVN'M+,$B5+VNRB MB*8;.M-XWPI;9;ENW9(X.DLNF)V!&+YO[S)+@YK9!,UMHE0[AI5&P MS=8-)H0VN2!Z`N;[9J.-X_JT3"JM+!).*$.X\.[1WELW<;%&4L_,"1@W4[(# MJ.!/U4(EN<D=FT(.[JW;8G036"9J!=TOU`++:+^?0@VGL-$]$ M!RQH<]!="]8J@@SYK(@<)QA_A@-Z/JCRK%YZ=FL(@+37:X1,D;!J_^.4EBMK MTVBWK4B75)AI)6&D44)$13$CCF%H9BH"(<3!&M(F(:H(`T\(SN)T#$,S,T2- MM:D`@)C'K+(1!,2)=IA4'-&Z/;P&I',B3TU\5ARB4/M8LRO]<=9H2I#5]O'0Z]%FAY+6GZCUR6?D(6]^0JSYW%<[)%1,_?2#(3%W?L2T":(0T15T,M1$C[`EVV[#QC7@ MJUUSN/#VXSU^8[]BMQS[8`->3(8VS%Y>.VH7)I\;_Q=X/LNG>G;FAF&&HCP@ MDS[G%KTBGF*.5[@KQ_.][F@\`DO[K"-8&\20I,AD`]A63E.]A[$&G(>QD.EV MV"39^8H1_2%34N>G)WV-C<#"'6?9N3/1"ZW.;6(O_I3107[FRS]7?DHKOO*0 M[3WN>[',]!QW/$^O2=1]B_NO.`I]FD MZ'#Y_4N8":J8,+G,44I#ZH?.A'4!E(ZA!IVAP:E!9TZHKYR&E`_\ M9521_/7O)G;)]]1RVCOL*;'=H-').E<2N3PO8]PB MJHLH[J3F\*.*@9_&56%]@W.Z*JP7G.!%%'G^R,M2)7) MO=!F/;#G0$0$D$GN$D8L9':^CM1.3TG`S#T/^[3D(><4N[`3>.0#]X[MQO]D M[]Y$=V%F_2'4E1YI4DH8&<$1P7TNEP,'J$]'@*&3UE%DIX%AOTK;]U`W:J=^\3`,4@Q@H;J"?I6V[Z%NU$Z_ MDK&.WZ4E&&;#V6&FL#I;_[OZV:V2-SX**TM6]C8LQ0X&HT2[?#=YX@`F@)[W MVQWEG[%KOB+Z\">MG6?K)GW0*ZD2E!$IC>HG^0G=J<9[.4=619;J@JDYEKD5 M>Z1HO_6=5;V\E\EAW@O-[V3^$;]S_1IFO%1+8$D;"MNIFY.RUU[F6O>HQRN_ M*"FE+Z_7Z@-_K\EH-T=`@,UXW!XE#%5QDR1YB$>PJWT2W9,^G64(@#'4/BNO M4VD$#+[%BA73S"0C@Z=_I)1N89O53ND> MJEEX\/NZF%':G/4O9BA:[/7']2Q)#)%]/4M)MOP![FJ6-GR5NYH3-?OGO6-/[]R/@5Z\JW(+-=A!VD5R#CQNLZEKD/L8MDJ9(Q:M/\7#&7AKZQA/UU/9[HN7GCK6F M@!'SP*E=]XD'Q?,I!NI6^\?:U-?['+Q^)XNYZ87^TPFOA"#E]GV>70@W3N!F$(@^UYO7B`I6X4-*LJ=.P2CF:Y96HH_3YS6BA%&X MD-3V#>PB>#+?,P`X>9@"-DG:4,$D7$!J>P'V`.!7;&<@<&["B]@D;44)J_!! MG>!Y.PG;`&4QU(M<53JC-(E$6D:&L'$*70'[6E"_Y%PQ;J`TKQ9(V222ADC) MR5D3TH(*%>'R\C2BG],_7I"'R4_^'U!+`P04````"``]B*A"T^O1KW-U```+ M.@<`%``<`'!I<"TR,#$S,#,S,5]L86(N>&UL550)``-&O8I11KV*475X"P`! M!"4.```$.0$``.V]:W/C.)8V^'TC]C]@:W>CJR.<*E%WS3O-=YVVL]H[KI0G M[>S>V8J-"5J";';+I)JDG.G^]0N`=Q$D<1=4U1$S74X1E^<`SSDXN!W\^__\ M_KH#;S"*_3#XTP_.8/@#@,$ZW/C!\Y]^^/KPX?+AZO;V!Q`G7K#Q=F$`__1# M$/[P/]W_]7_Y]__MPX>K"'H)W("G=_`7/TB\9P@^^3N4-P8__O"73S_\\<.' M+.4^"C>'-4H:!F`T=,8?AM,/PSGXO\#\WX8C%&B5_(`:#H"TZ:)P![_` M+<#__?KEMLB]]>(GDO,0?WCVO/U/.,%/.^\)[G[ROOOQ-=QZAQUN1U+,2P2W M]09O%(#ZX;]QU4K!MY2M5H!MY#V_PB"Y#M<'_%]"*Z5B=-:@1QC29EJ$J)7,#_Y8 M@Y8I^@W<1W"-K5@[\EK6710=Y\0*O,0*[,P(XI8R-6"^1O^C`W>C7&78`_@L MTMA9MF/$M-)40[V'D1]N;@+%F.G%Z@'_D'A1AV:*PV\6K%J`QS#Q=FJA-XM4 M#?HS5-S:QP4J;V7D`7(;DIY6;A2I$+1`\R9-G*QM2D:X._17EA*7V.&9I:-B MZFQ62H;?$QALX"9UV(JRPW66BM3RIQ_0#_]]B<:[#1[S/NV\YX$SF0P<9S!K M'U5CN!X\AV_(M/OI@(K^.!Y&T4_U!/__Y3B5F037/[V31G9-/T'-DTY6%3TF)+Q2DUE:/4 MU2&*<)E^O/9V_P6]"/DQV&<<.-.I(EO55H4CX4*1!6VM0XZD[-!SEK;F*!IW;C=-V030;4694+AYJIRD:3I` M$BKFJ`([>BJ.-BPI0^/.SIVC,T.VE`F*-J)BJYSW]5R+*2UJ4$G2=MATBA;I MRT:=GQ%!Z?#-FE`JA@8OR2BOGI7*C:<95O883DJ3+LZ;E8N3&$TJ$.74+/8@ MTDG&S%%L+FOEJZ%E-^1C4M92%TVY<,Z"DNW@39G)5@0E$[-16VX61.U4A0;2 M%`];C6-+0X[.F8 M[C;8P.__`=\'SD+5"B&U?#EVL4'.:49-G;?>?&BWG]8/7K?]ZD7@IBE`E@20 M-``E4LA#!<;--`\;YJZG(>WVT_K!&S&`O3#4DC%\?0V#AR1<__WAQ4/P5H>$ MG%+W@^>!LU3EO?57IH2F/,(<<;8C:]GX=OM_G)(8LJJ,<`I6D_2`9`!I#E#) MHHOCZJRO!1QOL\M,76&W<\HIB4F+S8B)1O0+14S_Y.]@=(6F[,]AA$=I58>( M**6KX'(WW#IY:VG+]K1[KZ8/NAD3W%I_3D62`.0IE!%/F4TU0[P6J]G2>G9O MQ_1!-V@76T&H8]\7^.S'R!<.DL_>*T3]J6J_FE:\"O[U`*X3L)ZX;,'E&3"P M`[L9V]<.(*=?F0+@).KXI\S\F>)?BP%L:4)G>+[\P]@-FL!V%$I(^!AYV&%\ M>']]"G<#9Z[*^M7*E:-=-\2<;[5463,MAC.[?;QVT+HM7&O-;O8%I)\4L$F! M+=/-IH;U:FD>NQVW=M!&[%5K]5*4RK=N+H--:N]N@VT8O9)K])=/V.ZMD\%T MX3BT^>K>WV,ZC8?CC$SH!Z82U6SO<6+&Y$-ELF4GYY'L75/DED.GP>,%4^X7 M>@$^RD"&V4IZ\&N>X__32>;C@!IGP>9*I(Z00"[R%Q$P.LHIC]K9N]\C)1,[ MS3?M`4-ZZ"X#4!OU+]?KZ``W-]_W,(AAC,BT2E[0Y#Z]SG/G>T_^SD]\&",J M#:E[1U3Z,Q&5O`?YOS'YC\D_-\9Y#V3RV,O\9O.CT!O MV.O4BPMDRNT10N=>>5'TCB>H;][N`($7@W`+4#[PY.UP[$$0OT"8@(V70/PE M?-KYSP1?#/Q@C$'W9>^_>TPY>@#V,$L\/<)%)"-9AG,2H/`\Y51'$@1R3 M`R+B.\H,`O1WA'+@#T59R,U"?46\K(.WJ]9W@:@!O#5JHL..H'E#"IKXKY#4 MC[PT\.W%7[^@HMY"?XW4^,5[@R`($_".!'B",``17$/_#=>"$ON['?GZ!-'O M`2(=W`S0&.CA`#Q$N-UA`T'B?8>H:C]`9@G&R06(<@?QD.0Z`+[&J$PD+=+; M'5PGI/W6V="Y#R/B/&;-6K$HX,<-:O%O?O*"&B,,(,+I12DT\A-.'F#G$S4# M:E74"JA-U^_K'6JN+=B%P3.,_C@`E[LXS.'&))/W_!R1*$A@G?>N]QH>`H2^ MJW\O?OL=G)KV;:T7<)(8[CW4P'#W#C9^O-Z%N$.S+J@UU&G[FGL,PIT>WZ<] MEQF"P70RZSO`VQTF$?]RO%*9_=Q2I_1@Q"0''G>Z<926S]ZCO1P2Z)Q.L,-P M\R0@2Y//&I2RM6,E_:S8.A=AJ[T+0AP2:)\!L&,I*9N-:MQ4S<:HS,4*7_<1 M?$%N%QI[;H-U^`KOPCC^%$;0?P[2^M?OCY$7Q+MT]6GSMT.<8%?O,TQ6VT?O M^V`ZG2]U6F75@*651'\+'FF8Z@I+0MD;F<.4^(9&(ITRN)7R\]6O:@T@K0+@ M.D!6"K'*P?3&=.W^DF"=WOK5]2 ME07DJVEF;_ZR@^P]Y2(HC9&1F0N26R8'.#T:6$&6HW:Y0YL2Z!D`[5$"^O#$ MT4?VGI`6E,;Y3^@Q]\6*S&+H3XK3^J0)'$+SAI1 M29HR5/096.0F8B-6MU&MF_XDQ9WEF7!GR<*=,S!D3<0,V#]P`W[;A0( MF0N7GT@1=^6RLBNC5%]0(T7\4SG&]@G12L?FF&'O>71V`8P;0QJ*(Z,HZ?RU M]+!&']`<33L\PM;VM??L.+L`AOW##BC%DSNI'?TW/H9^]'<[N+G*3CM^(6<3 M\6F3>#`;+O7YCJW5RE&50YHJ7UNSE>UL_Q(?FQ`FS"L3$C=-!?)DH)).-86U M6-J349AJ)CCE.;VH2`!^?")9_\CY*)\7OUP&&_R?FW\< M4%$[9-;CRR2___`7?/UA,)M.9]KL,A,$.8(+2EDE.U,112>-[3^9PB^0"3O. MCIK)_P9W MG"%,K^$6X@NE7^`;#!#-D,!][\>)J\A197(:THN\JB!'B8MX-6/[-^6ZH)LP MT1WUN_DWD'U4PSTMYMD(]ZC&N;4![=^BZX)NS#1W@"@)&(D1,$+>+3:;E;@. MG\,@V_8;+)R1/I^UIW)9@G)*5B=L9^:B`R;G0&!V4. M/E:DG?Y):=]GH7MZQOYU=RY93F'+>U$U#3S9/XHKF?Y`=OA5JT#Y&L9R MHN\J/2L*O1K1+BN/8AR?FEY8',-92B8;Q@<:,)9Q0OB.!3>'M"PS6*HOU%4* M_BZT?WE62"9CJQPBZ-R[V\N/MW>WC[%Q=_<>?5W?7-U\>_@!N M_O/K[>-_":M*?OO1<68:0RTW*U3&_W8!6JA^=!%Q8?$3%HSH#9M["H2:81>Z M0=S5H[I=?.V4['/C&RUJ_Z'&'O2G<-4I.(YN&*M8A3F^_SA:CO6%CVFO5S59 MV^7IYFQSQ++_,"2C%*6[,'A^A-'K-7Q*B@%W-%IH=&*;-4HRETF$&F>;.8IF/8/K M;7WPC5C<;@PN_@YP`H!3"#JS71VKQ[@:Y2;=GG8U[!D8TA[XYBQH-Y#"=%8> M<,)O+GU(,&/:#6*4=?5C&J[*7F*9I[:?]*;+\`)HQM+PHW?10HBUXF M:FE[>EB+H35/5*J9[6EA^]=G^P4P9F1[H61L+;W8-((9.4>QR>^>D<=;!?A+ MOZWBC"<3?2L%[14K8#*K0`TZ=UX-69[!NBVC%,8L<"^4C-@J+I:Q=+T^@WPB M+K>;YIZFM]\+9I3"K)'NQ=.PU,([:O<1Q,_(9"_`YP_`UR,R.Y/16-_58`8$ M<@P7$[%*=882BMX9V6^_><4Q8<@Y,;E9>I!E(*?8:LZVT((Q%U6TF'F[M(%J M^+FZROX1@%<<8T,!)[!")6":(?7;L^4)`4A*S7Z3%3R?K MX+8F0W]:;K>8=I9N.`^9$0S,2Q(X'/+O$!;&&1AHFD94LY# MQZ@#CW!'VW]S3$8T8\.3!,BJHN$PRKP:E'A^`#2R M3"=3?7.,?@"R>B(@8%TU^@HH>\/^60>G-&8&&1Y(;IX1_=,33FD,C@(\N-PJ[S'G$L4RBDIA8;;)::5"O; MV:[V>]I]\(W9T1X@*3]%#XH_),C@XC6AU?:3'WC!VO=V]V'LX^8O;EQ-EE-] MQVI8$$A25TC&&I492BCZ9&Q_7#5N>8S884Y0[M7J\_7-YX>;:X#^>EC=W5Y? M/J)_?+R\N_Q\=0,>_GQS\_@@?*.2%L%I-IMI]"84!Z1B$J#.\I:02*BY[9\+ M]J`WP^`N"*YT_+2N'M423L$D):GA%+I:U/Z960]Z#@]"+IQ"-XXLG()\;+.. MB$63Y4+?LY:ZXC'QR---VN;P9?])%D8I3F-7:5!H]E7AZ-_H>SWSMM-QF3Z) M8VAZ^P-5,TIA;DK'A*=&Z-PD4;,5)>`V4UF*<3TMIJGUF:G_[UX%9 MQ3!FH1D!E;SVF@_%"S^Y>N]%JX@LAVS(!OD]C![P:Y?X)5-]"W$,`.18+B1A MRUNM;044CX_.[8]JRBN."7O.B:G^T##*`5812/.D)Z``R@5(-GW:H/M-XM-K M0]_+Q?U=9?\E?%YQC`T%G,".GCPNGCH6YC^I(;XL'D7&K-`7Q*>C8F5\[Y>H MA>?'&@(PO=>'5>DM>WY$5ZS`!](81;*E7,YS9).KF<9BK;V_[U%!813F*5FSBH M%CE-II:UB]\,:Q="K+7_?!*+".RL?8/14ZC4]C;AT.VNKX*]JT,2)UZP\8-G MU/$S??$ENFI6S.-.F3K)7,E9MO]9K8=TRW$28]P"AFJ1*VDU$-N,EVR6V&Q^ M,K4/SFIIHUN.TWG*+8CH)CL4IG<:.>(V6(>O\-'[GD6C^`@#N/63P7RTT/?H M:7?=DA3GE`N3'!76EV\\L?@M.V;\.JTU*X@BOG::"J!D1;"?'[.4?]3"Y_CH M_+/G!W=A'*^":S_>9\>N5]LT0-#`&3I+?>$<.NN6(S.O6#F7N_/-YXZ]!_A8 MX>NVRPP87)P&_(A3_1$@-Z.2$+^`<"D08(JQP[7XT*?G\9R/Q\AX3)?VG@YA M%T"[X\P,):4TXF_R`D'L[2`F($W^GZ`KT= MWEOYND?33L3^573G_^/@;TBRP73AC,<4]V+O$X:.A^.,G^@'P]CDJ'_R=LP5 MRS`0$EG8;KT]48OH]KI.(U860CJ;A."*058SR*L&E;I)^*Q*[>"X>E#6#W(` M`",`&`(^9%8!<1ZF;?$OTZ:V';%I,]]H9>!T>Z_$GKA5#.PZGE9"-TWIY?/4 M+'"-_P9!4C%J7E'R>5@H9_0O$Z6X(4]MH^S=/CAQJ[#;J$V(U!N53>&CQ49J M7*P(QWE8#>"_[E%=V&#AM8GHV.4JS159HZA:LF>R3+R^_[$JL9%TD`'[P!K-:41T>KIJXC>@''!Z`=_N\ MN*WS!H,#',R'(YT79NJUR6Z3]V&O;XW74Q>;MLMS.#?:@=W,V8YV`&[U@B+Y MJHB"FDYM&*%@R^F,ME8\AR.?'=@-GL)H1U'P$!E<`1I>PSTR\+Z7#2V7K_A- MT]1C'2R&$WWGB#HJEB,GET15GG9DS!M\-K;_$!&K&,;8RPC(K:8C[Q!XE91\ MK,Y#B>;WKCYZL;]&=5_[NT,"-X/%;*EON.^I7([=W))5&=Z3N>B-,S@JQR.* M"5>!`X];A'`N[KP"DIRL=F89]/!=BR6W@N]4B\[<*?8NT8F(8LRR<`59">^.^UU+SGF(JE4,02/,?U@P,::U9HL"`3@O@CQ$N` MQ8%7&/_B!Z1#\Q,M"&^]E#2"VB\P>0G1EWPY$9^*FTWU!4HP*(GL\:M3-GE5 MH0TB*?V@.$*'1_I& M@5F`T10&J.`X`X.H)5CTOPPB4Y.?W"#:'S?[5,W"X7G)!>0^D8#NYWQJ_I3: M/;^X-`2%S%;Q9$,13'@T=72[7(U*55@#!DF:BMO(5#:VO=>#>$0PYR%TXG"_ M?K[\>GW[F+[T07OSX^$1_>>7F\^/#V#U":SN;[Y>.MLERK2XYAO;!KM*REC9ON<49O'G0#MS8 MI*T50C&MXJ1;&(3I?"]X3@LN/+;10N,YEM9Z)6G((4Z-DFWYRB:V?S+%)H2) MD9X)B5M-E0_V0IXJ0Z_KL9\G(S'=KO:WNOT1JMF$,&=O6>!DC]>%Y/IIMISU M8W;EG3.@4VM]Q9+0>#+5]UY2;_6:F-TN'1/!C]=K%F<0N)I/F)-:;1JB+NLM MO.#%S@\MDS=KV$^=S7%TSQFXTES"&)O?<<'*X@T<&WS.Q_%6>7U936CV-![. M],4Y:]0G1VH6^%46-]*7+6K_GF`W>!,VNA.!6WS-+3'G;+"C,[4XT.:X2'68 M.QK3_ME>-WAC#G(GC-PQ+F@)U="R'#"G8WW!>ENK5\/ILL(W[\#2@;CDL#7NJ-R-#0->>N)E@HY%_?%DHN\X37?EDJ3E%:S&W\[, M91"A,W!JV24Q8G"9X60+6,KVX5CYH,?1M8#H=)^7K3^<,W!\V24QY_TR8VI9 MKN6C^!<80]1H+_@B.GR#NW"/#P,51)B.EK00TFH8WEFW',%YQ:KRNS-OT0%3 M^U?4V`4Q8<:9T;AYRC3$1YE6S(@S4D&+#3\]PZD6G+$K[/=4V`4Q9K^9(94T M)W$^RK1\]/X:Y+$C*R]IP,A_(_?(T:1K[LST[3#WU"Y'<7[1JB3OR9UUQ6(X MM__$.X\HQHC.`D&EX)MQ8.OY$7CS=@?RA,NF2(^^Q4ET$+CK^U?H/[\D M<'/YAARF9_CY\/H$H]66Q-BI/,!X'`O)F8^7^IX2%P,EIR[*&J*J16*%%IU_ M!@_D*I#0A/LD#]/-BP!9&2`M!*RV66"U2CFR0=9DR:AEM#I'K:2.;;)DL'_( M4R"AL9%0'FNIFEZFFMFCP*@[-GC87'N[]2&+&X[&S2?E\>'(6L)5^+J/X`OR M5-&(7"X??X;):OOH?1\X8V>B[PH%"P0%RU[\0M:>>^K-/II8?$^=5PR=(QLG MEFRYJY8X7]U-'[N\`/C.$%(/E$DG^_7LP%G&_J40^R>SF%M'QX5ZBG;&2T< M>^=4:H6T8?!A0LHW-(F?N%-'37T[EK\-U:W-NA24BZWWW-[[``HEU#[K4HT,=@"QLZG:16C MR[_D?Q:Z\@HTMCLKQ>LE*A3&N'OZ6[4\[0?X-!+6WN5/@RU@]L"@5EGPV?DMLX/GBHKZ[".(D1 M5JS=F^M#Y`?/GU$?>O'+*KKW(OS<#I>')::B&ULG7@.6+ M'L]F]KY`KE)$W>N_BG"ZN!R0%P1(22`O"J1E@2PS?L4[*Z[XJ5+@J718TZ.U MOQ$=GJO7X0J*Z6S]`I6'M71.=#L($[#U_`[P8 M;^7\0@YOCQW>2,[E<=D';P=7V_L(W_5)WN^17`E^<(*<`A\X0V=)+F%-1CJT MDPV%G`J*2YIK&EL)DQ'VJQS+%8I;%@:]6:9Z$\!GY(INQ#2'%Y>+,P`T\T,3 M3[#QXWT8XY@X6]3B:49R,`WF&;F?0*GMV=P&E^MU>`CP<^YKZ+]Y3SO\PN%B M.M:G&BP8Y!1#5,I<+5CRYQUF]VD<3DD,J00?*C?_"*+BJRSK\T'H"WR#P2$E M@[[EC][Z5=.]7[QVJA_G7[[#B,/-TX$?\Y1_Q&>0"[\H2ZV- MXIH>LK"%XHWI1']>?&#!X_8L<+7/>5DP.#F:?`2(DEUM)>F@\!Z_(%3,[@Y^G?FFSJCT<3>%Q.9\1L: MZUFPN/C9<505'N0A>3LU3H"UYK5+1_5"KIIWSW M-C>2B\G$A.FOUZO*[/=+@RG?FGXT'XYG]KHKO;@-4+@/0^NY`.XGP:Z\^*6H MXW*=^&^H'XK3GM.%0WT#9.\3\HV'XXQZZ(?>TB2G:_Q8,0M9@)77G^QU0+CE MT.E-\X+![]D!G!H4R4&>7N8].T9"S,^(O'-Q\MIK4KGET+XMPXO(S0](EO;6 M2Y/[O`\NL7/!&9T1<9V1.'/M#0'&+0<[@WA M)OZ$N))//U?;J_#U-0S(G!0YV7_UH@BYVS%A"2U,"Y71/"5+NK1R,N1$YRFF MB+H[MG<+74HFW7Z'*#`WSPAPSG)9;[4%:>9LO0_?4,WSF]`(%N?$=HUH."UB MG63O43$:<&5%TI5J09WB*=<%PBV.18+6(B5K@99!O!M6"R?>Q72^:/I%0 M-XWLW6^4DLF4KR0*\$@W\!'S5OT(HW9]&:A0F+LP>'Z$T2N^6W)$M@EM'Y1# M85J*UJ$Q[%)T:TQ+.:5ELWLE1URHT[A7#,@Z_"N<&^#L@-Q.5.UA]7)*W,6R M23,8G:S>KK)[F4A]_6/W M`I2X4*?UL!@0'JG%;44MCD8-3WC4*`/*Q(_A%XB[Q-_!VD&UQQ`OCR$L;_X& M;CZ^?XWAYC8H7B^]+)9ZRS@H&M]FU@%83C^--&$UDHR."G/>3<_@-4CM\NOT M(TT)X58J`(\A**H@L>2J,>G01[+^G5<$/KX#7!5*!,HWLLO:A%?%=2J*EJMH MOR];0PU!IY>F]BYJ&I-?NV=N2I*:P4E"?&,B,SC%DS?H5_PWV2O.'\PI'X`N M]XPYHSECT#BB%_H//KGVYNTPALOD"GE$[ZCDO^!7[`:SZ93$KB@-O$I3P81! M3O=%Q:RJ,U,91:^.[5U;%1>(7>'V)#CY0^)%B;C:<0-TR6",/7JB)[#,=`&\ M!#S!9S\(L+[@@Y@$H59M<7X?VN(HT!;[PZGR"\2K+3>!P(E.87@]N@+Q#5:5 M6D)_K@"Q:+'4-N'E0:)#95AE[E<<>DE%?T[L#98H+9>)&:4HN%2)\,8#^:.2 M%Z2901%G),]N0)>TO-UFN2XMU>F2O4$5I.7BF#&)/?4FB["(RQ.G+X*V#%&\ M,4332PWI;.W1^Y[%<_@(`[CUD\%\-J)=1E`5(;2S>\LI-MK"(7T_+DH,LO1ZZ:PJ(:P'=J]E[#Y>O893X_R3_'"R&Z?U!37:]M6)9DG-( M5"=X:\:R\>UW;EC%,&/'F;"XU71D.E!-J9[06D+@G)30"V%"VWL@CU<,=D(+ M1]+AA%3G-7;$O4K*W&+S\?MFNX7K9+6]^;Y^0?#@%R^!JX`^7Q@LYHX^"\Z# M1$X#Y&2NJ@1/245/+NS?BQ"6R\0H(`K.33/BHZIY5H#S@E5V;8ZV<&1`F[0X M_I9K$W5*(-2Q%L>HE9;+V&1!%&&F4B2.%LQU*D*98QRL'R\3Z7VG0LM`9.,S M%=31AZV0O+_F9["2*B"1B1&''U;Z8`4YE(9&%YP+#SMY/D`R@B*GJO#ZK'_7Y2]782*C`YP<^=[3_XN/=B;O0Y0G/FM?$-40III5E\X MX&G0);G&Z=4SCN)+>MA[0U6+K"?33T'`K;J+RP.53&3=C!19N613^7XJW3;G M_9VA;K/[CD+TL?\`L5)93^MY"J)V^!8PK;^\GWJZXK#6:.?H6 M\=AQJ-9(=GF[5:^MG+(+[=]'$I3J-$,E"S3ZH%@.>UE6X8NE`G0R-,Q9HSZ, M(U=O;R[LWS@2E.J$HQ$+/O>*[!/%1W%RQDHM7-=`0#./D'JD=(L5XHG,8*JN2)7HG MZ#J?RZ1E>Y[#RE\+;C/LI%?NYA\`_J*":)KF#GJ)UC(!H+79.2Q#M>`VZ,33 M$:27:8D_L`TCY*RGR;@?C:4%8CE^SX`L38[FU`BWREZ4900B1UDI@:N$9B^H M>`-B:K]=%93*A-45@T;>O&T-.M9XB(/_&1D!/FFY<&ZS`E%OFXOTI_WCA:!4 M'*.)W$US,7Q$B\BM\A]Q-*T_XG<94V5Z>E?Q%A,SJ&*U<3R>Z3L@P(_'E$ZU MRR^F6HUWBJ;V;UI(2F?76$6#R#]FB;_>)\X\+7.3,](\ZC1'HN-G]N]W2$IG M;,HDA]/]I&M`NPW>T`RMX211WW;5JD\4(%KTB$U@!@6B%%1VF?W[%H)2G7"H MZH'6/405F55/JSKY9'):984"\4RK.OO3_FT*0:E./:WJP5=.JXKY5#:_0M,J MOU`B_:-0Q;E9&)]6=>`QI5/M\HNI5M.ML#_BI*1T=HU5-(C\8Y;J:14+\TQ. MJVS4/)YI%5/'VW^)5%*Z4T^K&'&ZM[H&-,JS`=A)FM.>NM:J3Q0@6O2(36`& M!:(45':9_==/!:4ZX5#5`ZU[B*(]D:-?@4Q.JZQ0()YI56=_VG^)55"J4T^K M>O!1IE5H/D5[_D67]E2]&GUW:/CQF%*F=OG%=*KI3YSM40I6Z>P:I&@0^0O>G)^4ZVYR."_X]F^O,+G^Q\&/ M8"TVZV6PJ033'<_G^AXW9`>BAN)"`M-(WU]0V7/V[W4)2F52,?B@E:KR&((L MXW$@87P]6S"8,"II#>$F_H0(EM?T*8S(96_JG8O)>*8OTB0G&DE-DA:]IDY\ MI15=?`9O[5Z`,X-"UU#V+."!_!4N89[IF1R,\1A'(SG2JT M+S!.(G^=0/+048M7LM!WUD\8EQ[-$FD.%FWK+;=DQ1DL$2L1\I1#%A?2SF&L M+"D]K*%VPB1(3:/CG?V:RC4N,7N4W5>DHJ._(,%ML%Q3(]\'%@ M.QKJ6E[N4[3@SDPJ[<.9?7K4.V0Q=ZK]]TQ$Q3K)L,0!L%0F,I-+7B"(L4*% M6SS'2Q4*!_R&8JKT\.)%\*,7HT$Q?,5''])'[)W92./!!7JE<@K"+$A5%^B9 MBN9?VG\[A$$"$R-%/PR7)`$D#:@F4LM7+5;^%'REVNZ^9K;_Q@6#!,8LWS[>7(.KU>?KF\\/Z5\/J[O;ZTO\\\,C M^L\O-Y\?'\#J$[BZ?/@S^'2W^NN#\`6AA\-^OR/8O%V.[3;8AM$K4:F"--/A M1-_I&$80DCHA*FE-/=@**3IU:O]<5T0D(TK#C\NMYLD6;5$N4,EF3%'T^#PV M*@K=*>+M/?LGLR(BF7.;^,'5M67CQ^M=&!\B,HLE:ZI;K#M^60B?PJRB9R_P M_TER7H5!'.[\38HEV-PCJ7"U^)_%<6IO5XR3E=N8TYF^*:\2B'+*IJF5L"JB M.A45/YH/)Q;?%%`OJ,[Q33E:MUH:67;Z>(CQL03Q:^-2^*X+2_((ORMP_=#P%- M<%]?O>@=3V@?_.?`W_IK62N/T'9@4D,K)XR@W+[=408?>/ESIZEDXMU!'ZRBEGU]D_2Q.0R-RZ M*37[T%V]W@*4/5@YISG*J+]A35\UR&L$G4^X;=>8B@[N]%U^9 M\>OVCUA`N#@1(*G`+]##:=)IOZ@[1*NT-'Q+-(LP2F)%=IU3JJHU[\Q:O$H\ MLO]N'KL@)OP;9C15AE?22G@S;&30XL.:>,$-JL^1\ MW+X*7U_])-UE"C97(7%G8(!]F1)`.7X/1_J6:KB@R'%?4NK<:^$K!H_`"WOC M%8@+I-NO$4+E5G*190C(3/I0XO)HV73:T2H2#%M/A=9Z!:5,],M(?M/]XM(9DQWTT<8_=H MQ7N]`17^$NY0=\;X+EOR_CE,RO%QLM08`:2[;MDK#GQRY5Y:3S[B+]@[&^>0 M0+ND'G*8S>8:-]Q8<>C@.)NX]4L]C.44Z]QG$`!# M3"@CFV\BR&J*DNL)SJ?&G1*@DIYM.&LUA[X9Q]^5]A]S$A/*W):<"#SJ.,-Y M)FFS\=.^*E[A`VA5& M&)I;AC)[C+P@QL]@A0'O$3YAPN@YVGD__MZ(R2T??P[VL**278`5EK6P%LI4P6HSL MG2$2&)@\X\#CEM+GKV^>)$>SWL'OV;_E=FBX..)KLT)&W5B+JP3Q$FUV_1S MRZ)]+B""ZD@]\*ND9+?A!G',(GS3RG*@3,AM4OP8B(HGL8X<3CYC\2 M]2AS@#3+!QL-L? M$A5)][`AB,M%^6HW1FLYU8THXJ32,KRJ6V3:K'K61*+@Y0 MC^R=\RB74^?PIAJL2PI*'QVJ1)[#]T?TQ1Y1PE4M8^&9ZR_UN*0:JMA_LTN9 MG-J'4M6(,R4.ZTK,N6_JQ2_X1@SZ#SZG^>;MRE&]0K3I7-]I,28(DCNF8E+6 M[F^Q%%'TSAF\!\8OD(D!CAN52YX6(!07R!CHP(.X7^!;NWO`4 M^,X/R(,L5Q'<^`FQJ(\P>@5WHO.(8L(,<^!Q\[0`)0;IJZ32!IJ5%UJ,M16,IQIQYFZQ M=Q-=1!1CQIT#%%E-61.K?NWO#OC`[6>8I"=Q"T7@#$\81M!_#JX.400#5&WE M\@?RX,D_=V3-IC';H%=+8(*D$;HO" M[@3V)-([+8_>]R:UYAHCK[=5*Z=(',)4]:0M6]'D<_N'+"893(Q(+$#<-!%` MJ>0'D_Y.US)6G(K!5$O?W^CV&W(F&8S9:18T%1KS1B?\`M]@<(!?X#I\#DB4 MA4:'3Z>.OD-4O?7+T5A$O"J?>_/GW;`\@YB=?,*8L-%?H(7MOP(H)8\S$<\&B:0%G)$*\IO71B^$&WRJ'R.TGCU'NLR-) M:"R!0>*_P7L$.'/^!\YLK#.:)S\B.:U0TP2U.(7$1;1\QQ[7R%0)9Z)P402 MHYMN>I`"0+4$D!9!EI^*0@`I)1M^#.J?GIB@9Z5_]#BA,IUO;_!#5>(9&\LD M@:9*^*&IA'PJ]C6&J^U-G/BO7@+C@3,?C?5MK=_#6DV^3+'2$)ML[;;"[Q3[BYAZC?4+HXJ;Z7.UW, M]`7ZT(9;TDO%"*5=4*HIYF*][X5EO/;&KQ_1]M\NKV,72`KLU)JIY&6C*Y:,OH M=$A[%)K(KGG'X;=J(QKN@]IZT.CC.';[#7H$-N(P:(%>LQ54H^`E%1LBJOS7 M,/+?R+I(I8[+I!"D25B=)YT%8:E2:>G&H.\+\A5;[ES;.ZHKE='L.0-QH+5C M!&4Q->6\K.HD2(=H%2<$1)FI>3@^+S7MV;X798:]XZI2&4^P^2Z.MCK/KBCD MGWT8H:9[>0?;,*H\ETWWO\65]2EIBK[5T8/.-J6IA@8IF3#8XJR@L+WU0# MUJ)FL^&YF'<^D#PE6*\7#`R^M-`\9=NM4Q]#"6!2V MD!-[+Q!)R61X`.)#Y]Y'/IHB[-$!P"H`CR]0-,XQ/5;]Y7<_'BSF M(\,OBN!JY;2"0YR<_1U91B/+AXY>[+K'B#X`[2\;@%]Q*N[X+W$2^>L$;N@5 MTW_]!;X^P6@PF3CZUHIED,E17FV;Y%HA5:J#IH/VOKV@2CS=NJ4`8Y?Z78>O MGA_PNEST"R=1A,^.X/'HXWN9)!NB+K]YT28-*A#_C!(F\6V07D;Y.0KC&+F- MH[F^F&4:$$LZ;D::L/#M=-0VG]CN_>F36ONL2QMTM_525Z5T\/1>N_R5U0!( M%1=9=)WX`J35X,-B:47X%U251=;$8/"=WZHU:9 MQJ(?NHN2GVCRH,0:U`NI?!/.WN&53PB=HR47$K?A`.=ILP%,"TGG9T'2N2!) M[8U,PB>$=A/,!2=EZLY':3>8GJ\Y3_?Z>.J,SH*H)4Q.IMKK7O`)P<[43;@^ MO.8/3NLBZ[QI5B_D[.I=3ON*;Y(O:4P7SH@6V(I*UHZ"Y*C*AS#G:4>NO#D7 M8WOW[WE$T#WD,^)PBW35Z6T,?DV348P)R`GTQ!_6G8VAW>6YAS9[8:RBF!J:&?$HY:APNL/U1LLA]=TC>$R"`[> M[E,8;:&/7`WXQ4L@)M&$=ER*2G/M<$ZTIB?16KG&::^[.!:]M%MOS3:$;J?) MJ#3MP?FK&PT?WVNQ+FL;#=5#\I6*05HS**L&N&YK;1&+0_@O6]1H+=.V:#$< MVCWU,ML01AQEHR+5=C[758.T+?+$(++9E#"Y[_^R)TC&-;FLX@?/Y/T6'\9W?@!O$_@: M$VUA7E!E*U/20(CB+I2:?UK(]^9,D+,7+/?`^*4Q M,R?CQG4JKI/;49@O4UH4`WZ>D_(T:BU4>6+U7P27)2?Z4!IY_. M)(M&)DM;;,-,YK/41PUN][XRIR2GM]`-3*>GL[S';9C/G)YVOT^"2Q MPL-NP-+#Z4M4R,;?'7!LIP<<#9'4,BC!/\3*+_^G2( M8NP[9$\<#N:.QG>46ZN5O$C!+DU5\5JS%1VTM/?U(#XA3`R/3$A"DQ(YRA*E=W_#[3:&^,<8X@"W M)`3)!K\C$^[))CA,B^&\&LST^NWG,'B#<0(W9*,]?@P3;U?]CM%^#I/_@DGY M-NY@L1CIBX>K#;::JLVY^3,XG"^9AO!Q%AG1!(WKP5DU=2.#M=. MX!15I0=M8D`JJZ=M//%F9^#'*&=EX5%.>3VR2,U6V)TTLO:G\(H^PFG&?\KBQB!SSZ#"A+@G(6-/"]O M[;=C(\WZ=3VJ8N_!0PM:YOP]P%X9E;F%),DZ^_:$4Q:E^@%(7J!0.*C;`,&` MC][W;!GO(PS@UD\&SG"V6&AS]%IJE;,V[*)4[4)+KKP+YW-[3U?RB&#"&V'` MX:9I`$J4;VR`+)EBWFH9?$_#6^IXUMO8]IZEY!'!V`C!`"8G;X+("T5VY3X? M<*24U7:%++6'#ZD]P&<21&7@C)8:WW9JK5>.N#SB5*G;FJ\(-[.P?[V>30@3 M9I<)B9NFPKO+13J0)U3.8BW&]W0LIAI@AF:W?Z&730AC1I@)3D[E<`O"@LIQ MFI#SF-^.D`5NZ/.!_)#!=#ZB!9A6=(Z/"8/D03U!.6LG\9C**(]OV7\Z2$`B M(R=IN6&Y19;V13BA4T2G2"425]MU:R=FY.EVR M*/=X+A08H)]A`"-O=QEL+C>O?N#'"=X?>,LOJ67OBXS&4WT+^DP0Y,R#H)15 M;67HR7E1R&%0&+4.%5LK^C2)><8P-$9S` M2HWPCC1"\*&Z]0O<''9PM54SI?KX7DZJ+K_[\6`R<_2=_-2-7DX'S;=M58%U MUUZP7Q;!E=MJPK1X`O\R8>UGD,VQ MW/ZCS$;;PICW8U*JTHZ%;79,9G7WR3Y+EL;Z1BJF[ZJC%LAVV:R65M1IJ*I1 MP!%W[5^>UM\`Y^A5-:30ZDJ)/6Z@55G.PF.RWN08\8V.N&K_LK_^!CA;+Z@A MBE;71\SP%,^0WOG>D[\C@:]_@5Y\B.!F%7S!P;`C/WA&POOQUR!\BA%87,UM ML#^0`!7!&N4BV.Z*XZVCX5A?!&L=B.7,CIDVQ%8'0=!3VVQF\?*19JEUNC1Z MH;OE8[X7H%(ZR(L'R&(4%0!2PP6HU@%():!>B\2A8(6RIH/O:#C1=XA&-5IK MS$A+VVDP(6E-L]G2WC>H-$I\1J:C`EN;V;#.`=$R\?F=.2#S8^NALQT&X]ER M,K/W^H`Q^;5/>DQ)8I^/-H_J0>%$BOF2I"K?[$3[[ M09".P*BV]4GTTOF77G8TBGJ]M']W09FW M"7[V_.`NC.-54`(C,2AFA&$+'5K74[N<8O&+5M6=GMS%J]]G/+N/_#46;]$TP>I>'FW4Z*9G-\A/\OS1T&D!:V1 M9;!FO>X5&HQ)P-)FR.(#/.-ZD&(\9X;A7+R@WQ.]Y;/&*S!M9D0FW8%,NYOBENRHZ$:RM M)9.+;E,TIZ'%=MK[A+SCX3BC+OJAJR!5LS(6A)BM/7`*CWUBKWGE$4'GJ,V! MH[JV6%U%%+M@Q]3K<^MY.1?BI;V!_WA$T.X+<(`Y`3F=D?7L=$9"]+3W#C^/ M".STW(1K,K22C4P]#!TJ9FBQ4)7MVF8+6?E>+V(`]7HQE:/=92DZ"<&*,R=J M=\8B-LC8WBDXIQ2Z1WEV*)43`J":6,4QQ!X:,-E4&_C:M*RL[6MO0#Q.*4S9 M5W9()R0NBZ=J`V\;_BIKZ]J[]LXIA1&OE1V/*J)'36GO^4T."4[J@3;@J.7FU4&RBK[XSR_) MZI#$B4?.H`QF\ZF^`&)]MZVOD"PZ/0,10"Y)C$,O M9,G!*@(D`ZCDT$1[+6 M#/'3@J]AD!Y2$'1%/KX7?_[9AQ$.:?E^A\-9DK!@SD+C22HV#(H\&DXYJYK` M5D8Q-#OV^CH2$ID8#/AA57V@C^_5"R9%/D`R"L4!XR2/WLNF]B@)=;C@[3M[ MUTXD)#(V=/!CJUW#+)5#4BWRC<5W,I;E+-$W3^BL6ID2L$C5POUFUK(3[)\> ML`MB>#CH1G,T"A2)03IAT,=QW1;_-!SOL^\=G3&R?R[`+L@IK'DW)%25PRC1KL;2]5DIRDS/WTL M>T"I@P-ZS?4I6-UMJKNZX(PFJ3UBF#?3W8!JGG::]$(5N>7CLQP/,?F;GJKKJJ+S>-SL@[,](81@=$$Q)5AU5JK*55(]820Z@EVIQ* MZ-U4^"W\[9CW6Z'?J+;>\_J-(UAW@4R(5;5F#TI-T'5(Q/--=2"\&,# MBYDL4#0<[&&7FJKF+$65W6GO%31YP8RZ$;SH6H\)43?+3"J5WC':5J7J'COY M>M?>.*GR@ID?TW@AUB;ZU1BH\40?NVM5R7&Y!W65N+6D15LN[%_,;@=N M@I2MM>?7F`3/P=![3HN?I)UO5$^EI>'L-XOMP(WY"JT0RKMS8JS[Q?ONOQY> ML_X;CR:.-BM7JTJ.=3VH\RB\]62.,W&&R)D>C6;V'GOM@ZW3PO74[6;?!)GV M!A;^.YJ$:.81UHN"K)M5+?6ZY'>A94R2 M,V,IZB%:U!N%?%)ALSH1USB5*]]DOK3X_GD;7.UC8DO%.9F$9K>TSM%GGG31 MB6ZB\F9"FK=,-<_>L(G=H(V8*5K-4MS*/+2;[WL_(J?#KKV$Q!R:,D>/HQ:A MQ''O1953B9Z>>*%VVZANX+HIU5E[,6,L/P/\G8]?'R/HK5]6VZLP2")OG1R\ MW57X^NHG9"/QFQ=M[LFK7ZASATO:L0HJY5A+E6.A!/8\0A=K$47$$8M/V`K+ MHY/&HJ#<-!/>CJID`V4^0#*"-*=NSK.$1+25\XUPB?S=8>^JGK`\VAU-463N MP^W/E^`I97^X!>L*^\.GG?^<6GJ/L#]]D1%LP]TN_(8W=_W`3_"6#8Y_!".R M>Q-[.^UC`E-L1EL5I!FWD;_?[/5BA.5AUQ"YF(XBX/+1X4@_UN7H4-./#R`X M8+\HG0)V_OT>,O`\[8>27^8(/E0A7!8.W#(F3H<#EC]:5Z M"I/3%GZDN8[TY"Q#M-G]+@2/&+K])`XL;M41"C:@EEHPSBDK%5B<(3M(VW!] MF%O8WC5^7C&,.#H<@$[)7"8WQ0[J-IT2YC:V=X&.5PQ3+@@')JWTC8^KOZN\ M&S*D1H_KH7![B:IXS(6YR>7V[$6K6WR>4$@60?07XLRHBL8WZ9HA$&=M:U/;Y?@=N]I]0*>6KWZ,AZRAYE%F. M4/U((3OJ=LDW@#\*'G!N[3F6`=(,AQK#8VN#V#TZ M=L$V,CAV`'!OWF#T#L9#L/'>8W!`?OP.;#U_=X@@\&.P)K$J%5.,:>0SP['F MN-?:6'8/>UVP38UZ'1@4&:Q'1!A8Z4/:+<=V-E5R*Z!3-Y8:G2I)BT:9V;T8 MUXG;R,C74GG&)/)5.968!S\#5*(/?]16L?N\7"=N(V.B"V@"AX]YKQ[K7" MN]P#JQ[`##;`VVS\M%6+7)44,'/EDA?DS/F[=^!MDO!V,/\)M&,%K/TXB_^E`/H71\4D[S+,Q\T15MC8Y'=$@ M:ZY2LD7G+%I8'*1#N9RZ70Z58%U4&$A+`T5Q`)<'2($@+1%4BT2N<02:=Q!. MI:`LCM!O14$;CI8Z+M@]9U0JIQ%'3B7B].)#@%1U3XJ,P8]>##9PZP=P@T9- ML,;KM'ASP,<#[M\.FV<25/B/X"E5WTU5?=$OE$L4IU)?)J?RMZ*_3:=5'4WL MGEDIE=.44ZP2-!EI4_4%2`G+"Q0:=)G760X3&-][[WBK\?+Y.8+(2X?WD1^L M_;VW^P+WWCLY`/H:'H*4S,R+65Q%2VJII!2%1O*44_2PQ>&6Y(32[LV*(G-) M3I!E!45>4&0&16Z09C>B%DS^J/5JT?0TQ?K))1/K'\L]-6&AC+EEH@C/<"'S'J*V0`WU#%?;IJRI MB%_@!KX2TA"RTEX.H*H<7]ER.B_+WI)2&?'3Q/%5500Y9EZGVX;:$@TW MB8^G.V0,-*,L3.[;.6A+TX$3[3B[3X)*2&7*A1.'**PQ`5DNB.#.PQ>`0!*" MY`4B?VT+UPG<@/C%B[B/-U?%*!8+L\/4A'=3$5_LN"1UVL*`D:8:Q]G*_K#[ M&ANS#"9]J"X@1QY397,V2ZR#GKS.T"GHV>GHM+;HR.Z#/\PR&'=BNM#P1&&# MFPL<:*IBKP4V,75PGMNG.07IN_V5=CNR.'_68QE.X8MT`3KR/$2VX_.;5$@_ ML/,1DR,VM7!J9,V)."DH&2I^+U$%0>74)/5->CKMC[-+X$KMV]Z*K=)5]!^EGP3'!''S)Y#\88U?03VIO&\A7!3N!F M/((N"&[EJWI6L8W/QFA%&8G;V\;N+<]NX,;&W"X4"JC5$X6?Q6B9?QN@8;RH MZL]_>!- MV;=>)#GK+N3>J,"O<=9"&GU\_^PEAPBFAQ#3G]_)"U%C9TR+3Z3F^1UV'')\ MEI&W^F8B>SG%^8&IO>964BJ=TQ,Y:"YY;;8>L^OC.TASYI=/LKQ"SYT)\$G+ M:V@6ZP_US5&1[K3WV).D5-K]&#E\QTI4Z(^\PF35I\]W(<9,]#WPUE&Q2I7H MD:A=!VH9R^:W]U@XKQCF1XE6+.V,%GI(CH4!!JR^84XSV/66#K!W@8-7C!-9 M[E9`#6)?R#&;_IZS%BYK?X6:RM=:TK(E[5W:[0=NC).M$)0_2*WO`6$=#U)3 MB58D*Q8JS\"?I8,V1C!J]1)O4S_`9[PBDXUCD_F"%J!##;EJ5U?>&@';L)K;*W=S;X(CI[TGM-BS+3SC6K46AK.?L/6#MR8<6N%($NZ MQ$O(:9&/A]C'D9VSXN)TC%I.::_C*2)A5]62I.23JD;2KJS%DKK%NZ[\@A@Q MFJQHW"(ER)."/*W8,,[$!3UF]M0,IYMAMJZP]P04OR#FS#0K)%<-N:]V7ARO MMMGNWBKZXC^_))_)$ZNK[0-<'U"G^3"^\G8[N/GXGJ6+LX3Q8#:?D;.?"QWT MEP0GIR#*6P:K$*I-NN"I,QHM[%TQ4"DBN]J]P>@I%%$\A7#S/?(8^'%\@!M\ M9V>/JG[Q8IC=UTD/H+^^A@&(DW#]=\X#:`C]9^\UG?Z/%W-'FVM5K4GRE%HG MYEPG:JF<\7QL[P7/-K@ZG:"6.EW\&\`_"ME^:M=H\6,TTVG>3:?IU)G8ZVZW MXM7N<[35K(A6^?[-8JYOW:M>EQIJM>$^)E>6#JGBR-YC9NV`3=FK6JU5:@DM M-[1TDE:KI9%SSYE9H3 M_KTX:J'D5\=GT^=3NV_6=:#6:9RZJ\X>P5@)'^5OZS3F!S`TDX?^^`6E+>P= MU'I0:S<]W?6[E1/2J(>GBGG$_JJ%9B*UO&A!:1-[![`>U.Q,4O":!16"&G/T M^"VL]-Z8[VFG/*\"%G7AJ#^+DB:]!*I[76F9IO8>T"Z![71L8P* M0=H`E\Y=PAYH_OOG'`37\G1_`VP2^QN2.(/,DK:,@V5U5'H0YUSIR%5M^ M$WM/5?&(H'LP9,3A5M.!-"'X%2<%)*T.8C(9N],RLVD&F=K3[K!5K"*8,I", M>$Y!41:_[K0,;7A\3*UI[PE!'A&,^(*,8+2S\Q%'2R?]SOQX2TLAJEG9AJR= MD21'V7KVGMU@A6]^%&]@H!.0)%/-/3&K:()[#-;PJ.'L7HIC@7\B*]@`4B/@ M'_0R4-!U-$%!%I?QJ.WL7HQA@7\Z5[&!134-;P,<,])_@W@3]?$;^OO]_X51 M^`#?8%"NFDR9UY`9"U7`4B'D-=+VEU"VO-V[8R+B&!G4^3"EY`9%)D!V]M-L M`.<#)*/,OX3G<4.#IC>@9S?$YQS#D2?,!<5/$LQ M^PUQG=WEL([L+2X)C^FQ^^",B#A&718^;'0K3[1`@NPKTD=Q_K;MP=MA;2(L M87YQK*,@!9QF1EBC,3U7:4#.8*V+000CSD@_CHR:64)024ELLP9:,OL8)Z,E MW9?H:TN[]TU913#G,_2#<7-6DBC](-'#1W8_X&2$;!GO^UKP##94&40P.J[W MXU%K,`_[_8[4KPM+":?!B*C-#7))1 MC6)R3LY.HYH.C5R76CYYE!;.C!,D"]/]B[<[D)>/OC6O9>]@L"'O7N/GP'+M M^H:U:Q=ZG(_Z2K*/S<$Z.Z6B.&5R/6KYKKFT<,8<.5FD]?$J4ZYKZB1&6,]D"8QK@C\G?7V86I1MMIS94?K9U:O#;/)X1.5XT+ MB4M2X8#]N3NVB@!)J2[(3K7CM5Q?/A6+J3&C&)K=WODXGQ#:W2,N.!F5PY+* MH7(J9]>OES/:PKI&,JNXF,\C4"^AZ]$5IQ:OQ?.*<3+3W,3299R%KOLS4,"< M@3;$:78C?=P!]B[D\XIQ6D/=!-1EJM416R"$G3F+?F[!_=B'!O;"2TK8NS2K M0]23#3%B>#N&H;1`_*DL$J1EXN?`BC"!>8:84ZU)`$&RT7+E[7TT"W\@P06_ MP!A&;W#S*8P^'?`K''A>[Z&>'LP6"WVQ`KGA2*JNO/0U9>4MKN#`_`R\.RGA MC"BD#$(WS0W2/<QC$9"G[$@^+SVGTZ_;S5=5@D@M53=Y73H+FNRQJSH>=[A=V-6Z.]( MZ..E_:ZY7N&-N1):Q7`S>^#M]U&(7?DM%VR$,>P[3`4#(VIPUX<5UM2SOX9AI$V.">GI$L0+;Y)7B%95R!5VF:) MK/95SLT2:?5_H`:B6Q:!]]?+0D!:R@4HR_E`"@(_ M%D6!O*P_GD)'M8SFYZZCC7=3I(J=S&:SN;T!793)IWTT586TJJYK-&@^0\XM M\H?#4PS_<4#Y;]X@?CWS*2;W$`=3-!#KFZVWU"I[$8-5EEP96G-,ED/'L7?) MG0F[[L&F#X!;)@`D!?@U3\(;IN*HID?X/?F(/OP=S3YF2XV[66WUJN5IESAM M3*WD60P7]DZ"F+";9NHQ@`938_`K3@-((O5DU;/N<#*R-GR,CCSCR7QN;UA# M-O!&O(->&$W2\A_601-JU-2K;W#S&#YX.S0M?\85?M\C@&CZ?AG?PPC'&O*> MX6I[^?PDD[QM4`#]=S`6!>$_!BL"_J MPK-Y+Z\-/./J$`'2^@#F/("H1E(43JKB%6XC^L-T*_SW;6+J-\RU<]3>(P4F M1&>W,>*WTPW(8=3,#/CL2AJZ>;7=PL@/GLF-6L3UZ8S9'#0+D--B-D!8^2@I M<8-;?/^Q`[$)JK=7[V81O/-O0K=TZ\5G-_]PWRT$R:3B5B(KJ":ALK2DA>R= M975B-D^J.H`FK81N%-:KN"O>Y\&#,OLC5RVEJ*17)[0FP\KDN+TL?N2O#[9Y MGC4P-*EV)_HL4+VF+,XS-AE+0:ZIB$?-"JK)LBPM44E[-X4[,9OG5QU`DUQ" M$:+K5:1/FF!#,13DE8*75A@A-5F5)B7*9^_63A=D\YRJU=^DE,CC*9>;OQWB MY)6L:8:7FXV?-O6]Y^/`6MDM*Q(;/0VVE9UBO@KC)!Y,9]17SM2LH,L@DZ.T MVC;)E^&E2IV/[74@U0BG>]=)&J%;*0'/O\LR`"X$AY#+BKG(;O:F)5T4UWP$^JEEA^O,];.Q3293ZGPP=293B_UO=0(:V6Y3`C4?(,-L@+PH[N"`-;\B M&ED;9@G]_?M>/6\,J[I77V=V#[PFQ-<]-!N0H;J`CBL!CR$@U0!2#R@J`I35`5P?P!62DLJ[-L)1.DAV?(Y@'?E/=8"G.EP-K$WJ*Z( M*.PZ@-CY%(IJ`2.KN/_#5$@_=XJ6_;EQF&4A;S2-M"Z8XBQM.IW=>T>471[9ESXG%Q M>E!FN`"5+/D_R-HOR:5;+[2X[=;J1<.59R_"&>-]G=^(9N3"&''ON6&E*K(N MOE[@IEY#?%<@/?8OHQ2WF:.$?:F;[1:_HO<&RUT4Y`%/]#W(P05%I7)P2TU7 MD+YBQC/GG`8/-G',#B!,F)J#2)X-X'P7H,A9V2`TH34&9L@6:DW/;+FO&&PD,VE.D.YML([REU>?PB@*O^$#JV1:?8C3ZVQK;[<^ M[/`O&S]>X\F,*MWZM`O#J`(.C8=#VG!$/6W#7*PN'>E'WZ\@QV7@Q;^)W8NI M_,*<;DAI070\H-3'$T!R:1A*6@G#$OW!7KKW3#-Z^^-;+ MJO7%TXOT2>TMH7RX!"_KG.UF6!1Q9FT]OU*$GZHGSA`\4@/"1QX@4D8*<7Y]F? MO!TYJ!R_0)B`3:I"+_[Z!7CK=72`<:E?'OJ_;(?B\/0WY(H1;^H%!P!.K_@G M_BL)V8O_>P%>PF\0>8*91GIUG>2\^M_>4@^H[>&FYM8O]3WEQXY#EQ;WR]NO MQ(TRQC/+@W-QRW(Z'XT.J'?.GV;3X*6U$L;`XK%5"L+AUS7*(/;W7!?'6J4Y ML6?7ALO]Y'^'F[I?)Z4-V66<:U0.WDV8Z8L^KB4Y>U<$C7!&Z-`]`,W MR\^CVAMK0N)!1NKU_.(E^,7N]^OTQ-ED9HBQS&65KSPY6+8\SGH]&]H:=8T1_DKTH&I*4NGZ% MNJ\Y=3>2U$UCL#BCQ="0A540HX=)`CI+T\1H[#JG:585M%DK6JG9?5B_P,TA MC:R)S^"G2W]'1C46"]M3K_5KX+WBY<=_PLUUMGF*K-!,WXLAO=6KY"N3='3V MTK*.9Y-S<@S:13#+[%8<33>ADA1<*]C,[R*`@>6R$]*[9W&,EG7JC$;S<[HL MTB7$"9;".N"D3!<[GM(5E)CE'(K)(,D-H]H6]M?NI:H.U+I-9WO5!N(D\]-) M?YCD'DI5@_[:'42K$[=96M4K-Q4IF9]=BM8OV9'1.797#_AK]V2[#[I9IC7J M-Q8KF9]M^D,E]_"L&OC7[D-GG;C-,JQ>N8EHR?S,TATLN8=7E>"_Y^1WU6&; M956M;C7QDC_Y)`XE>4C]$X2K+8ZL@*^-?TQ/;&7[YN08'VW]A. M/.EZ0'60:`:PAIORQOAJ6[E(CMR5S,:CA-[&23RG-VN$[\P1IPG;ECNC1?MWNLJ@B:_^+50 M$:5(#WYG=>#J$!-&B@URA*=1822TLW4R\G8[HEM.VC]!KRE9K>X4Y-] MNB"F62'[-!E?D^RC&-1F:J+6=E\)ZX)MR$BV`BB)F!E`$,$=N=^%;TP>!4+E M?,;AS@^07W\5P8V??/+6_@YURL?\EN>5MT<_)>_7L`B8C?I\J?%&)"\<.68K M$#ZG/7]1PZGE>WFB(NDVV(*X7)R/^-HD)\BS7H`B,\AS8TM?Y#>E4%I&@W-1 MJ,8XPET4682P^X*/L$Q&1B!1=(5BK5/%*@,EK;-,8*-5F[)EJ-7V/P_>SM_Z M1PU89J,[)XXZQ+9BJ&0 M'W>JT:O&4$D9*?.M.IRZ*!^D%8"\!N$WC+21GF7K[_>A_F(#+R^G[)[\Z1+9 MGF&;'_SQJ+[-;4!S>+\`_R@T_RG5?"_7_/+U),%-3FW$9]H,_7W8@.;FJA92 MV1VY49?(IC9K->'7Z`MP[OL*"O@U>**+2/C/?%I7=>TG,04\;2%I"MJK(L2R M^X2Q-IDMG1#T`I>V`GD-%#M@BQ70."S"U[UIG&2EJ9D)GM`0]LUUG M&I'1^(J93&>+\UL#ZY6'76NDHJ>)8'-S)6GZIO)*\LGSH[]XNP/ZD+YBNBI# MXF/.:(QCQ0M'O;)P"M^E,-U%#:>6GUP5%>D4@PT#KO8!!V<&)#?^G.8'E0), M:92QH<=&C6(:@CJ+(J=VSF^NQ233"899]-Q4W[.YS?HDF<>`OV!> M,ZTSG,_M#FO2#EH[\]IJ=LD7D'T2)E[PC.\CXYL2A?$=.*.1,]9(/DJ=LOQC M$Z/D(#7]<+&T?$SOPJV?B>V5N_48QU4_5RDA]1SO-T[(YLX@/?UD9K]A[`)N M9H^N"T*%F.6[>^*4S.+-^S#^`K,0#?%J>Q_YP=K?>[O;X#/\GCQ^@[LW^$L8 M)"_XA9710N,"N0PV=117T2PT51`HUQD.+=\05R&?25LO"K(Q)I0%78"R*.P\ M%X4!/P"X.)"6!]("3Z*O>E9(SEY?FVLGBTL0!E4OZZ&$-*[LD!R'?Y\?$H!R6S4 MK`9*K$I3W:KT+23\&5ND2-]"TVI$;01Q)<+%$:LX)5;1]DT`%?)9JU!-K%BM M)N)J=1_EM:&_7OW#:W&4JZB:1%-D#B+-6;@ZW1"3A*86+"614VSGX[WQB&1R MIL6!BTRNTJ"_)-1=F15D>:OG!(OLAE2#Z1;`6:A&YTH=:W_9?OA"4"3CJWL< MX-R*0NS3Q!?`WX*]YV_`-S]Y\0.0O$"P]:,X`6!?#IUQ]>,^@\\%&O_CA!ON#F'W, M3Q6)UF)4H;ID$U2LLDC2W99'4).5S3(/K@%0T)4#:4$`E61:MS2X=];HEJS# M=]2]EA]5EY7-1A>P@;)S,/.V")E%KB"%DCI\0FOT3=I+/.INRT\PRLIFJ=_8 M`*I:YP3\QR2#_XAD)J^PCA8+?0]9T&J4UZU^&:I:TTB]7-I^P;`=M0FWC5YU MX^`"_BST5N]Q'=FKK:@3=9[MI=6IEHIMZC<`WA M)OZ$B$6*13V`7U9Y?0T#4N[`F4PFM`!G:JQU;_UR6B(B7JX9+'F16EFM#,PR MZ.8_*Q`W3PAP)X(\:?J\%4Z'Y(W5G?Z\D^5PN+![;YM=""/K M-\Y/]"\0^$1H(6%V#^<1A#F#)6;@>A&<[V1LRAGE/:9W0LKXD*96F$41N@^ MON#'NW)U>/"13R^NE#W"=G?8=.+/96-_:J!PX.5U3WC"YZLD6/%\N['Y9 M1(V`NAT_)2C=TN=#PU1:3G;0XP*D15UTO'I=EJ=0:3_#;^03X>"(]O"7`>4L M0&A4PBY!F92M4L!\.;?[9@B?("=5GF,T3$J",J4I-*N"E@4S&U6AX?(Q%H#= M#L?NM01.28RX=WR8W,\''/T'CPM<"+ M%\._DAE=$I.3=[3@7M35"-%:E*F,KDIQGLSNBC+1L!K5,"&!=P]+U M\:H.D4(`*B5;'<_+`7E!IE6+9:'O7%6KRP_D[]V)W=>[I&4S[2L*HU:R0*4',LZ=JCQ;6N%CF)=7.8MQ&R```5SC]G@,<4S9R^<(DH5_0D?FLY]R M=!IU)#%K?PMJ&'#Q531^W8OQRN2T(B[J09KJ8N9WYF$I6]9/OYR`LZ7/ M&Y#U/IQ3,]M9_"4[V3Z79KN]:W"BXFCWDP2!N8]Y[!:R9[3+GL=;D^?Q+M#H MD/%_@\K03'@F_\=.QM=]'J&NL/=^DJ@X)OP>06QLAMX3,O17.R^.5]ML1SZ^7)O/W+.O\0#!TO=PJ0@B.052TP98EV1DR'M\.K77 M>U(FGTYW2A5(EQ2`[\IFJ<`J`B09R$L!I)A*DKA(PWDL2(J#6I[?.#,]7*C7 M0WM7D97)QZZ'PJ]OJ,*:+R`#F"O?'F>2K$?/^PCZ&U6P5^\R,>+!U_0 MD#J83S0^SW>P7Q,C=JF0SOJ-:M4B3Z9VO6@GK/H$*Q/<X,?\/?4K;X^^).^(!\NIQL#&'%#D M^"XI=%4%>(K*^W!A\=JMM%PFU$04G(LSXJ6B-"O(\X(\#FV1&^3936B3EA`# MMFO37)TVV;]8*RR7]EU`682I2A4;@&";Y;THSHD\%3JU%M,IR8>UM07A/[<7 MQNGCEU"A!0,F]D^X%4AH9$R3AGG\SEA9"BB+J3\Q=AN0_4I`RC+Y6KDE2GG: MU\H5*>2WL&3!&3B6LO+9J8QUD#*JR/O;/J,+OUR#[_]V'W#A#,9>U:-]'Q'_T@B\WUQY/$Y3*IOV<4EXM' M>]G*+NEAO_.K3M!3ZRX_9&;5Y5/73YX?$3"WP?Z0Q'?P#>Z<7R`.SS<8#4>T MH]AJ=+&C8CE-XY((JU%7!F?B."-[%8,%NG:J,X!PR8_``;^FOW.^`7>-=.;- M2_PW^,D//.1B8D>U.+QZYWM/>)4&*4P!Y=J/U[LP/D1PL'#2B\&:-F'%DKB6 MS2KX@@EHM5U.UUW"BVMI=(BI%7,1E-[3[GH$/4<+$$%;\4*Y-I. M'(*++GW_E10@JN0?WRL5?8K@/PXP6+^3)\@=G:_4,P!0I)@\$C94KB/S;+BP M.V0LNQ#&U*0/B5OY#(KO0B_>LZP5Z&7V*58_VIE,R32;#>U=_V`#;XRY;0AJ MCEN:Z`+(+8G0ZAR5_3PSRMR1+N:V2M3%W%'1]!8'4F`#?PKFUA!T,'>DD;G& M5IR-,;<1)+0KDS->C"Q_Y8X%OO:59T8@KB+"TMR2ZQ"_2XGF98X!-[@=@"(" M\TC8(')'YMEH;._1`#XAC)GD/B0UT]SB$J?I%?`]+N:6N6HMAP9\C`X$ZAG? M+V,7Y1NY9\[\_#C?(L4I2$^'TL;ZVO*'.CO?R@F]'HH=O&_W63IS3\:3^9DX M+RQRF/5B&!"YLD1_.#S%9(A(;M[0_Y2[#-.A1J/>5JODN2IF68JG:=IR.`MG M:/=B71]TW6:ZIWZW_`Y(`HD-IJ.J,@U`G:IO&YE:I5)VMDG10LU<[5'CVAL& MI1>W85+6*J+^60T9([*W%N>'!>%X&)6]F><+(?.T-[(3.P"L/-3/-HR,YKV M0*\7($]/(BUS/AE!`Q`GN*!/B"Q_??'7+\7A7]'0="+QNA M2\WZBILZ:8>>WXC((1F[6NW#V,>WLA[5JA<[5K?^Y("V"13+JV7VS)^87$"* MSW^&K*8*<0IGCHJDXZV,V@Q*&V]9WA^SA[=,GE`M[SQM:;N7I3BD.)E'0\?C MDI@/`A3-+?8C^M]X"Z,(;@;+F;[8?U21[M1LSK/(TDG8`@>:QCEV[X$RX3^) M>3T"T3X7EMBNIU:<[H`MI_JV[-NKU6!YZ>)T\OC\@Z,!E-IPMGNJ"$"J&._=0BE)C+7E0YY:CI%\C!GTRG=AO+ M'N3L=),*L-&-PBU_%Q_&\TBV2-4I3PC`7;$=6: M6?!LNZD-%)5^;`S6;QF[XLT,U2KE%_@W$HA1+"/<`W M&%0ZEG8LDX%RE6)4DJX;'9UVU3QDG+`[5%@_>+/4HR!HD(^DT4<_`8?/)/_Z M7+Y*IMQ5.2?;1X=_&J>/BD4G'?WOE=ZF72UCX6)>B%(F=B!KH6&1@[2;W3%Q M^J`;MH'']3(<;V6+\^2*ZO=]\G[P9_(ZC61:",@>7JHTL^T M\[8,#*P4HY*#W>CH)*SF(?.UVI/J+.3+ M"U%*O0YD+<0KM4H>H['HG^#,50H6I)E-*7+&2_)QL.TI>P]\=L'6[M-[`&@;?&= M.KT1,&DF9U]4LU9-2=INFLX=[)W_]P,W:-K:49344S?EHO4JOX$SR3F:D6NT MV2QM,WO7.?N!FS)T[1#,3O5%3)VAN3[=S!7I2*NEJW,6GUSL@VW2Q+5@*`DG M/,'O[4L!XV:(953#5F^I<=I2]LZ"^V`;,VHM`!0N)3V@[)O##J(),GXE]27< MH1Z);_YQ0'WQ.4S@\23Y$7Y//J*,?T>0EA/:[4)%(85$<^S M5J_<3HK!ZI#$B1=L_."YH7C5 M'^[07^C'_"?T/T]>#-$O_S]02P,$%`````@`/8BH0E#1%.LF,@``L`X#`!0` M'`!P:7`M,C`Q,S`S,S%?<')E+GAM;%54"0`#1KV*44:]BE%U>`L``00E#@`` M!#D!``#L75EWZS:2?I]SYC^HW0^3/%@61:WWY$Z/O"4^[6MYO"333WTH$I+9 M39$*%]O*KY\"=TF4")`L;C=YB)_7A^[G]R8QJ*(\-'#;W3[PGB>6]X MWAMW_J*`IG_N<_%Z:FV.&?T!^[AKF"S_6&%]X_AA^E4^T, M_B&ZGQ6FT^F%^Z_A1RTUZ8,PJ'#Q?]_NG^4WLI;.59T")1/X*TO]8KF_O#=D MR7;1C?UYG"KQ(ESQT4_0G\Z#CYW37YT+_7-1Z'Y:2D#BP6*2)SD#H#L=#VK3 MT,@367;HU]>GNY,XT\]<7!NRLR:Z/=.5&]U6[>V=OC3HQV"!0(<[Z)M)EE_/ M@&WG`6LHE7^EOU`DH@8?L[<;$"9+76\TP.LB#U57AJX0W2(*?&,9FJI0H;R4 M-,J*YS=";(N!-EE>6)70]BB9@.@;L559TA@)W2!0^JI+CJ+:+J6')#_;\'_* M>FN^G&^(Z;*^$OSREAO3`)#6.H[N3B(C*3!>J(0E22Q+$395`^223?_=W)-;$G5F%FK*T)E-%/W7'$T`A^#00AU@Q7J#\"^ZVYH-Y_T6]X5 MP?_@1%.6Q(8KO7J3P'1;=WKX,?!P'/.>O!/M!6@F]ZJT@%.8#0MG7Q'(.7@. MZO+=,#2MM$5E$"8@5,>@[\0.R4X<;)08M!WNE%FTD."H8)9S`^^9QW/$<7:Q MA45^=X":FW=&#\TB0E\L:T_@4`R[/%L4VM.8K?$_H,SL\&\XS8^VEI;O2-O$ M+I=YM`:'H`.-CC#]C>HV)Y&6\5&.X6'WYXC-`!PV:(?N?TJ0% MT;Z>P2_^>6K0V<*R3=#K[G`B",.NT.^.TX%D&G&77(V&'`TS0)J)WA?XRVX? M2#JD*AY)M8C<71GO%PI1:>2U3[^A)/?/>X(?C_PK_&IG6";BXH(P,P-"EZ:Q MSH6K;9Q=RZ_J?O^%'R"3D66Q`1[>>\QX^AX[F`V*"!Q/\G$U1FL5:'KO=6D M55<8#`IBZ\ZX=>#KL87ZC!VTC;$!7(\$%@2(*=?@7G6%D5"PWNZ,7P=&IRW< M9_BPK0R_52UPE?]!)/,6?F-U^[UQP2S?FZ%.3#^^>)_MHW:SW1/Z8.T3%,;' MYJ@?ZY,!\)D_;AOSX?Q'+^"?M^N%H76%<5&:OC-N'9A\;*$^8R=M8ZR'T1-9 MJ10:W7Z0UK"'38KB;]+P=6!SRK)];D_;R>TKF-^4M#LX/W[^G6QAW479[\3Q MZ\/OXPOW&2[TVL;Q*\F%DZ&Z$U+U5M.:.[>9)@D?3%:9% M1=+2)ZN/)#!"$@A&$\-N/UTDQJTY0MK]SGDGO!6#[Z_F#]):0)$;J,12U317>5R\GHA,``QZ[]4= M]:9IL?3L7MM[&/1$`2I5I[A/3UBD, MQ4$/358XJ:E`;O+@U=8+OI,(3AO@4.^J_7`R'I1#.;[\3O?E]^A2FW,-:=B2 MQBN<,5S2`EIY>$.#$@^$ M;M^C:=J]5!ZWYOC49;*>&8*VGG1BCMN#HA6"UJ.TI;<*$?C-)R,W+(9N*< MA<@J#VM"P4V%H*UN+ZS<=$@0O+*"Z)6/0`Q+T.I>XKU68ID&\[!5LCS#PMOJ M^=X;^NJ%F.MKLK##F&6_GYJ=E<.2'#C!.[OO35:9K3JQZ-`E&=:=SYG-%#AGA[77,=`0KQ%9 MJ2A:,CB7?-PF),E66P\SK@NB5PP(O,]'&_B2PG4Y@-)A.\%+\:^\VLP'3G+RF8DT=U0U1 MJ,S&U<]8I*/4G&8,O!;$+]6:+_T&?9+V:%CJ3F'<8#K$.VJQ4%"(Q&1;ZNY5 M>$*>1@O.WKC(9;'F;3VWQDI(_7(S/\L6IQ)O;[:"U(C=YPA+[TXL.]*??JM8 M/5,4U:/[45*5._U*VJA@FF-0=(]F+GW^RL2!#YK(%HCM$A!9=M:.1HN7 M#Y_PN--E8^T^Y'%KF$1=Z5[T5]ZZW7,UCQW*OQS+]O-YY\L7Z;,['([QXE\( M!%,MC(*`&X0Y. MF-IZM7C0\FGFV&^PLC^(0I>/YVN?F+A>TG$*EO:Z.!S@31IM(SWVWEF6X[%V MB+:D(Y.6+^V35&D_A*,QWM`[,1=&+@L8;WHWFHQ*B5[B-`4LV`8>`:;!EXSY M'>7!GJ/\^C![O;Y[\1SE))?Y^06^?+MY`'=Y?MN9/]X\S5[NX`-\SG*>QWZY M/68O6A0.&EUG#(4IVD'QR*39;;X/A+Z*@E]=0>PAEK,FS%B(6C/S(\RE3%EZ M8XP[Y]UO&E`H5KUPP8UU;_-3Z7M]S-/;[FRE2&S"WG-\S6T]BH5:&E9X!C") M0Q&O8.3HM-5PG@F%MIZ['@S=V+7508^^$(3!$*][9>KTU8@$%RH-]D89]C+W MR@Z0]-ZW=0"0R+^[)$O#]*_V7J1/8GU3=7?I=SK,12S:(&EW%"_J_8W8;P;\ MRSOQKOO`-^B-AMB>72DKJ<;=JHI5;4WA>R!VW''MC\=XJ9T[7VYR7 M=O@8'%PH!X'W2\E295"!:U5SX#C;G8RF>`YORN35;'DYS5G)Z\%)F/%K;WB!4+(O5_IG#JR;9.5C2LRR/= M@8?HX1"XE5U!&(AX55/'IBU$%#*2I"NQ M3.TG(FN29:E+5=[+W'XBDD9S5EXWAOXL:61NWJN_._22$#Y&GX,3Q02<$OLC MEDM;R;IUD!%1(2<:<[W!G6GQJIL^"C]+JDYQG>M1WP:+/DDTPGR:Z>3L5?LH M/.`TY[XV0S>DHQBZ?7_PG-?3DU`!I?Z1$JQ\,MRLUTSY9&PKH=FKHQ(2=X/Y M2A+CXXF[B0MOCJ//VR\;AI=5R8^OS-:&::M_>)&226^`V>KRZ,15&3)&+!H3 M-,*HP1CEK,%X^>7F"3[P[?'IYA?X]-VO-YW[^3->1<9!.X[#7"..ZHQ3W3V" MSAV/!.2!9I291++(-?&^1M(WPNXTG8N^G`%UCLXG23'=A#XH@BCV\%),<(@N MQH`AR-I.A`N75VT]`L3J_#S,Z-/!$$3F)R1,V2\R1Q,N,+3PO- MS;.4=-%F.P6EHUBL96N.9UZ.H4%J)522H6&1#=AGA`%>I)Z%A$K-TN'1E1>T MYEQJ(O1;&N<[PES-GG_IW-[/?T,[M%Q)UMNM9GQD/Z=$OIGU8CP1V=!E52,[ MN]>+0:=Y-(UW%<:\W+X"07=Z>&J>@3 MC]3JO4XF/ZC().[)"-QFSTZ!MX!X-Y4\:>U5,>$-ZU3PFE/FS/N,GS?VT=JT M41__76#,:KU2!8D#S>8T1N`3*.]QB;^KM%E$4-$F#J=X0G0X8?/D)@6T^A>% M9BYXW@E;Q\#S7R>)BFM'`F:-*"L=S1.M;!BWMH%#!CC0RNZ+E#G&QP)BO)N)B#K+3RIF]4_U+4Z`'DVR`5PXJK)F8BHB7!MFH MJK.(\:/:WIN#XP;\4=H&UALQ42YU_JH$B<$Q/(548Z+ERQ.'.356]JRXES_*'A1PAC8]*#E-'4]\4+:J?/76)Q.(=6< MHES.ZG-B)X4)_'B$D4P,HPE9@:F_D?9C"'I&")/ MX"IO_?RQ>U4G-(T,IJ7/A`X&?;Q.+TPTU%J6V)"K_VFV=%.+U,*N3%L;,CX< M_LJPZ*%2G'@WI#AK/#9OU7IR>"AG0ZB]Q^YCAN*)`'2J3+-Y:;+N(;9@/,0) M7J%?9KJJ%C%F4\R'<%N/\SR,FB1R',Y@\%UK^&DIM;BQ8OFGV?R`WRQ'@\IS4]DGXO6A`[PRO#8":E: MIY)>6LF"87/2R?CZKJ3N8/3T.BY"+&7*#LA M5>L3Z]DR#[N6#:8<2[7+"&^N<),2-5J MQ^K2I&'85I?,IOTGZBCP!M'.=`D4;@<(7&@5ZES3J>W4G M8P&OX0T/)14:O:R`M34G@PE%['[`V7;%Q/4DRIAH*$\)HD6>UH)3(#6F M\=#&567`Q;2+U@*AM5J`LK*Z:8&04PN$!O7^\[3@1N>XI']V-AO-15'2`A3O M]*5!^[)3W`,\A[T!7AXT(Q$5>M098&IM"ZT'0T\J-=E&($P$,:G?7V)]1=IH M5<:.>!8:L+O^MT7<30F\CH2T1R&80W&`5R0;GZH8OF>U;E&?@2.+C^X&^ZWB M-JT/WTD!A>,1?>%,N79,4`%0"1EPG)N/X&FIDN;_''O\K#L>3/!VBMSDU4.L M"D4YNAILERC&4?:+U"AF-"!Z9>@Z<8'X3;7?XKT-J$U.O.5(W'PR35','1C_ M)IKDBV3#)31>XK1I$I/W62.A)W3..]>J)6N&Y9@$?IB;*TGW'W;H2+K2N70L MVM\@C."RO5L4'P;.%_N#\+^A&ALO>@')&_PQML:PY%S2HL>18H_XCO#"X860 MF/VXFVOZ2`1>@"F7FEL8(PI]Q$=G"R:W$#N$)&7ABVN8+&I,?A:&&>OOF[%G M9[V6S&W'6':>U96N+E49=H:.W]0/MIC.(Z`OQY(XV.R:/^Y\&1LU&G1_3/XG MV`Z&BJ0*L1C@^+39[=%)@&(B/!H@UI2S$5&([>!@7>B[\$/T76NYN*_EMY)J M=MP09><;D>@OU_'+9C:5IH.X8R0-P:W!X6@1H9$@"-,AWM,/IV;.KL9)HT:B M.>V/\(IU3DY=B,[R,2M06V9(OFME'>PK*RVZ5KV<8/=@`1X0M7=$Y]^%8T.Y MK]\F#,2MN"?&C)81"4>OC[<=3Q#Y!)2ZY6.7/R?#P!BTS MBM^U>1@>>.RTWO[-T``3Z[\Z]#+2WG+ZYK$1=O^>VQ@<#O5@V/$WM1&[M)V> M.X=#GCANXK%R-!HC^N2L=!1TV<7'R=`WSX36=ZW2HP/W/(CG=F+!>E[O/!@C M:0ANO:;!WR3CWD>^I2ERVYXIBNK)4!@EBEVW)$GH$//90FYR"E%K5D9&!6DY M0&MPN5E>K>[G":UU?G"_V_Z($6/SAOXSTB;_\U*R5(MV@XBIC*XP!I=&/<35 MYJ&LJJ!<46BVH%HJ4=I>+3)?WEBV"GI+ZPC'?1'O3FUWLJI$XL226U"\E1SV M,TP"(G]%\S!T>1MWOD`;W!\U%V+?#L?'&IZU%:]3?WU_V>##`VWD2)JQ*"%+6WIRR+#Z6^V]7 MT>XAX'O1%1Q8R.%0P'->4^>O2A[X@&E,O09O0B0<'0DXZT2Y,M;TC4\O=6;C M.^QWN@RDJ>^$-L?S+697&(F8@4U^BBK+/,@)7FO+.;S^1"_2YZ$W-D:\NS\V M;57RP01#:XL\;B13![1H2;2K*/L@3,8]Q*X*IR>O2B(X,`GDHHGQTI0651\Q MY$Q#AV]E+U_(@^-`6_ICU!:^?.14)3JY8`N$J75QM&_2OPSSRK%L,+3F42`& M/;S7'!@HJ$ID>,%I3&D^;WP$O#.3O(&#!LZ8MRDG@S&:"G@-*5FIJ"Q*D@&E MMC[U\;-A*!^JIKE>O"WI*W6AD9EE$=L*_BGPYWMB'R]YDYF.JH0F&U"AH6F> MV.2]"A;S706_2("OA7(5[`W]YU4PG.OE-Z(X]&V`F_5&,[:$/!/S795)\H%_ MIKF#NR5'?CCI#Z)XG:#<2MQX2&DRPG-%T.BN+,!2"B.^XW0SD;D:)*/I22P+ MR6EIVE8<$DGY-8CJNT1#AO>JM%`UKRVG'4[K`A<7XC%F(#8C6176E!2"9(/- M`9O:Q!#QM5*9ZV`O'9,VBG`S=UYU8V&!J:4HW>D;QPZZSZLNQV)U.H,I8IH" M`L5UJ'A"8D"#$RS9!-<%PHJA][\.>+*J[>IY+!%U3[FG_2'>J3XG<740Q_RP MMC5++]I/0K"\LRT<=QF4^'"3$?!"!8726HL]O&C,PXW]>XPZ,):59'7SD^I+ M>&G MIJY80%*P:+!#G-?@#WK]PZYD/('F!]H%CCJ`/W9^N":VI&HX4>=P'G^2/^// M:1UMJ+R[K?>25#ZY)6'J>)4%>/E6VE;K?J1_^*=*GU)QV\..RDO:I]-FE]TG M`BQ799LHR:,G__8;62^(V1T,!!%MM7DH*T0_.+@<)2D7@V:%BL,B,_1!(1>' M@3`9XPE`,$T.Z:9#!/`*7M,#/%H+E+T3$(>REKRV!HC.'M$X=0R<##F2K?:I MKIVU3Z_8'^!=5>U,59P('8,Z2CD[LL)0C(1AJ[;N0BPT4N4-\GZ7B,>]"F,I MM.LT[2*]\BY\_>6"*]=/RGY(=%I/#%2,.!?*N$#^69IPTJ&'8RJY ML\G:HE`,F"6!;-*EX)5%^3PY5#UZSKS:ZZFN7X:+Y831K3%TO'-.B MD8>;3YI81KIC`3%E[^BT-9$+%E3:VE;A2))AM+%?;J.//$I;^JO9AV0J\8M+ M9[WQVU3HCJ3=&N:2J*!<[ONY+O!)^TOR-HA-3CU$KES4V]KI@2E?]L%PWU8G MBHN?]4(??(W_.]7^!\/^![&C;-KN9-+'NVM"([L>LET*5]K:J@`-/,_+`2,1 MZP4A`**(9_-RU])RX4_E7_O[+/A>V271R5*E;;9'B*'0([/60\I8(&EMRX49 MP*6HFD/OTY]I6IR;/'/S*6N.0I1;0)GJDA.\C[3?C6"VIH!3T=PX(<-?8K&V2T%]?2?X$RT:R)5M6[8S"*GPA5<1D2\.SL#S6!!8%$#+FVN%G1^*L: M:1"8<8WG MI5K7[WP@?P$'V_$0\'?V7CD"@, M7.N-Q<6<4@Q`HOEYG2R)*'P68%4-B7J`IK6CHU1OT_7>L`QDHR#?YSD0W=Y` MW"9`-81&:50H< M7*I67\;A6]19,X\M*MS42Z8^@8>9;^X`):1RS4R>F/",WNZ0@]YM&5;RX_`/ MBZ/3>D3V9:O72F2Z*>S\).9>C#RBP3#F5O2QQ0:.``]@";?$9):RLI[/J(N; M4_3C[P:T=Z!1?<(]XH5`&Q.#ZCDGZLH=0_'3%Q'M=$_ACC7IB3-"F(;"Q:(H MJN!4+C)6\!38[O/9%"1G0Q#VPD-`I]NM+)]=HF.^3"DV3;*2UV7@H^I1G"JU MFI"'Z6)2X/),C8G-H6['K^PG%@-.H^4[L:@H(2(GZ27P]D%$NNN+8I M)U4TQIPZX*/IJZ<[7BT9L--:&:L_X]\L!^@F\@P\0./LT7;=A153#[L&AEUA M6%SI7?YY.[Z:P%V=YTCYD)MV=PDY*@IK5;?O/U"B>01YD%?([-\U03B_2BW(@D_@1@_@1@_@1B%[/>;4V@, MGFY-W75#'"M@#ZEK*>[:+P<6T8*8YEFZXPEY^+SG(0UM!!P\KNM&U2E+K/T; MY^#ND%Z$$7-TY#0DVX&6=B:F'=7Y&*GZWO`GOHYS?-U037HH4F*>R(HH)0HQ MZP)Q1A6G6?B)O.8S)/ M&/&5,?VNRG9W1APC/@DL-H%N%LZ+L=UY"VC.>;JUABQH#T<#<>Z+:[V+,W?S MU!#E-F3`)N:P]BTYW._62&+J(,G+438PZI1:#\P1I.BK<8B%K(^A)CZ-+;!% M29$8\PL_.\8*H%RT`N\NXH[J7;TR!([C"F35<.G7\TPGV?)!;$VV9<5`21W* MU>@TYJ)IF'\I$"+8Y``AL0A>7S"_>7**?D>[C%JXM?=[P_,C%:"1"_^-DXX" MRT_(6RQ>(=$H2A6>;+)LL$)>TY%=S&^,BP%34D5QF4%ZN55U,B'C_4STF],3*L,)%IOXUR>\4_0T@>&_].,H MSO/S/H+V`Q=33^N+2P*=TS&7^5!&B5$):3IP5)T'#XY]/.`$1(FRV22'*W'1 MN_RV`*U>H6N4T#%/CKC\=V,/:MG*N[>/3D)F4G[L;-W%7ZY9=1E2Q)IK7"AL M\^JD9(\TS+JK":QSE^B("Q=S(#ZKW9*63=6U_I?^9>R/^T#@7K09'6NG^%@;K_?$H'#B MKI7Z.A=R78$QI%?^V.-E8Z(6QR!N?JVZHVM8P'4#M'P_6G\R$%>^,K=K/IIG M$RZZ$<@BC`)[![T7@M9M$J%&"_9W2$Q<',9BQ][O<,=2'-/<,GY-OAA@]?4F MW?L=XG.;*^[/[!8Y^T!95_9L3>&7W<6K+%- M0_UH(Z\ET3[O/*I&)ANMI*KFKKUQ@+[:^3L#NA8XZF9B"B$@_+SS&$-2!#-1 M[;2MRD"!0@C$T3MJ.9ZB.?`"/#@(*`&JG/ZJF]"*`!O;06\!/,=X/^(_V'C.4/L8R_8F`WVX(A:'#*GUP.O6/CKALGH/@(\GZ=8LPW@X_[8,:L^5*%!C M7S6[((C/G7T=#`<#>PJ:35I`TVW6P?'>SX[ M!H3NH)O3/2J'^P+68(^EP^L5*:;SJOUWO6T9>%`"C8`@0]4(\F1[P'W63^@` ME8;D!1ST$[:5,#88$>H;8J:F9:!'<2P"=HP;R([R`7"#=`#O_MS9)D3% M_:TU^^L(L>"1LR?9KM\JMX0]Q&571)%W[9 MP0$+KGA0:015#U1L\/9/FT$R)3G\K/OUNOUL@B1,=J3:VW7428L#MY M,JSXS1^WJS%ZF7)?^:7(HL`5&=G,-G7K2=]'\4[CD;C+^/.^BN\1>"^=6\@@ MAMLG:G7Y"7\^_0@WT^.J175#5B>K?$(Y'XL*` MDCUQ53=YZ-$1+Y,4JJJ48!/#]O"3=_J!\/33?STUWT!*!D< M6-_;SOT115K,7?>HP]VD/1R/Q2V?S,,11.L\%25OUPM#I^KE*X9C@8?N)JX? ME\#98RBIW:PY#=6H?`<8BNE)Z.R-A< M;/PI,CUZ.XC'_\"ZK0U[`A,D MN/QWHH:M`']S-:'J/345Y./:K$B2&RQ2&\HSC//_WNJF"=8WI^!S;O!!MST< M#0<$`03Z#.D'5]V,2=7OY`AK8V[ZF#P<3VQFZ&:"`#N9@/;?@2[2M+3K0W8%W'.XPH`X-+]1%G199:4@:'`%2'-HLIVSN@GIQC?@= MWGNQ(T=+8R7>J?"'+^NN*"9;\]Q190.U.IT!CLP*WF'"G]^>IF]W\^7LKG6[ M>+J;/;WZ/[TN'N=W4_3KUR7\WZ_9T_*UM;AO+9YG+]/E''Z@];=G+.L.>,9* M-QF#N-XL_;@V/'3ZM=;P](M_<&W36*-,\HZ^??YMYQE\V%!$"KO\"DQ=G]%KB0ORBQ27$ MX`;^X<^V-AP*K(R7V2\?8YU:.[&A3H/#-YZ+_J.-%Q;.QJW9&XK3FCT^+3%#6QV-Q"]1O>O;[">8>#Q$0W MMN/8GQ"U6_T`_^*=VIHV(9ZH.25@9!@*E\E,K<$HET51L%0MZGX-02$^VDKF MP.W10;`2U3KI"I.-92B5S(&4R[DP6(VYWF/V-9,@B;*1+S;^ZZMD_1@(B\`[ M#-;AR,,C:M#4O1(CP9*:5W?`73F&_^0333%Q07VLPY%G7Z8&K3%W8*Q)PVE` M"=X7+S;_/.JFL3'`^L9`-]+3U0K-/_<%K("!"PNWQX/>A/KNC'/G$M.J((*J M7M45Q.S->B>CAD&CSLW!N_=&\8X.0P6N_2B.(G,+?AVXWHON^;[5=9Q)H3WJ M"]PQZ<=1#[F*X12P9J(V:VYTUW!?88?Z>F']2W<,M&PC:"`4FCB#G7(0]=CI M!1!J3O).9O/\'(U?*)$I,BU]`/K#BBB2[%<&5F3AT)R4I"6)D%Q&9YL-BK[Y M`&"Z'%@*M/>KY,5,52'+6 M<24<'U[A>!82<:[.R@E-57TKCA8,5G4#/8L,$DFYBTV476IN/8$O;_D)S`_P MR[:\'<*F.Q;H&R\SMIJSTX("OQI;QSWD7LN M0J@]'O0[U,FH&1NOR5%9`H&0&,HY(AE!\=.YHU49H4.=4:1H+XT@"AF3D#'* M.2'#%WK^`YZE_7QT5CO=!8DL)WIJK?%' MPBD9PH0G'6,.1O9>ZEF.N&`2$U@5M,S8:B=;23A#QLGO0>+#.#_E#!5&Q`IB0BE'.3BI.%<$T)!T M\GN72@4.)("(\<&6`_+]3TC6N8A;D)QAR!!L0HE2R!GY74:,G)E;Z^,*OQTF MS2"$U>P+)=<"*.&\P$SLU..HAS3%8`I9HUQ$94+VT(V2+/O2'I%KE_%*ZIK; M>3T$84`D9(5R7L8PAB*8"CB[BZ9U!:9')_18U_J0+WJH<^7\A$DO:O#D"M\1 MB\N63NBQ?@-E[T[:=1*PL@H,ZR2%ULS)X"VBE5B$=7Z$` MX4D#`X1O=<O*%L M5(:]C4[B*#.![/HOM;&]6?K>=CQ4U02E`//7PK[`^L57NY>!(5=0B7U<2G/# MSYJK=<>=BMX1\:NW1R4(6?=ILC3BW9`7'-67\)LXC7%W/!;W_HO48_6*NR9W ME->Q^FE*.=GBM(M1+DLH;4_H?$OWR4US-.*09UU*TS7FY*30G9]6?+&!2S%* M;!DDF.D/22LET5PB-%"+%JX)TJR%+ZCB"Y>`065+7]FZVH^)?#-!9>E>Q\_F M(&;\J?ZX$(]6%:0T.VFQY9[]R#$:WG='8Q^(I-QE?_6H+%=L:58*5K')UE*6 MC9$&26ZNGB_P6%:XO@^&Q38J:CN/8BP!DF@TXV*C85AZKY&""B;RIDF0HTF4 M"&8R&CXI\P6%&C@N290,(2N"((DTBF`3/,N@),N=8JLT4E/0+SYN(W&U8@Q\ M9+HI$:D+LCC2[(W%%$+C_RVC$.*H@M3N04;B*"H>:>/-@G#Z%<6#_O!8J9]A M,C4M@%)Y$(>T*BY^@ZM97`G%W>\-%XXI%#4P MZA.+&1)W/L;&:Z)(&0A4K4>0^ZKT"7SB/^'7HUUQRPW=(&IB30&$&A,BQ$B6 MZ?J_1]?#H3)+>[I>&[X0S[J!"ESK!\/3S01VQX,!^)>W)8964V\ MX@5F5,6L>60K7Z2P1RA2J!M."Z_PK5]`1[_$&+?^]KK:@?71!"U[TWHT]'=4 MP<$`;OBI=4OW$E_^>^&RAN&;B&3O8=^+3:+GL.-I_(ZB;/G#J*&;4Z+[>P?7 MNER=L$=0$QD`0C&`XJX?$K11TX%36)MH%4B7/0`NJTDA-49O-MA0DMLIG$`B M^O%W`SCP^[O3(_@`9@#&1-S-.-T8^-+:3?<4J:Y7+<$SA\*;ZDP*SF,[%7@- MX3W%)!9B4?%:ZN@9_X*2U23NZ[1)9UBI>)Y[!'QJW!2E/XBEK0@AV06JM_*(B-T!Q_C042U%E$O'6AFH M*D_TXCPQI/@.(+K-:(^UCKC*;65&)HW5FT.F^$$A'PTTQB)@3OQ`$-R-GPA. M!J3H:\Z3E-`S7XY1B<;SL)0ZC]7N_2A_W3I*7[>BD"KL[O%:LP__HK78O6G< MD-].V:O0R_8BK0\Z'7$NP*Q>BV\@%RWZM((RD-Y&"9&!GT>27B51\,T5X6N? M4TRJBY\)0A'$/0O-[)8;"0.#%THASDM'[%($#?/4DL'#M/R-(F)L-$$)Q)WX MLWHM0<-O%JU(K[?RT8K]!@:0?:^(9W8V<(AX5BZ(]>?5!4>"<7YUH5Q2O>_Q M`(R=-X4>@(U48P?!$,67_E!,<2%^&9V*LJS)`F6=[XBFN#2V-:OXY*-ZCNR7 M8$DC>;%3117\93M5"-4@$8#:HW;*>_T&G6[*ZX?6Z)UM0MGB52,75P)WY*#X\)K&D7G+DS%P%0U10$1 MHO!TB'+R(_]4EU2(G)R.YUISHK$DN8NNBS`!5-#_F+%!]LU4)C;DML4$1)W*&J&!`W.O@Z&@ZF#=]3! M6/.3Q(XI3`9B$Z(IFPI8O"Y(0$GY:RDSAR(2R1&XA"<"RP_E]%N:D4CGJQU8 M6&%V]`D<`W4"U8Q&Q!W,,]"^8&>N4(T)E2UF302R+S_MA.S4668S&I%$H62A M5'WN`#6`D92->4-(J)FY%%-1F"U>ADXP`!\3(YU\N2`DWNF]=T MQ,&3[<6U\OJ3L<`W-[E]\XEM810O5[67M[>U:[9LF$NO,Z`+`L``00E#@``!#D! M``#M7=USXC@2?[^J^Q]\O-SL`R&$R4Q-:K)[3@(W5"4A!V3V[EZVA"V#[FS) M*\DD[%]_+=D&?T$,<1;GUB\S1NZ6NJ6?NEL?[GS]Z=ESC27F@C!ZV>J>G+8, M3"UF$SJ_;#U.VN;D>CAL&4(B:B.747S9HJSUTX]__M/7O[3;UQPCB6UCMC*^ M$RK1'!L#X@*O,#ZTO@]:/[3;$:7/F1U80,JH<7;:[;5/S]NGGXV_&9\O3L\, M\RXD?!;VA;`6V$.&1'R.Y3WRL/"1!\&.RAPY67KUP"YQ"'8;AF@+!47/O%+5A?2/\^X2U(< MJN2$\3F0GO8ZA*KNL7!,3P.OF-J6O"-7/NX`!>;$2C9@RS5/LO;S3OAR73>C M):IGM)UM0M@IIJ=>W$*W\\^[VXGN]!:,@6'H44"4,HDDH$*7Q:6^3ZC#HB(H MA+'^[X7Z9X8$'F/'>-8EG+EX1X>IUQT+N5;@ZB9N-Q6THAH6'#N7+1BI=CP: MOP##"2@34RA-+UN">+Z+XS+$K5S3D:;=+U^^=#15![#H8RX)%IU8]'4WJ8+= M[#%ICC*MXZ;F3B7=96.'4%*^MX#^#]Q;+IIAMUQ'`>D?N*-\C@48S#VF(7#\ M7_27DG`*PAOJX7$\W.D2=%]=,\\C4OD785+[FE$)G@Z\)6C0,H@=]I.%K'U% M6PL6B[:9ZS]V3S\:;>.&",ME(N`8?B3$,,`K&RE!OG:R-60K#P2V1_1'_9RQ MP1%S1+&+,6V-RO-EX5:>AV>&-.X<>5>6O>7_>-R;=^?SII$%-S MQ#P@$`FX)('.3\/'KQ8_O4/P8WQ("=A8H./BZ899@1H^\%I]\!!R-81UGB(# M?3?@L1$FU6)'.ZRH[>2C\E6A($9"D@8D1P7)@%"P+Q`^3#FB`EE*SX1G^G;#"S;M]("M"`HGZ@R`6[CJPXUOV4CW6+X=$$N74&RA3-7)S"2:5&I%?6 MB!@?0DD:D!P9)(CP[\@-\!U&:L#TRC4!CZ57K8_IY>`!`AA:`B,I0@.+^L'B M'G$.&B]QWMLL/5JQO^F5AHKQ82W8#XWSJ3.`)H'G(;X:.=<+1.=8#.F:;.2, M`GZ+E]B=+C@&0=&,N$06[>,!V`2SB+-DS'4K1]U9:=1%VAC,,2)]#$*3Y/`" ME#*T5D;/2.C4X+3>.+46V`Y<`&5BS"("VY1KGF)HNAYREG:W:F#FP^^MP(S$ M5P!,*!!3V0:2">8&B[7&8BY@7WH51^SE_6P3LM#@N'H*9P+\&H&)_F5[8"]P]ZU4+B,\Y0*Q;-\+F&S34"@VY M\!6:KSAL_9SW'3E4-/%G7?"1\Q[;=WR@(ZK&RGD!5@I<2K/=\RZ@LUE#_ZR& MJ]C<"/94\0;.>7X#IQA$R45R+&&#I_KB*;L.%EA6:G]ZY0+:9A%<$X#$6\D3 M,J?$(1;,7].R6*"O6SXPEZ2O"0LF4*77L+H%AF:S(9R0RMB(9<1R->!Y!^#9 M$?PH,%4>_YP5Q\69_K_509=E=JJL]?8*N-#*&`#IO<`IDW8/8%* ML(*&?Z;_K!ZWF#3XQ\(5!^2OQ%XR3-<:M;5*1E(G(U*J,7SO"ZNY MD%YAL.+#K5>!KPGUZP"F1XH"FTC]Z47^&XSUAQ!BY%PCL1BX["F!J<"R!+.< M:B_1?\Y\@/%X;S[>#*?A!QA%GV),IO#?7?]^.C%&`^/:G'PS!K>CGYN/>MX+ MLD8^YBAS_5Y#BU6+K(^O0];HH3\VIT,@:)#U7I`%G%Q%,QQ#%0+6;[=,Y%!F MN=7B[-,K<3;]UA\#P=W#N/\-J(??^\;M:-*@[MV@;FW/MGRV&,*NX@\7SZNR M;LW'C&^`NZ^=;,J9J"2=FD8GIB&>S[@T:&&ZH&W9>L),0[?,TI7M8%&_VC%? M6Q6UNV?M7O<$FHX32^PKQAJB>XH1\QTDAJY/8.MDSI8=&Q.5ZNBL?=IMJV1' M6^0HY%$/[0WSGA+DE^?F#G%R=)*B-`DO,^9%2"?%&#T/WT:G$. M$^45#4.$@,=.*!:(]1\@O+4[4L0EKY9'];.H M2"!=U^'S)NYUO37`5WN/5I(O_G&0--F)^27T]Q3/E6,OAV&7\Q37+@Q':=VT M))S M,+7"9MD!I"(:]EA!F3 MPA*/42P17PWAC:IEA]97'"-K,7)4!A>.+!D@=Y/50@)09PI MH.LMK%,_CAQS/N=Z,D/[0CQP9F%LBP%G7A^`J-BC8X#$S'S31E[NO_TF+;A; MQ:UD*=M_,LJJD4J\I#=R,WVPBS"K!P)9U8Q^!2YL>;%8*5V"F<9"&B%0/"AO<3V`*?!FWUSL/`L05@[5\8\6V: M[6!X(P,\5[7KEDIIQ\'?J9L4J:__O!E.:;2#Z,TG5)B5]L)F'B)EO.2N;$-F M)%Q"MU+4=;,:X?V\D>-@Q6`^DX3=*'KW-C;>)I[:Q0UCETHTN=&#O$V7^&WM M()<6L\`W;26H-["RAJ#X;HJL;T+9___N"3O4? M,4*1^X!6.E<\A@7#%'/OEB$:95",0IN$FF49*@\8]HN$=#4#B$JS9B'WHG86 M05%U(39^3\(_X;$%>@![:CVU5BC"T,87/*HE5>\9%-PH'Z/-)9 ML4:O[JD=-1^]JR#P`&56IMJ2FX?.+#LS=A+5;YHP"*"P^FLH,_G`L1^Z,'CR M2."MQ^8!_*9%?)0AOY"CN,XQNBXL*9 M;G;`>/949-,AKZ^IMKM_]XSJRZAQ[DO3DF2I;%ANL^5ERKHM4^Z9Q`)B5MDHKNQ?;"T-IX=IR1U>>80VHQ3U_4`UAB,J?AP::U2J0X M-:FM?X47C<#IJN,G?=U#B178U6I#$NW3:;.SWI\T0>O0E`H3YAURP6,Y M&`3E>)RZEO$[-'5D.[CS([B"?>NR]'4+#%_^V*^DCK7?S\ZG)RD:QEU$M1N[ MXH0KN[1Y'Z,$(;-:6R[Q`]C4Z1,\K_Z-.9O@):;9J*0T0^UBE;6CP;8VB;!$ M7JJ_]0@RZG47N%U-\A!P:P&&-.^Z#Z^AMBN%T->&CB%Q)U.%(AF]MQ$=_W[C M)/#]L`"Y49>'@S2D("W%>LGW,Y&+9)"5T.XP]KH&9I$*_6>?A`VE;WAN>7W< M6YWQ1`G[?Q/6`@_` MP&;-[W:*VMG;C*@%!\#;*6JN3,&1\%:"FJM2Z.1WD-1='?+\@C(;@IJK4GA\ MOX.D[NKD#_2W$AQ3E?"#SO!K(?CY/U!+`0(>`Q0````(`#V(J$+(%(K\27X` M`![-!``0`!@```````$```"D@0````!P:7`M,C`Q,S`S,S$N>&UL550%``-& MO8I1=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`/8BH0CI!\QL&#@``):L` M`!0`&````````0```*2!DWX``'!I<"TR,#$S,#,S,5]C86PN>&UL550%``-& MO8I1=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`/8BH0@&!MR!$'@``'<$! M`!0`&````````0```*2!YXP``'!I<"TR,#$S,#,S,5]D968N>&UL550%``-& MO8I1=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`/8BH0M/KT:]S=0``"SH' M`!0`&````````0```*2!>:L``'!I<"TR,#$S,#,S,5]L86(N>&UL550%``-& MO8I1=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`/8BH0E#1%.LF,@``L`X# M`!0`&````````0```*2!.B$!`'!I<"TR,#$S,#,S,5]P&UL550%``-& MO8I1=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`/8BH0O,00BYB#```CH(` M`!``&````````0```*2!KE,!`'!I<"TR,#$S,#,S,2YX`L``00E#@``!#D!``!02P4&``````8`!@`4`@``6F`!```` ` end XML 21 R6.htm IDEA: XBRL DOCUMENT v2.4.0.6

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)
3 Months Ended

Mar. 31, 2013

Mar. 31, 2012

Operating activities

Net loss $ (2,111,385) $ (2,679,888)

Adjustments to reconcile net loss to net cash used in operating activities:

Change in fair value of derivative instruments 905,777 991,662

Depreciation and amortization expense 52,602 85,910

Gain on the disposal of property and equipment    (66,626)

Deferred income tax expenses 9,743 150,405

Non-cash interest expense 32,431

Share-based compensation expense 328,581 548,664

Changes in operating assets and liabilities:

Accounts receivable 566,725 3,278,062

Unbilled accounts receivable 400,645 (1,254,867)

Prepaid expenses and other current assets 39,486 137,362

Accounts payable (407,653) (35,280)

Accrued expenses and other liabilities 950,800 131,338

Deferred revenue (507,351) (495,372)

Net cash provided by operating activities 260,401 791,370

Investing activities

Purchase of property and equipment (25,468)

Proceeds from the sale of property and equipment    67,400

Net cash provided (used) by investing activities (25,468) 67,400

Financing activities

Proceeds from issuance of long-term debt    2,500,000

Net (repayment of) proceeds from revolving credit agreement (1,274) 857,808

Deferred financing costs    (220,234)

Controlled equity offering issuance costs (112,500)

Change in restricted cash requirements    100,000

Proceeds from issuance of common stock 53,413

Other    (32,960)

Net cash (used) provided by financing activities (60,361) 3,204,614

Effects of exchange rates on cash (2,678) 4,034

Increases in cash and cash equivalents 171,894 4,067,418

Cash and cash equivalents, at beginning of period 12,701,517 11,236,771

Cash and cash equivalents, at end of period 12,873,411 15,304,189

Supplemental disclosure of cash flow information

Cash paid for interest 67,360 3,028

Noncash financing activities

Value of warrants issued to lender in connection with loan    $ 69,876

X

- Details

Name: pip_NonCashFinancingActivityAbstract

Namespace Prefix: pip_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Proceeds from Issuance of Long Term Debt and Warrants

+ References

No definition available.

+ Details

Name: pip_ProceedsFromIssuanceOfLongTermDebtAndWarrants

Namespace Prefix: pip_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Supplemental warrant issued in connection with long-term debt

+ References

No definition available.

+ Details

Name: pip_SupplementalWarrantIssuedInConnectionWithLongTermDebt

Namespace Prefix: pip_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 8, 9

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 7, 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3044-108585

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 7

-Footnote 1

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The component of income tax expense for the period representing the increase (decrease) in the entity's deferred tax assets and liabilities pertaining to continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 109

-Paragraph 289

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 109

-Paragraph 45

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 6.I.7)

-URI http://asc.fasb.org/extlink&oid=6889476&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Deferred Tax Expense (or Benefit)

-URI http://asc.fasb.org/extlink&oid=6510177

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Article 4

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 6

-Section I

-Subsection 7

+ Details

Name: us-gaap_DeferredIncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 5

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_DepreciationAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The effect of exchange rate changes on cash balances held in foreign currencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450594&loc=d3e33268-110906

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 25

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The difference between the sale price or salvage price and the book value of a property, plant, and equipment asset that was sold or retired during the reporting period. This element refers to the gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_GainLossOnSaleOfPropertyPlantEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate amount of accrued expenses and other operating obligations not separately disclosed in the statement of cash flows.

+ References

No definition available.

+ Details

Name: us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInDeferredRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period of the amount of revenue for work performed for which billing has not occurred, net of uncollectible accounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInUnbilledReceivables

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The amount of cash paid for interest during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 29

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3536-108585

+ Details

Name: us-gaap_InterestPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The net cash inflow or outflow from financing activity for the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3574-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The net cash inflow or outflow from investing activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3574-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities generally involve producing and delivering goods and providing services. Operating activity cash flows include transactions, adjustments, and changes in value that are not defined as investing or financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3536-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 130

-Paragraph 10, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 87-21

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28, 29, 30

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e565-108580

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A7

-Appendix A

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_PaidInKindInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash outflow for loan and debt issuance costs.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 18, 19, 20

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3291-108585

+ Details

Name: us-gaap_PaymentsOfFinancingCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow for cost incurred directly with the issuance of an equity security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 18, 19, 20

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3291-108585

+ Details

Name: us-gaap_PaymentsOfStockIssuanceCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3213-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 17

-Subparagraph c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash inflow from the additional capital contribution to the entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 19

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 18

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The net cash inflow or outflow from other financing activities. This element is used when there is not a more specific and appropriate element in the taxonomy.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 18, 19, 20

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3095-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3098-108585

+ Details

Name: us-gaap_ProceedsFromPaymentsForOtherFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The net cash inflow or cash outflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 9

-Subparagraph c

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3098-108585

+ Details

Name: us-gaap_ProceedsFromRepaymentsOfLinesOfCredit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The net cash inflow or outflow from cash and cash items that are not available for withdrawal or usage.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3291-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3255-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 18

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ProceedsFromRepaymentsOfRestrictedCashFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 16

-Subparagraph c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 12

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3179-108585

+ Details

Name: us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_SupplementalCashFlowInformationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_UnrealizedGainLossOnDerivatives

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 22 R22.htm IDEA: XBRL DOCUMENT v2.4.0.6

Fair Value Measurements (Summary of Changes in Fair Value of Our Level 3 Liabilities) (Details) (USD $)
3 Months Ended

Mar. 31, 2013

Mar. 31, 2012

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]

Unrealized Gains (Losses) $ (905,777) $ (991,662)

Fair Value, Inputs, Level 3 [Member] | Warrants [Member]

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]

Beginning Balance 1,295,613 1,886,652

Unrealized Gains (Losses) (905,777) (991,662)

Ending Balance $ 2,201,390 $ 2,878,314

X

- Definition

Derivative instrument obligations meeting the definition of a liability which the Company is a party to as of the balance sheet date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 15

-Paragraph 83

-URI http://asc.fasb.org/extlink&oid=6913464&loc=d3e34841-113949

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 133

-Paragraph 10

-Subparagraph i

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 133

-Paragraph 6

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_UnrealizedGainLossOnDerivatives

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 23 R24.htm IDEA: XBRL DOCUMENT v2.4.0.6

Commitments and Contingencies (Details) (USD $)
In Millions, unless otherwise specified
1 Months Ended 3 Months Ended 1 Months Ended

Mar. 30, 2012

Jul. 31, 2009

Mar. 31, 2013

Initial Maximum Maintenance Failure Obligation [Member]

Mar. 31, 2013

Every 30 days until failure is cured [Member]

Sep. 30, 2011

PharmAthene [Member]

Sep. 30, 2011

PharmAthene [Member]

Maximum [Member]

Commitments and Contingencies [Line Items]

SIGA breach of contractual obligation awarded, percentage of net profits (as defined in court's final judgement) 50.00%

SIGA breach of contractual obligation award period following initial commercial sale 10 years

SIGA net profits (as defined in court's final judgement) before distribution for breach of contract $ 40

Awarded 1/3 reasonable attorney's fees and expert witness fees, plus interest. 2.4

Warrant expiration date Mar. 30, 2022 Jan. 28, 2015

Percentage of aggregate principal amount of convertible Notes 1.00% 1.00%

Aggregate principal amount of obligation $ 0.2 $ 0.2

X

- Definition

Breach of contractual commitment award period - number of years following initial commercial sale of ArestvyrTM.

+ References

No definition available.

+ Details

Name: pip_BreachOfContractualCommitmentAwardPeriod

Namespace Prefix: pip_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: pip_CommitmentsAndContingenciesLineItems

Namespace Prefix: pip_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Court awarded fees.

+ References

No definition available.

+ Details

Name: pip_CourtAwardedFees

Namespace Prefix: pip_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Net profit on ArestvyrTM (as defined in court's final judgement) before distribution for breach of contract.

+ References

No definition available.

+ Details

Name: pip_NetProfitRetentionFromSalesBeforeDistributionForBreachOfContract

Namespace Prefix: pip_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Initial maximum maintenance failure obligation and additional maximum obligation every 30th daily after initial maintenance failure.

+ References

No definition available.

+ Details

Name: pip_NotesPayableAggregatePrincipalRepaymentAmount

Namespace Prefix: pip_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Percentage of aggregate principal amount of convertible notes relating to the affected shares.

+ References

No definition available.

+ Details

Name: pip_PercentageOfAggregatePrincipalAmountRedemption

Namespace Prefix: pip_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Percentage of net profits (as defined in court's final judgement) awarded on the sales of ArestvyrTM and related products.

+ References

No definition available.

+ Details

Name: pip_PercentageOfNetProfitAwarded

Namespace Prefix: pip_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Warrant, Expiration Date

+ References

No definition available.

+ Details

Name: pip_WarrantExpirationDate

Namespace Prefix: pip_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

XML 24 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.1.0.1 * */ var moreDialog = null; var Show = { Default:'raw', more:function( obj ){ var bClosed = false; if( moreDialog != null ) { try { bClosed = moreDialog.closed; } catch(e) { //Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control // that somtimes causes it to throw when checking the closed property on a child window that has been //closed. So if the exception occurs we assume the window is closed and move on from there. bClosed = true; } if( !bClosed ){ moreDialog.close(); } } obj = obj.parentNode.getElementsByTagName( 'pre' )[0]; var hasHtmlTag = false; var objHtml = ''; var raw = ''; //Check for raw HTML var nodes = obj.getElementsByTagName( '*' ); if( nodes.length ){ objHtml = obj.innerHTML; }else{ if( obj.innerText ){ raw = obj.innerText; }else{ raw = obj.textContent; } var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g ); if( matches && matches.length ){ objHtml = raw; //If there is an html node it will be 1st or 2nd, // but we can check a little further. var n = Math.min( 5, matches.length ); for( var i = 0; i < n; i++ ){ var el = matches[ i ].toString().toLowerCase(); if( el.indexOf( '= 0 ){ hasHtmlTag = true; break; } } } } if( objHtml.length ){ var html = ''; if( hasHtmlTag ){ html = objHtml; }else{ html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ objHtml + "\n"+''+ "\n"+''; } moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write( html ); moreDialog.document.close(); if( !hasHtmlTag ){ moreDialog.document.body.style.margin = '0.5em'; } } else { //default view logic var lines = raw.split( "\n" ); var longest = 0; if( lines.length > 0 ){ for( var p = 0; p < lines.length; p++ ){ longest = Math.max( longest, lines[p].length ); } } //Decide on the default view this.Default = longest < 120 ? 'raw' : 'formatted'; //Build formatted view var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ; var formatted = ''; if( text.length > 0 ){ if( text.length == 1 ){ text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ; formatted = "
"+ text.join( "

\n" ) +"
"; }else{ for( var p = 0; p < text.length; p++ ){ formatted += "
" + text[p] + "
\n"; } } }else{ formatted = '
' + raw + '
'; } html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+'
'+ "\n"+' formatted: '+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +''+ "\n"+'
'+ "\n"+'
'+formatted+'
'+ "\n"+'
'+ "\n"+'
'+raw+'
'+ "\n"+'
'+ "\n"+''+ "\n"+''; moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write(html); moreDialog.document.close(); this.toggle( moreDialog ); } moreDialog.document.title = 'Report Preview Details'; }, toggle:function( win, domLink ){ var domId = this.Default; var doc = win.document; var domEl = doc.getElementById( domId ); domEl.style.display = 'block'; this.Default = domId == 'raw' ? 'formatted' : 'raw'; if( domLink ){ domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed'; } var domElOpposite = doc.getElementById( this.Default ); domElOpposite.style.display = 'none'; }, LastAR : null, showAR : function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }, toggleNext : function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }, hideAR : function(){ Show.LastAR.style.display = 'none'; } } XML 25 R7.htm IDEA: XBRL DOCUMENT v2.4.0.6

Organization and Business
3 Months Ended

Mar. 31, 2013

Organization and Business [Abstract]

Organization and Business

Note 1 - Organization and Business

We are a biopharmaceutical company focused on developing biodefense countermeasure applications. We are subject to those risks associated with any biopharmaceutical company that has substantial expenditures for research and development. There can be no assurance that our research and development projects will be successful, that products developed will obtain necessary regulatory approval, or that any approved product will be commercially viable. In addition, we operate in an environment of rapid technological change and are largely dependent on the services and expertise of our employees, consultants and other third parties.

Historically, we have performed under government contracts and grants and raised funds from investors to sustain our operations.

X

- Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 852

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2209116

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2122150

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7668296&loc=d3e288-107754

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2134480

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 720

-SubTopic 15

-URI http://asc.fasb.org/subtopic&trid=2122524

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Staff Position (FSP)

-Number FAS140-4/FIN46(R)-8

-Paragraph 8, C1, C7

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2197480

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Statement of Position (SOP)

-Number 94-6

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Interpretation (FIN)

-Number 46R

-Paragraph 4, 14, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 272

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=7880789&loc=SL6228881-111685

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 2-6

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 915

-SubTopic 235

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6472506&loc=d3e38932-110933

+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 26 R3.htm IDEA: XBRL DOCUMENT v2.4.0.6

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)

Mar. 31, 2013

Dec. 31, 2012

CONDENSED CONSOLIDATED BALANCE SHEETS [Abstract]

Common stock, par value $ 0.0001 $ 0.0001

Common stock, shares authorized 100,000,000 100,000,000

Common stock, shares issued 48,416,483 48,352,651

Common stock, shares outstanding 48,416,483 48,352,651

X

- Definition

Face amount or stated value of common stock per share; generally not indicative of the fair market value per share.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of common shares permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_StatementOfFinancialPositionAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 27 R17.htm IDEA: XBRL DOCUMENT v2.4.0.6

Stockholders' Equity (Tables)
3 Months Ended

Mar. 31, 2013

Stockholders' Equity [Abstract]

Summary of Warrants Outstanding

At March 31, 2013 and 2012 there were warrants outstanding to purchase 5,620,128 shares of our common stock, respectively. The warrants outstanding as of March 31, 2013 and 2012 were as follows:

Number of Common Shares Underlying Warrants Issue Date/Exercisable Date Exercise Price Expiration Date

100,778 (1) Mar-07 / Mar-07 $ 3.97 Mar-17

705,354 (2) Mar-09 / Sep-09 $ 3.00 Sep-14

2,572,775 (1) Jul-09 / Jan-10 $ 2.50 Jan-15

500,000 (2) Apr-10 / Oct-10 $ 1.89 Oct-15

1,323,214 (2) Jul-10 / Jan-11 $ 1.63 Jan-17

371,423 (2) Jun-11 / Jun-11 $ 3.50 Jun-16

46,584 (1) Mar-12 / Mar-12 $ 1.61 Mar-22

5,620,128

(1) These warrants to purchase common stock are classified as equity.

(2) These warrants to purchase common stock are classified as derivative liabilities. The fair value of these liabilities (see note 3) is remeasured at the end of every reporting period and the change in fair value is reported in the unaudited condensed consolidated statements of operations as other income (expense).

X

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 50

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph i

-Article 4

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 28

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 50

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number D-98

-Paragraph 2

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StockholdersEquityNoteAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 28 R1.htm IDEA: XBRL DOCUMENT v2.4.0.6

Document and Entity Information
3 Months Ended

Mar. 31, 2013

May 02, 2013

Document and Entity Information [Abstract]

Document Type 10-Q

Amendment Flag false

Document Period End Date Mar. 31, 2013

Document Fiscal Year Focus 2013

Document Fiscal Period Focus Q1

Trading Symbol PIP

Entity Registrant Name PHARMATHENE, INC

Entity Central Index Key 0001326190

Current Fiscal Year End Date --12-31

Entity Filer Category Accelerated Filer

Entity Common Stock, Shares Outstanding 49,460,686

X

- Definition

If the value is true, then the document is an amendment to previously-filed/accepted document.

+ References

No definition available.

+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition

End date of current fiscal year in the format --MM-DD.

+ References

No definition available.

+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition

The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.

+ References

No definition available.

+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".

+ References

No definition available.

+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.

+ References

No definition available.

+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ References

No definition available.

+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name: dei_TradingSymbol

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: pip_DocumentAndEntityInformationAbstract

Namespace Prefix: pip_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 29 R18.htm IDEA: XBRL DOCUMENT v2.4.0.6

Financing Transactions (Tables)
3 Months Ended

Mar. 31, 2013

Financing Transactions [Abstract]

Principal Payments On The Term Loan

Year Principal
Payments

2013 $749,997

2014 999,996

2015 750,007

$2,500,000

Term Loan, Net of Debt Discount

The term loan, net of discount of $39,587, is recorded on the 2013 condensed consolidated balance sheet, net of debt discount, as follows:

Current portion of long-term debt $ 999,996

Long-term debt, less current portion $ 1,460,417

X

- Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.

+ References

No definition available.

+ Details

Name: us-gaap_ScheduleOfDebtTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the combined aggregate amount of maturities and sinking fund requirements for all long-term borrowings for each of the five years following the date of the latest balance sheet date presented.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601

+ Details

Name: us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 30 R4.htm IDEA: XBRL DOCUMENT v2.4.0.6

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)
3 Months Ended

Mar. 31, 2013

Mar. 31, 2012

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]

Contract revenue $ 6,475,138 $ 6,149,052

Operating expenses:

Research and development 5,233,475 4,705,357

General and administrative 2,279,795 2,948,481

Depreciation and amortization 52,602 85,910

Total operating expenses 7,565,872 7,739,748

Loss from operations (1,090,734) (1,590,696)

Other income (expense):

Interest income 783 2,988

Interest expense (99,791) (3,028)

Other income (expense) (6,123) 52,915

Change in fair value of derivative instruments (905,777) (991,662)

Total other income (expense) (1,010,908) (938,787)

Net loss before income taxes (2,101,642) (2,529,483)

Income tax expense (9,743) (150,405)

Net loss $ (2,111,385) $ (2,679,888)

Basic and diluted net loss per share $ (0.04) $ (0.06)

Weighted average shares used in calculation of basic and diluted net loss per share 48,359,181 48,269,894

X

- Definition

Revenue earned during the period arising from products sold or services provided under the terms of a contract, not elsewhere specified in the taxonomy. May include government contracts, construction contracts, and any other contract related to a particular project or product.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_ContractsRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The component of income tax expense for the period representing amounts of income taxes paid or payable (or refundable) for the period for all income tax obligations as determined by applying the provisions of relevant enacted tax laws to relevant amounts of taxable Income or Loss from continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 109

-Paragraph 289

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Tax Expense (or Benefit)

-URI http://asc.fasb.org/extlink&oid=6509736

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 6.I.7)

-URI http://asc.fasb.org/extlink&oid=6889476&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 109

-Paragraph 45

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Article 4

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 6

-Section I

-Subsection 7

+ Details

Name: us-gaap_CurrentIncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 5

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_DepreciationAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

No definition available.

+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Sum of operating profit and nonoperating income or expense before Income or Loss from equity method investments, income taxes, extraordinary items, and noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h)(1)(i))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Subparagraph 1(i)

-Article 4

+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_IncomeStatementAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The cost of borrowed funds accounted for as interest that was charged against earnings during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 9

-Article 9

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher OTS

-Name Federal Regulation (FR)

-Number Title 12

-Section 563c.102

-Paragraph 9

-Chapter V

-Subsection II

-LegacyDoc This is a non-GAAP reference that was included in the 2009 taxonomy. It will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 34

-Paragraph 21

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.9)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

+ Details

Name: us-gaap_InterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Income derived from investments in debt securities and on cash and cash equivalents the earnings of which reflect the time value of money or transactions in which the payments are for the use or forbearance of money.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 115

-Paragraph 14

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 7

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.7(b))

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_InvestmentIncomeInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 130

-Paragraph 10, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 87-21

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28, 29, 30

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e565-108580

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A7

-Appendix A

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.7)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 7

-Article 5

+ Details

Name: us-gaap_NonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_NonoperatingIncomeExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The net result for the period of deducting operating expenses from operating revenues.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 9

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.9)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_OtherNonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 141

-Paragraph 51

-Subparagraph g

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 86

-Paragraph 11, 12

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 2

-Paragraph 12, 13

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_UnrealizedGainLossOnDerivatives

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).

+ References

No definition available.

+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 31 R12.htm IDEA: XBRL DOCUMENT v2.4.0.6

Financing Transactions
3 Months Ended

Mar. 31, 2013

Financing Transactions [Abstract]

Financing Transactions

Note 6 - Financing Transactions

Controlled Equity Offering

On March 25, 2013, we entered into a controlled equity offering with a sales agent pursuant to which we may offer and sell, from time to time, through the agent shares of our common stock having an aggregate offering price of up to $15.0 million. Under the arrangement, the agent may sell shares by any method permitted by law and deemed to be an "at-the-market" offering as defined in Rule 415 promulgated under the Securities Act of 1933, as amended, including sales made directly on NYSE MKT, or any other existing trading market for our Common Stock or to or through a market maker. We are not obligated to sell any shares under the arrangement. Subject to the terms and conditions of that agreement, the agent will use commercially reasonable efforts, consistent with its normal trading and sales practices and applicable state and federal law, rules and regulations and the rules of NYSE MKT, to sell shares from time to time based upon our instructions. We are obligated to pay the agent a commission of 3.0% of the aggregate gross proceeds from each sale of shares. Total expenses incurred for the offering, excluding commission payable to the agent, were approximately $277,000. Through March 31, 2013, we sold 19,900 shares of our common stock under this arrangement, which did not settle until April 2013, that resulted in net proceeds to the company of approximately $33,000. As of March 31, 2013, aggregate gross sales for additional common stock of approximately $14.97 million remained available under the arrangement.

Loan Agreement with GE Capital

On March 30, 2012, we entered into a Loan Agreement with GE Capital. The Loan Agreement provides for a senior secured debt facility including a $2.5 million term loan and a revolving line of credit of up to $5 million based on our outstanding qualified accounts receivable. On March 30, 2012, the term loan was funded for an aggregate amount of $2.5 million.

Under the terms of the revolving line of credit, the Company may draw down from the revolving line of credit up to 85% of qualified billed accounts receivable and 80% of qualified unbilled accounts receivable. As of March 31, 2013, the total amount available to draw was approximately $2.3 million, of which $1.3 million was drawn and outstanding.

The fixed interest rate on the term loan is 10.14% per annum. The revolving line of credit has an adjustable interest rate based upon the 3-month London Interbank Offered Rate (LIBOR), with a floor of 1.5%, plus 5%. As of March 31, 2013, the interest rate was 6.5%. Both the term loan and the revolving line of credit mature in September 2015. Payments on the term loan were originally interest-only for the first 10 months, which has since been extended to 12 months pursuant to terms of the agreement. Subsequently, the term loan will fully amortize over its remaining term as of March 31, 2013. Principal payments on the term loan are scheduled as follows:

Year Principal
Payments

2013 $749,997

2014 999,996

2015 750,007

$2,500,000

The term loan, net of discount of $39,587, is recorded on the 2013 condensed consolidated balance sheet, net of debt discount, as follows:

Current portion of long-term debt $ 999,996

Long-term debt, less current portion $ 1,460,417

If we prepay the term loan and terminate the revolving line of credit prior to the scheduled maturity date, we are obligated to pay a prepayment premium equal to 3% of the then outstanding principal amount of the term loan if prepaid during the first two years of the loan and 2% if prepaid during the third year or thereafter. In addition, we are obligated to pay a final payment fee of 3% of the term loan balance. The final payment fee is being accrued and expensed over the term of the agreement, using the effective interest method and is included in other long-term liabilities on the condensed consolidated balance sheet.

Our obligations under the Loan Agreement are collateralized by a security interest in substantially all of our assets. While the security interest does not, except in limited circumstances, cover our intellectual property, it does cover any proceeds received by us from the use or sale of our intellectual property.

In connection with the Loan Agreement, we issued GE Capital warrants to purchase 46,584 shares of the Company's common stock at an exercise price of $1.61 per share. The warrants are exercisable immediately and subject to customary and standard anti-dilution adjustments. The warrants are classified in equity and, as a result, the fair value of the warrants was charged to additional paid-in capital resulting in a debt discount at the date of issuance. The debt discount is being amortized over the term of the loan agreement using the effective interest method. Financing costs incurred in connection with this agreement are also being amortized over the term of the agreement using the effective interest method.

The fair value of the Company's outstanding borrowings under its revolving credit facility at March 31, 2013 was consistent with its carrying value as of that date primarily due to the short term nature of the Revolver's repayment terms. The Company determined the fair value of the Term Loan approximated its carrying value as of March 31, 2013.

X

- Definition

The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.

+ References

No definition available.

+ Details

Name: us-gaap_AdditionalFinancialInformationDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 32 R11.htm IDEA: XBRL DOCUMENT v2.4.0.6

Stockholders' Equity
3 Months Ended

Mar. 31, 2013

Stockholders' Equity [Abstract]

Stockholders' Equity

Note 5 - Stockholders' Equity

Long-Term Incentive Plan

In 2007, the Company's stockholders approved the 2007 Long-Term Incentive Compensation Plan (the "2007 Plan") which provides for the granting of incentive and non-qualified stock options, stock appreciation rights, performance units, restricted common awards and performance bonuses (collectively "awards") to Company officers and employees. Additionally, the 2007 Plan authorizes the granting of non-qualified stock options and restricted stock awards to Company directors and to independent consultants.

In 2008, the Company's shareholders approved amendments to the 2007 Plan, increasing from 3.5 million shares to 4.6 million shares the maximum number of shares authorized for issuance under the plan and adding an evergreen provision pursuant to which the number of shares authorized for issuance under the plan will increase automatically in each year, beginning in 2009 and continuing through 2015, according to certain limits set forth in the 2007 Plan. At March 31, 2013, there are approximately 9.3 million shares approved for issuance under the 2007 plan, of which approximately 2.6 million shares are available to be issued. The Board of Directors in conjunction with management determines who receives awards, the vesting conditions and the exercise price. Options may have a maximum term of ten years.

Warrants Classified as Equity

In connection with the July 2009 private placement, we issued warrants to purchase an aggregate of 2,572,775 shares of the Company's common stock at an exercise price of $2.50 per share. The warrants will expire on January 28, 2015. Also outstanding are warrants to purchase an aggregate of 100,778 shares of common stock at $3.97 per share, which will expire on March 30, 2017.

In connection with the March 30, 2012, debt financing (see Note 6), we issued warrants to purchase an aggregate of 46,584 shares of the Company's common stock at an exercise price of $1.61 per share to GE Capital Equity Investments, Inc. The relative fair value attributable to the warrants of $69,876 was recorded in equity during the quarter ended March 31, 2012. The warrants will expire on March 30, 2022.

Warrants

At March 31, 2013 and 2012 there were warrants outstanding to purchase 5,620,128 shares of our common stock, respectively. The warrants outstanding as of March 31, 2013 and 2012 were as follows:

Number of Common Shares Underlying Warrants Issue Date/Exercisable Date Exercise Price Expiration Date

100,778 (1) Mar-07 / Mar-07 $ 3.97 Mar-17

705,354 (2) Mar-09 / Sep-09 $ 3.00 Sep-14

2,572,775 (1) Jul-09 / Jan-10 $ 2.50 Jan-15

500,000 (2) Apr-10 / Oct-10 $ 1.89 Oct-15

1,323,214 (2) Jul-10 / Jan-11 $ 1.63 Jan-17

371,423 (2) Jun-11 / Jun-11 $ 3.50 Jun-16

46,584 (1) Mar-12 / Mar-12 $ 1.61 Mar-22

5,620,128

(1) These warrants to purchase common stock are classified as equity.

(2) These warrants to purchase common stock are classified as derivative liabilities. The fair value of these liabilities (see note 3) is remeasured at the end of every reporting period and the change in fair value is reported in the unaudited condensed consolidated statements of operations as other income (expense).

X

- Details

Name: us-gaap_StockholdersEquityNoteAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable). Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Preferred Stock

-URI http://asc.fasb.org/extlink&oid=6521494

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Section B

-Paragraph 7, 11A

-Chapter 1

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section C

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph d

-Article 4

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 17: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707

Reference 18: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 5

-Paragraph 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 19: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 20: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 2, 3, 4, 5, 6, 7, 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 21: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 22: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(d),(e))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 23: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Article 4

+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 33 R23.htm IDEA: XBRL DOCUMENT v2.4.0.6

Fair Value Measurements (Narrative) (Details) (USD $)
3 Months Ended

Mar. 31, 2013

Mar. 31, 2012

Mar. 31, 2013

Fair Value, Inputs, Level 3 [Member]

Warrants [Member]

Mar. 31, 2012

Fair Value, Inputs, Level 3 [Member]

Warrants [Member]

Mar. 31, 2013

Fair Value, Inputs, Level 3 [Member]

Warrants [Member]

Derivative Liabilities [Member]

Mar. 28, 2013

Fair Value, Inputs, Level 3 [Member]

Warrants [Member]

Derivative Liabilities [Member]

Dec. 31, 2012

Fair Value, Inputs, Level 3 [Member]

Warrants [Member]

Derivative Liabilities [Member]

Mar. 31, 2012

Fair Value, Inputs, Level 3 [Member]

Warrants [Member]

Derivative Liabilities [Member]

Mar. 30, 2012

Fair Value, Inputs, Level 3 [Member]

Warrants [Member]

Derivative Liabilities [Member]

Dec. 30, 2011

Fair Value, Inputs, Level 3 [Member]

Warrants [Member]

Derivative Liabilities [Member]

Fair Value Measurements [Line Items]

Warrants to purchase common stock 2,899,991 2,899,991

Change in fair value of derivative instruments $ 905,777 $ 991,662 $ 905,777 $ 991,662

Closing stock price, per share $ 1.70 $ 1.12 $ 1.77 $ 1.27

X

- Details

Name: pip_FairValueMeasurementsLineItems

Namespace Prefix: pip_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Aggregate amount of each class of warrants or rights outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph i

-Article 4

+ Details

Name: us-gaap_ClassOfWarrantOrRightOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Price of a single share of a number of saleable stocks of a company.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=7578670&loc=d3e19207-110258

+ Details

Name: us-gaap_SharePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_UnrealizedGainLossOnDerivatives

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 34 R19.htm IDEA: XBRL DOCUMENT v2.4.0.6

Summary of Significant Accounting Policies (Narrative) (Details) (USD $)
3 Months Ended

Mar. 31, 2013

Mar. 31, 2012

Significant Accounting Policies [Line Items]

Number of operating segment 1

Cost reimbursed to offset research and development expenses $ 20,000 $ 500,000

Share-based compensation forfeitures rate 12.00% 12.00%

Share options granted to employees 60,000 15,948

Unrecognized share-based compensation expense related to unvested awards 2,000,000

Unrecognized share-based compensation expense related to unvested awards expected to be recognized in the period 2 years 3 months

Income tax expense $ 9,743 $ 150,405

Anti-dilutive securities excluded from computation of earnings per share 11,600,000 11,500,000

Liquidity Arrangements [Member] | Maximum [Member]

Significant Accounting Policies [Line Items]

Cash liquidity maturity period 3 months

X

- Definition

Cash Equivalents, Maturity Period

+ References

No definition available.

+ Details

Name: pip_CashEquivalentsMaturityPeriod

Namespace Prefix: pip_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Share based Compensation Arrangement by Share based Payment Award, Fair Value Assumptions, Annual Forfeiture Rate

+ References

No definition available.

+ Details

Name: pip_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAnnualForfeitureRate

Namespace Prefix: pip_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Details

Name: pip_SignificantAccountingPoliciesLineItems

Namespace Prefix: pip_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 07-4

-Paragraph 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Diluted Earnings Per Share

-URI http://asc.fasb.org/extlink&oid=6510752

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Contingent Stock Agreement

-URI http://asc.fasb.org/extlink&oid=6508534

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Antidilution

-URI http://asc.fasb.org/extlink&oid=6505113

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 171

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 40

-Subparagraph c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 13, 14

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Cost associated with reimbursable income. This occurs when a services entity incurs expenses on behalf of the client and passes through the cost of reimbursable expenses to a client.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.2)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_CostOfReimbursableExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

As of the balance sheet date, the aggregate unrecognized cost of equity-based awards made to employees under equity-based compensation awards that have yet to vest.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph h

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

The sum of the current income tax expense or benefit and the deferred income tax expense or benefit pertaining to continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 109

-Paragraph 45

-Subparagraph a, b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Article 4

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Income Tax Expense (or Benefit)

-URI http://asc.fasb.org/extlink&oid=6515339

+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.

+ References

No definition available.

+ Details

Name: us-gaap_NumberOfOperatingSegments

Namespace Prefix: us-gaap_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition

Gross number of share options (or share units) granted during the period.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 35 R15.htm IDEA: XBRL DOCUMENT v2.4.0.6

Summary of Significant Accounting Policies (Tables)
3 Months Ended

Mar. 31, 2013

Summary of Significant Accounting Policies [Abstract]

Schedule of Share-based Compensation Expense

Share-based compensation expense for the three months ended March 31, 2013 and 2012 was:

Three months ended March 31,

2013 2012

Research and development $ 88,634 $ 117,067

General and administrative 239,947 431,597

Total share-based compensation expense $ 328,581 $ 548,664

X

- Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph g(1)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section F

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph 64

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.F)

-URI http://asc.fasb.org/extlink&oid=6793087&loc=d3e301413-122809

+ Details

Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 36 R13.htm IDEA: XBRL DOCUMENT v2.4.0.6

Subsequent Events
3 Months Ended

Mar. 31, 2013

Subsequent Event [Abstract]

Subsequent Events

Note 7 - Subsequent Events

Subsequent to March 31, 2013, we sold 1,030,870 shares of our common stock under the controlled equity offering, which resulted in net proceeds of approximately $1.63 million. (See Note 6). Aggregate gross proceeds of up to approximately $13.29 million remain available under the arrangement.

X

- Details

Name: us-gaap_SubsequentEventsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.

+ References

No definition available.

+ Details

Name: us-gaap_SubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 37 R14.htm IDEA: XBRL DOCUMENT v2.4.0.6

Summary of Significant Accounting Policies (Policy)
3 Months Ended

Mar. 31, 2013

Summary of Significant Accounting Policies [Abstract]

Basis of Presentation

Basis of Presentation

Our unaudited condensed consolidated financial statements include the accounts of PharmAthene, Inc. and its wholly-owned subsidiaries. All significant intercompany transactions and balances have been eliminated in consolidation. Our unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States ("U.S. GAAP"). In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to present fairly our financial position, results of operations and cash flows. The unaudited condensed consolidated balance sheet at December 31, 2012 has been derived from audited consolidated financial statements at that date. The interim results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and footnote disclosure normally included in the financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to instructions, rules and regulations prescribed by the U.S. Securities and Exchange Commission. We believe that the disclosures provided herein are adequate to make the information presented not misleading when these unaudited condensed consolidated financial statements are read in conjunction with the Consolidated Financial Statements and Notes included in our Annual Report on Form 10-K for the year ended December 31, 2012, filed with the Securities and Exchange Commission. We currently operate in one business segment.

Use of Estimates

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Our unaudited condensed consolidated financial statements include significant estimates for the expected economic life and value of our intangible assets, the amount of our net operating losses, our share-based compensation, the value of our financial instruments, among other things. Because of the use of estimates inherent in the financial reporting process, actual results could differ significantly from those estimates.

Foreign Currency Translation

Foreign Currency Translation

The functional currency of our wholly owned foreign subsidiaries is their local currency. Assets and liabilities of our foreign subsidiaries are translated into United States dollars based on exchange rates at the end of the reporting period. Income and expense items are translated at the weighted average exchange rates prevailing during the reporting period. Translation adjustments for subsidiaries that have not been sold, substantially liquidated or otherwise disposed of, are accumulated in other comprehensive income (loss), a component of stockholders' equity. Foreign currency translation adjustments are the sole component of accumulated other comprehensive loss at March 31, 2013 and December 31, 2012. Transaction gains or losses are included in the determination of net loss.

Comprehensive Loss and Accumulated Other Comprehensive Income

Comprehensive Loss and Accumulated Other Comprehensive Income

Comprehensive loss includes the total of our net loss and all other changes in equity other than transactions with owners, including (i) changes in equity for cumulative translation adjustments resulting from the consolidation of foreign subsidiaries as the financial statements of the subsidiaries located outside of the United States are accounted for using the local currency as the functional currency, and (ii) unrealized gains and losses on short term available-for-sale investments.

Cash and Cash Equivalents

Cash and Cash Equivalents

Cash and cash equivalents are stated at market value. We consider all highly liquid investments with original maturities of three months or less to be cash equivalents.

Revolving Line of Credit and Term Loan

Revolving Line of Credit and Term Loan

As discussed further in Note 6, we entered into a loan agreement with General Electric Capital Corporation ("GE Capital") in March 2012. As part of that agreement, we issued stock purchase warrants to GE Capital that expire in March 2022. The fair value of the warrants was charged to additional paid-in-capital, resulting in a debt discount to the Term Loan at the date of issuance. The debt discount and the financing costs, incurred in connections with the agreement, are being amortized over the term of the loan using the effective interest method. The amortization of both the debt discount and deferred financing costs are included in interest expense in the unaudited condensed consolidated statements of operations.

Significant Customers and Accounts Receivable

Significant Customers and Accounts Receivable

Our primary customers are the U.S. Department of Defense (the "DoD") - Chemical Biological Medical Systems ("CBMS"), and the Biomedical Advanced Research and Development Authority ("BARDA"). As of March 31, 2013 and December 31, 2012, the Company's trade receivable and unbilled receivable balances were comprised solely of receivables from CBMS and BARDA.

Goodwill

Goodwill

Goodwill represents the excess of purchase price over the fair value of net identifiable assets associated with acquisitions. We review the recoverability of goodwill annually as of December 31^st by comparing our market value (as measured by our stock price multiplied by the number of outstanding shares as of the end of the year) to the net book value of our equity. If our market value exceeds our net book value, no further analysis is required. Changes in our business strategy or adverse changes in market conditions could impact the impairment analyses and require the recognition of an impairment charge equal to the excess of the carrying value over its estimated fair value. We completed our last annual impairment assessment of goodwill as of December 31, 2012 and determined that there was no impairment as of that date.

Revenue Recognition

Revenue Recognition

We generate our revenue from different types of contractual arrangements: cost-plus-fee contracts, cost reimbursable grants and fixed price contracts.

Revenues on cost-plus-fee contracts are recognized in an amount equal to the costs incurred during the period plus an estimate of the applicable fee earned. The estimate of the applicable fee earned is determined by reference to the contract: if the contract defines the fee in terms of risk-based milestones and specifies the fees to be earned upon the completion of each milestone, then the fee is recognized when the related milestones are earned, as further described below; otherwise, we estimate the fee earned in a given period by using a proportional performance method based on costs incurred during the period as compared to total estimated project costs and application of the resulting fraction to the total project fee specified in the contract.

Under the milestone method of revenue recognition, milestone payments (including milestone payments for fees) contained in research and development arrangements are recognized as revenue when: (i) the milestones are achieved; (ii) no further performance obligations with respect to the milestone exist; (iii) collection is reasonably assured; and (iv) substantive effort was necessary to achieve the milestone.

Milestones are considered substantive if all of the following conditions are met:

· it is commensurate with either our performance to meet the milestone or the enhancement of the value of the delivered item or items as a result of a specific outcome resulting from our performance to achieve the milestone,

· it relates solely to past performance,

· the value of the milestone is reasonable relative to all the deliverables and payment terms (including other potential milestone consideration) within the arrangement.

If a milestone is deemed not to be substantive, the Company recognizes the portion of the milestone payment as revenue that correlates to work already performed; the remaining portion of the milestone payment is deferred and recognized as revenue as the Company completes its performance obligations.

Revenue on fixed price contracts (without substantive milestones as described above) is recognized on the percentage-of-completion method. The percentage-of-completion method recognizes income as the contract progresses (generally related to the costs incurred in providing the services required under the contract). The use of the percentage-of-completion method depends on the ability to make reasonable dependable estimates and the fact that circumstances may necessitate frequent revision of estimates does not indicate that the estimates are unreliable for the purpose for which they are used.

As a result of our revenue recognition policies and the billing provisions contained in our contracts, the timing of customer billings may differ from the timing of recognizing revenue. Amounts invoiced to customers in excess of revenue recognized are reflected on the balance sheet as deferred revenue. Amounts recognized as revenue in excess of amounts billed to customers are reflected on the balance sheet as unbilled accounts receivable.

We analyze each cost reimbursable grant to determine whether we should report such reimbursements as revenue or as an offset to our expenses incurred. For the three months ended March 31, 2013 and 2012, we recorded approximately $0.02 million and $0.5 million, respectively, of costs reimbursed by the government as an offset to research and development expenses.

Share-Based Compensation

Share-Based Compensation

We expense the estimated fair value of share-based awards granted to employees under our stock compensation plans. The fair value of stock options is determined at the grant date using an option pricing model. We have estimated the fair value of each stock option award using the Black-Scholes option pricing model. The Black-Scholes model considers, among other factors, the expected life of the award and the expected volatility of our stock price. The value of the award that is ultimately expected to vest is recognized as expense on a straight line basis over the employee's requisite service period.

The fair value of restricted stock grants is determined based on the closing price of our common stock on the award date and is recognized as expense ratably over the requisite service period.

Employee share-based compensation expense recognized in the three months ended March 31, 2013 and 2012 was calculated based on awards ultimately expected to vest and has been reduced for estimated forfeitures at a rate of approximately 12%, based on historical forfeitures.

Share-based compensation expense for the three months ended March 31, 2013 and 2012 was:

Three months ended March 31,

2013 2012

Research and development $ 88,634 $ 117,067

General and administrative 239,947 431,597

Total share-based compensation expense $ 328,581 $ 548,664

During the three months ended March 31, 2013, we granted 60,000 options to employees and consultants and made no restricted stock grants. During the three months ended March 31, 2012, we granted 15,948 options to employees and made no restricted stock grants. At March 31, 2013, we had total unrecognized share-based compensation expense related to unvested awards of approximately $2.0 million net of estimated forfeitures, which we expect to recognize as expense over a weighted-average period of 2.25 years.

Income Taxes

Income Taxes

We account for income taxes using the asset and liability approach, which requires the recognition of future tax benefits or liabilities on the temporary differences between the financial reporting and tax bases of our assets and liabilities. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized. We also recognize a tax benefit from uncertain tax positions only if it is "more likely than not" that the position is sustainable based on its technical merits. Our policy is to recognize interest and penalties on uncertain tax positions as a component of income tax expense.

Income tax expense was $9,743 and $150,405 during the three months ended March 31, 2013 and 2012, respectively. Income tax expense is a result of the difference between the treatment of goodwill for income tax purposes and for U.S. GAAP, resulting in a deferred tax liability, which cannot offset deferred tax assets. This deferred tax liability is included in our condensed consolidated balance sheet in other long-term liabilities.

Basic and Diluted Net Loss Per Share

Basic and Diluted Net Loss Per Share

Income (loss) per share: Basic income (loss) per share is computed by dividing consolidated net income (loss) by the weighted average number of common shares outstanding during the period, excluding unvested restricted stock.

For periods of net income when the effects are not anti-dilutive, diluted earnings per share is computed by dividing our net income by the weighted average number of shares outstanding and the impact of all potential dilutive common shares, consisting primarily of stock options, unvested restricted stock and stock purchase warrants. The dilutive impact of our dilutive potential common shares resulting from stock options and stock purchase warrants is determined by applying the treasury stock method.

For the periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all dilutive potential common shares is anti-dilutive due to the net losses. A total of approximately 11.6 million and 11.5 million potential dilutive securities have been excluded in the calculation of diluted net loss per share in the three months ended March 31, 2013 and 2012, respectively, because their inclusion would be anti-dilutive.

Recent Accounting Pronouncements

Recent Accounting Pronouncements

We have evaluated all Accounting Standards Updates through the date the unaudited condensed consolidated financial statements were issued and believe the adoption of these will not have a material impact on our results of operations, financial position, or cash flows.

X

- Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.

+ References

No definition available.

+ Details

Name: us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Financial Reporting Release (FRR)

-Number 203

-Paragraph 02-03

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 7, 8, 9, 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Technical Practice Aid (TPA)

-Number 2110

-Paragraph 6

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4273-108586

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 305

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2122427

+ Details

Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for comprehensive income.

+ References

No definition available.

+ Details

Name: us-gaap_ComprehensiveIncomePolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for costs incurred to obtain or issue debt, the effects of refinancings, method of amortizing deferred financing costs and original issue discount, and classifications of debt on the balance sheet.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2208565

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 22

-Paragraph 8, 12

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_DebtPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 40

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 6, 8-16, 60

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2144384

+ Details

Name: us-gaap_EarningsPerSharePolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 30

-URI http://asc.fasb.org/subtopic&trid=2175892

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 52

-Paragraph 5, 7-20, 80

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 20

-URI http://asc.fasb.org/subtopic&trid=2175856

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2175826

+ Details

Name: us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-URI http://asc.fasb.org/subtopic&trid=2144439

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 142

-Paragraph 18-23, 26, 34

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 17

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32809-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Interpretation (FIN)

-Number 48

-Paragraph 20

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=21917399&loc=d3e32247-109318

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 4

-Paragraph 11

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 19

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32840-109319

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 109

-Paragraph 6-34, 43, 47, 49

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=21917399&loc=d3e32280-109318

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 954

-SubTopic 740

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 30

-URI http://asc.fasb.org/subtopic&trid=2144749

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2144681

+ Details

Name: us-gaap_IncomeTaxPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for major customers. Major customers are those that the loss of such customers would have a material adverse effect on the entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 42

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9054-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6404-108592

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6327-108592

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 18

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6351-108592

+ Details

Name: us-gaap_MajorCustomersPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of the adoption of new accounting pronouncements that may impact the entity's financial reporting.

+ References

No definition available.

+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.B.Q1)

-URI http://asc.fasb.org/extlink&oid=6600647&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 22

-Paragraph 8, 12, 13

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18823-107790

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18726-107790

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section B

-Paragraph Question 1

+ Details

Name: us-gaap_RevenueRecognitionPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2228939

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 06-11

-Paragraph 7

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (b),(f)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Statement of Position (SOP)

-Number 94-6

-Paragraph 11, 14

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6143-108592

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6132-108592

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6061-108592

+ Details

Name: us-gaap_UseOfEstimates

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 38 R16.htm IDEA: XBRL DOCUMENT v2.4.0.6

Fair Value Measurements (Tables)
3 Months Ended

Mar. 31, 2013

Fair Value Measurements [Abstract]

Schedule of Liabilities Measured at Fair Value

The following table represents the Company's fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis:

As of March 31, 2013

Level 1 Level 2 Level 3 Balance

Liabilities

Derivatives instruments $ - $ - $ 2,201,390 $ 2,201,390

As of December 31, 2012

Level 1 Level 2 Level 3 Balance

Liabilities

Derivatives instruments $ - $ - $ 1,295,613 $ 1,295,613

Summary of Changes in Fair Value of Level 3 Liabilities

The following table sets forth a summary of changes in the fair value of our Level 3 liabilities for the three months ended March 31, 2013:

Description Balance as of
December 31,
2012 Unrealized Losses Balance as of
March 31,
2013

Derivative liabilities related to stock purchase warrants $ 1,295,613 $ 905,777 $ 2,201,390

The following table sets forth a summary of changes in the fair value of the Company's Level 3 liabilities for the three months ended March 31, 2012:

Description Balance as of
December 31,
2011 Unrealized Losses Balance as of
March 31,
2012

Derivative liabilities related to stock purchase warrants $ 1,886,652 $ 991,662 $ 2,878,314

Schedule of Quantitative Information about Level 3 Fair Value Measurements

Quantitative Information about Level 3 Fair Value Measurements

Fair Value at 3/31/2013 Valuation Technique Unobservable Inputs

$ 2,201,390 Black-Scholes option pricing model Expected term

Expected dividends

Anticipated volatility

X

- Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of quantitative information about the inputs used in the fair value measurement of liabilities. This disclosure may include, but is not limited to, the fair value of the liability, valuation technique used to measure fair value, the inputs used to measure fair value, the ranges of the inputs, and the weighted averages of the inputs.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (bbb)

-URI http://asc.fasb.org/extlink&oid=7578670&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=7578670&loc=d3e19207-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7578670&loc=d3e19279-110258

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 157

-Paragraph 32

-Subparagraph c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=7578670&loc=d3e19190-110258

+ Details

Name: us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 39 R21.htm IDEA: XBRL DOCUMENT v2.4.0.6

Fair Value Measurements (Schedule of Liabilities Measured at Fair Value) (Details) (Recurring [Member], USD $)

Mar. 31, 2013

Dec. 31, 2012

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Derivatives $ 2,201,390 $ 1,295,613

Level 1 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Derivatives

Level 2 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Derivatives

Fair Value, Inputs, Level 3 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Derivatives $ 2,201,390 $ 1,295,613

X

- Definition

Derivative instrument obligations meeting the definition of a liability which the Company is a party to as of the balance sheet date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 15

-Paragraph 83

-URI http://asc.fasb.org/extlink&oid=6913464&loc=d3e34841-113949

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 133

-Paragraph 10

-Subparagraph i

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 133

-Paragraph 6

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_DerivativeFinancialInstrumentsLiabilitiesFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 40 R26.htm IDEA: XBRL DOCUMENT v2.4.0.6

Stockholders' Equity (Schedule of Warrants) (Details)
1 Months Ended 3 Months Ended

Mar. 30, 2012

Jul. 31, 2009

Mar. 31, 2013

Mar. 31, 2012

Mar. 31, 2013

Warrant Tranche One [Member]

Mar. 31, 2013

Warrant Tranche Two [Member]

Mar. 31, 2013

Warrant Tranche Three [Member]

Mar. 31, 2013

Warrant Tranche Four [Member]

Mar. 31, 2013

Warrant Tranche Five [Member]

Mar. 31, 2013

Warrant Tranche Six [Member]

Mar. 31, 2013

Warrant Tranche Seven [Member]

Class of Warrant or Right [Line Items]

Number of Common Shares Underlying Warrants 46,584 5,620,128 5,620,128 100,778 ^[1] 705,354 ^[2] 2,572,775 ^[1] 500,000 ^[2] 1,323,214 ^[2] 371,423 ^[2] 46,584 ^[1]

Issue Date Mar. 01, 2007 Mar. 01, 2009 Jul. 01, 2009 Apr. 01, 2010 Jul. 01, 2010 Jun. 01, 2011 Mar. 01, 2012

Exercisable Date Mar. 01, 2007 Sep. 01, 2009 Jan. 01, 2010 Oct. 01, 2010 Jan. 01, 2011 Jun. 01, 2011 Mar. 01, 2012

Exercise Price 1.61 3.97 3.00 2.50 1.89 1.63 3.50 1.61

Expiration Date Mar. 30, 2022 Jan. 28, 2015 Mar. 30, 2017 Sep. 30, 2014 Jan. 28, 2015 Oct. 31, 2015 Jan. 31, 2017 Jun. 30, 2016 Mar. 30, 2022

[1] These warrants to purchase common stock are classified as equity.

[2] These warrants to purchase common stock are classified as derivative liabilities. The fair value of these liabilities (see note 3) is remeasured at the end of every reporting period and the change in fair value is reported in the unaudited condensed consolidated statements of operations as other income (expense).

X

- Definition

Class Of Warrant Or Right, Issuance Date.

+ References

No definition available.

+ Details

Name: pip_ClassOfWarrantOrRightIssuanceDate

Namespace Prefix: pip_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

Warrant, Expiration Date

+ References

No definition available.

+ Details

Name: pip_WarrantExpirationDate

Namespace Prefix: pip_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

Date the warrants or rights are exercisable, in CCYY-MM-DD format.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i)(3))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph i

-Subparagraph 3

-Article 4

+ Details

Name: us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable

Namespace Prefix: us-gaap_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

The exercise price of each class of warrants or rights outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i)(4))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph i

-Subparagraph 4

-Article 4

+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights

Namespace Prefix: us-gaap_

Data Type: us-types:perUnitItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_ClassOfWarrantOrRightLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The specified number of securities that each class of warrants or rights outstanding give the holder the right but not the obligation to purchase from the issuer at a specific price, on or before a certain date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i)(2))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph i

-Subparagraph 2

-Article 4

+ Details

Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

XML 41 R5.htm IDEA: XBRL DOCUMENT v2.4.0.6

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OTHER COMPREHENSIVE LOSS (USD $)
3 Months Ended

Mar. 31, 2013

Mar. 31, 2012

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OTHER COMPREHENSIVE LOSS [Abstract]

Net Loss $ (2,111,385) $ (2,679,888)

Other comprehensive income (loss):

Foreign currency translation adjustment (1,684) 13,369

Comprehensive loss $ (2,113,069) $ (2,666,519)

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 130

-Paragraph 10, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 87-21

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28, 29, 30

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e565-108580

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A7

-Appendix A

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Net of tax and reclassification adjustments of the change in the balance sheet adjustment that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency of the reporting entity. Also includes the following: gain (loss) on foreign currency forward exchange contracts; foreign currency transactions designated as hedges of net investment in a foreign entity and intercompany foreign currency transactions that are of a long-term nature, when the entities to the transaction are consolidated, combined, or accounted for by the equity method in the reporting enterprise's financial statements; and gain (loss) on a derivative instrument or nonderivative financial instrument that may give rise to a foreign currency transaction gain (loss) that has been designated and qualified as a hedging instrument for hedging of the foreign currency exposure of a net investment in a foreign operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 10A

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=20435746&loc=SL7669646-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 30

-Section 45

-Paragraph 20

-Subparagraph (b,c)

-URI http://asc.fasb.org/extlink&oid=6915805&loc=d3e32211-110900

+ Details

Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Net of tax amount of other comprehensive income (loss) attributable to both parent entity and noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 1A

-URI http://asc.fasb.org/extlink&oid=20435746&loc=SL7669619-108580

+ Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 42 R10.htm IDEA: XBRL DOCUMENT v2.4.0.6

Commitments and Contingencies
3 Months Ended

Mar. 31, 2013

Commitments and Contingencies [Abstract]

Commitments and Contingencies

Note 4 - Commitments and Contingencies

SIGA Litigation

In December 2006, we filed a complaint against SIGA Technologies, Inc. ("SIGA") in the Delaware Court of Chancery. The complaint alleged, among other things, that we have the right to license exclusively development and marketing rights for SIGA's drug candidate, Arestvyr™ (Tecovirimat), pursuant to a merger agreement between the parties that was terminated in 2006. The complaint also alleged that SIGA failed to negotiate in good faith the terms of such a license pursuant to the terminated merger agreement.

In September 2011, the Court issued an opinion in the case finding that SIGA had breached certain contractual obligations to us and upholding our claims of promissory estoppel. The Court awarded us the right to receive 50% of all net profits (as defined in the court's final judgment) related to the sale of Arestvyr™ and related products for 10 years following initial commercial sale of the drug once SIGA earns $40 million in net profits from the sale of Arestvyr™ and related products. The Court also awarded us one-third of our reasonable attorney's fees and expert witness fees, which amounts to approximately $2.4 million plus interest. In May 2012, the Court issued its final judgment. SIGA has appealed aspects of the decision to the Delaware Supreme Court. In response, we cross-appealed other aspects of the decision. In January 2013, the Delaware Supreme Court heard oral argument in the case.

We can provide no assurances that SIGA will not prevail on its appeal, that we will be successful in our appeal, and that the Delaware Supreme Court will not overturn the trial court's decision awarding us a 10 year 50% net profit of the sales of Arestvyr™ and related products (once SIGA retains the first $40 million in net profit). We have not yet recorded any amount due from SIGA in relation to this case.

Vendor Litigation

One of our vendors mishandled the storage of certain biological materials. While we have been engaged in discussions with the vendor to address our concerns, so far we have not come to agreement. The vendor filed suit against us in Delaware state court seeking a declaration that they are not liable for damages and seeking damages from us for allegedly not maintaining the required amount and type of insurance. We filed suit against the vendor in Maryland state court seeking damages related to the loss of the property. We believe we did maintain the appropriate amount and type of insurance, that in no event did we harm the vendor, and thus their damages claim is without merit. We plan to vigorously defend against their claims while pursuing our own.

Government Contracting

Payments to the Company on cost-plus-fee contracts are provisional and are subject to adjustment upon audit by the Defense Contract Audit Agency and BARDA. In our opinion, adjustments that may result from audits are not expected to have a material effect on our financial position, results of operations, or cash flows.

Registration Rights Agreements

We entered into a Registration Rights Agreement with the investors who participated in the July 2009 private placement of convertible notes and related warrants. We subsequently filed two registration statements on Form S-3 with the Securities and Exchange Commission to register the shares underlying the convertible notes and related warrants, which registration statements have been declared effective. We are obligated to maintain the registration statements effective until the date when all shares underlying the convertible notes and related warrants (and any other securities issued or issuable with respect to in exchange for such shares) have been sold. The convertible notes were converted or extinguished in 2010, although the related warrants remain outstanding. The warrants will expire on January 28, 2015.

We have separate registration rights agreements with investors, under which we have obligations to keep the corresponding registration statements effective until the registrable securities (as defined in each agreement) have been sold, and under which we may have separate obligations to file registration statements in the future on either a demand or "piggy-back" basis or both.

Under the terms of the convertible notes, which were converted or extinguished in 2010, if after the 2nd consecutive business day (other than during an allowable blackout period) on which sales of all of the securities required to be included on the registration statement cannot be made pursuant to the registration statement (a "Maintenance Failure"), we will be required to pay to each selling stockholder a one-time payment of 1.0% of the aggregate principal amount of the convertible notes relating to the affected shares on the initial day of a Maintenance Failure. Our total maximum obligation under this provision at March 31, 2013, would be approximately $0.2 million.

Following a Maintenance Failure, we will also be required to make to each selling stockholder monthly payments of 1.0% of the aggregate principal amount of the convertible notes relating to the affected shares on every 30th day after the initial day of a Maintenance Failure, in each case prorated for shorter periods and until the failure is cured. Our total maximum obligation under this provision would be approximate $0.2 million for each month until the failure, if it occurs, is cured.

X

- Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14435-108349

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Interpretation (FIN)

-Number 14

-Paragraph 3

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 440

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 5

-Paragraph 9, 10, 11, 12

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 43 R27.htm IDEA: XBRL DOCUMENT v2.4.0.6

Financing Transactions (Details) (USD $)
3 Months Ended 3 Months Ended 3 Months Ended 3 Months Ended

Mar. 31, 2013

Mar. 31, 2012

Dec. 31, 2012

Mar. 30, 2012

Mar. 31, 2013

Equity Offering [Member]

Mar. 25, 2013

Equity Offering [Member]

Mar. 31, 2013

Line of Credit [Member]

Mar. 30, 2012

Line of Credit [Member]

Mar. 31, 2013

Loans Payable [Member]

Mar. 30, 2012

Loans Payable [Member]

Debt Instrument [Line Items]

Line of credit facility, maximum borrowing capacity $ 5,000,000

Current borrowing capacity 2,300,000

Line of Credit Facility, Amount Outstanding 1,300,000

Term loan, payment terms Payments on the term loan were originally interest-only for the first 10 months, which has since been extended to 12 months pursuant to terms of the agreement. Subsequently, the term loan will fully amortize over its remaining term as of March 31, 2013.

Line of credit borrowing capacity description Under the terms of the revolving line of credit, the Company may draw down from the revolving line of credit up to 85% of qualified billed accounts receivable and 80% of qualified unbilled accounts receivable.

Term loan and line of credit, maturity date 2015-09

Line of credit facility borrowing capacity, qualified billed accounts receivable, percent 85.00%

Line of credit facility borrowing capacity, qualified unbilled accounts receivable, percent 80.00%

Fixed interest rate 10.14%

Variable interest rate, with floor of 1.5% 1.50%

Loan payable, interest rate spread 5.00%

Incremental borrowing rate used to calculate discount 6.50%

2013 749,997

2014 999,996

2015 750,007

Total 2,500,000 2,500,000

Prepayment premium, if paid within the first two years of the term loan, percent 3.00%

Prepayment premium, if paid after the first two years of the term loan, percent 2.00%

Final payment fee payable on term loan balance, percent 3.00%

Warrants issued to purchase common stock, in connection to loan agreement 46,584

Warrant exercise price 1.61 1.61

Debt discount 39,587

Current portion of long-term debt 999,996 749,997

Long-term debt, less current portion 1,460,417 1,704,108

Equity Offering [Line Items]

The maximum value of common stock issuable under the controlled equity offering 15,000,000

Commission owed to sales agent, expressed as percentage of aggregate gross proceeds from each sale of shares of common stock 3.00%

Equity offering, issuance costs 277,000

Proceeds from issuance of common stock 53,413

Common stock - receivable 33,000

Number of shares sold 19,900

Amount remaining available under the arrangement $ 14,970,000

X

- Definition

Commission owed to sales agent, expressed as percentage of aggregate gross proceeds from each sale of shares.

+ References

No definition available.

+ Details

Name: pip_CommissionOwedToSalesAgentExpressedAsPercentageOfAggregateGrossProceedsFromEachSaleOfShares

Namespace Prefix: pip_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition

The portion of the carrying amount of short-term borrowings outstanding as of the balance sheet date, which accrues interest at a rate subject to change from time to time, however, with a floor of 1.5%.

+ References

No definition available.

+ Details

Name: pip_DebtInstrumentInterestRateFloorPercentage

Namespace Prefix: pip_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition

Debt Instruments Maturity Date Month and Year

+ References

No definition available.

+ Details

Name: pip_DebtInstrumentsMaturityDateMonthAndYear

Namespace Prefix: pip_

Data Type: xbrli:gYearMonthItemType

Balance Type: na

Period Type: duration

X

- Details

Name: pip_EquityOfferingLineItems

Namespace Prefix: pip_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Final payment fee payable on term loan balance, percent.

+ References

No definition available.

+ Details

Name: pip_FinalPaymentFeeOfTermLoanBalancePercent

Namespace Prefix: pip_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Line Of Credit Facility Borrowing Capacity Percent Of Qualified Billed Accounts Receivable.

+ References

No definition available.

+ Details

Name: pip_LineOfCreditFacilityBorrowingCapacityPercentOfQualifiedBilledAccountsReceivable

Namespace Prefix: pip_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Line Of Credit Facility Borrowing Capacity Percent Of Qualified Unbilled Accounts Receivable.

+ References

No definition available.

+ Details

Name: pip_LineOfCreditFacilityBorrowingCapacityPercentOfQualifiedUnbilledAccountsReceivabl

Namespace Prefix: pip_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Prepayment premium, if paid within the first two years of the term loan, percent.

+ References

No definition available.

+ Details

Name: pip_LongTermDebtPrepaymentPremiumPercentOfPrincipal

Namespace Prefix: pip_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Prepayment premium, if paid after the first two years of the term loan, percent.

+ References

No definition available.

+ Details

Name: pip_LongTermDebtPrepaymentPremiumPercentOfPrincipalPeriodTwo

Namespace Prefix: pip_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

The maximum value of common stock issuable under the controlled equity offering.

+ References

No definition available.

+ Details

Name: pip_MaximumValueOfStockIssuableUnderStockOffering

Namespace Prefix: pip_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The remaining value of common stock issuable under the controlled equity offering.

+ References

No definition available.

+ Details

Name: pip_RemainingValueOfStockIssuableUnderStockOffering

Namespace Prefix: pip_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Warrants Issued To Purchase Common Stock In Connection To Loan Agreement.

+ References

No definition available.

+ Details

Name: pip_WarrantsIssuedToPurchaseCommonStockInConnectionToLoanAgreement

Namespace Prefix: pip_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Direct costs (e.g., legal and accounting fees) associated with issuing stock that is deducted from additional paid in capital. Also includes any direct costs associated with stock issues under a shelf registration.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Technical Practice Aid (TPA)

-Number 4110

-Paragraph 1, 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The exercise price of each class of warrants or rights outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i)(4))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph i

-Subparagraph 4

-Article 4

+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights

Namespace Prefix: us-gaap_

Data Type: us-types:perUnitItemType

Balance Type: na

Period Type: instant

X

- Definition

Amount of subscription receivable from investors who have been allocated common stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 85-1

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The percentage points added to the reference rate to compute the variable rate on the debt instrument.

+ References

No definition available.

+ Details

Name: us-gaap_DebtInstrumentBasisSpreadOnVariableRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition

Including current and noncurrent portions, aggregate carrying amount of long-term borrowings as of the balance sheet date before deducting unamortized discount or premiums (if any). May include notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt, which had initial maturities beyond one year or beyond the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 16

-Article 9

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Staff Position (FSP)

-Number APB14-1

-Paragraph 31

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

+ Details

Name: us-gaap_DebtInstrumentCarryingAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtInstrumentInterestRateEffectivePercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition

Interest rate stated in the contractual debt agreement.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtInstrumentInterestRateStatedPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_DebtInstrumentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Description of the payment terms of the debt instrument (for example, whether periodic payments include principal and frequency of payments) and discussion about any contingencies associated with the payment.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 470

-Section 50

-Paragraph 3

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6479336&loc=d3e64711-112823

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 2, 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_DebtInstrumentPaymentTerms

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount of debt discount that was originally recognized at the issuance of the instrument that has yet to be amortized.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 21

-Paragraph 16, 20

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 1A

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28541-108399

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Staff Position (FSP)

-Number APB14-1

-Paragraph 31

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 55

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6584090&loc=d3e28878-108400

+ Details

Name: us-gaap_DebtInstrumentUnamortizedDiscount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Description of the credit facility's borrowing capacity including discussion of how the borrowing capacity is determined (for example, borrowing capacity based on the amount of current assets).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 2, 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19, 22

-Article 5

+ Details

Name: us-gaap_LineOfCreditFacilityBorrowingCapacityDescription

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(b),22(b))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19, 22

-Article 5

+ Details

Name: us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Fair value of the amount outstanding under the credit facility.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13433-108611

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13476-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 2, 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(b),22(b))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19, 22

-Article 5

+ Details

Name: us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying amount of long-term debt, net of unamortized discount or premium, scheduled to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Article 5

+ Details

Name: us-gaap_LongTermDebtCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of long-term debt, sinking fund requirements, and other securities redeemable at fixed or determinable prices and dates maturing in the next fiscal year following the latest fiscal year.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 47

-Paragraph 10

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of long-term debt, sinking fund requirements, and other securities redeemable at fixed or determinable prices and dates maturing in the third fiscal year following the latest fiscal year.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 47

-Paragraph 10

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of long-term debt, sinking fund requirements, and other securities redeemable at fixed or determinable prices and dates maturing in the second fiscal year following the latest fiscal year.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 47

-Paragraph 10

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying amount of long-term debt, net of unamortized discount or premium, excluding amounts to be repaid within one year or the normal operating cycle, if longer (current maturities). Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

+ Details

Name: us-gaap_LongTermDebtNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The cash inflow from the additional capital contribution to the entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 19

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 18

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Number of new stock issued during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 44 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.6 Html 72 166 1 true 27 0 false 5 false false R1.htm 001 - Document - Document and Entity Information Sheet http://www.pharmathene.com/role/DocumentAndEntityInformation Document and Entity Information true false R2.htm 002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.pharmathene.com/role/CondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS false false R3.htm 003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.pharmathene.com/role/CondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) false false R4.htm 004 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.pharmathene.com/role/UnauditedCondensedConsolidatedStatementsOfOperations UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS false false R5.htm 006 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OTHER COMPREHENSIVE LOSS Sheet http://www.pharmathene.com/role/UnauditedCondensedConsolidatedStatementsOfOtherComprehensiveLoss UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OTHER COMPREHENSIVE LOSS false false R6.htm 007 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.pharmathene.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS false false R7.htm 101 - Disclosure - Organization and Business Sheet http://www.pharmathene.com/role/OrganizationAndBusiness Organization and Business false false R8.htm 102 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.pharmathene.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies false false R9.htm 103 - Disclosure - Fair Value Measurements Sheet http://www.pharmathene.com/role/FairValueMeasurements Fair Value Measurements false false R10.htm 104 - Disclosure - Commitments and Contingencies Sheet http://www.pharmathene.com/role/CommitmentsAndContingencies Commitments and Contingencies false false R11.htm 105 - Disclosure - Stockholders' Equity Sheet http://www.pharmathene.com/role/StockholdersEquity Stockholders' Equity false false R12.htm 106 - Disclosure - Financing Transactions Sheet http://www.pharmathene.com/role/FinancingTransactions Financing Transactions false false R13.htm 107 - Disclosure - Subsequent Events Sheet http://www.pharmathene.com/role/SubsequentEvents Subsequent Events false false R14.htm 202 - Disclosure - Summary of Significant Accounting Policies (Policy) Sheet http://www.pharmathene.com/role/SummaryOfSignificantAccountingPoliciesPolicy Summary of Significant Accounting Policies (Policy) false false R15.htm 302 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.pharmathene.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) false false R16.htm 303 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.pharmathene.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) false false R17.htm 305 - Disclosure - Stockholders' Equity (Tables) Sheet http://www.pharmathene.com/role/StockholdersEquityTables Stockholders' Equity (Tables) false false R18.htm 306 - Disclosure - Financing Transactions (Tables) Sheet http://www.pharmathene.com/role/FinancingTransactionsTables Financing Transactions (Tables) false false R19.htm 40201 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details) Sheet http://www.pharmathene.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails Summary of Significant Accounting Policies (Narrative) (Details) false false R20.htm 40202 - Disclosure - Summary of Significant Accounting Policies (Schedule of Share-based Compensation Expense) (Details) Sheet http://www.pharmathene.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfSharebasedCompensationExpenseDetails Summary of Significant Accounting Policies (Schedule of Share-based Compensation Expense) (Details) false false R21.htm 40301 - Disclosure - Fair Value Measurements (Schedule of Liabilities Measured at Fair Value) (Details) Sheet http://www.pharmathene.com/role/FairValueMeasurementsScheduleOfLiabilitiesMeasuredAtFairValueDetails Fair Value Measurements (Schedule of Liabilities Measured at Fair Value) (Details) false false R22.htm 40302 - Disclosure - Fair Value Measurements (Summary of Changes in Fair Value of Our Level 3 Liabilities) (Details) Sheet http://www.pharmathene.com/role/FairValueMeasurementsSummaryOfChangesInFairValueOfOurLevelThreeLiabilitiesDetails Fair Value Measurements (Summary of Changes in Fair Value of Our Level 3 Liabilities) (Details) false false R23.htm 40303 - Disclosure - Fair Value Measurements (Narrative) (Details) Sheet http://www.pharmathene.com/role/FairValueMeasurementsNarrativeDetails Fair Value Measurements (Narrative) (Details) false false R24.htm 40401 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.pharmathene.com/role/CommitmentsAndContingenciesDetails Commitments and Contingencies (Details) false false R25.htm 40501 - Disclosure - Stockholders' Equity (Narrative) (Details) Sheet http://www.pharmathene.com/role/StockholdersEquityNarrativeDetails Stockholders' Equity (Narrative) (Details) false false R26.htm 40502 - Disclosure - Stockholders' Equity (Schedule of Warrants) (Details) Sheet http://www.pharmathene.com/role/StockholdersEquityScheduleOfWarrantsDetails Stockholders' Equity (Schedule of Warrants) (Details) false false R27.htm 40601 - Disclosure - Financing Transactions (Details) Sheet http://www.pharmathene.com/role/FinancingTransactionsDetails Financing Transactions (Details) false false R28.htm 40701 - Disclosure - Subsequent Events (Details) Sheet http://www.pharmathene.com/role/SubsequentEventsDetails Subsequent Events (Details) false false All Reports Book All Reports Element us-gaap_CostOfReimbursableExpense had a mix of decimals attribute values: -5 -4. Element us-gaap_ProceedsFromIssuanceOfCommonStock had a mix of decimals attribute values: -4 0. 'Monetary' elements on report '40201 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details)' had a mix of different decimal attribute values. 'Shares' elements on report '40501 - Disclosure - Stockholders' Equity (Narrative) (Details)' had a mix of different decimal attribute values. 'Monetary' elements on report '40701 - Disclosure - Subsequent Events (Details)' had a mix of different decimal attribute values. Process Flow-Through: 002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Process Flow-Through: Removing column 'Mar. 31, 2012' Process Flow-Through: Removing column 'Dec. 31, 2011' Process Flow-Through: 003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Process Flow-Through: 004 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Process Flow-Through: 006 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OTHER COMPREHENSIVE LOSS Process Flow-Through: 007 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS pip-20130331.xml pip-20130331.xsd pip-20130331_cal.xml pip-20130331_def.xml pip-20130331_lab.xml pip-20130331_pre.xml true true XML 45 R20.htm IDEA: XBRL DOCUMENT v2.4.0.6

Summary of Significant Accounting Policies (Schedule of Share-based Compensation Expense) (Details) (USD $)
3 Months Ended

Mar. 31, 2013

Mar. 31, 2012

Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]

Total share-based compensation expense $ 328,581 $ 548,664

Research and Development [Member]

Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]

Total share-based compensation expense 88,634 117,067

General and Administrative Expense [Member]

Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]

Total share-based compensation expense $ 239,947 $ 431,597

X

- Definition

Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph g(1)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section F

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph 64

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.F)

-URI http://asc.fasb.org/extlink&oid=6793087&loc=d3e301413-122809

+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

Subsequent Events (Details) (USD $)	3 Months Ended		1 Months Ended
Subsequent Events (Details) (USD $)	Mar. 31, 2013	Mar. 31, 2012	May 08, 2013 Subsequent Event [Member]
Subsequent Event [Line Items]
Number of shares sold			1,030,870
Amount remaining available under the arrangement			$ 13,290,000
Proceeds from issuance of common stock	$ 53,413		$ 1,630,000

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Mar. 31, 2013	Dec. 31, 2012
Current assets:
Cash and cash equivalents	$ 12,873,411	$ 12,701,517
Accounts receivable (billed)	1,865,916	2,432,641
Unbilled accounts receivable	3,713,797	4,114,442
Prepaid expenses and other current assets	614,388	547,245
Total current assets	19,067,512	19,795,845
Property and equipment, net	456,842	483,976
Other long-term assets and deferred costs	99,578	113,130
Goodwill	2,348,453	2,348,453
Total assets	21,972,385	22,741,404
Current liabilities:
Accounts payable	1,289,627	1,697,280
Accrued expenses and other liabilities	3,294,315	2,328,877
Deferred revenue	874,404	1,381,755
Current portion of long-term debt	999,996	749,997
Short-term debt	1,329,233	1,330,507
Total current liabilities	7,787,575	7,488,416
Other long-term liabilities	580,238	579,427
Long-term debt, less current portion	1,460,417	1,704,108
Derivative instruments	2,201,390	1,295,613
Total liabilities	12,029,620	11,067,564
Stockholders' equity:
Common stock, $0.0001 par value; 100,000,000 shares authorized; 48,416,483 and 48,352,651 shares issued and outstanding at March 31, 2013 and December 31, 2012, respectively	4,842	4,835
Additional paid-in-capital	210,877,892	210,495,905
Accumulated other comprehensive loss	(219,012)	(217,328)
Accumulated deficit	(200,720,957)	(198,609,572)
Total stockholders' equity	9,942,765	11,673,840
Total liabilities and stockholders' equity	$ 21,972,385	$ 22,741,404

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Operating activities
Net loss	$ (2,111,385)	$ (2,679,888)
Adjustments to reconcile net loss to net cash used in operating activities:
Change in fair value of derivative instruments	905,777	991,662
Depreciation and amortization expense	52,602	85,910
Gain on the disposal of property and equipment		(66,626)
Deferred income tax expenses	9,743	150,405
Non-cash interest expense	32,431
Share-based compensation expense	328,581	548,664
Changes in operating assets and liabilities:
Accounts receivable	566,725	3,278,062
Unbilled accounts receivable	400,645	(1,254,867)
Prepaid expenses and other current assets	39,486	137,362
Accounts payable	(407,653)	(35,280)
Accrued expenses and other liabilities	950,800	131,338
Deferred revenue	(507,351)	(495,372)
Net cash provided by operating activities	260,401	791,370
Investing activities
Purchase of property and equipment	(25,468)
Proceeds from the sale of property and equipment		67,400
Net cash provided (used) by investing activities	(25,468)	67,400
Financing activities
Proceeds from issuance of long-term debt		2,500,000
Net (repayment of) proceeds from revolving credit agreement	(1,274)	857,808
Deferred financing costs		(220,234)
Controlled equity offering issuance costs	(112,500)
Change in restricted cash requirements		100,000
Proceeds from issuance of common stock	53,413
Other		(32,960)
Net cash (used) provided by financing activities	(60,361)	3,204,614
Effects of exchange rates on cash	(2,678)	4,034
Increases in cash and cash equivalents	171,894	4,067,418
Cash and cash equivalents, at beginning of period	12,701,517	11,236,771
Cash and cash equivalents, at end of period	12,873,411	15,304,189
Supplemental disclosure of cash flow information
Cash paid for interest	67,360	3,028
Noncash financing activities
Value of warrants issued to lender in connection with loan		$ 69,876

Fair Value Measurements (Summary of Changes in Fair Value of Our Level 3 Liabilities) (Details) (USD $)	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Unrealized Gains (Losses)	$ (905,777)	$ (991,662)
Fair Value, Inputs, Level 3 [Member] \| Warrants [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning Balance	1,295,613	1,886,652
Unrealized Gains (Losses)	(905,777)	(991,662)
Ending Balance	$ 2,201,390	$ 2,878,314

Commitments and Contingencies (Details) (USD $) In Millions, unless otherwise specified	1 Months Ended		3 Months Ended		1 Months Ended
	Mar. 30, 2012	Jul. 31, 2009	Mar. 31, 2013 Initial Maximum Maintenance Failure Obligation [Member]	Mar. 31, 2013 Every 30 days until failure is cured [Member]	Sep. 30, 2011 PharmAthene [Member]	Sep. 30, 2011 PharmAthene [Member] Maximum [Member]
Commitments and Contingencies [Line Items]
SIGA breach of contractual obligation awarded, percentage of net profits (as defined in court's final judgement)					50.00%
SIGA breach of contractual obligation award period following initial commercial sale						10 years
SIGA net profits (as defined in court's final judgement) before distribution for breach of contract					$ 40
Awarded 1/3 reasonable attorney's fees and expert witness fees, plus interest.					2.4
Warrant expiration date	Mar. 30, 2022	Jan. 28, 2015
Percentage of aggregate principal amount of convertible Notes			1.00%	1.00%
Aggregate principal amount of obligation			$ 0.2	$ 0.2

Organization and Business	3 Months Ended
Organization and Business	Mar. 31, 2013
Organization and Business [Abstract]
Organization and Business	Note 1 - Organization and Business We are a biopharmaceutical company focused on developing biodefense countermeasure applications. We are subject to those risks associated with any biopharmaceutical company that has substantial expenditures for research and development. There can be no assurance that our research and development projects will be successful, that products developed will obtain necessary regulatory approval, or that any approved product will be commercially viable. In addition, we operate in an environment of rapid technological change and are largely dependent on the services and expertise of our employees, consultants and other third parties. Historically, we have performed under government contracts and grants and raised funds from investors to sustain our operations.

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Mar. 31, 2013	Dec. 31, 2012
CONDENSED CONSOLIDATED BALANCE SHEETS [Abstract]
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	48,416,483	48,352,651
Common stock, shares outstanding	48,416,483	48,352,651

Document and Entity Information	3 Months Ended
Document and Entity Information	Mar. 31, 2013	May 02, 2013
Document and Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2013
Document Fiscal Year Focus	2013
Document Fiscal Period Focus	Q1
Trading Symbol	PIP
Entity Registrant Name	PHARMATHENE, INC
Entity Central Index Key	0001326190
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		49,460,686

Fair Value Measurements (Narrative) (Details) (USD $)	3 Months Ended
Fair Value Measurements (Narrative) (Details) (USD $)	Mar. 31, 2013	Mar. 31, 2012	Mar. 31, 2013 Fair Value, Inputs, Level 3 [Member] Warrants [Member]	Mar. 31, 2012 Fair Value, Inputs, Level 3 [Member] Warrants [Member]	Mar. 31, 2013 Fair Value, Inputs, Level 3 [Member] Warrants [Member] Derivative Liabilities [Member]	Mar. 28, 2013 Fair Value, Inputs, Level 3 [Member] Warrants [Member] Derivative Liabilities [Member]	Dec. 31, 2012 Fair Value, Inputs, Level 3 [Member] Warrants [Member] Derivative Liabilities [Member]	Mar. 31, 2012 Fair Value, Inputs, Level 3 [Member] Warrants [Member] Derivative Liabilities [Member]	Mar. 30, 2012 Fair Value, Inputs, Level 3 [Member] Warrants [Member] Derivative Liabilities [Member]	Dec. 30, 2011 Fair Value, Inputs, Level 3 [Member] Warrants [Member] Derivative Liabilities [Member]
Fair Value Measurements [Line Items]
Warrants to purchase common stock					2,899,991			2,899,991
Change in fair value of derivative instruments	$ 905,777	$ 991,662	$ 905,777	$ 991,662
Closing stock price, per share						$ 1.70	$ 1.12		$ 1.77	$ 1.27

Summary of Significant Accounting Policies (Narrative) (Details) (USD $)	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Significant Accounting Policies [Line Items]
Number of operating segment	1
Cost reimbursed to offset research and development expenses	$ 20,000	$ 500,000
Share-based compensation forfeitures rate	12.00%	12.00%
Share options granted to employees	60,000	15,948
Unrecognized share-based compensation expense related to unvested awards	2,000,000
Unrecognized share-based compensation expense related to unvested awards expected to be recognized in the period	2 years 3 months
Income tax expense	$ 9,743	$ 150,405
Anti-dilutive securities excluded from computation of earnings per share	11,600,000	11,500,000
Liquidity Arrangements [Member] \| Maximum [Member]
Significant Accounting Policies [Line Items]
Cash liquidity maturity period	3 months

Subsequent Events	3 Months Ended
Subsequent Events	Mar. 31, 2013
Subsequent Event [Abstract]
Subsequent Events	Note 7 - Subsequent Events Subsequent to March 31, 2013, we sold 1,030,870 shares of our common stock under the controlled equity offering, which resulted in net proceeds of approximately $1.63 million. (See Note 6). Aggregate gross proceeds of up to approximately $13.29 million remain available under the arrangement.

Fair Value Measurements (Schedule of Liabilities Measured at Fair Value) (Details) (Recurring [Member], USD $)	Mar. 31, 2013	Dec. 31, 2012
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivatives	$ 2,201,390	$ 1,295,613
Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivatives
Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivatives
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivatives	$ 2,201,390	$ 1,295,613

Commitments and Contingencies	3 Months Ended
Commitments and Contingencies	Mar. 31, 2013
Commitments and Contingencies [Abstract]
Commitments and Contingencies	Note 4 - Commitments and Contingencies SIGA Litigation In December 2006, we filed a complaint against SIGA Technologies, Inc. ("SIGA") in the Delaware Court of Chancery. The complaint alleged, among other things, that we have the right to license exclusively development and marketing rights for SIGA's drug candidate, Arestvyr™ (Tecovirimat), pursuant to a merger agreement between the parties that was terminated in 2006. The complaint also alleged that SIGA failed to negotiate in good faith the terms of such a license pursuant to the terminated merger agreement. In September 2011, the Court issued an opinion in the case finding that SIGA had breached certain contractual obligations to us and upholding our claims of promissory estoppel. The Court awarded us the right to receive 50% of all net profits (as defined in the court's final judgment) related to the sale of Arestvyr™ and related products for 10 years following initial commercial sale of the drug once SIGA earns $40 million in net profits from the sale of Arestvyr™ and related products. The Court also awarded us one-third of our reasonable attorney's fees and expert witness fees, which amounts to approximately $2.4 million plus interest. In May 2012, the Court issued its final judgment. SIGA has appealed aspects of the decision to the Delaware Supreme Court. In response, we cross-appealed other aspects of the decision. In January 2013, the Delaware Supreme Court heard oral argument in the case. We can provide no assurances that SIGA will not prevail on its appeal, that we will be successful in our appeal, and that the Delaware Supreme Court will not overturn the trial court's decision awarding us a 10 year 50% net profit of the sales of Arestvyr™ and related products (once SIGA retains the first $40 million in net profit). We have not yet recorded any amount due from SIGA in relation to this case. Vendor Litigation One of our vendors mishandled the storage of certain biological materials. While we have been engaged in discussions with the vendor to address our concerns, so far we have not come to agreement. The vendor filed suit against us in Delaware state court seeking a declaration that they are not liable for damages and seeking damages from us for allegedly not maintaining the required amount and type of insurance. We filed suit against the vendor in Maryland state court seeking damages related to the loss of the property. We believe we did maintain the appropriate amount and type of insurance, that in no event did we harm the vendor, and thus their damages claim is without merit. We plan to vigorously defend against their claims while pursuing our own. Government Contracting Payments to the Company on cost-plus-fee contracts are provisional and are subject to adjustment upon audit by the Defense Contract Audit Agency and BARDA. In our opinion, adjustments that may result from audits are not expected to have a material effect on our financial position, results of operations, or cash flows. Registration Rights Agreements We entered into a Registration Rights Agreement with the investors who participated in the July 2009 private placement of convertible notes and related warrants. We subsequently filed two registration statements on Form S-3 with the Securities and Exchange Commission to register the shares underlying the convertible notes and related warrants, which registration statements have been declared effective. We are obligated to maintain the registration statements effective until the date when all shares underlying the convertible notes and related warrants (and any other securities issued or issuable with respect to in exchange for such shares) have been sold. The convertible notes were converted or extinguished in 2010, although the related warrants remain outstanding. The warrants will expire on January 28, 2015. We have separate registration rights agreements with investors, under which we have obligations to keep the corresponding registration statements effective until the registrable securities (as defined in each agreement) have been sold, and under which we may have separate obligations to file registration statements in the future on either a demand or "piggy-back" basis or both. Under the terms of the convertible notes, which were converted or extinguished in 2010, if after the 2nd consecutive business day (other than during an allowable blackout period) on which sales of all of the securities required to be included on the registration statement cannot be made pursuant to the registration statement (a "Maintenance Failure"), we will be required to pay to each selling stockholder a one-time payment of 1.0% of the aggregate principal amount of the convertible notes relating to the affected shares on the initial day of a Maintenance Failure. Our total maximum obligation under this provision at March 31, 2013, would be approximately $0.2 million. Following a Maintenance Failure, we will also be required to make to each selling stockholder monthly payments of 1.0% of the aggregate principal amount of the convertible notes relating to the affected shares on every 30th day after the initial day of a Maintenance Failure, in each case prorated for shorter periods and until the failure is cured. Our total maximum obligation under this provision would be approximate $0.2 million for each month until the failure, if it occurs, is cured.

Financing Transactions (Details) (USD $)	3 Months Ended				3 Months Ended		3 Months Ended		3 Months Ended
Financing Transactions (Details) (USD $)	Mar. 31, 2013	Mar. 31, 2012	Dec. 31, 2012	Mar. 30, 2012	Mar. 31, 2013 Equity Offering [Member]	Mar. 25, 2013 Equity Offering [Member]	Mar. 31, 2013 Line of Credit [Member]	Mar. 30, 2012 Line of Credit [Member]	Mar. 31, 2013 Loans Payable [Member]	Mar. 30, 2012 Loans Payable [Member]
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity								$ 5,000,000
Current borrowing capacity							2,300,000
Line of Credit Facility, Amount Outstanding							1,300,000
Term loan, payment terms									Payments on the term loan were originally interest-only for the first 10 months, which has since been extended to 12 months pursuant to terms of the agreement. Subsequently, the term loan will fully amortize over its remaining term as of March 31, 2013.
Line of credit borrowing capacity description							Under the terms of the revolving line of credit, the Company may draw down from the revolving line of credit up to 85% of qualified billed accounts receivable and 80% of qualified unbilled accounts receivable.
Term loan and line of credit, maturity date							2015-09
Line of credit facility borrowing capacity, qualified billed accounts receivable, percent							85.00%
Line of credit facility borrowing capacity, qualified unbilled accounts receivable, percent							80.00%
Fixed interest rate										10.14%
Variable interest rate, with floor of 1.5%								1.50%
Loan payable, interest rate spread								5.00%
Incremental borrowing rate used to calculate discount							6.50%
2013									749,997
2014									999,996
2015									750,007
Total									2,500,000	2,500,000
Prepayment premium, if paid within the first two years of the term loan, percent									3.00%
Prepayment premium, if paid after the first two years of the term loan, percent									2.00%
Final payment fee payable on term loan balance, percent									3.00%
Warrants issued to purchase common stock, in connection to loan agreement									46,584
Warrant exercise price				1.61					1.61
Debt discount									39,587
Current portion of long-term debt	999,996		749,997
Long-term debt, less current portion	1,460,417		1,704,108
Equity Offering [Line Items]
The maximum value of common stock issuable under the controlled equity offering						15,000,000
Commission owed to sales agent, expressed as percentage of aggregate gross proceeds from each sale of shares of common stock						3.00%
Equity offering, issuance costs					277,000
Proceeds from issuance of common stock	53,413
Common stock - receivable					33,000
Number of shares sold					19,900
Amount remaining available under the arrangement					$ 14,970,000

Summary of Significant Accounting Policies (Schedule of Share-based Compensation Expense) (Details) (USD $)	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total share-based compensation expense	$ 328,581	$ 548,664
Research and Development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total share-based compensation expense	88,634	117,067
General and Administrative Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total share-based compensation expense	$ 239,947	$ 431,597

Quantitative Information about Level 3 Fair Value Measurements

Fair Value at 3/31/2013

Valuation Technique

Unobservable Inputs

Black-Scholes option pricing model

Expected term

Expected dividends

Anticipated volatility